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ABSTRACT 
AARON JACOB KATZ: The Use, Effectiveness, and Safety of Bevacizumab In Older Adults With 
Advanced Stage Non-Small Cell Lung Cancer 
(Under the direction of Joel F. Farley, PhD) 
Background: In clinical trials, the addition of bevacizumab to standard platinum-based doublet 
chemotherapy significantly improved overall survival in patients with advanced non-small cell lung 
cancer (NSCLC). However, a significant survival advantage with bevacizumab was not detected in 
subsequent analyses of patients aged 65 years and older.  
Objectives: To identify patient and health system characteristics associated with the use of 
bevacizumab and evaluate its effectiveness and safety in older patients with advanced NSCLC. 
Methods: Retrospective cohort study of adults 66 years or older identified within the Surveillance, 
Epidemiology, and End Results (SEER)-Medicare database with a diagnosis of stage IIIB or stage IV 
non-squamous NSCLC between 2004 and 2007. Descriptive statistics were used to characterize the 
utilization of bevacizumab. Multivariable logistic regression models were run to estimate the odds of 
bevacizumab use based on patient demographic, clinical, and health system characteristics. Logistic 
regression and Cox proportional hazards models were used to evaluate the effect of adding 
bevacizumab to platinum-based doublet chemotherapy on overall survival and hospitalization for 
severe treatment-related adverse events.   
Results: Clinical characteristics including stage of disease and comorbidity burden as well as receipt 
of chemotherapy from a provider affiliated with the National Cancer Institute’s (NCI) Community 
Clinical Oncology Program (CCOP) were independent predictors of the use of bevacizumab. Median 
iv 
survival was 9.8 months among patients receiving bevacizumab plus platinum-based doublet 
chemotherapy and 8.9 months among patients receiving chemotherapy alone (hazard ratio [HR], 1.02; 
95% CI, 0.91 to 1.13; P = 0.76). Neither multivariable nor propensity score-adjusted Cox models 
demonstrated a survival advantage with the addition of bevacizumab to platinum-based 
chemotherapy. Compared to platinum-based doublet chemotherapy alone, the addition of 
bevacizumab was associated with a higher incidence of hospitalization for any severe treatment-
related adverse event (10% vs. 14%, respectively; P = 0.003); however, this association was not 
statistically significant after adjusting for confounders in a multivariable-adjusted Cox proportional 
hazards model (HR, 1.31; 95% CI, 0.94 to 1.79). 
Conclusions: Patient clinical characteristics and provider affiliation with the CCOP were important 
predictors of bevacizumab use. However, adding bevacizumab to platinum-based doublet 
chemotherapy was not associated with better survival among Medicare patients with advanced 
NSCLC.  
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Overview 
 Lung cancer is the second most common form of cancer among men and women and is the 
leading cause of cancer-related deaths in the United States.
1
 With a median age of 71 years at 
diagnosis and over 70% of newly diagnosed patients at least 65 years of age, lung cancer is a disease 
that occurs primarily in older adults.
2
 Approximately 85% of lung cancer diagnoses are of the non-
small cell lung cancer type (NSCLC) and the majority of patients present with locally advanced or 
metastatic disease at the time of diagnosis, contributing to a poor survival rate.
2
 Platinum-based 
doublet chemotherapy is the standard treatment for patients with advanced stage disease and has been 
shown to lessen cancer-related symptoms, lengthen survival, and improve quality of life.  However, 
the overall survival benefit from chemotherapy for most patients with advanced NSCLC remains poor 
with a median progression-free survival of approximately 4-5 months and median overall survival 
around 8-11 months.
3,4
 In addition, chemotherapy is associated with toxic adverse effects that may be 
especially problematic for older adults and patients with poor overall health. As a result, efforts have 
been dedicated toward developing targeted treatments that direct their effect toward tumor-specific 
characteristics, have greater activity at the cancer site, and result in lower systemic toxicity compared 
to standard chemotherapy. 
Bevacizumab is the only monoclonal antibody currently approved in addition to 
chemotherapy for the first-line treatment of advanced NSCLC in the United States. Knowledge about 
the efficacy and safety of bevacizumab generally stems from the results of several clinical trials that 
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show bevacizumab improves response rate, progression-free survival, and overall survival beyond 
that of standard platinum-based chemotherapy alone; however, bevacizumab is also associated with a 
prohibitive rate of life-threatening or fatal pulmonary hemorrhage in patients with squamous 
histology, thus its use is limited to patients with non-squamous histology tumors. Still, although most 
lung cancer patients are over the age of 65 at the time of diagnosis, the utility of bevacizumab among 
elderly patients is not well defined. In subgroup analyses of older clinical trial participants, the 
addition of bevacizumab to platinum-based doublet chemotherapy did not provide a significant 
improvement in overall survival, but may be associated with an increased risk of treatment-related 
harms in older patients.
5,6
 Furthermore, a recent observational study
7
 also found no survival benefit 
with the use of bevacizumab among a cohort of Medicare beneficiaries within the Surveillance, 
Epidemiology, and End Results (SEER)-Medicare database.        
Given the questionable utility of bevacizumab in the treatment of advanced NSCLC in elderly 
patients, additional research is warranted to better understand whether bevacizumab is a safe and 
effective therapy in this patient population. Although previous research has examined the safety 
and/or effectiveness of bevacizumab among older adults, these studies have important limitations. 
First, elderly clinical trial participants usually represent “fit” or healthy older adults rather than sicker 
elderly patients more commonly seen in a real-world clinical setting. Thus, treatment outcomes 
observed among elderly trial participants may not be generalizable to the larger population of older 
adults with advanced NSCLC. Second, little research has been done to evaluate associations between 
patient or health care system characteristics and the use, safety, or effectiveness of bevacizumab. In 
particular, previous research has not examined whether the use of bevacizumab differs among older 
patients based on age, race, socioeconomic status, or provider affiliation with provider-based cancer 
research networks such as the National Cancer Institute’s (NCI) Community Clinical Oncology 
Program (CCOP). Third, the evaluation of the effectiveness of bevacizumab on survival among older 
patients has been largely restricted to patients receiving carboplatin-paclitaxel chemotherapy with or 
without bevacizumab. Although the FDA explicitly approved bevacizumab for use in combination 
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with carboplatin-paclitaxel chemotherapy, exclusion of other platinum-based chemotherapy regimens 
that are considered standard of care in advanced NSCLC may prohibit the complete capture of 
bevacizumab as a first-line treatment in the real-world setting. Last, although bevacizumab has been 
associated with an increased risk of severe bleeding including life-threatening or fatal pulmonary 
hemorrhage in clinical trials, research has not assessed the potential relationship between 
bevacizumab and severe treatment-related adverse events in the real-world setting.  
This study utilizes a retrospective cohort design to examine the use, safety, and effectiveness 
of bevacizumab among a cohort of Medicare beneficiaries within the SEER-Medicare database who 
were diagnosed with advanced NSCLC and treated first-line with standard platinum-based doublet 
chemotherapy. It evaluates associations between the use of bevacizumab and clinical, 
sociodemographic, and health care system characteristics including age, race, socioeconomic status, 
and provider affiliation with the CCOP. Furthermore, this study evaluates the impact of bevacizumab 
on overall survival and hospitalization for severe treatment-related adverse events in order to better 
understand the utility of bevacizumab in the first-line treatment of older adults with advanced 
NSCLC. 
 
1.2 Background 
1.2.1 Lung Cancer in the United States 
 More than 200,000 new cases of lung cancer occur each year in the United States.
1
 The 
probability of developing lung cancer increases with age and peaks at approximately 1 in 15 males 
and 1 in 22 females aged 70 years and older.
1
 The overall age-adjusted incidence rate of lung cancer 
between 2002 and 2006 was 86.4 per 100,000 males and 55.5 per 100,000 females per year; however, 
the incidence rate for men has steadily declined while the incidence rate for women has gradually 
increased over the last twenty years.
1
 The incidence rate of lung cancer also varies widely across the 
regions of the United States and is reflective of the differences in smoking prevalence among the 
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states; for example, during 2002 to 2006, the incidence rate of lung cancer exceeded 100 per 100,000 
males in most Southern states whereas the incidence rate was less than 70 per 100,000 males in a 
majority of states in the West.
1
   
 Lung cancer leads to more than 150,000 deaths in the United States annually, representing 
approximately 28% of all cancer mortalities; each year more individuals die from lung cancer than 
from prostate, breast and colorectal cancer combined.
1
 Traditionally, men have had higher mortality 
rates from lung cancer compared to women, but the gap has decreased considerably over the past two 
decades. The age-adjusted death rate for lung cancer in men in 2006 was 67.5 per 100,000 males, 
continuing its decline of 1% to 2% per year since its peak in 1990.  The age-adjusted death rate for 
lung cancer in women on the other hand, has remained relatively constant since 1990 and was 40.2 
per 100,000 females in 2006.
1
    
 Poor survival among lung cancer patients is due in large part to the high prevalence of 
advanced stage disease at the time patients are diagnosed; the five-year relative survival rate is less 
than 5% among patients diagnosed with advanced stage disease compared to a rate greater than 50% 
among patients diagnosed with localized stage lung cancer.
1
 Unfortunately, detection of early stage 
lung cancer is difficult as symptoms typically do not manifest until after the disease has progressed. 
In addition, because lung cancer is most often present in smokers during their later years of life, 
symptoms can be difficult to distinguish from other lung complications brought about by smoking, 
such as emphysema and chronic obstructive pulmonary disease (COPD).  When combined with the 
lack of acceptable and effective screening methods for lung cancer, the absence of discernible signs 
and symptoms contributes to a substantial proportion of advanced disease present at diagnosis.   
 As lung cancer progresses, symptoms may eventually become evident and can be quite 
distressful to patients. Tumor-induced changes in the lung, such as blocked airways and fluid 
accumulation in the chest cavity, can bring about symptoms and complications that may include 
shortness of breath, recurrent lung infection, hemoptysis and pain. These disease-related symptoms 
can significantly impact the health-related quality of life of patients by impairing functional ability, 
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causing psychological distress, and creating a substantial strain on family and social resources.  
Regrettably, because of the high prevalence of advanced disease present at diagnosis, treatment for 
many patients with lung cancer is palliative in nature and aims to prolong survival, reduce symptom 
burden, and maximize the quality of life.         
 Lung cancer is not only a physiologically debilitating disease, but it is also a tremendous 
financial burden to patients, their families, and society. Recent projections estimate that between 2010 
and 2020, the United States will spend approximately $12 to $15 billion annually on lung cancer 
care.
8
 Medical care costs for lung cancer are generally greatest during the initial stage of treatment 
and the last year of life because of the short time of survival. The annual cost of care for an individual 
lung cancer patient 65 years of age and older during initial treatment is estimated to be $60,000 (in 
2010 dollars), whereas it will cost approximately $8,000 per year for patients continuing treatment 
and over $92,000 during the last year of life when the death is due to cancer.
8
 By comparison, the 
costs of initial treatment for patients 65 years and older with colorectal, female breast or prostate 
cancer is approximately $52,000, $23,000, and $20,000, respectively.  The cost of treatment during 
the last year of life for these patients when cancer is the cause of death is approximately $85,000 for 
colorectal cancer, $63,000 for female breast cancer, and $62,000 for prostate cancer.
8
 In addition to 
the impact on direct medical care costs, lung cancer far surpasses other forms of cancer in the annual 
loss of time and economic productivity due to cancer-related illness and death; lung cancer 
contributed an estimated $39 billion in lost productivity in the United States among adults 20 years of 
age and older in 2010 compared to an estimated $13, $11, and $4 billion for colorectal, female breast, 
and prostate cancer, respectively.
9
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1.2.2 Population Differences in Lung Cancer 
1.2.2.1 Differences by age 
Lung cancer is a disease that generally affects older adults; nearly 70% of diagnoses occur in 
patients aged 65 years or older.
2
 Furthermore, although the overall incidence of lung cancer in the 
United States decreased between 2000 and 2009, the incidence rate remained significantly higher in 
older adults and even increased among adults 75 years and older during this time period.
10
 In addition, 
despite overall improvement in lung cancer mortality over the last few decades, survival remains 
poorest among individuals diagnosed at age 75 and older.
10
  
Age differences in survival may be partly explained by age differences in the utilization of 
certain lung cancer treatments, such as chemotherapy and bevacizumab. Knowledge about the 
potential benefits and harms associated with various treatment options are generally derived from 
cancer clinical trials. However, older adults are often underrepresented in cancer clinical trials
11,12
 
limiting knowledge about the potential benefits and harms associated with various treatment options 
in these patients.  In some cases older adults do not have the opportunity to take part in clinical trials 
due to restrictions on age, functional ability, and/or comorbidities among participants.
13,14
 As a result, 
older adults who participate in clinical trials are more likely to be “fit” or healthy older patients. This 
is particularly concerning, as the overall health and performance status of patients within an age 
group can vary significantly and, thus, treatment outcomes among older trial participants may not be 
generalizable to sicker or more frail elderly patients. For example, older patients with good overall 
health may benefit from adjuvant chemotherapy, whereas older patients who are frail may have 
extreme difficulty tolerating such treatment and stand to gain little overall benefit from it. 
  The scarcity of information available to inform clinicians about the benefits and risks of 
therapies among both healthy and frail older adult patients can place significant uncertainty in the 
treatment decision process. Choosing to treat poorer functioning patients based on post-hoc analyses 
of healthier older adults may place sicker patients at unnecessary risk of treatment-related harm; not 
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treating poorer functioning patients based on the lack of safety and efficacy information may prevent 
patients from having a longer survival duration and/or better quality of life. Still, when evidence is 
available to support the use of certain treatments in select older lung cancer patients, chronological 
age remains a factor in determining whether patients receive guideline-recommended treatment; as a 
result, a significant proportion of older patients fail to receive more aggressive therapy from which 
they may benefit.
15
    
 
1.2.2.2 Differences by race 
Racial and ethnic disparities exist in the incidence, diagnosis, treatment, and outcomes 
associated with lung cancer in the U.S.
15-27
 The burden of disease is disproportionately greater for 
blacks who are more likely to be diagnosed with and die from lung cancer. Black men in particular 
have the highest incidence rates of lung cancer among all racial, ethnic and gender groups; despite a 
steady decline since the mid-1980s, the incidence rate of lung cancer among black men in 2007 was 
95.4 per 100,000 compared to a rate of 72.1 per 100,000 among white men.
2
 Conversely, the 
difference in incidence rates among women has historically been much smaller.  In 2007 the 
incidence rate of lung cancer among black women was 58.1 per 100,000 compared to a rate of 55.1 
per 100,000 among white women.
2
 Of note, the incidence rate of lung cancer among both men and 
women has traditionally been lowest among Hispanics who in 2007 had a combined incidence rate of 
29.3 per 100,000.
2
   
 Historical differences in the prevalence of cigarette smoking have likely contributed to the 
disparities in lung cancer incidence between white and black Americans. An analysis
28
 of the 
National Health Interview Survey (NHIS) from 1965 to 2008 showed that black males have been 
significantly more likely than white males to be smokers, but the difference in smoking prevalence 
has dramatically decreased over time. Black females were more also likely to be smokers than white 
females during the 1970s and 1980s, but that difference has been reversed. Other reasons behind 
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racial disparities in cancer incidence, although not entirely clear, are likely to include a combination 
of biological, environmental, and cultural influences including genetics, access to health care, and 
engagement in unhealthy behaviors that increase cancer risk.   
Differences in the receipt of lung cancer treatment across racial and ethnic groups are well 
documented in previous studies of both early and late stage disease.
15,17-20,25,27
 For example, in a recent 
study of patients with early-stage operable lung cancer, only 62 of 113 (55%) black patients chose 
surgery compared to 179 of 273 (66%) of white patients.
27
 Similarly, additional studies found that 
blacks are less likely than whites to receive radiation or chemotherapy for advanced stages of lung 
cancer and are also less likely to receive appropriate treatment in a timely manner.
15,18,20
  
Mortality from lung cancer remains highest among black patients, although the difference in 
lung cancer mortality between black and white patients has improved over the last two decades. 
Similar to observations in the incidence of lung cancer, the greatest difference in mortality rates is 
between black and white men; in 2007, the estimated mortality rate among black men was 82.7 per 
100,000 compared to a rate of 64.9 per 100,000 among white men.
2
 However, during the same time 
period, black women had a slightly lower mortality rate (39.2 per 100,000) compared to the rate 
among white women (41.1 per 100,000).
2
 Higher incidence rates of lung cancer directly contribute to 
the increased mortality seen among black men. Still, the higher rate of mortality is also partly 
attributable to smaller proportions of blacks presenting with curable stages of disease. Between 2003 
and 2007, only 12% of black males and 15% of black females presented with localized lung cancer 
compared to 15% of white males and 19% of white females.
2
   
 Underlying causes of the racial disparities seen in the treatment and mortality rates of lung 
cancer may be similar to those factors that contribute to disparities in the incidence of disease, 
particularly unequal access to and quality of care. Research has shown that when black patients 
receive treatment equal to that of non-black patients with similar prognoses, equal outcomes are 
observed.
29
 Unfortunately, research has also shown that treatment of lung cancer across racial and 
ethnic groups is hardly equal.
15,18,20,25,27
 Lower income and lack of insurance are significant 
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contributors to disparities in health care access and quality,
30
 and because a significant proportion of 
blacks are poor and/or uninsured, they are less likely to have access to quality health care.  In turn, we 
see the disproportionate rates of advanced disease at diagnosis, underutilization of available 
treatments, and worse survival outcomes in blacks as a result of poorer access to care.  Thus, 
socioeconomic status is likely to be an important determinant of access to and receipt of appropriate 
and/or novel treatment for lung cancer and therefore may help to explain some of the racial 
differences observed in treatment utilization and outcomes among lung cancer patients.  Finally, the 
unequal receipt of treatment among blacks may also be ascribed to differences in the rate of referral to 
oncologists, the availability of novel diagnostic technologies, poorer overall health, or the acceptance 
of treatment options by patients.
27,31-33
  
 
1.2.2.3 Differences by socioeconomic status 
Measures of socioeconomic status including education and income have been associated with 
lung cancer incidence,
34
 treatment,
35,36
 and survival outcomes.
35,37
  Adults with less education, lower 
household income, and greater poverty have a higher incidence of lung cancer compared to adults 
with greater educational attainment (e.g., college), higher household income, and less poverty.
34
 One 
probable explanation for the higher incidence of lung cancer among adults with lower socioeconomic 
status is an elevated rate of smoking in this population. Although differences in smoking prevalence 
have diminished over time, socioeconomic status still remains a significant predictor of smoking. A 
recent analysis
28
 of the NHIS found that Americans who had less than a high school education, were 
unemployed, or lived below the poverty threshold were significantly more likely to be smokers 
compared to individuals who at least graduated high school, were in the work force or retired, or lived 
above the poverty threshold.  
In addition to an increased incidence of lung cancer, socioeconomic status has also been 
associated with lower receipt of treatment
35,36
 and higher mortality,
35,37
 although evidence is 
 22 
inconsistent. Still, recent research found that patients of lower socioeconomic status, such as those 
enrolled in an indigent health plan, are less likely to receive standard treatment compared to patients 
of higher socioeconomic status who are treated within the same single academic medical center.
35
 
Similarly, a separate study found that lung cancer patients residing in census tract areas of low 
median household income, high poverty, and low education attainment have poorer survival 
outcomes than patients living in census tract areas with higher median income, lower poverty, and 
greater education attainment, even when patients receive treatment within the same academic health 
care system.
37
 However, these findings are contradicted by other research
38-40
 results that suggest lung 
cancer outcomes do not differ based on the socioeconomic status of patients. Thus, it is not clearly 
understood if and to what extent an association exists between socioeconomic status measures and 
lung cancer mortality. 
 
1.2.3 Provider-based Research Network Affiliation in Lung Cancer 
Patient access to novel treatments for lung cancer and the quality of care they receive may be 
influenced by where and from whom care is provided; provider affiliations with academic medical 
centers and comprehensive provider-based cancer research networks, including the National Cancer 
Institute’s (NCI) Community Clinical Oncology Program (CCOP) may promote earlier and more 
extensive use of new, advanced technology and interventions among patients. For example, previous 
research showed that lung cancer patients in the early to mid-1990s were more likely to be referred to 
an oncology specialist
31
 or treated with chemotherapy for metastatic disease
41
 if they received care 
from an academic medical center; the researchers proposed that diffusion of novel therapies into real-
world practice is greater in settings such as academic medical centers where providers are more likely 
to be exposed to or involved in the development of such treatments.          
Community-based physicians and provider groups not directly affiliated with large academic 
medical centers also have the opportunity to engage in the early use and development of novel 
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therapies through provider-based research networks like the CCOP. The CCOP assists in the 
dissemination and implementation of novel cancer care advancements through a research 
infrastructure that connects community-based physicians and provider groups with principal 
investigators and academic medical institutions.
42,43
 Community-based providers and provider groups 
participating in the CCOP gain access to clinical trials and research results concerning novel therapies 
and technological advancements that may not otherwise be accessible outside of the research 
network.
43
 An important motivating factor for participation, providers perceive involvement in the 
CCOP enables them to deliver higher quality of care to their patients by keeping them updated on 
state-of-the-art treatment.
44
 Indeed, research findings support that community-based physician 
participation in provider-based research networks results in increased patient accrual into clinical 
trials and enhanced adoption of novel cancer care, ultimately characterizing an effective translation 
between research and clinical practice.
45-48
 
 
1.2.4 Advanced Non-Small Cell Lung Cancer 
Lung cancer is divided into two major types based on microscopic evaluation of the size and 
appearance of malignant cells: small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC). Small cell lung cancer is strongly associated with smoking and is considered to be the 
more aggressive form of lung cancer, with greater potential for metastasis. SCLC comprises nearly 
13% of newly diagnosed lung cancers
49
 and patients typically present with distant spread of disease at 
diagnosis resulting in poor prognosis and survival.
50
 Non-small cell lung cancer (NSCLC) is the most 
common type of lung cancer, accounting for approximately 80% to 85% of all cases and includes 
adenocarcinoma, squamous cell, large cell, and not otherwise specified (NOS) histologies. Smoking 
is the greatest risk factor for the development of NSCLC, and a majority of patients have locally 
advanced or metastatic disease at the time they are diagnosed.
51
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Prognostic factors such as stage at diagnosis and the performance status (PS) of the patient 
can be predictive of survival in patients with NSCLC. Performance status of the patient is commonly 
measured using the Eastern Cooperative Oncology Group Performance Status scale (ECOG) which 
grades the functional ability of the patient and helps to determine whether patients are likely to 
tolerate and benefit from certain treatments, such as chemotherapy.
52
 Patients are graded on a scale of 
0 to 4, with 0 indicating that the patient is fully active and able to physically perform without 
restriction and 4 indicating that the patient is completely disabled and incapable of ambulation or self-
care. Prognostic factors that indicate improved survival in NSCLC include early stage at diagnosis, 
good performance status (Eastern Cooperative Oncology Group 0 or 1), less than 5% weight loss 
from baseline, and female gender.
53
 Age and histology subtype of NSCLC do not appear to 
significantly influence prognosis. However, histology can influence treatment choice and biomarkers 
such as the epidermal growth factor receptor (EGFR) and the k-ras oncogene may have important 
predictive value for treatment response and/or prognosis and survival.
54
 
Platinum-based doublet chemotherapy containing either carboplatin or cisplatin is considered 
the standard treatment option for most patients with advanced stage NSCLC. Platinum-based doublet 
regimens lessen cancer-related symptoms, prolong survival, and improve quality of life.
55
 However, 
the survival benefit of standard chemotherapy remains poor. Median time to tumor progression with 
platinum-based chemotherapy is approximately 4-5 months while median overall survival duration is 
approximately 8-11 months; further, 1-year survival with standard treatment is less than 50% and 2-
year survival is less than 20%.
3,4
 Scientific and clinical progression in understanding the pathogenesis 
of cancerous tumors as well as the  need to improve upon the survival benefits of standard platinum-
based chemotherapy in the treatment of advanced NSCLC guided the development of novel, targeted 
therapies, including bevacizumab. 
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1.2.5 Bevacizumab in Advanced Non-Small Cell Lung Cancer 
Bevacizumab, a humanized monoclonal antibody that inhibits angiogenesis and tumor growth 
by targeting the vascular endothelial growth factor (VEGF) in tumors, is currently the only 
monoclonal antibody approved by the FDA for the first-line treatment of advanced NSCLC. Based on 
improvements in response rate, progression-free survival, and overall survival during clinical trials, 
bevacizumab is specifically approved for use in combination with carboplatin-paclitaxel 
chemotherapy as first-line treatment of patients with advanced stage non-squamous NSCLC;
56,57
 use 
of bevacizumab is restricted to patients with non-squamous histology due to a prohibitive rate of life-
threatening or fatal pulmonary hemorrhage in patients with squamous histology tumors.
57
  
Knowledge about the efficacy and safety of bevacizumab in treating advanced NSCLC is 
largely based on the results of several clinical trials. However, information about the use of 
bevacizumab and its potential benefits or safety concerns among specific subpopulations of interest 
including older adults, racial minority patients, and patients of lower socioeconomic status is limited. 
Subgroup analyses
5,6
 of older clinical trial participants have found that the addition of bevacizumab to 
platinum-based doublet chemotherapy improves progression-free survival among older adults, but 
does not appear to significantly improve overall survival; in addition, the use of bevacizumab may 
increase the risk of treatment-related harms among older patients, although this potential association 
remains questionable as subgroup analyses yielded conflicting results. However, results of subgroup 
analyses must be interpreted cautiously as older clinical trial participants are typically “fit” or 
otherwise healthy individuals with greater functional ability than sicker or frailer elderly adults; 
treatment outcomes among older trial participants may not be representative of expected outcomes in 
the general population of older adults with advanced NSCLC. Nevertheless, findings from a recent 
observational study
7
also suggest that the addition of bevacizumab to carboplatin-paclitaxel 
chemotherapy is ineffective in improving overall survival among Medicare beneficiaries with 
advanced NSCLC treated in the real-world setting.  
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Although subgroup analyses of older clinical trial participants and an observational study of 
Medicare beneficiaries provide some level of knowledge about the safety and effectiveness of 
bevacizumab among older adults with advanced NSCLC, there is a significant absence of information 
on whether treatment outcomes with bevacizumab vary across racial or socioeconomic groups. For 
example, overall survival results among ECOG 4599 clinical trial participants receiving carboplatin-
paclitaxel with or without bevacizumab suggest that both white and black participants benefit from 
the use of bevacizumab; however, as blacks only made up approximately 5% of the total clinical trial 
sample, their underrepresentation significantly limited any comparison of treatment effectiveness 
between racial groups.
56
 Similarly, the infrequent inclusion of socioeconomic measures in clinical 
trials and the scarcity of observational studies on bevacizumab in NSCLC contribute to the absence of 
information on the potential associations between bevacizumab outcomes and socioeconomic status.   
 
1.3 Significance 
Lung cancer is a significant burden to public health in the United States, particularly among 
older adults who make up the majority of annual lung cancer diagnoses. Older adults typically present 
with advanced stage disease, are less likely to receive definitive treatment, and have poorer survival 
outcomes compared to younger patients. Similarly, blacks are also disproportionately affected by lung 
cancer. Blacks are more likely to develop lung cancer, present with advanced stages of disease, and 
die from lung cancer compared to members of all other races and ethnicities in the US. Furthermore, 
although research indicates that equal outcomes are observed when treatment of lung cancer is similar 
across various racial and ethnic groups,
17,19,24,29,58-64
 racial disparities in the receipt of lung cancer 
treatment and subsequent outcomes continue to exist. In addition, although evidence is significantly 
limited, socioeconomically disadvantaged patients are less likely to receive standard care
35
 and have 
poorer survival outcomes
35,37
 than patients of higher socioeconomic status. Lastly, participation in 
provider-based research networks such as the CCOP has been associated with provider adoption of 
 27 
novel therapies and greater utilization of these state-of-the-art treatments among community-treated 
patients.
45-48
 Together these research findings suggest that patient and health system characteristics 
are important determinants of patient access to, receipt of, and benefits from available treatments.   
Bevacizumab, a novel targeted therapy used in combination with standard platinum-based 
doublet chemotherapy, provides an additional treatment option for select patients with advanced 
NSCLC. However, the effectiveness and safety of bevacizumab in the treatment of advanced non-
small cell lung cancer in the broader population of patients is limited, especially among older adults 
and patients of racial minority and lower socioeconomic backgrounds. Results from a recent 
observational study concur with subgroup analyses of older clinical trial participants suggesting that 
the addition of bevacizumab to platinum-based chemotherapy does not yield a significant overall 
survival benefit in older patients. Nevertheless, this observational study restricted its analysis of 
bevacizumab to older patients specifically treated with carboplatin-paclitaxel chemotherapy. 
Including older patients treated with other platinum-based chemotherapy regimens that are standard 
of care in advanced NSCLC would allow for more complete capture of the utilization of 
bevacizumab. In turn, greater capture of bevacizumab utilization may permit the assessment and 
increased understanding of the safety and effectiveness of bevacizumab in a broader population of 
older patients with advanced NSCLC, including patients of different racial and socioeconomic 
backgrounds.  
Given that previous research has identified disparities in the receipt of traditional lung cancer 
treatments among older adults, patients of minority race, and socioeconomically disadvantaged 
patients, it is important to understand if the same differences exist in the use of newer therapies such 
as bevacizumab. In addition, it is imperative to determine whether bevacizumab is beneficial when 
administered to older patients in the larger NSCLC population. Recognition of patient and health 
system characteristics associated with the utilization, safety, and effectiveness of bevacizumab will 
help clinicians, policy makers, and other researchers improve dissemination of information, patient-
provider communication about treatment decisions, and increase access to novel therapies for all 
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cancer patients in order to minimize differences in treatment utilization and outcomes. Therefore, the 
overall objectives of this study are to identify patient and health system characteristics associated with 
the use of bevacizumab and to evaluate the effectiveness and safety of bevacizumab in older patients 
with advanced NSCLC. 
 To address the objectives of this study, we used the Surveillance, Epidemiology and End 
Results (SEER)-Medicare linked database available through a collaborative effort between the 
National Cancer Institute (NCI) and the Centers for Medicare and Medicaid Services (CMS). Briefly, 
the SEER Program of the NCI is a coordinated system of 17 distinct population-based cancer 
registries strategically distributed throughout the United States to represent approximately 28 percent 
of the US population and is the only comprehensive population-based source in the country that 
contains data on stage at diagnosis and patient survival.  SEER registries collect data on patient 
demographics, primary tumor site, tumor morphology and stage at diagnosis, first course of treatment, 
and follow-up for vital status. For eligible patients enrolled in fee-for-service coverage for Medicare 
Parts A and B, all Medicare claims for covered healthcare services provided during patient Medicare 
eligibility are linked to SEER data. For our study, we used SEER-Medicare data that included all 
locally advanced and metastatic non-small cell lung cancer cases diagnosed between January 1, 2004 
and December 31, 2007 as well as all Medicare fee-for-service claims for each patient starting 12 
months prior to the date of diagnosis (as early as January 1, 2003) through the end of 2009.  
 
1.4 Specific Aims and Hypotheses 
 Assessing the utilization of bevacizumab and the resultant treatment effects among older 
adults with advanced non-small cell lung cancer will provide crucial evidence regarding potential 
sociodemographic differences in the use of novel cancer treatments as well as the utility of 
bevacizumab in treating older adults with advanced non-small cell lung cancer. These important 
issues will be addressed by the following research aims: 
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Aim 1: To describe the utilization of bevacizumab in combination with standard 
platinum-based doublet chemotherapy as first line treatment for older adults with advanced 
non-small cell lung cancer and to identify the clinical, sociodemographic, and health system 
factors associated with its use. 
 Bevacizumab is a monoclonal antibody approved in the United States in combination with 
carboplatin and paclitaxel chemotherapy for the first-line treatment of patients with unresectable, 
locally advanced or metastatic nonsquamous non-small cell lung cancer. The following hypotheses 
will be tested in Aim 1:  
 H1: Among older adults with a primary diagnosis of advanced nonsquamous non-small cell 
lung cancer, non-white patients are significantly less likely than white patients to receive 
bevacizumab in combination with standard platinum-based doublet chemotherapy. 
 H2: Among older adults with advanced non-small cell lung cancer, patients of lower 
socioeconomic status are significantly less likely than patients of higher socioeconomic status to 
receive bevacizumab in combination with standard platinum-based doublet chemotherapy.   
 H3: Among older adults with advanced non-small cell lung cancer, patients 70 years or older 
are significantly less likely than patients 66 to 69 years of age to receive bevacizumab in combination 
with standard platinum-based doublet chemotherapy. 
 H4: Among older adults with advanced non-small cell lung cancer, patients who receive 
treatment from a provider affiliated with the National Cancer Institute (NCI) Community Clinical 
Oncology Program (CCOP) are significantly more likely to receive bevacizumab in combination with 
standard platinum-based doublet chemotherapy compared to patients who receive treatment from 
non-CCOP-affiliated providers. 
 
 Aim 2: To determine whether the use of bevacizumab in combination with standard 
platinum-based doublet chemotherapy as first-line treatment of older adults with advanced 
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non-small cell lung cancer is associated with a benefit of improved overall survival. 
 The following hypothesis will be tested under Aim 2: 
 H5: Among older adults with advanced non-small cell lung cancer, patients who receive 
bevacizumab in combination with standard platinum-based doublet chemotherapy as first line 
treatment do not have significantly improved overall survival compared to patients receiving standard 
platinum-based doublet chemotherapy only. 
 
 Aim 3: To determine whether the use of bevacizumab in combination with standard 
platinum-based doublet chemotherapy as first-line treatment of older adults with advanced 
non-small cell lung cancer is associated with an increase in hospitalizations for severe 
treatment-related adverse events.  
 The following hypothesis will be tested under Aim 3: 
 H6: Among older adults with advanced non-small cell lung cancer, patients who receive 
bevacizumab in combination with standard platinum-based doublet chemotherapy as first line 
treatment have a significantly greater incidence of severe adverse events (i.e., neutropenia, 
gastrointestinal perforation, or severe hemorrhage) resulting in hospitalization compared to patients 
receiving standard platinum-based doublet chemotherapy only.  
 
1.5 Summary 
Lung cancer primarily occurs among older adults over the age of 65 and the majority of 
patients with newly diagnosed non-small cell lung cancer present with advanced stage disease.  
Although there is no cure, platinum-based doublet chemotherapy is the standard of treatment for 
patients with advanced stage disease and has been shown to improve both survival and quality of 
life.
55
 The addition of bevacizumab to platinum-based double agent chemotherapy has further 
improved response to treatment and overall survival in advanced non-small cell lung cancer 
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patients.
65
  However, retrospective subgroup analyses
5,6
 of elderly trial participants and results of a 
recent observational study
7
 of Medicare beneficiaries found no overall survival benefit with the 
addition of bevacizumab to platinum-based doublet chemotherapy, suggesting that bevacizumab may 
not be effective in prolonging survival among older patients. Furthermore, knowledge about the 
benefits and harms of adding bevacizumab to standard platinum-based chemotherapy among minority 
or socioeconomically disadvantaged patients is limited as minority patients are often 
underrepresented in clinical trials; this is particularly concerning as lung cancer incidence and 
mortality is disproportionately higher among blacks. Clearly additional research is needed to delineate 
whether the utilization of bevacizumab in combination with standard platinum-based doublet 
chemotherapy differs by age, race, socioeconomic status, or health system factors such as provider 
affiliation with community-based research networks. In addition, further research within a broader 
population of older patients is essential to verify previous associations between bevacizumab and 
overall survival and to determine if this association differs across age, race, or socioeconomic groups. 
Lastly, an assessment of the relationship between the use of bevacizumab and hospitalization for 
severe adverse events is needed; determining whether any potential association differs by age, race, or 
socioeconomic status would provide valuable information about the safety of bevacizumab and 
identification of patients who may be at greater risk for harms with its use.     
This study evaluated the utilization, safety, and effectiveness of bevacizumab among older 
adults with advanced non-small cell lung cancer using SEER-Medicare data for incident cases 
diagnosed between 2004 and 2007.  In particular, the study assessed whether the use of bevacizumab 
varied according to chronological age, race, socioeconomic status, or provider affiliation with the 
CCOP, a provider-based research network.  Detection of differences in the use of bevacizumab across 
age, race, socioeconomic status, or provider affiliation with the CCOP in this study will support the 
need for future research to identify why variations exist. Chronological age as a determinant of 
bevacizumab use independent of relevant clinical factors may result due to the scarcity of information 
available to clinicians to make sound risk-benefit assessments and treatment decisions with older 
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patients. Physician bias toward older adults or patient willingness to accept treatment may also 
influence the use of bevacizumab among older adults.  Similarly, physician and patient characteristics 
may explain differences in the use of bevacizumab across racial groups. Understanding reasons 
behind age, race, and socioeconomic differences in the use of bevacizumab will in turn help to guide 
future policy development. For example, identifying generational, cultural and linguistic barriers 
between patients and physicians can assist in developing policies to improve cultural competence 
among clinicians, patient-provider communication strategies, and informational resources available to 
patients. Furthermore, association between the use of bevacizumab and provider affiliation with the 
CCOP may better inform clinicians and policymakers as to the effectiveness of provider-based 
research networks in rapidly disseminating clinical trial information into the community setting as 
well as promoting the quick diffusion of novel, evidence-based treatments into community practice.  
Identification of significantly improved overall survival and similar incidence rates of 
hospitalization for severe adverse event outcomes with the addition of bevacizumab to standard 
platinum-based doublet chemotherapy will demonstrate the utility of bevacizumab among older adults 
and will also have important research and policy implications.  For example, future research may be 
warranted to delineate clinical or genetic characteristics of older patients to help understand why 
survival or adverse event outcomes differ.  Also, recognition of age differences in survival or adverse 
event outcomes associated with bevacizumab will encourage the development of policies to improve 
the availability and completeness of clinical information for treatment decision making.  For example, 
better recruitment and inclusion of older adults and minority patients in clinical trials of novel cancer 
therapies along with improvements in the speed, breadth, and efficiency at which trial results are 
disseminated may enhance the ability and confidence of physicians in communicating treatment 
options with patients and making sound clinical decisions.  
 
 
  
CHAPTER TWO 
 LITERATURE REVIEW 
 
2.1 Non-Small Cell Lung Cancer: Disease and Management 
2.1.1 Risk Factors of Non-Small Cell Lung Cancer 
 A number of lifestyle and environmental risk factors contribute to the incidence of lung 
cancer. However, smoking is clearly the single most important risk factor for the development of lung 
cancer and is responsible for approximately 90% of lung cancer cases in the United States. Smoking 
leads to the development of lung cancer by producing mutations in tumor suppressor genes and 
dominant oncogenes and by impairing mucociliary clearance in the lungs and inhibiting the 
responsiveness of the immune system.
66
 The risk of lung cancer for current smokers is approximately 
10 to 20 times the risk of lung cancer for persons who have never smoked.
67
  In addition, the risk of 
developing lung cancer among smokers increases with the number of cigarettes and the duration of 
smoking.  Conversely, quitting smoking gradually reduces the risk of developing lung cancer up to 
the point where the risk remains about twice that of someone who never smoked.
68
  
 Researchers have estimated that up to 60% of patients are current smokers at the time of 
diagnosis and over 80% of them continue to smoke following the detection of lung cancer.
69
  These 
estimates are concerning considering that continued smoking has been associated with an increased 
risk of developing second primary lung cancer and an increased risk of dying.
70,71
 Furthermore, 
research suggests that continued smoking following the diagnosis of cancer may impair the 
effectiveness and/or worsen the adverse effects of treatment.
72,73
  On the other hand, lung cancer 
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patients who quit smoking after their diagnosis have improved oxygenation and immune response, 
increased fatigue and shortness of breath, and improved performance status, appetite, and mood.
74-76
 
In addition to improving the quality of life for patients, smoking cessation has been associated with 
increased survival time.
71,77
 Thus, successful smoking cessation is a critical component in reducing 
the risk of lung cancer among smokers and in maximizing survival and the quality of life in lung 
cancer patients.  
 Although smoking is the predominant risk factor in most cases, lung cancer is still a 
significant health concern among individuals who have never smoked.
78
  Lung cancer in persons who 
have never smoked appears to occur more often in women compared to men, particularly in Asia 
where as much as 80 percent of women with lung cancer are never smokers compared to only 10 to 
15 percent of men.
79,80
  In contrast, Wakelee et al. estimated that 19 percent of women with lung 
cancer in the United States are never smokers versus just 9 percent of men.
79
  Thus, although the 
evidence is not as well established, it is apparent that a number of risk factors other than smoking 
contribute to the development of lung cancer in a noticeable proportion of patients.  Of these other 
risk factors, those more commonly associated with lung cancer include the environmental toxins 
second-hand smoke, asbestos, and radon gas.
67
  In addition, individuals with pulmonary fibrosis, HIV 
infection, a family history of lung cancer or specific genetic markers may also be at an increased risk 
of developing lung cancer, particularly if they are also smokers.
81-84
  Still, the extent to which these 
other risk factors contribute to the development of lung cancer either in addition to or independent of 
smoking needs to be clarified.  
 
2.1.2 Symptoms of Non-Small Cell Lung Cancer 
 Early detection of lung cancer is difficult as pulmonary tumors are often asymptomatic during 
early stages of development.
85
 Detection of early stage disease is also challenged by the lack of an 
effective screening method that has been shown to significantly reduce mortality from lung cancer. 
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Furthermore, signs of lung cancer are similar to those of other respiratory diseases common to 
smokers including chronic obstructive pulmonary disease (COPD) and pneumonia.  For example, 
both lung cancer and COPD may involve symptoms related to respiratory distress, such as cough and 
hemoptysis, as well as non-specific symptoms, such as fatigue and weight loss.  Thus, even if 
symptoms of lung cancer are present at an early stage of disease, they may be difficult to distinguish 
from complications of other respiratory diseases, particularly if lung cancer is not suspected to begin 
with.  In addition, there is often a delay between the time when symptoms first present and the time 
when patients seek out medical care and receive treatment from a physician, further decreasing the 
likelihood of discovering lung cancer at an early stage of development.
86,87
  
 The symptoms present at diagnosis may include symptoms related to the primary tumor in the 
lung as well as non-specific symptoms that indicate the tumor has spread beyond the pulmonary 
cavity.
88
 Common symptoms include those related to the primary tumor and respiratory distress such 
as cough, difficulty breathing, chest pain, and hemoptysis.
85,88
 Cough is the most common symptom 
of lung cancer and often occurs along with difficulty breathing and increasing amounts of sputum that 
may even contain traces of blood; although hemoptysis is also common, it is rarely severe in lung 
cancer and therefore may not always be a tell-tale sign of malignancy.
88
 In patients with COPD, 
difficulty resolving acute exacerbations of the disease may also signify the presence of a tumor.
88
   
 Other respiratory related symptoms may occur as a result of the cancer extending within the 
chest area.  Intrathoracic spread of a tumor may lead to: laryngeal nerve damage resulting in 
hoarseness, poor expectoration, and increased risk of aspiration; persistent and dull chest pain 
unrelated to coughing or breathing; and the buildup of fluid around the lungs that leads to shortness of 
breath.
88
 Furthermore, the spread of lung cancer to common sites of distant metastases including the 
bones, liver and brain can result in the presence of non-specific systemic symptoms such as bone 
pain, weakness, fatigue, anorexia, weight loss, headache, confusion, and nausea and vomiting.
88
      
 Given the apparent association of constitutional symptoms with advanced stages of disease, 
previous research has examined the relationship between the types of symptoms present during 
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examination and prognosis.
89,90
 Prognosis was poorest among patients with non-specific systemic 
symptoms such as weight loss and fatigue or symptoms attributable to metastases such as bone pain. 
Furthermore, within each tumor stage, the presence of systemic symptoms was associated with a 
declining prognosis, suggesting the presence of extensive disease.
88
 Conversely, prognosis was most 
favorable among patients who were asymptomatic or presented with symptoms related to the primary 
tumor only.  Additional research further confirmed the association between non-specific symptoms 
and advanced disease by finding that abnormal clinical presentations were associated with evidence 
of metastatic disease upon radiographic evaluation and CT scans; patients without non-specific 
systemic symptoms at presentation were highly unlikely to have metastases detected.
91
 As a result of 
these findings, it has since been recommended that patients with known or suspected lung cancer 
receive timely and efficient care that includes a thorough medical history, physical examination, and 
standard laboratory tests in order to effectively identify patients with a greater likelihood of metastatic 
disease.
88
  
 
2.1.3 Diagnosis and Staging of Non-Small Cell Lung Cancer 
 Diagnosis of non-small cell lung cancer in a patient suspected of having the disease is 
dependent on a complete detailed history and examination of the patient that serves to identify signs 
and symptoms associated with extensive or metastatic disease, significant comorbid conditions, and 
assess pulmonary and overall health status.  These assessments, in turn, help determine what course 
of therapy is likely to be most effective and tolerated by the patient.  In addition to a complete history 
and physical examination, common tests performed to assist in the diagnosis and staging of non-small 
cell lung cancer include laboratory tests, radiographic imaging, and tissue sampling.  Laboratory tests 
are conducted to identify abnormalities that may suggest the presence of advanced or metastatic 
disease such as elevated liver enzymes, calcium, alkaline phosphatase, and anemia. Contrast-
enhanced computed tomography (CT) is useful for staging as it can illustrate the size of a tumor and 
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where it is located in relationship to the chest wall and other mediastinal structures; CT can also 
identify lymph nodes and other lesions that suggest metastasis.  Additional imaging methods such as 
positron emission tomography (PET) and contrast-enhanced magnetic resonance imaging (MRI) may 
also be used to further evaluate and detect suspected malignant tumors and metastases.  Further, 
abnormal imaging findings are then followed up and confirmed with histopathologic results from 
tissue samples of the primary tumor or lymph nodes that can be obtained by needle aspiration, biopsy 
or surgical procedures; noninvasive techniques alone are not enough to confirm a diagnosis or 
accurately determine the stage of the disease.
92
    
 Staging of non-small cell lung cancer is essential in determining the prognosis and 
appropriate course of treatment and can be divided into two components, clinical staging and 
pathologic staging. Clinical staging is done initially and occurs following the completion of the 
medical history, physical examination, laboratory testing, imaging, and tissue sampling.  Pathologic 
staging combines clinical staging information with histopathologic data collected during pathologist 
evaluation of a resected tumor; in some cases, the determined stage of the cancer changes following 
pathologic evaluation which can then alter the prognosis and course of treatment. Both clinical and 
pathologic staging are based upon the tumor node metastasis (TNM) staging system for non-small 
cell lung cancer (NSCLC). The TNM staging system grades the characteristics of the primary tumor 
such as size (T), involvement of regional or distant lymph nodes (N), and the presence or absence of 
distant metastasis (M). The combination of the T, N, and M grades determine the overall disease stage 
that is then used to determine prognosis and assist in deciding the appropriate treatment options.
92
 
Since the 7the edition of the TNM staging system recently went into effect in January of 2010, the 6
th
 
edition will be used for this study. 
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2.1.4 Treatment of Advanced Non-Small Cell Lung Cancer 
2.1.4.1 Evaluation of performance status and the comprehensive geriatric assessment 
 The prognosis and management of non-small cell lung cancer are largely dependent on the 
stage of disease at the time of diagnosis.  However, the performance status (PS) of the patient and the 
presence of other comorbid conditions can have an important influence on the selection of treatment 
and the projected outcome of the disease. As may be expected, patients with poor performance status 
and significant weight loss often have shortened survival.
93,94
 Furthermore, older adults are more 
likely than younger patients to have comorbid conditions and age associated physiologic changes that 
can contribute to greater frailty, poorer performance status, and limit the tolerability and benefits of 
aggressive treatment. However, given the large heterogeneity in comorbid conditions and 
performance status among patients of the same age, chronologic age alone is not enough to determine 
whether a patient will benefit or tolerate a specific treatment. As a result, clinicians have developed 
the comprehensive geriatric assessment (CGA) to use as part of the baseline evaluation of older adults 
with cancer. The CGA, in addition to providing a more comprehensive appraisal of the functional 
status of older patients,
95
 evaluates cognitive functioning, nutrition, comorbidity, mental well-being, 
and social support.  Each component of the CGA provides additional information that can be used to 
identify potential complications of treatment, predict survival, improve mental health, and effectively 
manage pain in older patients.
96
 Furthermore, recent studies have shown that the utilization of a brief, 
self-administered questionnaire consisting of the measures of geriatric assessment is feasible, well 
accepted by patients, and reliable in both clinical practice and clinical trial settings.
97,98
  
 
2.1.4.2 Surgery 
 Although surgical resection provides the best chance for long-term survival and is the 
standard of care for patients with stage I and II non-small cell lung cancer,
99
 surgical resection is 
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rarely indicated for advanced stages of disease. However, other surgical procedures may be 
performed among patients who have stage IIIB tumors with pleural effusion and among certain 
patients with solitary brain metastases.   
 Among patients with pleural effusion, fluid collects in the pleural space between the lungs 
and chest wall, prohibiting the lungs from fully expanding and leading to shortness of breath.  To 
remove the fluid from the pleural cavity and relieve related symptoms, a physician may perform one 
or more of the following options: thoracentesis, tunneled catheter placement, or pleurodesis. 
Thoracentesis is the simplest method to treat pleural effusion, and involves the insertion of a small 
catheter into the pleural space to allow the fluid to drain out.
100
 For patients who experience rapid 
fluid accumulation following thoracentesis, more aggressive measures may be necessary, including 
the placement of a tunneled catheter or pleurodesis. The tunneled catheter is similar to thoracentesis 
except that the catheter is left in the pleural space and connected to a container and hand pump, 
allowing fluid accumulation to be managed on a daily basis.
100
 Pleurodesis is a more invasive 
treatment option in which a chemical irritant (e.g., talcum powder) is placed into the pleural space 
following fluid drainage; the membranes lining the lungs and chest wall become inflamed and attach 
to one another, closing off the pleural space and thereby preventing further fluid accumulation.  
 Brain metastases are associated with poor prognosis and quality of life and appear within one 
year of diagnosis in up to half of all patients with non-small cell lung cancer.
101
 Among patients with 
a solitary brain metastasis, surgical removal is the standard of care and has been shown to prolong 
survival and prevent recurrent metastases in the brain.
102,103
 However, only 14-44% of brain 
metastases are resectable
104
 and there is no evidence to support the use of surgery among patients with 
multiple brain metastases.
105
 Instead, two distinct radiation treatments are commonly used to manage 
multiple or unresectable brain metastases and these methods are described below.    
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2.1.4.3 Radiation therapy 
 Radiation therapy (RT) may be used in advanced non-small cell lung cancer to treat brain 
metastases and also to manage symptoms in the palliative care setting.  Two distinct radiation 
therapies, whole-brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS), have been used in 
the treatment of brain metastases. When these therapies are used alone, median survival may be 
prolonged 3-5 months with WBRT
106
 and approximately 9 months with SRS.
107
 However, when 
WBRT is combined with SRS, control of brain disease is significantly improved and survival can be 
prolonged up to 11 months.
108
 Still, recent concerns that WBRT may significantly impair learning and 
memory function
109
 may lead to greater use of SRS as a single modality, particularly if 
neurocognitive function can be maintained and survival rates comparable to combined treatment can 
be achieved.
104
   
 In patients with stage IV NSCLC, radiation therapy can also be used to manage symptoms 
brought about by localized and distant metastatic disease (e.g., dyspnea, hemoptysis, and bone 
pain).
110
 However, the duration and dose of RT to be used in the palliative setting is unclear and may 
be dependent on the performance status and prognosis of the patient. For example, a recent review 
found that both higher and lower doses of RT were effective in reducing symptoms, but higher doses 
were associated with significant increases in both survival and toxicity.
111
 Furthermore, stereotactic 
body radiation therapy that delivers high doses of radiation to a precise target in the body may be 
useful in the palliative care setting, particularly among older adults who otherwise may not receive or 
tolerate standard radiation therapy.
112
  
 
2.1.4.4 Chemotherapy 
 The American Society of Clinical Oncology (ASCO) guideline
55
 recommends the use of first-
line chemotherapy among patients with advanced non-small cell lung cancer (stage IIIB with pleural 
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effusion and stage IV) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 
0, 1, and possibly 2.  A meta-anlysis
113
 that evaluated the benefit of adding another cytotoxic agent to 
a single- or double-agent chemotherapy regimen found that the use of two cytotoxic drugs as first-line 
treatment significantly improves overall survival and is preferred over the use of a single cytotoxic 
agent.
55
  However, because the addition of a third cytotoxic agent does not provide further survival 
benefit beyond the use of double-agent chemotherapy and is associated with significantly greater 
toxicity,
113-116
 the concurrent use of three cytotoxic drugs is not recommended.
55
  
 Chemotherapy combinations that may be used to treat advanced non-small cell lung cancer 
are included in Table 2.1. Generally, chemotherapy combinations are divided into platinum-based and 
non-platinum combinations.  Current platinum-based doublet regimens typically include the use of 
cisplatin or carboplatin along with one of the following “third-generation” agents: paclitaxel, 
gemcitabine, docetaxel, vinorelbine, irinotecan or pemetrexed.  In addition, common non-platinum 
regimens that may be used include gemcitabine plus docetaxel, paclitaxel, pemetrexed or vinorelbine 
and paclitaxel plus vinorelbine.  Regimens may vary by administration frequency and schedule, but 
current recommendations for the duration of treatment suggest that no more than six cycles of any 
double-agent chemotherapy should be administered.
55
 The administration of first-line treatment 
beyond four to six cycles provides no overall survival advantage and may increase the risk for toxic 
effects.
117-120
  
 
Table 2.1 Chemotherapy regimens used for advanced non-small cell lung cancer 
Platinum-based regimen Possible administration schedule and frequency
a 
Carboplatin (or cisplatin) & paclitaxel Platinum agent & paclitaxel: Administer on Day 1; 
 Repeat every 3 weeks (21 days) for max of 6 cycles 
Carboplatin (or cisplatin) & docetaxel Platinum agent & docetaxel: Administer on Day 1; 
 Repeat every 3 weeks (21 days) for max of 6 cycles 
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Table 2.1 (continued) 
Carboplatin (or cisplatin) & pemetrexed Platinum agent & pemetrexed: Administer on Day 1; 
 Repeat every 3 weeks (21 days) for max of 6 cycles 
Carboplatin (or cisplatin) & gemcitabine Platinum agent: Administer on Day 1; 
 Gemcitabine: Administer on Days 1 and 8; 
 Repeat every 3 weeks (21 days) for max of 6 cycles 
Carboplatin (or cisplatin) & vinorelbine Platinum agent: Administer on Day 1; 
 Vinorelbine: Administer on Days 1 and 8; 
 Repeat every 3 weeks (21 days) for max of 6 cycles 
Non-platinum-based regimen 
Gemcitabine & paclitaxel Gemcitabine: Administer on Days 1 and 8; 
 Paclitaxel: Administer on Day 8; 
 Repeat every 3 weeks (21 days) for max 6 cycles 
Gemcitabine & docetaxel Gemcitabine: Administer on Days 1 and 8; 
 Docetaxel: Administer on Day 8; 
 Repeat every 3 weeks (21 days) for max 6 cycles 
Gemcitabine & pemetrexed Gemcitabine: Administer on Days 1 and 8; 
 Pemetrexed: Administer on Day 8; 
 Repeat every 3 weeks (21 days) for max 6 cycles 
Gemcitabine & vinorelbine Gemcitabine/vinorelbine: Administer on Days 1 and 8; 
 Repeat every 3 weeks (21 days) for max 6 cycles 
Paclitaxel & vinorelbine Paclitaxel/vinorelbine: Administer on Day 1; 
 Repeat every 2 weeks (14 days) for max 9 cycles 
a
The dosing schedules and frequencies presented in the table represent those that have been used in phase III 
randomized trials of each regimen. Actual schedules and frequencies used in clinically practice may differ from 
those described in the table. 
 
 Although multiple chemotherapy combinations are beneficial in advanced non-small cell lung 
cancer, platinum-based regimens with cisplatin or carboplatin are preferred based on better response 
rates and prolonged overall survival compared to non-platinum-based regimens.
55
 However, no one 
single platinum-based regimen stands out as the superior treatment option in advanced non-small cell 
lung cancer.
55
 In addition, there is little convincing evidence to support the use of either platinum 
agent (carboplatin or cisplatin) over the other. A meta-analysis
121
 of nine randomized trials comparing 
carboplatin- to cisplatin-based regimens found that patients treated with carboplatin had a lower 
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response rate (24% vs. 30%), slight increase in hazard of mortality (hazard ratio [HR] = 1.07; 95% CI 
0.99-1.15), and greater thrombocytopenia (12% vs. 6%; OR = 2.27; 95% CI 1.71-3.01) compared to 
patients treated with cisplatin. However, patients who received carboplatin were less likely to have 
nausea and vomiting (8% vs. 18%; OR = .42; 95% CI 0.33-0.53) or nephrotoxic effects (0.5% vs. 
1.5%; OR = 0.37; 95% CI 0.15-0.88) compared to patients who received cisplatin.  Thus, when 
making treatment decisions between carboplatin and cisplatin, physicians and patients may consider 
the potential tradeoff between efficacy and adverse effects.  Given the relatively small survival 
benefit and lower tolerability profile of cisplatin, carboplatin may be used more often in advanced 
stage non-small cell lung cancer where the intent of treatment is to manage symptoms and maximize 
quality of life.
122
   
 Furthermore, the small improvements in survival seen with regimens that utilize either of the 
platinum agents may not outweigh increases in toxicity for some patients.  For example, a meta-
analysis comparing platinum-based and non-platinum regimens found a slight improvement in 1-year 
survival (34% vs. 29%) as well as significantly greater hematologic toxicity, nephrotoxicity, and 
gastrointestinal complications with the use of platinum-based chemotherapy.
123
 Therefore, non-
platinum chemotherapy regimens may be appropriate alternatives for patients who may not tolerate or 
have contraindications (e.g., poor renal function or allergy to platinum agents) to platinum-based 
treatment.      
 The appropriate use of chemotherapy in elderly patients and patients with a PS of 2 is not 
well delineated.  Some elderly patients and patients with a PS of 2 may have difficulty tolerating 
either platinum-based or non-platinum double-agent chemotherapy regimens.  In addition, the 
concern for greater toxicity and the exclusion or underrepresentation of these patients from 
randomized trials has inhibited our ability to reveal the benefit of combination therapy among elderly 
patients and patients with a PS of 2 to some degree.  Furthermore, comparisons of double-agent and 
single-agent regimens in elderly patients and patients with a PS of 2 have found mixed results; two 
trials
124,125
 did not find any additional benefit in overall survival with double-agent therapy among 
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elderly patients and patients with a PS of 2, while another trial
126
 found that the survival benefit from 
combination therapy was similar between older and younger patients.  Given the previous lack of 
consistent evidence, data from trials supported the use of single-agent chemotherapy for elderly 
patients and patients with a PS of 2, but was insufficient to recommend for or against the use of 
double-agent chemotherapy.
55
 Subgroup analyses of several additional trials
127
 have shown that fit 
elderly patients are able to tolerate and benefit from platinum-based and non-platinum doublet 
chemotherapy regimens. In addition, a recent prospective open-label trial of patients 70 years and 
older found a significant survival advantage with carboplatin and weekly paclitaxel doublet 
chemotherapy with compared to gemcitabine or vinorelbine monotherapy, suggesting the standard 
treatment of older patients should be reconsidered.
128
  
 Tumor histology may also be an important consideration for treatment selection and efficacy. 
In a phase III study
4,129
 that randomized advanced non-small cell lung cancer patients to either 
cisplatin with pemetrexed or cisplatin with gemcitabine, no significant difference in median survival 
was found between the two regimens overall.  However, when patients with adenocarcinoma were 
evaluated separately, overall survival was significantly greater among patients receiving cisplatin 
with pemetrexed compared to those receiving cisplatin with gemcitabine (median survival 12.6 vs. 
10.9 months; HR = 0.84; 95% CI, 0.71 to 0.99; P = .03); conversely, when patients with squamous 
cell carcinoma were evaluated, overall survival was significantly greater in the cisplatin with 
gemcitabine group (median survival 9.4 vs. 10.8 months; HR = 1.23; 95% CI, 1.00 to 1.51; P = .05).  
The differential efficacy of pemetrexed according to histology was also found in a secondary analysis 
of a phase III trial evaluating second-line treatment with either pemetrexed or docetaxel.
130
 The 
consistency of differential efficacy across studies confirms the survival advantage for pemetrexed in 
patients with nonsquamous histology, but also points out its activity is limited to 70-80% of NSCLC 
tumors as pemetrexed is not efficacious in patients with squamous histology.
128
          
 Second-line treatment with single-agent chemotherapy may be necessary and feasible in 
advanced NSCLC patients whose disease has progressed during or after first-line, platinum-based 
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chemotherapy. This treatment option extends to elderly patients who received prior chemotherapy as 
evidence indicates that efficacy and toxicity is similar between younger and older patients.
131
 
Monotherapy is preferred in the second-line setting as combination regimens are associated with 
greater toxicity and no improvement in overall survival compared to single-agent chemotherapy in 
previously treated patients.
132
  Currently, docetaxel and pemetrexed are the only cytotoxic agents 
approved by the FDA for second-line monotherapy.  
 Given that advanced non-small cell lung cancer is incurable, a goal of treatment is to 
maximize the quality of life of the patient by balancing the palliative effects of chemotherapy against 
toxicity, cost, and the potential burden of frequent treatment administrations.  Current evidence 
supports the use of first- and second-line chemotherapy in patients with advanced non-small cell lung 
cancer and good performance status, as treatment can significantly prolong survival and successfully 
manage symptoms.  However, the use of cytotoxic chemotherapy beyond second-line treatment is not 
recommended;
55
  administration of third- and fourth-line chemotherapy provides little benefit to 
overall survival but significantly increases toxic effects.
133
  Thus, in patients whose disease progresses 
beyond second-line chemotherapy, further approved treatment is currently limited to the use of 
erlotinib, a targeted oral anticancer medication, or best supportive care. The role of targeted therapies 
and the use of best supportive care are each described in the two sections that follow.   
 
2.1.4.5 Targeted therapy: Bevacizumab 
 Bevacizumab is a recombinant monoclonal antibody that targets the vascular endothelial 
growth factor (VEGF) pathway. VEGF is a multifunctional cytokine that stimulates vascular 
endothelial cells to migrate and divide, form new blood vessels, and protects endothelial cells from 
apoptosis and senescence; overexpression of VEGF in cancer cells promotes angiogenesis, 
vascularization, and allows tumors to enlarge and metastasize.
134
 Inhibition of tumor vascularization 
may reduce the supply of oxygen and nutrients to the tumor thereby slowing tumor growth.
135
 Thus, 
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VEGF represents a critical component of tumor development and is an important therapeutic target.  
Bevacizumab is the only treatment currently approved for use in non-small cell lung cancer that 
targets VEGF; bevacizumab binds to and neutralizes VEGF, thereby blocking angiogenesis and tumor 
growth.
136
     
 Bevacizumab first received FDA approval for the first-line treatment of metastatic colorectal 
cancer in February of 2004. Approximately two and a half years later, in October of 2006, the FDA 
approved the use of bevacizumab in combination with carboplatin and paclitaxel for the first-line 
treatment of patients with unresectable, locally advanced, recurrent, or metastatic, non-squamous, 
non-small cell lung cancer.  Treatment with bevacizumab is restricted to patients with non-squamous 
NSCLC tumors based on evidence from an early phase II study in which squamous cell histology was 
correlated with an increased risk of serious pulmonary hemorrhage including life-threatening 
bleeding.
57
 FDA approval of bevacizumab for the treatment of advanced NSCLC followed results of 
the phase III ECOG 4599 trial
56
 evaluating the use of bevacizumab in combination with carboplatin 
and paclitaxel in previously untreated patients with advanced non-small cell lung cancer and a 
performance status of 0 or 1. The addition of bevacizumab prolonged both progression-free survival 
(6.2 months vs. 4.5 months) and overall survival (median survival 12.3 months vs. 10.3 months) 
compared to chemotherapy alone;  in a separate analysis
137
 of trial results by histology, the 
prolongation of overall survival was particularly significant among patients with adenocarcinoma 
(median survival 14.2 months vs. 10.3 months). However, patients receiving bevacizumab were more 
likely than those receiving chemotherapy only to experience grade 4 neutropenia (25.5% vs. 16.8%) 
and thrombocytopenia (1.6% vs. 0.2%) as well as grade 3 rash (2.3% vs. 0.5%) and grade 3 or greater 
bleeding events (4.4% vs. 0.7%).
56
 In addition, fifteen treatment-related deaths occurred in the 
bevacizumab arm compared to just two in the chemotherapy-only arm.    
 In the recent phase III Avastin in Lung (AVAiL) trial
138
 that evaluated the use of 
bevacizumab in combination with gemcitabine and cisplatin as first-line therapy for non-squamous 
NSCLC, progression-free survival was significantly improved among patients receiving bevacizumab 
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compared to those receiving placebo; median overall survival exceeded 13 months but was not 
significantly different between groups, possibly due to the use of efficacious second-line therapies 
during the trial. The overall incidence of grade 3 or greater toxicities was similar across treatment 
groups, but incidence of severe toxicities was higher among patients receiving high-dose (15mg/kg) 
bevacizumab compared to patients receiving either low-dose (7.5mg/kg) or placebo.  Also, severe 
pulmonary hemorrhage was increased among patients receiving bevacizumab, including seven fatal 
cases; however, the rate of pulmonary hemorrhage was similar to that seen in the ECOG 4599 trial of 
bevacizumab with carboplatin and paclitaxel.
139
  
 Use of bevacizumab in addition to carboplatin and paclitaxel in healthy elderly patients did 
not result in an increase in overall survival compared to carboplatin and paclitaxel alone (median 
survival 11.3 months vs. 12.1 months; HR = 0.87; 95% CI, 0.64 to 1.19; P = 0.4). However, the 
combination of bevacizumab with carboplatin and paclitaxel was associated with a significant 
increase in grade 3 to 5 toxicities compared to carboplatin and paclitaxel alone (87% vs. 61%). In 
addition, elderly patients had a higher incidence of grade 3 or greater neutropenia and bleeding with 
the use of bevacizumab compared to younger patients. In a subgroup analysis of the AVAiL trial,
6
 
patients aged 65 years and older who received bevacizumab had similar reductions in the risk of 
progression or death versus placebo as patients younger than 65 years. In addition, the overall 
incidence of adverse effects among elderly patients was similar to that of younger patients. Grade 3 or 
greater thrombocytopenia occurred more often with bevacizumab in older patients, but the incidence 
of other severe adverse effects was similar between older and younger patients.
6
     
 Other clinical trials continue to evaluate the role of bevacizumab in advanced non-small cell 
lung cancer, including its use with alternative chemotherapy regimens for first-line treatment, and its 
use with or without other therapies for second-line or maintenance treatment. Current evidence from 
several phase II trials suggests that bevacizumab is well tolerated and shows promise in improving 
overall survival with other platinum-based regimens for first-line treatment of advanced non-
squamous NSCLC, including carboplatin/docetaxel,
140
 carboplatin/gemcitabine,
141
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carboplatin/pemetrexed,
142
 oxaliplatin/pemetrexed,
143
 oxaliplatin/gemcitabine.
144
 Results of future 
trials will provide additional insight on how bevacizumab fares as maintenance treatment following 
initial platinum-based doublet therapy, including how bevacizumab compares to currently approved 
maintenance treatments such as pemetrexed.
145
        
 
2.2 Population Differences in Non-Small Cell Lung Cancer 
2.2.1 Age  
2.2.1.1 Diagnosis and stage 
 Lung cancer is a disease that generally affects older adults; nearly 70% of diagnoses occur in 
patients aged 65 years or older.
2
  Although the incidence of lung cancer in the United States has been 
decreasing over the last decade, particularly in younger age groups, the incidence rate remains 
significantly higher in older adults and has increased in adults 75 and older.
10
  For example, from 
2000 to 2008, the incidence rate of cancer in the lung and bronchus among adults between ages 20 
and 49 decreased from approximately 8 individuals per 100,000 in 2000 to 6 per 100,000 in 2008.  
Among adults aged 50 to 64, the incidence rate decreased from 113 per 100,000 in 2000 to 87 per 
100,000 in 2008.  Furthermore, the rate also decreased among adults aged 65 to 74 years, going from 
330 per 100,000 in 2000 to 308 per 100,000.  Conversely, the incidence rate in adults aged 75 years 
and older went from 365 per 100,000 in 2000 to a peak of 407 per 100,000 in 2007 and has now 
begun to decline with approximately 399 cases per 100,000 in 2008.
10
        
 Although the incidence rate is much higher among older adults, younger adults with non-
small cell lung cancer have a greater proportion of distant stage disease at diagnosis.
10
  In the SEER 
database from 2000 to 2008 and among adult cases age 20 to 49, approximately 13% presented with 
localized disease, 22% with regional spread, 61% with distant metastases, and 5% were unstaged at 
diagnosis. In comparison, among adult cases aged 65 to 74, approximately 18% presented with 
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localized disease, 23% with regional spread, 52% with distant metastases, and 7% were unstaged.  
Adult patients age 75 and older had similar rates of localized and metastatic disease as patients age 65 
to 74, but only 19% presented with regional spread and 13% were unstaged at diagnosis.
10
  Similar 
findings were present in a single-institution study of patients undergoing surgical resection at a 
hospital in California.
146
  Among patients under the age of 50, greater than 54% presented with 
metastatic disease compared to 45% or less of patients in the age groups 60 to 69, 70 to 79, or 80 and 
older.  Also, localized disease was present in just 20% of patients under the age of 50 compared to 
30% or more in the older age groups.
146
  
 
2.2.1.2 Treatment 
 It has been established that older adults are underrepresented in cancer clinical trials,
11,12
 
which limits our knowledge about the potential benefits and harms associated with various treatments 
in patients aged 70 years and older.  Much of our understanding about the efficacy and safety of 
treatment in older adults is established through post hoc analyses of clinical trials comparing 
outcomes between older and younger patients. However, the limited number of adults over the age of 
70 enrolled in clinical trials and the tendency for clinical trial participants to be in better overall health 
compared to the general population restricts the generalization of clinical trial data. As a result, 
clinicians may be hesitant to recommend or use certain treatments for older patients, particularly 
those treatments that may be difficult for older adults or patients with less than optimal performance 
status to tolerate, such as surgery and chemotherapy. Unfortunately, chronological age may act as a 
proxy for poor performance status in the clinical setting despite the heterogeneity of performance 
status among older adults age 65 to 70 years and older.  Older patients in good health may be denied 
access to more effective or novel treatments because of their age rather than clinical factors that are 
more representative of the patient’s ability to tolerate and receive benefit from treatment.       
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 Given that patients participating in clinical trials are randomized to treatment or placebo, 
understanding of the use of specific treatments and the clinical and non-clinical factors associated 
with their use is dependent on retrospective evaluations of observational data. Several analyses using 
such an approach with SEER-Medicare data provide insight into the use and outcomes of various 
treatments among older adults with non-small cell lung cancer. One such study evaluated the use of 
surgical resection among older adults diagnosed with stage I or II non-small cell lung cancer between 
1985 and 1993.
2521
 Although their main independent factor of interest was race, differences in the use 
of surgical resection across chronological age groups were apparent. In both black and white patients, 
the use of surgical resection declined with increasing age including a decrease of 15% or more 
between patients age 70 to 74 and patients age 75 and older. Another study evaluating the use of 
surgical resection among older adults diagnosed with stage I NSCLC between 1995 and 2004 also 
found a decline in surgical resection with increasing age; 90% or more of patients in age groups ≤ 60, 
61 to 70, and 71 to 80 received surgical resection compared to less than 80% of patients 80 years and 
older.
147
 Furthermore, an analysis of treatment use among older adults diagnosed with stage I through 
IV NSCLC between 1988 and 2003 found that the use of surgery and/or radiation declined with 
increasing age and that nearly half of patients 80 years and older received no initial treatment after 
diagnosis compared to approximately 30% of patients age 70 to 79, and 20% of patients younger than 
70 years of age.
148
 These age differences in surgical resection and radiation therapy remain even after 
controlling for other factors that influence the receipt of treatment, such as marital status, 
comorbidity, and socioeconomic status.
18,20
       
 Disparity across age groups regarding the use of chemotherapy for advanced stage NSCLC is 
of particular concern given the risk-benefit tradeoff of cytotoxic therapy. Clinical trials have shown 
that chemotherapy, particularly platinum-based doublet chemotherapy, improves quality of life and 
overall survival in patients with advanced NSCLC.
55
 However, chemotherapy also carries the risk of 
treatment toxicity, including a potential risk of life-threatening adverse effects that may prevent 
clinicians from administering chemotherapy to older patients, particularly if the expected benefit of 
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treatment is small. Previous analyses of SEER-Medicare data clearly indicate that chronological age 
is in fact an independent predictor of chemotherapy use among patients with advanced non-small cell 
lung cancer. For example, among patients diagnosed with stage III of IV NSCLC between 1994 and 
1999, patients age 75 years and older were significantly less likely to receive chemotherapy compared 
to patients under the age of 75 (OR 0.91; 95% CI 0.91, 0.92).
149
 Similar results were observed among 
cases of stage III or IV NSCLC diagnosed between 1991 and 2002 where patients in age groups 70-
74 years (OR 0.81; 95% CI 0.77, 0.85), 75-79 years (OR 0.54; 95% CI 0.51, 0.57), 80-84 years (OR 
0.30; 95% CI 0.28, 0.32), and 85 years or older (OR 0.16; 95% CI 0.14, 0.18) were all significantly 
less likely to receive chemotherapy treatment compared to patients age 65-69.
18
 In addition, a 
comparable analysis of stage III or IV cases diagnosed through 2002 in the SEER-Medicare data 
found that patients in age groups 70-74 years (OR 1.32; 95% CI 1.09, 1.59), 75-79 years (OR 1.86; 
95% CI 1.53, 2.26), 80-84 years (OR 4.03; 95% CI 3.20, 5.08), and 85 years or older (OR 7.24; 95% 
CI 5.06, 10.35) were all significantly more likely to receive single agent as opposed to platinum-
based doublet chemotherapy compared to patients age 66-69.
15
  
 Data sources other than SEER-Medicare have also been used in retrospective analyses of 
chemotherapy use among older adults with advanced NSCLC. For example, Rasco et al.
150
 evaluated 
individuals diagnosed with stage IV NSCLC from 2000 to 2007 at the University of Texas 
Southwestern Medical Center and found in their multivariable analysis that patients under 65 years of 
age were more likely than patients age 65 years and older to receive chemotherapy (OR 1.96; 95% CI 
1.26, 3.06). However, a potentially important limitation of the study was that although the authors 
considered sociodemographic factors such as race and insurance status in their analysis, they did not 
control for important clinical characteristics including patient performance status or comorbidities 
that may further predict the use or non-use of chemotherapy in older adults with advanced NSCLC. 
Conversely, the presence of cardiovascular disease, pulmonary disease and a measure of the severity 
of comorbidity was accounted for in a study of participants from the Cancer Care Outcomes Research 
and Surveillance Consortium with newly diagnosed stage IIB or IV NSCLC between 2003 and 
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2005.
151
 In the unadjusted analysis of chemotherapy use, 78.7%, 64.0%, 60.5%, and 42.4% of patients 
under the age of 55, age 55-64 years, age 65-74 years, age 75 years and older, respectively, received 
chemotherapy treatment.  In addition, approximately 85% of patients under the age of 65 received 
platinum-based chemotherapy compared to less than 78% of patients age 65-74 years and less than 
68% of patients age 75 years and older. After adjusting for clinical and sociodemographic factors, 
including those previously mentioned, age remained an important predictor of chemotherapy use and 
use of a platinum-based regimen among those patients receiving chemotherapy.           
 The results of several observational studies clearly indicate that chronological age is an 
important predictor of treatment, including surgical resection and chemotherapy use, two treatments 
that carry a greater risk for complications and/or toxicity. Perhaps it is the belief that the oldest of 
older adult patients have limited life expectancy and would receive little benefit from surgical 
resection or chemotherapy that influences the disparate use of these therapeutic modalities among 
older adults with NSCLC. However, chronological age alone is not the most appropriate determinant 
of care. The overall health and performance status of patients within an age group can vary 
significantly and, in turn, influence the use and outcomes of available treatments. As will be 
described in the section that follows, older patients with good overall health may benefit from 
surgical resection of localized disease as well as from chemotherapy for advanced NSCLC. At the 
same time, older patients who are frail may have extreme difficulty tolerating such treatments, may 
experience life-threatening toxicity and stand to gain little overall benefit from them. Still, despite 
evidence to support the use of certain treatments in select older lung cancer patients, chronological 
age remains a factor in determining whether patients receive guideline-recommended treatment; as a 
result, a significant proportion of older patients fail to receive more aggressive therapy from which 
they may benefit.
15
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2.2.1.3 Survival 
 Although mortality has improved slightly over the last few decades, survival remains poorest 
among patients ages 75 and older.
10
 The relative 1-year survival of lung and bronchus cases 
diagnosed between 1988 and 2007 in SEER registries is 49.9%, 47.1%, 42.6%, and 33.7% among 
patients ages 20-49 years, 50-64 years, 65-74 years, and 75 years or older is 20.9% 17.6%, 15.2% and 
respectively. Also, the 5-year survival of the same cases is 20.9%, 17.6%, 15.2%m and 10.4%, among 
patients ages 20-49 years, 50-64 years, 65-74 years, and 75 years or older, respectively. Differences 
in the duration of survival among age groups are partly due to a relatively limited life expectancy 
among older adults as they are closer to the end of the natural lifespan and may be at greater risk of 
death from other causes. However, survival differences may also be explained by decreased 
utilization of lung cancer treatments that may cure disease and/or prolong overall survival. 
Furthermore, even among patients diagnosed over the age of 80, the argument that a limited life 
expectancy among older adults negates the usefulness of treatment is challenged from national life 
table data that shows that 75-year-old to 85-year-old Americans have a conditional life expectancy of 
11.6 to 6.8 years.
152
 Therefore, it seems reasonable that older healthy patients should be offered 
potentially curable surgical resection as well as chemotherapy and targeted treatments that may not 
only prolong survival, but also improve the quality of life. However, given the low representation of 
older adults in clinical trials and the hesitancy to ascribe certain treatments such as surgical resection 
and chemotherapy to the oldest of older patients, knowledge of the efficacy and safety of these 
treatments in older adults is largely reliant on post-hoc analyses of clinical trials and retrospective 
analyses of observational data.  
 The benefit of surgical resection among older adults with early stage disease has been 
evaluated in several observational analyses, with some differences in the results. Interestingly, in a 
study of SEER-Medicare cases of stage I or II NSCLC diagnosed between 1985 and 1993, older age 
(70 or older) was significantly associated with poorer survival even when controlling for race, 
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income, comorbidity, and receipt of surgical resection.
25
 However, in a similar study of patients with 
stage I NSCLC diagnosed between 1995 and 2004, despite a lower rate of surgical resection among 
older adults, there were no significant differences in survival with respect to age among resected 
patients; lung cancer was found to be the major contributor to mortality among patients who did not 
receive surgery, even among the oldest patients, which suggests that surgical resection should be 
considered in elderly patients when feasible.
147
 In a retrospective analysis of patients with NSCLC 
treated at a single-institution, older adults were less likely to receive surgical resection for localized or 
regional-stage disease, but 5-year survival rates among patients age under 50, age 50-59 years, age 
60-69 years, age 70-79 years, and age 80 years or older were comparable across groups.
146
  
 There has been continued debate over the use of chemotherapy among older adult patients 
with NSCLC, particularly the use of platinum-based doublet chemotherapy for patients with advanced 
stage disease. Information regarding the efficacy of chemotherapeutic agents among older adults with 
NSCLC has been largely gained from post-hoc or subgroup analyses of phase II and phase III clinical 
trials. For instance, the use of chemotherapy in elderly patients with early-stage disease was evaluated 
in a phase III trial subgroup analysis
153
 of vinorelbine with cisplatin following complete surgical 
resection of stage IB or II NSCLC. Patients over the age of 65 received significantly fewer doses as 
well as significantly lower average dose-intensities of cisplatin and vinorelbine compared to patients 
65 years old and younger. However, overall survival between the two groups was not statistically 
significant (HR for ≤ 65 vs. > 65, 0.77; 95% CI 0.57, 1.03); patients over the age of 65 received a 
benefit in survival (HR, 0.61; 95% CI 0.38, 0.98) that was similar to the effect seen in the total trial 
population. Still, when age was categorized into smaller groups, the survival benefit seemed to 
disappear among patients over the age of 75 (HR, 2.35; 95% CI 0.84, 6.58), although there were only 
12 patients in the chemotherapy arm and 11 in the observation arm for this group.  
 Most analyses of clinical trial data regarding the use of chemotherapy in older adults with 
NSCLC have focused on the use of chemotherapy in advanced stages of disease. In a clinical trial 
designed specifically for the evaluation of single-agent vinorelbine treatment in patients 70 years or 
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older with stage IIIB or IV NSCLC and performance status of 0, 1, or 2, patients who received 
vinorelbine had significantly greater survival at 1-year compared to patients in the control arm (32% 
vs. 14%), and after adjusting for stage of disease and performance status, vinorelbine was associated 
with a significant survival advantage (HR, 0.65; 95% CI 0.45, 0.93).
154
 A follow-up study comparing 
single-agent treatment with either vinorelbine or gemcitabine with the doublet therapy of vinorelbine 
and gemcitabine among patients 70 years or older found no survival benefit with the combination 
treatment and increased toxicity compared to either of the single-agent regimens.
155
    
 Several subgroup analyses of clinical trials have examined the benefit of platinum-based 
chemotherapy in older adults. For instance, Langer et al.
156
 carried out a subgroup analysis of older 
patients with stage IIIB or IV NSCLC and performance status of 0 or 1 who were randomized to 
receive cisplatin plus either etoposide or paclitaxel as first-line treatment. Overall survival was similar 
between patients age 70 years and older and patients under the age of 70 (median survival 8.5 months 
vs. 9.0 months) as was 1-year survival (29% vs. 38%). Belani et al.
127
 performed a subgroup analysis 
of adults 65 years and older who participated in a phase III trial comparing docetaxel/cisplatin (DC), 
docetaxel/carboplatin (DCb), and vinorelbine/cisplatin (VC) for first-line treatment of chemotherapy-
naïve patients with stage IIIB or IV NSCLC.  Patients age 65 and older and patients under the age of 
65 had similar estimates for median survival, 1-year survival, and 2-year survival in each of the three 
treatment arms. Furthermore, both older and younger patients randomized to DC had higher median 
survival, 1-year and 2-year survival than patients randomized to VC.
127
 A phase III trial evaluation of 
carboplatin and paclitaxel for the treatment of stage IIIB or IV NSCLC also demonstrated that 
patients age 70 years and older received similar benefit as patients under the age of 70 with regard to 
both overall survival (median survival 7.1 months vs. 7.8 months) and 1-year survival (33% vs. 
30%).
157
 Conversely, a pooled analysis of patients from two separate Southwest Oncology Group 
trials found that although patients age 70 and older derived benefit from either cisplatin and 
gemcitabine or carboplatin and paclitaxel, overall survival and 1-year survival rates were better 
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among patients under the age of 70 (median survival, 7 months vs. 9 months; 1-year survival, 27% vs. 
40%).
158
             
 SEER-Medicare analyses have also evaluated the effectiveness of chemotherapy among older 
adults with advanced stage NSCLC. For example in a study of patients aged 65 and older  with stage 
IV NSCLC diagnosed between 1991 and 1996, chemotherapy use was associated with prolonged 
survival (HR, 0.81; 95% CI 0.76, 0.85);  furthermore, analysis with instrumental variable methods 
indicated an increase in survival of 33 days and an increase in 1-year survival of 9% with 
chemotherapy use.
159
 A study by Ramsey et al.
149
 also evaluated the use and outcomes of 
chemotherapy among patients diagnosed with stage IIIB or IV NSCLC between 1994 and 1999,  and 
found that although adult patients 75 years and older were significantly less likely to receive 
treatment there was no relationship between age and survival in their multivariate analysis. However, 
an analysis of patients with stage III or IV NSCLC diagnosed between 1997 and 2002 revealed that 
despite a survival benefit from the receipt of chemotherapy, increasing age remained associated with 
increasing mortality risk; the hazard ratio was 4% to 12% higher (statistically significant) among 
patients ages 70 to 85 and older compared to patients ages 66 to 69. Still, there were no significant 
age group differences with regard to the survival benefit of platinum-based doublet chemotherapy 
over single-agent treatment.
15
   
 Although the use of targeted therapy is a relatively new treatment modality in non-small cell 
lung cancer, the potential benefit of extending overall survival in healthy older adults beyond the 
rather stagnant 10 to 11 months with doublet chemotherapy has prompted publication of two 
subgroup analyses of phase III clinical trials involving the use of bevacizumab.
18,58
 In a subgroup 
analysis of patients aged 65 years or older in the AVAiL trial, patients received cisplatin and 
gemcitabine for up to 6 cycles in addition to either low dose (7.5 mg/kg) or high dose (15 mg/kg) 
bevacizumab or placebo.
6
 Overall survival in each arm of bevacizumab was favorable versus placebo 
(HR for 7.5 mg/kg, 0.84; HR for 15 mg/kg, 0.88) although neither treatment arm resulted in a 
statistically significant benefit. Conversely, in a subgroup analysis of the ECOG 4599 trial that lead to 
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the approval of bevacizumab for treatment of advanced NSCLC, patients aged 70 years and older 
who were randomized to receive bevacizumab (15 mg/kg) in addition to carboplatin and paclitaxel 
received no benefit in overall survival compared to patients of the same age group who received 
carboplatin and paclitaxel only (median survival, 11.3 months vs. 12.1 months). Furthermore, a recent 
analysis
7
 of older adults with advanced NSCLC (stage IIIB and stage IV) in the SEER-Medicare 
database found no significant survival advantage among older patients receiving bevacizumab with 
carboplatin-paclitaxel chemotherapy compared to older patients receiving carboplatin-paclitaxel 
chemotherapy alone (multivariable-adjusted HR 1.01, 95% CI 0.88-1.15). Given the lack of overall 
survival benefit in subgroup analysis of clinical trials or observational studies, it remains unclear 
whether bevacizumab should be considered in addition to standard platinum-based doublet 
chemotherapy among older adults aged 65-70 years or older.   
 Other than the study by Zhu et al.
7
 of older adults receiving carboplatin-paclitaxel 
chemotherapy with or without bevacizumab, no observational analyses have been published regarding 
the use and outcomes of bevacizumab in advanced non-small cell lung cancer. By including patients 
treated with a broader range of platinum-based doublet chemotherapy regimens (i.e., supplementary 
to carboplatin-paclitaxel), the addition of retrospective analyses with larger treatment group sizes 
could provide greater insight about the potential benefit of bevacizumab among older patients with 
advanced NSCLC, particularly whether or not younger subgroups of fit older adults (e.g., 65 to 69 
years) benefit compared to older subgroups (e.g., 75 to 79 years).   
 
2.2.1.4 Adverse effects 
 A large concern with the use of systemic chemotherapy and targeted therapies such as 
bevacizumab among older patients with advanced NSCLC is the potential for severe toxicity, 
especially toxicity that can be life-threatening, decrease quality of life, and diminish or outweigh any 
potential benefit in overall survival. As with the efficacy of chemotherapy and bevacizumab, 
subgroup analyses of clinical trials and retrospective analyses of observational data provide the 
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evidence currently available regarding the tolerability of these agents among older patients with 
advanced non-small cell lung cancer. In an evaluation of cisplatin-based treatment among elderly 
patients with advanced NSCLC participating in the ECOG 5592 trial, toxic effects were generally 
similar between younger (< 70 years) and older (70 years and older) patients despite significantly 
greater cardiovascular and pulmonary comorbidity among older patients at baseline.
156
   
 Patients 65 years and older tolerated and benefited from platinum-docetaxel combination 
therapy in a subgroup analysis a phase III trial comparing docetaxel/cisplatin (DC), 
docetaxel/carboplatin (DCb), and vinorelbine/cisplatin (VC).
127
 When compared to patients less than 
65 years of age, older patients had slightly increased grade 3-4 non-hematologic and hematologic 
toxicities, including a greater incidence of leukopenia and neutropenia in the platinum-docetaxel 
arms. Despite a trend toward significance for greater neutropenia among older (70 years and older) 
patients with stage IIIB or IV NSCLC who received cisplatin/gemcitabine or carboplatin/ paclitaxel in 
a pooled analysis of two separate Southwest Oncology Group trials, grade 3-5 hematologic and non-
hematologic toxicities were similar between older and younger patients.
158
 Furthermore, additional 
evidence that fit older patients can tolerate platinum-based chemotherapy is provided in a subgroup 
analysis of patients randomized to receive carboplatin/paclitaxel which found that younger (< 70 
years) and older (70 years and older) patients had similar rates of grade 3-4 hematologic and non-
hematologic toxicities.
157
 Combined with the improvement in overall survival, evidence of tolerability 
with the of carboplatin and paclitaxel shows that fit older patients with advanced non-small cell lung 
cancer stand to benefit from platinum-based doublet chemotherapy and that chronological age alone 
is a poor determinant of whether or not older patients should receive treatment with these agents. 
 In a study of the SEER-Medicare data that included patients diagnosed with stage I to IV 
NSCLC between 1991 and 2002, chemotherapy use was not associated with the development of 
cardiac conditions in a crude analysis model.
160
 However, in a multivariable analysis that accounted 
for age, stage at diagnosis, and comorbidity, chemotherapy use was associated with an increased risk 
of ischemic heart disease, cardiac dysfunction and heart failure; increased age, particularly age 80 
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years and older, was also associated with increased risk for cardiac functions in the multivariable 
model. With the lack of an association between chemotherapy and cardiac conditions in unadjusted 
analyses and the relationship between each of the conditions and increased age, it is difficult to 
determine what the true association between chemotherapy use and toxicity is among older adults in 
the study. 
 In a cohort of adults from the Cancer Care Outcomes Research and Surveillance Consortium 
diagnosed with stage IIIB or IV NSCLC between 2003 and 2005, patients aged 65-74 and patients 
aged 75 or older had a higher rate of any adverse events during chemotherapy compared to patients 
younger than 55 years of age (IRR for patients 65-74, 1.70; 95% CI 1.19, 2.43; IRR for patients 75 
and older, 1.34; 95% CI 0.90, 2.00).
151
 Further, compared to patients younger than 55 years of age, 
older patients had higher rates for specific adverse events, including higher incidences of neuropathy, 
fever with neutropenia, and sepsis. However, higher incidence rates were only statistically significant 
between patients aged 65-74 and patients younger than 55 for the incidence of either neuropathy, 
fever with neutropenia, and sepsis (IRR, 2.03; 95% CI 1.01, 4.08). Thus, although the adjusted 
incidence rate estimates for toxic effects with chemotherapy use are greater among older adults, the 
variation around the estimates creates a bit of uncertainty as to whether or not the risk of adverse 
events is really increased among the oldest patients.  
 The safety of bevacizumab among older adults has been limited to two subgroup analyses of 
clinical trials, one conducted in Europe
6
 and the other in the United States.
5
 In the former study, 
patients received cisplatin and gemcitabine plus either low dose (7.5 mg/kg) or high dose (15 mg/kg) 
bevacizumab or placebo. Toxicity patterns between patients aged 65 years and older and patients 
younger than 65 years were generally similar in this study including similar percentages of patients in 
the bevacizumab arms who reported at least one grade 3 or higher adverse effect. Notably, 
approximately 40% of older patients receiving either low or high dose bevacizumab had grade 3 or 
greater thrombocytopenia compared to less than 30% of younger patients. In the US-based study, 
adults aged 70 years and older who received bevacizumab (15 mg/kg) in addition to 
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carboplatin/paclitaxel were more likely to have grade 4 or 5 neutropenia (34% vs. 22%), febrile 
neutropenia (6.2% vs. 0.9%), and thromobocytopenia (3.5% vs. 0%) compared to older patients who 
received carboplatin/paclitaxel only. In addition, among patients receiving bevacizumab, older 
patients were significantly more likely than younger patients to have grade 4 neutropenia as well as 
grade 3-5 GI bleed, proteinuria, muscle weakness, neuropathy, and dizziness. By comparison, among 
patients receiving carboplatin/paclitaxel only, no significant differences were found between older 
and younger patients for the same adverse effects just listed. The lack of benefit from bevacizumab 
and the greater risk for severe toxicity among older adults in clinical trials brings into question the 
utility of bevacizumab in the older population of patients with advanced non-small cell lung cancer. 
 
2.2.2 Race 
2.2.2.1 Diagnosis and stage 
 Racial and ethnic disparities exist in the incidence and stage at diagnosis of non-small cell 
lung cancer in the U.S.
2,26
 The burden of disease is disproportionately greater for black males who are 
more likely to be diagnosed with and die from lung cancer. Black men have the highest incidence 
rates of lung cancer among all racial, ethnic and gender groups; despite a steady decline since the 
mid-1980s, the incidence rate of lung cancer among black men in 2007 was 95.4 per 100,000 
compared to a rate of 72.1 per 100,000 among white men.
2
 However, racial differences in the 
incidence rates among women have historically been much smaller. In 2007 the incidence rate of lung 
cancer among black women was 58.1 per 100,000 compared to a rate of 55.1 per 100,000 among 
white women.
2
      
 Blacks are also more likely to be diagnosed at advanced stages of disease.
2,26
 Among all cases 
diagnosed in the United States between 1999 and 2006, 15% were diagnosed at a localized stage, 
22% had spread to regional lymph nodes, and 56% had distant metastases at the time of diagnosis. 
When these cases were stratified by race, 15% of whites were diagnosed with localized disease, 22% 
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with regional spread, and 55% with distant metastases. However, only 12% of blacks were diagnosed 
at a localized stage and 60% were diagnosed with distant metastases. The reasons behind these racial 
disparities in cancer incidence, although not entirely clear, are likely to include a combination of 
biological, environmental, and cultural influences including genetics, access to health care and 
smoking prevalence. 
 
2.2.2.2 Treatment 
 Race and ethnicity may be important factors that influence the use and outcomes of staging 
procedures and treatment for non-small cell lung cancer. Staging methods, both invasive and non-
invasive, allow physicians to determine the prognosis and appropriate treatment options available to 
patients. However, evidence suggests that the use of staging procedures may not be consistent across 
racial groups and contribute to differences in the use of related treatments. In a study of the 
Surveillance, Epidemiology, and End Results (SEER) data from 1991 to 2001, blacks with non-
metastatic NSCLC were 25% less likely than whites to undergo invasive staging with bronchoscopy, 
mediastinoscopy, or thoracoscopy;
161
 even when blacks underwent invasive staging, they were 
significantly less likely to receive a recommendation for or undergo surgery. A more recent 
evaluation of patients diagnosed between 1994 and 2004 in the California Cancer Registry did not 
find an association between race and the use of either invasive or non-invasive staging, but black 
patients were less likely to undergo surgery compared to whites regardless of staging use.
162
 While 
the relationship between race and the use of staging procedures is less clear, the association between 
race and a decreased utilization of curative surgery for lung cancer has been a consistent finding in 
studies. For example, in an early study by Greenwald et al., whites were 20% more likely to undergo 
curative surgery for early-stage disease.
61
 In a study by Bach et al.
25
 examining the use of surgery 
among patients diagnosed between 1985 and 1993 in SEER-Medicare, 76.7% of whites received 
surgery compared to only 64.0% of black patients, a difference that remained significant after 
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adjusting for factors that predicted surgical candidacy. Similar findings were realized in a study of 
patients diagnosed between 1996 and 2002 in the South Carolina Cancer Registry which found that 
blacks were significantly less likely than whites to undergo surgical resection (44.7% vs. 63.4%).
163
 
Furthermore, the difference in receipt of surgery for early stage lung cancer is not limited to the 
comparison between blacks and whites.  Evaluation of patients diagnosed between 1991 and 2000 in 
the SEER registry demonstrated that Hispanics were also less likely than non-Hispanic whites to 
receive surgical resection of early stage NSCLC and that the disparity in surgical resection explains 
any differences seen in survival.
17
 Similarly, compared to whites, American Indian and Alaskan 
Natives are more likely to be diagnosed with advanced stage disease and less likely to undergo 
surgical resection, but have similar survival outcomes to whites and other racial/ethnic groups when 
stage and treatment are equal.
19
      
 Several factors may influence the disparity in surgical resection seen among racial and ethnic 
groups.  In a study of the California Cancer Registry data between 1989 and 2003, low 
socioeconomic status was more common among black and Hispanic patients with stage I NSCLC and 
was significantly associated with fewer surgical resections performed and worse survival.
164
 In a 
prospective cohort study of patients with early-stage operable lung cancer in which only 62 of 113 
(55%) black patients chose surgery compared to 179 of 273 (66%) of white patients, the presence of 
two or more comorbid conditions and the lack of a regular source of care were significant predictors 
of a decision against surgery in black patients but not in whites.
27
 The relationship between greater 
comorbidity, black race and non-receipt of surgical treatment was also found in a retrospective 
analysis of medical records for nearly 1,200 patients identified through the Josephine Ford Cancer 
Center Tumor Registry.
38
 In a separate retrospective cohort study of patients seen at the pulmonary 
clinic of the Henry Ford Health System in Detroit, MI, race was not a significant predictor of being 
offered surgical treatment after controlling for influential clinical characteristics, but the surgical rate 
was significantly lower among black patients than in whites (58% vs. 74%) suggesting that black 
patients were less likely to accept surgical treatment.
33
 A retrospective analysis of patients diagnosed 
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between 1992 and 2002 in the SEER-Medicare basis also found that blacks were less likely to 
undergo recommended surgical therapy than whites (69% vs. 83%); the authors of the study suggest 
that distrust of the healthcare system, differences in the beliefs and perceptions about lung cancer and 
its treatment, and limited access to care are likely to explain racial disparities in surgical resection of 
non-small cell lung cancer.
23
 In addition, lower acceptance of surgical treatment among black patients 
may be related to less engaging relationships and poorer, less effective communication with 
providers.
27
  
 Besides lower rates of surgical resection compared to whites, blacks are also less likely to 
receive chemotherapy for advanced stages of lung cancer and are less likely to receive appropriate 
treatment in a timely manner.
18,20,24,41,58,165
  For example, an early study of metastatic NSCLC cases 
diagnosed between 1991 and 1993 in SEER-Medicare revealed that black patients were 30% less 
likely to receive chemotherapy compared to whites (OR 0.70; 95% CI 0.55-0.88).
41
 Furthermore, in 
an analysis of NSCLC cases in the SEER-Medicare database between 1995 and 1999, Shugarman et 
al.
20
 found black patients were significantly less likely than whites to receive timely and clinically 
appropriate treatment for each stage of NSCLC; black patients were 66% less likely to receive timely 
surgical resection for stage I or II disease, 34% less likely to receive timely chemotherapy, radiation, 
and/or surgical resection for stage III disease, and 51% less likely to receive chemotherapy for stage 
IV disease. Perhaps important to note, based on the findings of additional studies using SEER-
Medicare data that have indicated that the use of radiation therapy does not vary by race or 
ethnicity,
18,166
 the lower receipt of treatment among blacks compared to whites with stage III NSCLC 
is most likely due to lower utilization of chemotherapy and/or surgery than to less use of radiation.       
 An analysis of SEER-Medicare cases between 1991 and 2002 by Hardy et al.
18
 resulted in 
similar findings to the Shugarman et al. study. Blacks were 37% less likely to receive surgical 
resection and 42% less likely to receive chemotherapy for stage I or II NSCLC, and 57% less likely to 
receive chemotherapy for stage III or IV disease compared to whites. Interestingly, when adjusted 
results from the Hardy study were stratified by years of diagnosis, the odds ratio comparing the 
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receipt of chemotherapy for stage III or IV NSCLC between black and white patients changed 
significantly between cases diagnosed in 1991-1995 (OR 0.74; 95% CI 0.35-1.54) or 1996-1999 (OR 
0.76; 95% CI 0.39-1.47) and cases diagnosed in 2000-2002 (OR 0.24; 95% CI 0.14-0.40). Based on 
the findings of disparate use of chemotherapy among racial/ethnic groups in the aforementioned study 
of metastatic cancer by Earle et al.,
41
 the non-significant findings in earlier years of the Hardy et al. 
study may be more heavily influenced by insignificant differences in chemotherapy use for stage III 
NSCLC as opposed to stage IV.   
 Additional analyses of SEER-Medicare, including more recently published studies, have 
consistently found variation in the use of chemotherapy for advanced NSCLC. A study of patients 
diagnosed with stage IIIB or IV NSCLC in SEER-Medicare data between 1994 and 1999 found that 
blacks were about 50% less likely to receive chemotherapy treatment compared to whites; significant 
differences were not seen between whites and other non-black non-white patients.
149
 In a similar 
study that included stage IIIB or IV NSCLC cases diagnosed between 1997 and 2002 in SEER-
Medicare data, black patients were still more than 40% less likely than whites to receive first-line 
chemotherapy (OR 0.59; 95% CI 0.52, 0.67).
167
 Again, although a trend towards a similar disparity 
was seen when comparing patients of other racial/ethnic groups to whites, the differences were not 
significant. However, black (OR 0.61; 95% CI 0.48, 0.77), Hispanic (OR 0.46; 95% CI 0.31, 0.67), 
and Asian (OR 0.49; 95% CI 0.31, 0.76) patients were all significantly less likely than whites to 
receive doublet chemotherapy with a platinum agent and a taxane, and black patients were also 
significantly less likely to receive treatment with a platinum agent and gemcitabine compared to 
whites (OR 0.59; 95% CI 0.35, 0.98). Davidoff et al.
15
 completed a separate analysis of advanced 
NSCLC cases diagnosed between 1997 and 2002 in SEER-Medicare with similar results. Black 
patients were 38% less likely than white patients to receive any chemotherapy within 90 days of 
diagnosis (OR 0.72; 95% CI 0.63, 0.82), and were 53% more likely than white patients to receive 
treatment with single agent chemotherapy as opposed to platinum-based doublet therapy (OR 1.53; 
95% CI 1.16, 2.01).   
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 The unequal receipt of chemotherapy treatment among black patients with advanced non-
small cell lung cancer may be ascribed to differences in the rate of referral to oncologists, the 
availability of novel diagnostic technologies, poorer overall health, or the acceptance of treatment 
options by patients.
27,31-33
 In a study of patients over age 65 with metastatic NSCLC diagnosed 
between 1991 and 1996 in SEER-Medicare, black patients were nearly 50% less likely to receive 
chemotherapy or see an oncologist compared to white patients.
31
 Even among patients who saw an 
oncologist, blacks remained 36% less likely than white patients to receive chemotherapy.   
 
2.2.2.3 Survival 
 Mortality from lung cancer remains highest among black patients, although the difference in 
lung cancer mortality between black and white patients has improved over the last two decades. The 
greatest difference in mortality rates has been observed between black men and white men; in 2007, 
the estimated mortality rate among black men was 82.7 per 100,000 compared to a rate of 64.9 per 
100,000 among white men. Conversely, black women actually had a slightly lower mortality rate 
(39.2 per 100,000) compared to the rate among white women (41.1 per 100,000) during the same time 
period.
2
 Two important contributors to the increased mortality seen among black men include the 
higher incidence rate of lung cancer and greater proportion of black males presenting with incurable 
stages of disease.
1
      
 Other underlying causes of the racial disparities seen in mortality rates of lung cancer may be 
similar to those factors that contribute to disparities in the incidence and treatment of disease, 
particularly unequal access to and quality of care. Lower income and lack of insurance are significant 
contributors to disparities in health care access and quality,
30
 and because a significant proportion of 
blacks are poor and/or uninsured,
21
 they are less likely to have access to quality health care. 
Inequitable access to quality care may then lead to disproportionate rates of advanced disease at 
diagnosis, underutilization of available treatments, and worse survival outcomes.   
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 Despite the fact that treatment of lung cancer across racial and ethnic groups is hardly 
equal,
17-19,25,27,161
 research has shown that when black patients receive treatment equal to that of non-
black patients with similar prognoses, equal outcomes are observed.
17,19,24,25,29,58-64
 A prime example is 
the study by Bach et al.
25
 that evaluated the use and outcomes of surgical resection among patients 
diagnosed with stage I or II NSCLC in SEER-Medicare between 1985 and 1993. The rate of surgical 
resection was approximately 13% lower among black patients compared to whites, and 5-year 
survival was significantly lower for black patients. However, both unadjusted and adjusted analyses 
showed that black patients who underwent surgical resection had similar survival benefit to that of 
white patients who received surgery. Greenwald et al.
61
 also examined the use of surgical resection 
and outcomes among patients diagnosed with stage I NSCLC and found that differences in overall 
survival between black and white patients disappears when treatment and socioeconomic status are 
accounted for in the regression model. Furthermore, Wisnivesky et al.
17
 found similar results in their 
comparison of surgical resection and outcomes between Hispanic and white patients; although 
Hispanic patients were less likely to undergo surgical resection and were more likely to have a lower 
household income and poorer survival than white patients, the survival difference ceased when 
surgery and stage were adjusted for.  In addition, similar to the Greenwald study, income remained a 
significant independent predictor of survival.      
 Equal outcomes with equal treatment is further evidenced in a retrospective analysis of four 
randomized studies on irradiation treatment for NSCLC conducted by the Radiation Therapy 
Oncology Group found that, despite variation in the presentation of black and white patients, there 
was no significant difference in overall survival between the two groups.
60
 In a case-control analysis 
of patients with stage I, II, or III NSCLC, black patients were more likely to be smokers, have lower 
annual income, a greater delay in receiving treatment, were less likely to accept neo-adjuvant 
chemotherapy prior to surgical resection, and had worse 5-year overall survival compared to white 
patients.
24
 However, when the poor prognostic factors (i.e., smoking status, socioeconomic status, and 
refusal of treatment) were controlled for overall survival rates for black and white patients were 
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similar. In a study of the Florida cancer registry with patients diagnosed between 1998 and 2002, 
black patients were less likely to receive surgical resection, more likely to receive radiation therapy 
and have poorer overall survival compared to white patients.
62
 However, in multivariable analyses 
that adjusted for treatment and socioeconomic variables, no difference in overall survival existed 
between black and white patients; patients in the lowest poverty level and those with no insurance or 
Medicaid had significantly poorer survival.   
 Similar survival outcomes between racial and ethnic groups have also been observed with 
equal use of chemotherapy for advanced stages of NSCLC. In a comparison of white and black 
patients with stage IIIB or IV non-small cell lung cancer who participated in a three-arm phase III 
trial of chemotherapy, median survival was greater among black patients overall (9.1 months vs. 8.3 
months).
59
 An analysis of trials conducted by the Southwest Oncology Group also found no racial 
disparities in survival among white and black patients with advanced-stage non-small cell lung 
cancer.
64
 However, in an analysis of patients receiving chemotherapy in phase II and phase III Cancer 
and Leukemia Group B trials found significantly poorer 1-year survival among black patients 
compared to non-black patients.
63
 Yet, when performance status and weight loss were adjusted for in 
a multivariable analysis, the effect of race on survival disappeared; the authors attributed the greater 
likelihood of black patients to present in poorer health, with greater weight loss, and less favorable 
socioeconomic status to poor social circumstances.
63
   
 Comparable outcomes across racial and ethnic groups have also been observed in analyses 
using SEER-Medicare data. In patients diagnosed with stage III or IV NSCLC between 1994 and 
1999, black patients were significantly less likely to receive chemotherapy compared to white 
patients, but when treatment was adjusted for in a multivariable hazards model, there was no 
significant difference in survival between the two groups.
149
 An analysis of patients with stage I to 
IIIA NSCLC diagnosed in SEER between 1998 and 2006 evaluated disparities among American 
Indians and Alaskan Natives (AI/AN). Similar to black patients, AI/AN patients were more likely 
than whites to be diagnosed with advanced stage disease, less likely to receive surgical resection, and 
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have poor overall survival.
19
 When treatment was accounted for in a multivariable regression, 
survival among AI/AN patients remained worse than among whites but the difference was not 
significant statistically. Finally, in a study of patients with stage I to IV NSCLC in SEER-Medicare 
diagnosed between 1991 and 2002 in which black patients were significantly less likely than white 
patients to receive chemotherapy for stage III or IV disease, blacks had worse overall survival in the 
crude analysis.
58
 However, just as with the previous findings in both clinical trials and observational 
studies, the difference in overall survival between black and white patients disappeared when 
treatment and socioeconomic status were adjusted for in the proportional hazards model. Receipt of 
treatment was associated with a 30% reduction in mortality while the lowest socioeconomic status 
quartile had a 9% increase in mortality compared to the highest quartile. Given the findings of these 
studies, the evidence supports the idea that lower survival from non-small cell lung cancer among 
black patients can be largely explained by poorer socioeconomic status, greater likelihood of 
advanced stage disease and poorer performance status at diagnosis, and lower offering, acceptance or 
use of appropriate and/or novel treatments. 
 
2.2.2.4 Adverse effects 
 Few studies have examined the association between race and adverse effects from treatment 
for non-small cell lung cancer, particularly chemotherapy for advanced stage disease. However there 
are a couple of analyses that may provide some insight as to whether racial differences exist in 
relation to the incidence of toxicity following receipt of various treatments. For example, in a 
multivariable analysis of patients diagnosed with stage I to IV NSCLC in SEER-Medicare between 
1991 and 2002, black patients were more likely than white patients to develop cardiomyopathy, 
cardiac dysfunction, and heart failure.
160
 Hispanic patients were also more likely to develop heart 
failure compared to white patients, but no other differences between racial/ethnic groups were found. 
In a separate analysis of the same data by Hardy et al., all racial/ethnic groups were at an increased 
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risk for long-term chemotherapy (considered > 3 months) toxicity compared to white patients even 
after adjusting for disease stage, age, and comorbidity.
168
 However, when toxic effects were evaluated 
among participants of a three-arm phase III trial of advanced or metastatic NSCLC, no significant 
differences were seen between white and black patients for any hematologic or non-hematologic 
adverse effects.
59
 Given the uncertainty across studies, variation in the presence of previous 
comorbidities and the potential for differences in toxicity outcomes among racial/ethnic groups with 
the use of chemotherapy or targeted therapies, this is an area where additional investigation could 
provide useful information to clinicians regarding the safety of treatments.   
 
2.2.3 Socioeconomic Status 
2.2.3.1 Diagnosis and stage 
Measures of socioeconomic status including education and income have been associated with 
lung cancer incidence.
34
 Adults with less education, lower household income, and greater poverty 
have a higher incidence of lung cancer compared to adults with greater educational attainment (e.g., 
college), higher household income, and less poverty.
34
 The elevated smoking prevalence among 
adults with lower socioeconomic status is a likely contributor to the higher incidence of lung cancer 
in this population; differences in smoking prevalence across socioeconomic groups have lessened 
over time, but socioeconomic status remains a significant predictor of smoking. Analysis
28
 of the 
National Health Interview Survey (NHIS) found that Americans who had less than a high school 
education, were unemployed, or lived below the poverty threshold were significantly more likely to 
be smokers compared to individuals who at least graduated high school, were in the work force or 
retired, or lived above the poverty threshold.  
Furthermore, an increased prevalence of smoking among adults with lower socioeconomic 
status may contribute to a higher rate of advanced disease observed at the time of diagnosis among 
this population. An evaluation of a national sample of lung cancer patients found that individuals 
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without medical coverage were twice as likely to present with advanced stage disease compared to 
individuals with health insurance.
169
 Similarly, evaluation of lung cancer patients seen at a single 
academic medical center found that patients with indigent health care coverage were  significantly 
more likely to present with advanced stage disease that patients with Medicare or private insurance.
35
 
 
2.2.3.2 Treatment 
Differences in the utilization of treatments within a population may be explained by 
socioeconomic status which is likely to be an important determinant of access to and receipt of 
appropriate and/or novel treatment for advanced stage NSCLC. For example, in the study by Hardy et 
al.,
18
 patients from the lowest quartile of socioeconomic status (as measured by the percentage of 
individuals living below the poverty line at the census tract level) were significantly less likely than 
patients in the highest socioeconomic status quartile to receive chemotherapy for the treatment of 
stage III or IV NSCLC (OR 0.60; 95% CI 0.45, 0.79). Also, in the Davidoff et al. analysis, patients 
from the lowest median household income quartile and those enrolled in Medicaid or Medicare 
Savings Programs in the year prior to diagnosis were significantly less likely to receive any 
chemotherapy within 90 days of diagnosis.
15
 These findings are complemented by an analysis of 
patients diagnosed between 2000 and 2007 with stage IV NSCLC at the University of Texas 
Southwestern Medical Center which found that uninsured patients (possibly reflecting lower 
socioeconomic status) were significantly less likely than private insured patients to receive 
chemotherapy even after controlling for other sociodemographic variables (OR 0.44; 95% CI 0.30, 
0.64).
150
 A separate analysis at the same academic medical center also found that patients of lower 
socioeconomic status, as measured by enrollment in an indigent health plan, were significantly less 
likely to receive ‘standard’ treatment compared to patients enrolled in Medicare or a private health 
insurance plan.
35
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2.2.3.3 Survival 
In addition to an increased incidence of lung cancer, higher rate of advanced disease at 
diagnosis, and lower receipt of standard treatment, socioeconomic status has also been associated 
with higher mortality,
35,37
 although evidence is limited and inconsistent. For example, a recent study 
of patients seen within the Duke Health System found that lung cancer patients residing in census 
tract areas of low median household income, high poverty, and low education attainment have poorer 
survival outcomes than patients living in census tract areas with higher median income, lower 
poverty, and greater education attainment.
37
 Similarly, among stage I and stage II NSCLC patients 
seen within a single academic medical center, patients enrolled in an indigent health plan had 
significantly poorer survival compared to patients enrolled in Medicare or a private health plan, even 
after controlling for other demographic and clinical characteristics (HR 1.98, 95% CI 1.16-3.37). 
However, these findings are contradicted by other research
38-40
 results that suggest NSCLC mortality 
is not associated with the socioeconomic status of patients. Thus, it is not clearly understood if and to 
what extent an association exists between socioeconomic status measures and lung cancer mortality.  
 
2.2.4 Provider Affiliation 
 Patient access to novel treatments for lung cancer and the quality of care they receive may be 
influenced by where and from whom care is provided. However, limited information is available 
about the relationship between provider affiliations (e.g., with a teaching hospital) and the utilization 
of certain treatments or procedures among patients with non-small cell lung cancer. In a study using 
SEER-Medicare data, researchers determined that patients diagnosed with NSCLC between 1991 and 
1996 were more likely to be referred to an oncology specialist if they received care at a teaching 
hospital.
31
 In addition, among patients diagnosed with metastatic NSCLC between 1991 and 1993, 
those who received care at a teaching hospital were more likely to receive chemotherapy treatment 
compared to patients treated elsewhere.
41
 The authors of this latter study also noted that the 
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prevalence of chemotherapy use for advanced non-small cell lung cancer was increasing, suggesting 
that the diffusion of newer therapies into real-world practice may occur earlier in settings such as 
teaching hospitals where physicians and institutions may be more likely to be exposed to or involved 
with the development of novel treatments.   
 However, community physicians and provider institutions not affiliated with a teaching 
hospital may still be engaged in the use of newly developed treatments through their participation in 
the National Cancer Institute’s (NCI) Community Clinical Oncology Program (CCOP).  The CCOP 
was designed to connect NCI Research Bases (NCI Cooperative Groups and Cancer Centers; 
primarily academic institutions) with a nationwide physician-based research network of community 
physicians to develop local clinical research infrastructures; goals of the program include patient 
enrollment in studies, real-world implementation of cancer treatment clinical trials, and rapid 
diffusion of novel evidence-based treatments into practice.
43
 Thus, providers participating in the 
CCOP, particularly those who accrue and enroll patients in NCI treatment trials, gain access to 
clinical trials and research results concerning novel therapies and technological advancements that 
may not otherwise be accessible outside of the research network.
43
 Furthermore, research suggests 
that CCOP-affiliated providers feel that their involvement in the provider-based research network 
enables them to deliver higher quality of care to their patients by keeping them updated on state-of-
the-art treatment which in turn serves as an important motivating factor for their continued 
participation in the CCOP.
44
 Indeed, research findings also support that community-based physician 
participation in provider-based research networks results in increased patient accrual into clinical 
trials and enhanced adoption of novel cancer care, ultimately characterizing an effective translation 
between research and clinical practice.
45-48
 However, empirical evidence is still needed to support the 
conception of greater adoption of novel treatments among CCOP-affiliated providers within NSCLC 
specifically. In addition, empirical evidence is also needed to demonstrate whether treatment 
outcomes among NSCLC patients vary according to provider affiliation with the CCOP.  
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2.3 Summary of Literature Review 
 Non-small cell lung cancer is a common form of cancer that primarily occurs among older 
adults and is associated with significant morbidity and mortality. Given the asymptomatic nature of 
early-stage disease, most cases are diagnosed after the cancer has spread to regional lymph nodes or 
has metastasized to distant sites. The greater incidence of advanced disease at diagnosis contributes to 
the poor prognosis and bleak survival rates associated with non-small cell lung cancer, particularly 
among older adults who are already in poor health at the time of diagnosis. Blacks, particularly black 
males, are at an increased risk for developing non-small cell lung cancer and presenting with 
advanced stages of disease at diagnosis. In addition, blacks are less likely to receive timely, definitive 
and/or novel treatment despite obvious benefits and are more likely to die from non-small cell lung 
cancer in the United States than any other racial or ethnic group.    
 Platinum-based doublet chemotherapy is the standard treatment for patients with advanced 
stage disease and has been shown to lessen cancer-related symptoms, lengthen survival, and improve 
quality of life. Furthermore, previous retrospective analyses of both clinical trial and observational 
data have shown that the use of chemotherapy, including the use of platinum-based doublets, can 
improve survival among older patients. However, chemotherapy is associated with toxic adverse 
effects that may be especially problematic for older adults and patients with poor overall health. In 
some patients, the risk of toxicity may outweigh the potential benefit of treatment. 
Underrepresentation of older adults in cancer clinical trials and the tendency for those included being 
in better overall health then the general older adult population restricts the generalizability of efficacy 
and safety findings from clinical trials. Unfortunately, the fear of treatment toxicity and a limited 
amount of knowledge in the literature about the safety and efficacy of chemotherapy agents in older 
adults and patients with poorer performance status precludes many older patients from receiving 
treatment they would likely benefit from.   
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 Efforts have been dedicated toward developing targeted treatments such as monoclonal 
antibodies that direct their effect toward tumor-specific characteristics, have greater activity at the 
cancer site and, in some cases, may result in lower systemic toxicity compared to standard 
chemotherapy. Bevacizumab is the only monoclonal antibody currently approved in addition to 
chemotherapy for the first-line treatment of advanced NSCLC in the United States. However, 
knowledge about the efficacy and safety of bevacizumab is limited to the results of several clinical 
trials. The use, safety, and effectiveness of bevacizumab in real-world practice are not well known, 
particularly among elderly and racial/ethnic minority patients.   
 The lack of knowledge about the use of bevacizumab in real-world practice, including 
identification of the clinical and non-clinical factors associated with its utilization, uncertainty 
surrounding the ability of bevacizumab to provide a survival benefit to older adults in addition to 
standard platinum-based doublet chemotherapy, and the concern for an increased risk of severe 
adverse events (especially hematologic effects) with bevacizumab warrants the need for the proposed 
study to evaluate the use, safety, and effectiveness of bevacizumab among older adults with advanced 
non-squamous non-small cell lung cancer. 
 
2.4 Theoretical Framework 
 The following sections describe the theoretical framework used to guide this dissertation by 
illustrating the factors that contribute to the use of targeted therapies in older adults with non-small 
cell lung cancer and the subsequent clinical outcomes of survival and treatment-related adverse 
events. Andersen’s Behavioral Model of Health Services Use provides the basis for the proposed 
theoretical framework and is described below followed by an explanation of the adaptations that were 
made to develop the proposed theoretical framework for the purposes of this dissertation. 
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2.4.1 Andersen’s Behavioral Model of Health Services Use 
 The first edition of Andersen’s Behavioral Model of Health Services Use was developed in 
the late 1960s.
170
 The initial model was created with the intent of providing a theoretical framework 
to assist in understanding families’ use of health services, to define and evaluate equitable access to 
health care, and to facilitate the development of policies to promote equitable access.
171
 The original 
Behavioral Model presumed that the use of health services is influenced by people’s inclinations to 
use services, factors that promote or inhibit service use, and the need for care.
172
 Furthermore, an 
important goal of the model was to help define and measure multiple dimensions of access to care, 
including potential access, realized access, equitable access, and inequitable access.
171,172
  
 Along with the emergence of various matters in health policy and health care delivery, new 
developments and ideas within health services research has led to some important additions and 
revisions to the Behavioral Model over the last forty years.
171
 For example, in the 1970s, the health 
care system was explicitly included in the model to account for the influence of policies, resources, 
and the organizational structure of the health care system on health services use in the population. In 
the 1980s, a third edition of the model emerged following recognition of the important impact 
personal health practices such as diet and exercise have on health outcomes as well as the utility of 
health status as an outcome and indicator of effective or efficient health services delivery.
173,174
 A 
fourth edition of the model was developed in the 1990s that recognized health services use as a 
dynamic and repetitive process; multiple factors influence health services use and subsequent health 
outcomes that, in turn, can affect subsequent determinants of use and health services utilization.
172
 
Finally, in 2007, the most recent version of the Behavioral Model was developed (Figure 2.1).
174
 This 
latest edition delineates contextual and individual characteristics that influence health services use 
and also adds in the process of medical care (i.e., the interaction of providers and patients in the 
delivery of care services) as a component of health behavior.
171
 It is the fifth edition of Andersen’s 
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Behavioral Model of Health Services Use that serves as the backbone for the theoretical framework of 
this dissertation and is described in more detail below. 
 
Figure 2.1 Andersen’s Behavioral Model of Health Services Use 
 
 
2.4.1.1 Contextual characteristics 
 Contextual characteristics refer to the circumstances and setting of health care access, 
involving organization, provider-related factors, and characteristics of the surrounding community.
174
 
These characteristics are measured at an aggregate level and individuals may be related to them 
through membership (e.g., health plan) or residence. Within contextual characteristics are three 
subcategories of determinants of health services use: predisposing characteristics, enabling 
characteristics, and need. Contextual predisposing characteristics, in turn, include demographic, 
social, and belief characteristics of the community. Demographic characteristics consist of the age, 
gender, and marital status arrangement within a community. Meanwhile, social characteristics include 
measures of education, race and ethnicity, employment rates, and crime that help to describe how the 
structure of a community might be supportive or detrimental to the health of its constituents and their 
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access to health care services. Furthermore, contextual beliefs refer to underlying community and 
organizational values, cultural norms, and political perspectives regarding the organization, 
distribution, and accessibility of health care resources in the community. However, because measures 
of contextual demographics and health beliefs are not available in the data source used for this study, 
the dissertation includes only variables that describe the social (education, race and ethnicity) 
constructs of the communities represented. 
 Contextual enabling characteristics can be broken down further into health policy, financial, 
and organizational characteristics.
174
 Health policies can directly influence access to health care 
services as authoritative decisions made in both the private and public sectors. Financial 
characteristics, such as the rate of health insurance coverage within a community, are suggestive of 
the resources that are potentially available to pay for health care services; ideally, the greater the 
amount of financial resources per capita, the less access is inhibited because of cost or inability to pay 
for needed services. Organizational characteristics not only describe the amount and distribution of 
health care facilities and personnel that exist within a community, but also how these health care 
resources are structured to provide services. Measures of organizational structure include the supply 
of services (e.g., number of hospital beds), location, provider mix, and community outreach 
programs. Since this study did not intend to assess the impact of any particular health policy and the 
individuals included in the study were required to receive benefits through Medicare, measures of 
health policy and financial characteristics were not considered in the framework of this dissertation. 
However, organizational variables that distinguish potentially important differences between sites of 
care (e.g., community versus teaching hospital) were included in the conceptual model.       
 Contextual need variables include both environmental characteristics and population health 
indices.
174
 Environmental need characteristics depict the physical environment of a community, such 
as water and air quality, that may shape the health service needs of those who reside in the area. 
Population health indices, on the other hand, often include rates of mortality, morbidity, and disability 
within a given region, and though they are typically more general than environmental need 
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characteristics, they are also useful in describing the need for health services within an area. 
Environmental characteristics are not available in the data source used for this study, however, 
regional variation in the prevalence and mortality rates of non-small cell lung cancer were considered 
in the theoretical framework. 
 
2.4.1.2 Individual characteristics 
 Similar to contextual characteristics, individual characteristics also consist of predisposing, 
enabling, and need variables that predict and quantify health services use. The main difference 
between contextual and individual characteristics is the level of measurement with contextual 
referring to aggregate measures at a population level and individual referring to characteristics of a 
single person. Individual predisposing characteristics describe factors that exist prior to the onset of 
disease and help to predict use of health services by individuals based on their ability to identify, cope 
with, and utilize resources to manage health problems.
172,174
 Predisposing characteristics include 
demographics (age, gender), social factors (race, ethnicity, occupation, social network), and personal 
health beliefs (attitudes, values, knowledge of health and services). However, because individual 
health beliefs and information about occupation and social support variables are not available in the 
data source used for this study, the framework of this dissertation only includes the predisposing 
variables of age, gender, race, and race. 
 Enabling characteristics of individuals refers to the resources available to individuals that can 
promote the use of health services.
174
 More specifically, financial characteristics describe the 
monetary resources of income and wealth available to an individual to pay for services as well as the 
price of care to them based on the presence of insurance and cost-sharing responsibilities. 
Furthermore, organizational resources, such as a usual source of care, transportation, and travel time 
between residence and site of care can either facilitate or impede the use of health services. Measures 
of both financial (median household income) and organizational (usual source of care, distance 
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between residence and site of care) resources are used in the theoretical framework of this 
dissertation. 
 Need, both as perceived by an individual and as evaluated by health professionals, is the 
remaining component of individual characteristics that influence the use of health services.
172,174
 
Perceived need is a measure of how an individual views their own general health and functional state, 
experiences and responds to symptoms of illness, and worries about their health.
174
 Individual 
perceptions about the significance of a health problem can ultimately lead to a decision about whether 
or not to seek medical care and, in turn, are useful to researchers evaluating the care-seeking process 
of individuals and their adherence to prescribed regimens. Evaluated need on the other hand, 
represents the judgment of health care professionals and/or objective measures regarding the health 
and functional status of an individual and the need for medical care. Thus, evaluated need 
characteristics often include both a diagnosis and the prognosis of particular health conditions. 
However, it is important to recognize that evaluated need is not always steadfast and can vary over 
time as clinical guidelines, prevailing practice patterns, and diffusion of innovation patterns change 
within the art and science of medicine. Furthermore, evaluated need is particularly useful to 
researchers interested in examining the types and quantities of health services being provided to 
individuals following initial evaluation for disease, and is an important construct in the theoretical 
framework of this dissertation.   
 
2.4.1.3 Health behaviors 
 As depicted in Figure 2.1, both contextual and individual characteristics can influence health 
behaviors and health outcomes. Health behaviors are represented by the personal health practices of 
individuals, the process of medical care, and the actual use of personal health services. Personal 
health practices include measures of diet, exercise, self-care, and treatment adherence, each of which 
can directly affect health status as well as the need for subsequent health services. The process of 
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medical care involves the interaction between the provider and the patient during care delivery, and 
may include measures of patient counseling, prescribing patterns, and the quality of patient-provider 
communication.
174
 Measurements of the use of health services can be general (e.g., physician office 
visits), as in the original Behavioral Model, or more specific to a type of service, medical condition, 
or provider (e.g., chemotherapy ordered by medical oncologist for non-small cell lung cancer). 
Although the influences of personal health practices and patient-provider communication cannot be 
analyzed with the data source used in this study, treatment prescribing patterns by provider specialty 
and the administration of chemotherapy and targeted agents were identified and used as integral 
components of this dissertation.  
 
2.4.1.4 Health outcomes 
 Health outcomes in Andersen’s Behavioral Model include both the perceived and evaluated 
health status of an individual; these variables are essentially the same as perceived and evaluated need 
characteristics as an expectation of improved access to health services is a reduction in the health 
service needs of an individual that were previously measured and evaluated.
174
 Specifically, the 
perceived health status of an individual refers to the extent to which a person can function (i.e., 
perform activities of daily living), and live comfortably and pain-free, and is dependent on factors 
from other components in the model (contextual, individual, and health behavior characteristics). 
Evaluated health status represents the judgment of a health care professional, influenced by 
established clinical standards and provider experience, and involves measures similar to those of 
evaluated need, including functional status and prognosis. The data source used in this study does not 
include measures of perceived health status, and therefore, this dissertation only included measures of 
evaluated health status (diagnosis, survival) as outcomes. 
 Further, components of Andersen’s Behavioral Model are useful in defining and evaluating 
various dimensions of access to health services.
174
 For example, enabling variables measured at the 
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contextual and individual levels help to define potential access to care, with the idea that a greater 
amount of enabling resources amounts to increased likelihood for use of services. Similarly, the 
actual use of services represents realized access, and measures of use can be used to evaluate policies 
designed to have an effect on health services use.  However, more important to this dissertation are 
the concepts of equitable and inequitable access. Both equitable and inequitable access is defined 
based on the characteristics that dominate the prediction of health services utilization. Although open 
to interpretation, traditionally, access has been defined as equitable when demographic and need 
variables in particular direct the greatest amount of health services use. In contrast, inequitable access 
results when social and enabling resources dictate which individuals receive care.  
 A final and relevant note about the Behavioral Model is that although predisposing, enabling, 
and need characteristics are all influential in determining health services use and health outcomes, the 
explanatory power of each component of characteristics may vary based on the type of health services 
being evaluated. For example, it is often expected that predisposing and need characteristics will 
dominate in predicting the use of hospital services because of the more serious nature of problems 
typically encountered in the emergency department and hospital settings.
174
 Conversely, it is expected 
that all three components will predict the use of ambulatory services because conditions stimulating 
individuals to seek care in the outpatient setting are often less serious and more discretionary than 
those that result in inpatient treatment. Therefore, given the ambulatory nature of care for individuals 
in this study, it was expected that predisposing, enabling, and need variables would all factor into the 
use of targeted therapies among older adults with advanced non-small cell lung cancer.  
 
2.4.2 Proposed Conceptual Framework 
 The proposed conceptual framework for this study, depicted in Figure 2.2, is an adaptation to 
the fifth version of Andersen’s Behavioral Model of Health Services Use and contains three main 
components: individual and contextual characteristics, health behaviors, and health outcomes.  
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Individual characteristics influence both health behaviors and health outcomes through the 
predisposing, enabling, and need attributes of individuals.  Contextual characteristics are represented 
by predisposing, enabling, and need attributes measured at a population level; these factors affect the 
health behaviors and outcomes of individuals within a given community through the facilitation and 
promotion of health services and optimal health, or lack thereof.   Health behaviors, in turn, not only 
influence health outcomes, but also feedback into individual and contextual characteristics that 
determine subsequent health services utilization.  Similarly, health outcomes may affect future health 
behaviors of individuals and also stimulate changes to the individual and contextual determinants of 
subsequent health behaviors and health outcomes. 
 Perceived health, evaluated health, and consumer satisfaction are identified as the 
components of health outcomes in Andersen’s Behavioral Model.  However, the health outcomes of 
interest in this study are solely evaluated health measures (survival and hospitalization for adverse 
events related to the administration of bevacizumab).  Furthermore, measures of patients’ perceived 
health or satisfaction with care are not available in SEER-Medicare data and therefore are only 
included in the proposed framework of this study to show completeness and to identify their potential 
relevance as health outcomes in future studies related to treatment utilization in patients with non-
small cell lung cancer. Likewise, although personal health practices and the process of medical care 
are components of health behaviors in Andersen’s model, they are not quantifiable in the SEER-
Medicare data source and therefore the utilization of bevacizumab is the sole “health behavior” 
measured in this study. 
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Figure 2.2 Proposed conceptual framework 
Perceived Need*
Evaluated Need
o Tumor:
•Stage
• Histology
oComorbid conditions
Individual & Contextual Characteristics Health Behaviors
Personal health practices*
Process of medical care*
Use of targeted therapy
o Bevacizumab
Health Outcomes
Perceived health*
Consumer satisfaction*
Evaluated health
oOverall survival
oHospitalizations for severe 
treatment–related adverse effects
Demographic
oAge
oGender
oMarital status
Social factors
oRace
o Ethnicity
o Education
Health beliefs*
Predisposing Need
Financing
o SES
• Median household 
income
• % living below poverty
oUrban residence
o Supplemental insurance
Organization
oUsual source of care
o Provider affiliations
- CCOP
- Teaching hospital
Enabling
* Italicized variables are not measurable with the SEER-Medicare data but are included in the conceptual model for completeness  
SOURCE: Adapted from Andersen’s Behavioral Model of Health Services Use171 
 
2.4.2.1 Individual predisposing characteristics 
 Following Andersen’s Behavioral Model, the individual characteristics in the proposed 
framework include predisposing, enabling, and need characteristics of individuals that are predictive 
of health services use and health outcomes. Predisposing characteristics of the proposed framework 
include the demographic factors of age, sex, and marital status along with the social determinants of 
race and education level (a proxy measure of socioeconomic status).  Increasing age has been 
associated with lower receipt of local
148,175
 and systemic
15
 therapies for non-small cell lung cancer, as 
well as with poorer survival
15,176,177
 and greater sensitivity to the toxic effects of systemic 
treatment.
160,178
 Gender has also been related to differences in the receipt of timely and appropriate 
treatment and women tend to have improved survival
20,176,179-184
 and potentially greater sensitivity to 
the toxic effects of treatment
179,183
 compared to men. 
Furthermore, marital status is another potentially important prognostic factor in lung cancer 
that has been associated with receipt of treatment and survival outcomes.
165,185
 Arguably, marital 
status is an enabling factor in that marriage may afford patients the social support needed to seek out 
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and/or receive certain treatments that otherwise may not be made available to them. However, in this 
study, marital status is believed to have greater influence as a predisposing factor than as an enabling 
resource; marriage may enable patients to receive chemotherapy, but it predisposes individuals to 
seek out treatment that may prolong survival in addition to chemotherapy, such as bevacizumab. The 
social determinant of race has also been linked to differences in the receipt of treatment and overall 
survival in non-small cell lung cancer, with worse outcomes being experienced by minority 
patients.
17-20,22,23,25,27,58,165
 Finally, the educational makeup of the community in which a patient resides 
is the lone quantifiable contextual predisposing characteristic. Because socioeconomic measures are 
not available at the individual level within the SEER-Medicare database, the census tract level 
measurement of education attained serves as a proxy measure of an individual’s education level as 
well as their socioeconomic status. Indeed, previous research has shown that lower education 
attainment is associated with lower receipt of treatment and poorer survival outcomes among cancer 
patients.
186
 
 
2.4.2.2 Enabling characteristics  
State buy-in of Medicare coverage is the lone individual enabling characteristic included in 
the proposed framework (additional enabling characteristics are contextual and described below). 
State buy-in of Medicare coverage is a potentially important predictor of the use and outcomes 
associated with bevacizumab as state buy-in coverage has been associated with lower use of 
chemotherapy and poorer survival outcomes among older adults with advanced NSCLC. Contextual 
enabling characteristics include census tract level measure of median household income (another 
proxy measure of socioeconomic status), population density, provider affiliations, diagnosis year, and 
SEER region. Census tract level estimates of median household income have been associated with the 
use of chemotherapy and survival outcomes among older adults with advanced NSCLC; patients from 
census tract areas with lower median household income are less likely to receive chemotherapy and 
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have poorer survival compared to patients from census tracts with a higher median household 
income.
15
 Furthermore, although population density was not associated with receipt of treatment or 
survival in previous studies of lung cancer patients,
15,187
 individuals residing in rural areas may be 
poorer and have limited access to health care providers.
187
 Characteristics of health system resources 
and the sites of care where patients undergo evaluation and treatment for non-small cell lung cancer 
can also influence what therapies are offered and received by individuals.
47
 Health care providers who 
participate in NCI’s Community Clinical Oncology Program may be more knowledgeable about and 
early adopters of novel therapies.  In addition, provider affiliation with a teaching hospital/academic 
center may also influence the use of newly developed treatments. Thus, greater knowledge and earlier 
adoption of novel therapies by select providers may be demonstrated through an observable increase 
in the utilization of bevacizumab among patients with advanced NSCLC who receive treatment from 
providers with identifiable affiliations with provider-based research networks or academic medical 
centers. Furthermore, although year of diagnosis is not expected to be associated with health 
outcomes given the relatively short timeframe of the study, year of diagnosis is expected to have a 
large influence on the utilization of bevacizumab. Given that bevacizumab was approved for use in 
NSCLC in 2006, it is expected that utilization among older patients diagnosed in 2007 will be much 
greater than the rate of use seen in preceding years. Finally, the SEER region in which a patient 
resided at the time of diagnosis may be an important predictor of the use of bevacizumab and/or 
health outcomes; treatment patterns, environmental factors, and health behaviors may differ and 
therefore contribute to differences in the use and outcomes of bevacizumab across SEER regions. 
 
2.4.2.3 Need characteristics 
Evaluated need factors in the proposed framework include important tumor characteristics 
such as stage, grade, and histology, as well as the presence of comorbid conditions, hemoptysis, brain 
metastases, and receipt of radiation therapy and/or cancer-directed surgery. Stage and histology are 
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particularly important predictors of the use of bevacizumab and survival as bevacizumab is 
specifically indicated for the treatment of locally advanced or metastatic non-squamous NSCLC and 
has shown improved survival outcomes among patients with adenocarcinoma histology in 
particular.
188
 Although grade is not expected to be associated with the utilization of bevacizumab, 
differences in tumor differentiation may influence survival outcomes among patients with poor or 
undifferentiated tumors likely to result in poorer survival compared to well or moderately 
differentiated tumors. In addition, comorbid conditions may significantly influence the need for and 
expected benefit from treatment among patients with NSCLC.
52,53,93,94
 Similarly, the presence of 
hemoptysis and brain metastases are likely to affect the use of bevacizumab; patients with hemoptysis 
or brain metastases at diagnosis may not be good candidates for treatment with bevacizumab because 
of the significant increase in severe bleeding risk with its use. In addition, hemoptysis and/or brain 
metastases may indicate more advanced disease and worse prognosis and therefore not only influence 
treatment but survival outcomes.    
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER THREE 
 METHODS 
 
3.1 Overview of Research Design and Aims 
 This dissertation utilized a retrospective cohort design and the Surveillance, Epidemiology 
and End Results (SEER)-Medicare linked database to evaluate the use of bevacizumab and associated 
outcomes in older adults diagnosed with locally advanced or metastatic non-small cell lung cancer 
between January 1, 2004 and December 31, 2007. Briefly, the dissertation consisted of three distinct 
studies aimed at identifying the utilization, safety, and effectiveness of bevacizumab use among older 
adults with advanced non-small cell lung cancer.  Although each study addressed a separate question, 
the analyses are interrelated conceptually and methodologically.  The first study measured the 
utilization of bevacizumab in combination with double agent platinum-based chemotherapy as first-
line treatment for advanced non-small cell lung cancer and identified important clinical, 
sociodemographic, and health system characteristics that predict bevacizumab use.  In particular, we 
were interested in whether sociodemographic variables including chronological age, race, or proxy 
measures of socioeconomic status explained utilization of bevacizumab after controlling for clinical 
factors such as tumor histology, and comorbidity.  Characteristics that influenced the use of 
bevacizumab were evaluated in the second and third studies as potential confounders of the effect of 
bevacizumab on overall survival and hospitalization for severe treatment-related adverse events, 
respectively; confounders and other independent variables of interest were then adjusted for in the 
second and third studies to estimate unbiased effects of bevacizumab use on overall survival and 
hospitalization.  The aims and a brief overview of the analyses performed are described below: 
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Aim 1: To describe the utilization of bevacizumab in combination with standard 
platinum-based doublet chemotherapy as first line treatment for older adults with advanced 
non-small cell lung cancer and to identify the clinical, sociodemographic, and health system 
factors associated with its use. In Aim 1, we first described the use of bevacizumab in older adults 
with advanced non-small cell lung cancer and identified bivariate associations between the use of 
bevacizumab and observable clinical, sociodemographic, and health system characteristics.  We then 
estimated multivariable logistic regression models to identify characteristics that remained associated 
with the use of bevacizumab after controlling for other confounding variables. 
 Aim 2: To determine whether the use of bevacizumab in combination with standard 
platinum-based doublet chemotherapy as first-line treatment of older adults with advanced 
non-small cell lung cancer is associated with a benefit of improved overall survival.  In Aim 2, 
we estimated the effect of bevacizumab on the probability of 1-year survival and survival duration.  
Unadjusted hazard ratios were generated to identify factors thought to contribute to the prediction of 
survival.  Cox proportional hazards models were then estimated to evaluate the influence of 
bevacizumab on overall survival after controlling for identified risk factors.  Propensity score 
adjustments were also utilized in the proportional hazards models to account for the confounding 
influence of observable characteristics associated with both treatment selection and survival.     
 Aim 3: To determine whether the use of bevacizumab in combination with standard 
platinum-based doublet chemotherapy as first-line treatment of older adults with advanced 
non-small cell lung cancer is associated with an increase in hospitalizations for severe 
treatment-related adverse events.  In Aim 3, we compared the cumulative incidence of 
hospitalization for pre-specified adverse events (detailed below in section 3.4) among users and 
nonusers of bevacizumab during the first 180 days of treatment as well as within a specified window 
during first-line treatment. We then estimated multivariable logistic regression and Cox proportional 
hazards models to identify whether the association between bevacizumab and severe adverse events 
was independent of other factors associated with toxicities resulting in hospitalization.   
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3.2 Data Source 
 This project used the Surveillance, Epidemiology and End Results (SEER)-Medicare linked 
database. Each component of the linked database is first described individually below followed by a 
brief description of the most current version of the SEER-Medicare database. 
 
3.2.1 Surveillance, Epidemiology, and End Results (SEER) 
 The SEER Program of the National Cancer Institute (NCI) is a coordinated system of 
population-based cancer registries strategically distributed throughout the United States and is the 
only comprehensive population-based source in the country that contains data on stage at diagnosis 
and patient survival. Currently, the SEER Program includes data from 17 distinct registries 
representing approximately 28 percent of the US population, and coverage of 26 percent of blacks, 41 
percent of Hispanics, 43 percent of American Indians and Alaska Natives, 54 percent of Asians, and 
71 percent of Hawaiian/Pacific Islanders.  SEER registries collect data on patient demographics, 
primary tumor site, tumor morphology and stage at diagnosis, first course of treatment, and follow-up 
for vital status. Demographic and cancer variables are contained within a Patient Entitlement and 
Diagnosis Summary File (PEDSF) and include race, ethnicity, gender, marital status, date of birth, 
place of birth, vital status, and cause of death (provided by the National Center for Health Statistics); 
cancer variables include month and year of diagnosis, type of cancer, histology, grade, AJCC 
(American Joint Committee on Cancer) cancer stage, and initial treatment (although information may 
be incomplete). In addition, census tract and zip code level socioeconomic data (education, poverty, 
median household income) is provided in the PEDSF via the 1990 and 2000 U.S. Census.
189
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3.2.2 Medicare 
 Medicare is a federally funded program that provides health insurance for individuals age 65 
and over as well as those under 65 with end-stage renal disease (ESRD) or certain disabilities.  
Among individuals in the US population aged 65 and older, approximately 97 percent are eligible to 
receive Medicare benefits. Nearly all Medicare beneficiaries receive Medicare Part A benefits that 
provide coverage for inpatient care in hospitals and use of skilled nursing facility, hospice, and some 
home health care services. In addition, almost all individuals who receive Medicare Part A also elect 
to pay a monthly premium to receive Part B benefits that provide coverage for outpatient care 
services including doctor visits, hospital outpatient care, durable medical equipment (e.g., blood 
glucose monitors), home health care, and some preventive services (e.g., flu shots). Furthermore, 
although most Medicare beneficiaries receive Part A and Part B benefits through traditional fee-for-
service (FFS) plans administered by Medicare, some individuals opt to enroll in “Part C” or a 
Medicare Advantage Plan. Medicare Advantage Plans are managed care plans (similar to HMOs and 
PPOs) administered by private insurance companies approved by Medicare that provide coverage for 
all Part A and Part B eligible services. Also, Medicare Advantage Plans may offer coverage of 
additional services not available through the traditional Medicare FFS plan, such as prescription 
drugs, vision services, and health/wellness programs.   
 Prior to January 1, 2006, Medicare did not offer outpatient prescription drug benefits; adults 
aged 65 and older were reliant on other sources such as Medicaid and employer-sponsored health 
plans to assist them in paying for outpatient medications. Still, a large proportion of older adults did 
not qualify for assistance from Medicaid and over time many employers began cutting health benefits 
to their retirees. By 2003, nearly 1 in 4 adults aged 65 years and older lacked prescription drug 
coverage.
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 In order to help subsidize the costs of prescription drugs for Medicare beneficiaries, the 
Medicare Prescription Drug, Improvement, and Modernization Act was signed into federal law in late 
2003, establishing the voluntary Medicare outpatient prescription benefit, known as Part D, that 
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became effective January 1, 2006. With the establishment of Part D, all Medicare beneficiaries are 
eligible to access the prescription drug benefit through enrollment into one of the private plans 
approved by the federal government, either as a stand-alone prescription drug plan (PDP) or as part of 
their Medicare Advantage health plan (MA-PD). Plans available to beneficiaries vary in benefit 
design including monthly premiums and copayment structure, medications covered, and cost-
containment strategies utilized. According to 2010 estimates, approximately 60% of the 47 million 
Medicare beneficiaries were enrolled in a Part D plan and an additional 30% received other forms of 
drug coverage.
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 Furthermore, Medicare has supplanted Medicaid as the prime source of drug 
coverage for “dual eligible” beneficiaries (those who receive both Medicare and Medicaid benefits) 
and some low-income beneficiaries may also qualify for additional assistance with Part D plan 
premiums and cost-sharing responsibilities.   
 
3.2.3 SEER-Medicare 
 The SEER-Medicare data represent a linkage of population-based tumor registry and health 
services use data that provide comprehensive information about Medicare beneficiaries diagnosed 
with cancer.
192
 The linkage, first completed in 1991 and now updated biennially, is a coordinated 
effort between the National Cancer Institute, the SEER registries, and the Centers for Medicare and 
Medicaid Services (CMS). The current SEER-Medicare linkage includes all Medicare eligible 
persons appearing in SEER data who were diagnosed with cancer through December 31, 2007, and 
their Medicare claims through the end of 2009; 93 percent of adults age 65 and older appearing in 
SEER data files have been matched to the Medicare enrollment file. The SEER-Medicare data consist 
of one SEER file and several Medicare files that are described below. SEER data contain one record 
for each individual who has been matched between the SEER database and Medicare enrollment 
records; information in the SEER file includes basic demographic characteristics and diagnostic 
information for up to 10 identified cancers per individual. Medicare files include claims data for Part 
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A institutional services (MEDPAR), Part B institutional services (Outpatient Claims), services billed 
by individual providers under Part B (National Claims History (NCH) or Carrier Claims), home 
health services (HHA), hospice care, and durable medical equipment (DME). Also, as of the most 
recent update (early 2011), SEER-Medicare now includes yearly Part D patient enrollment 
information (beginning in 2006) as well as prescription drug utilization for years 2007 and 2008. The 
SEER-Medicare files that were available for the current study are summarized in Table 3.1; the home 
health services, hospice care, and Part D files were not included in the data use agreement that was 
made prior to the construction of this study. 
There are notable limitations of the SEER-Medicare data that restrict the analyses conducted 
in this study. First, SEER-Medicare does not include healthcare claims information for individuals 
enrolled in Medicare Advantage Plans. Thus, we had to exclude patients who were covered by a 
Medicare Advantage Plan for any duration of time stating twelve months prior to the date of 
diagnosis up until the time of death or censoring given the possibility that important clinical or 
treatment information could be missing for these individuals. Second, SEER-Medicare also does not 
have information for provided services that are not billed to or covered by Medicare (e.g., services 
provided by Veterans Affairs, billed solely to Medicaid, or paid exclusively out-of-pocket by a 
beneficiary). The dependent and independent variables of interest in our study only concerned those 
health services covered by Medicare (e.g., hospitalization, outpatient physician visits, chemotherapy 
administration) so long as an individual was enrolled in Medicare Parts A and B, and although it 
might be possible, it seems rather unlikely that patients with continual Medicare coverage would use 
it to pay for some services (e.g., hospitalization) and not others (e.g., chemotherapy). However, 
patients with gaps in their Medicare coverage (e.g., an individual may choose not to pay for Part B 
while receiving benefits through Part A) may have information missing about health services they 
received during the time they were not enrolled in a Medicare fee-for-service plan. Therefore, we had 
to exclude patients who did not have continuous enrollment in both Medicare Parts A and B during 
the twelve months prior to the date of diagnosis through the time of death or censoring at the end of 
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the study period. Third, measures of patient beliefs and preferences and other potential explanatory 
variables that may influence the decision to use bevacizumab in advanced stage non-small cell lung 
cancer are absent from the SEER-Medicare data. A fourth limitation is that SEER-Medicare data does 
not include individual-level socioeconomic information such as household income or education 
attained. In an effort to get around this issue, we created a proxy measure using median household 
income at the census tract and zip code-levels that has been used in prior research
193,194
 with SEER-
Medicare data to reflect an individual patient’s socioeconomic status.  In addition, we paid careful 
attention in the assessment and interpretation of this proxy measure given the potential for 
misclassification of individual socioeconomic status using census tract and zip code-level 
information.
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 Finally,  the older adults living in SEER regions are less likely to be white, live in 
poverty, or reside in a rural area compared to the general older adult population in the United 
States.
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 Therefore, we recognize that the results from this study may not be nationally representative 
or applicable to individuals outside of the Medicare fee-for-service population age 65 years and older 
who reside within the SEER regions. The remaining sections of this chapter describe cohort selection 
and variable measurement followed by a detailed description of the hypotheses, dependent and key 
independent variables, and analytical methods used in each study. 
 
Table 3.1 Summary of SEER-Medicare data files used 
Name of file Source Description Variables available 
Patient Entitlement SEER SEER registry and Cancer specific: month/year of  
and Diagnosis   Medicare entitlement diagnosis, site, stage, histology, 
Summary File  information; basic treatment interventions within the  
(PEDSF)  socioeconomic status first 4 months of diagnosis, SEER 
  variables from Census region 
  Bureau at the census tract  
  and zip code levels Patient-specific: month/year of 
   birth, date of death, gender, race,  
   marital status, Medicare eligibility 
   and entitlement, HMO enrollment, 
   census tract/zip code level data on 
   median household income, education 
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Table 3.1 (Continued)    
Medicare Provider Medicare Medicare Part A inpatient ICD-9 diagnosis and procedure 
Analysis and  claims including those for codes; date and length of stay; 
Review (MEDPAR)  skilled nursing facility use charges and payments made per 
   admission 
Carrier Claims (NCH) Medicare Medicare Part B claims Date and place of service; nature 
  from physicians and other of billed service using Health Care 
  non-institutional providers Procedure Classification Codes 
   (HCPCS; primarily Common 
  One record is created for Procedural Terminology (CPT)-4 
  each service provided  codes), and ICD-9 dx codes; 
  during a visit J-codes identify specific 
   chemotherapeutic and targeted  
   agents administered intravenously 
Outpatient Claims Medicare Medicare Part B claims Date of service; beneficiary 
  for outpatient services demographic information; facility 
  from institutional  provider number; ICD-9 diagnosis 
  providers including and procedure codes (sporadic);  
  hospital outpatient HCPCS J-codes to identify 
  departments; One record specific chemotherapeutic and  
  is created for each service targeted agents administered 
  provided during a visit intravenously 
Durable Medical Medicare Claims submitted to  Date of service; ICD-9 diagnosis 
Equipment (DME)  durable Medical codes; HCPCS service codes;  
  equipment Regional reimbursement amount; DME 
  carriers (DMERCs); provider number; beneficiary 
  claims for oral demographic information 
  chemotherapies that have 
  an intravenous equivalent 
 
3.3 Cohort Selection 
 This study investigated the utilization of bevacizumab and associated health outcomes using a 
cohort design consisting of incident cases of locally advanced or metastatic (TNM stages IIIB and IV) 
non-small cell lung cancer. We excluded patients diagnosed with carcinoma in situ or stage I-IIIA as 
these patients are not likely to receive bevacizumab as part of their initial treatment regimen. We 
excluded patients with a history of cancer because prior cancer diagnoses and/or therapies may 
influence the use of subsequent treatments as well as survival outcomes. Similarly, patients with 
Medicare eligibility based on end-stage renal disease or disability were excluded as these patients are 
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likely to be frailer and may receive different treatment or have different treatment outcomes than the 
general Medicare patient population. In addition, in order to accurately identify eligible patients and 
account for the outcomes of interest, we excluded individuals who had information missing regarding 
their diagnosis or death, died within 30 days of diagnosis, were enrolled in a Medicare Advantage 
Plan or had any period without Medicare Parts A and B during the 12 months before or any time 
following diagnosis. Furthermore, to correctly identify and describe first-line treatment received by 
patients within the cohort, individuals who received ‘other’ or unspecified chemotherapy agents or 
received chemotherapy in an inpatient setting (i.e., in a hospital) ≤ 8 days from the date of the first 
chemotherapy claim were excluded. The selection of patients evaluated in this study is further 
described in the inclusion and exclusion criteria below. 
 
3.3.1 Inclusion criteria 
a. Patients with a primary incidence of cancer of the lung and bronchus between January 1, 
2004 and December 31, 2007.  
b. Patients who maintained enrollment in Medicare Parts A and B beginning 12 months prior 
to their diagnosis date until their date of death or censoring.  
c. Patients who received chemotherapy ≤ 120 days from the date of diagnosis. 
d. Patients who received initial chemotherapy consisting of the administration of a platinum 
and non-platinum chemotherapy agent ≤ 8 days from the first date of chemotherapy.   
 
3.3.2 Exclusion criteria 
a. Patients with a prior or simultaneous diagnosis of other cancer.  
b. Patients with missing or invalid data for the date of diagnosis. 
c. Patients diagnosed prior to their 66th birthday.   
d. Patients diagnosed at the time of death or autopsy. 
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e. Patients originally entitled to Medicare due to end-stage renal disease or disability. 
f. Patients enrolled in a Medicare Advantage Plan during the 12 months before or any time 
following diagnosis. 
g. Patients diagnosed with carcinoma in situ, stage I – IIIA, or stage unknown.   
h. Patients diagnosed with tumors of unknown histology or not of non-small cell histology. 
i. Patients diagnosed with squamous cell tumors.  Bevacizumab is only indicated for use in 
patients with tumors of non-squamous histology; squamous histology is associated with a 
significant increased risk for bleeding complications with use of bevacizumab.
196
  
j. Patients whose date of death was ≤ 30 days from the date of diagnosis. 
k. Patients who received ‘other’ or unspecified chemotherapy agents or received 
chemotherapy in an inpatient setting (i.e., in a hospital) ≤ 8 days from the date of first 
chemotherapy claim. 
 
3.4 Measurement of Variables 
 This section describes how the clinical, sociodemographic, and health system characteristics, 
identified by clinical theory and previous literature as potential factors in the utilization and outcomes 
of bevacizumab treatment, were measured using SEER-Medicare data.  Operationalization of the 
dependent variables, key independent variables, and additional covariates used in the analyses are 
detailed in text and summarized in Tables 3.2, 3.3, and 3.4 below.   
 
3.4.1 Dependent variables 
 Use of bevacizumab:  Use of bevacizumab was the dependent variable of interest in the first 
study and the main exposure (independent variable) of interest in the second and third studies. 
Use of bevacizumab was measured through identification of claims from NCH (provider) and 
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outpatient facility files with the HCPCS code for bevacizumab administration, J9035. A 
dichotomous variable was created to indicate any or no use of bevacizumab; an individual 
patient was considered a user of bevacizumab if at least one claim with code J9035 was 
present following diagnosis and occurred within 8 days of the start of the initial 
chemotherapy regimen (i.e., the ‘treatment identification window’). A separate dichotomous 
variable was also created to identify whether or not patients had at least one claim for 
bevacizumab present within the first 30 days of chemotherapy treatment. Several additional 
variables were created to more completely illustrate the use of bevacizumab including the 
time (in days) between diagnosis and bevacizumab initiation, total duration (in months) of 
bevacizumab use, and the total number of bevacizumab cycles (administrations). Given that 
SEER only provides the month and year of diagnosis, we created an artificial date of 
diagnosis using the 1st day of the diagnosis month in order to measure the number of days 
between the date of diagnosis and the date bevacizumab was first administered.   
 Overall survival:  Overall survival, a measure of the benefit of bevacizumab and a major 
outcome of interest, was evaluated using two separate measures. The first measure was the 
probability of 1-year overall survival. Follow-up time started on the first date of 
chemotherapy and/or bevacizumab administration, whichever occurred earlier. Patients were 
followed daily until the date of death or until the date of one year was reached. A 
dichotomous variable, one-year survival (yes/no), was created to indicate whether or not a 
patient survived one-year following the initiation of treatment. The second measure, overall 
survival duration, also started from the time of treatment initiation and followed the survival 
of patients daily until the date of death or date of censoring (loss to follow-up or end of study 
period), whichever occurred earlier. A continuous variable, time-to-event (death), was created 
to indicate the number of days a patient survived, calculated as the date of death minus the 
date treatment was initiated. To assess for the possibility of immortal time bias, follow-up 
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time in a sensitivity analysis was initiated on the first day following the treatment 
identification window. Thus, when the utilization of treatment was assessed over the first 8 
days of chemotherapy, follow-up began on the 9
th
 day of treatment; when utilization was 
assessed over the first 30 days of chemotherapy, follow-up began on the 31
st
 day of treatment.     
 Hospitalization for severe treatment-related adverse events:  Hospitalizations for severe 
adverse events previously evaluated and/or associated with bevacizumab,
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 including arterial 
thromboembolic events, neutropenia, gastrointestinal perforation, and severe hemorrhage 
were identified using hospitalization claims from the MEDPAR (inpatient) file. Claims from 
the MEDPAR file were evaluated beginning on the date of first chemotherapy or 
bevacizumab administration, whichever came earlier. Hospitalizations for severe adverse 
events were assessed over the first 180 days following the initiation of treatment as well as 
during a specified first-line treatment window. These measures are described separately 
below: 
Hospitalization during the first 180 days of treatment: Hospitalizations for specific severe 
adverse events were considered to have occurred during the first 180 days of treatment if 
within that time period an inpatient service claim was present and contained at least one of 
the ICD-9 or CPT codes included in Table A-1 of Appendix A. Follow-up time started on the 
date of treatment initiation (day 1) and followed patients daily until the date of hospitalization 
or day 180, whichever occurred first. A dichotomous variable (yes/no) was created to indicate 
whether or not the patient was ever hospitalized for each of the specified adverse events 
during the first 180 days of treatment.     
Hospitalization during first-line treatment window: The first-line treatment window was 
defined as the duration of time between the date initial treatment started to the earlier of two 
possible endpoints: 1) the date of cessation of first-line treatment + 30 days or 2) the date a 
 99 
new treatment agent was initiated, where ‘new treatment’ refers to any agent not previously 
administered within the 8-day treatment identification window. Because patients were treated 
with multiple agents that may have been administered and/or stopped at different points in 
time, the ‘date of cessation of first-line treatment’ was considered the earliest time point that 
a final claim for any of the first-line agents was identified. Hospitalizations were considered 
due to specific treatment-related adverse events if they occurred during the first-line 
treatment window and the inpatient service claims contained at least one of the ICD-9 
diagnosis codes included in Table A-1 of Appendix A. Follow-up time started on the date of 
treatment initiation and followed patients daily until the date of hospitalization or the end of 
the first-line treatment window, whichever occurred first. A dichotomous variable, treatment-
related hospitalization (yes/no), was created to indicate whether or not a patient was ever 
hospitalized for each of the adverse events of interest during the first-line treatment window. 
In addition, a continuous variable, time-to-event (hospitalization), was created to indicate the 
number of days a patient was free from hospitalization for the specific treatment-related 
adverse events, measured as the as the date of hospitalization minus the date treatment was 
initiated. 
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Table 3.2 Summary of dependent variables 
Aim Variable description Type Source File Definition 
Aim 1 Use of bevacizumab Dichotomous Medicare 
NCH & 
Outpatient 
Use of bevacizumab within 8 days 
from the first claim date for 
chemotherapy 
Aim 2 One-year survival Dichotomous PEDSF; 
Medicare 
NCH & 
Outpatient 
Survival one-year from the first 
claim date for chemotherapy and/or 
bevacizumab (whichever occurred 
first) 
Time-to-event (death) Continuous PEDSF; 
Medicare 
NCH & 
Outpatient 
Time in days from the first claim 
date for chemotherapy and/or 
bevacizumab (whichever occurred 
first) to date of death; patients 
censored at date lost to follow-up or 
end of the study 
 
Aim 3 Treatment-related 
hospitalization (180 days) 
Dichotomous MEDPAR Hospitalization for arterial 
thromboembolic events, 
gastrointestinal perforation, 
neutropenia, or severe hemorrhage 
between the first claim date for 
chemotherapy and/or bevacizumab 
(whichever occurred first) and day 
180 of treatment 
 
  Treatment-related 
hospitalization (first-line 
treatment window) 
Dichotomous MEDPAR Hospitalization for arterial 
thromboembolic events, 
gastrointestinal perforation, 
neutropenia, or severe hemorrhage 
between the first claim date for 
chemotherapy and/or bevacizumab 
(whichever occurred first) and the 
cessation of first-line treatment 
  
  Time-to-event 
(hospitalization during 
first-line treatment 
window) 
Continuous MEDPAR Time in days from the first claim for 
chemotherapy and/or bevacizumab 
(whichever first) to date of 
hospitalization for specified adverse 
event; patients censored at date of 
death or end of the study 
 
3.4.2 Key independent variables 
 Age:  Age was specified as both a continuous variable and a categorical variable to classify 
patients into different age groups.  Age was classified in 2 different ways: into 3 distinct 
groups, 66-69, 70-79, and 80+ and into 2 distinct groups, 66-69 and 70+.  Age was calculated 
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by subtracting the month and year of birth from the month and year of diagnosis in the 
PEDSF file.  
 Race: Race was identified in the PEDSF file and categorized as white, black, other 
(representing patients not identified as being of white or black race). Race information is 
available from both SEER and Medicare data, and there is a high degree of correlation 
between the two sources for both blacks and whites.
195
  However, there is less certainty in 
identifying non-white and non-black race groups within either of the two data sources. In 
addition, because of the lower incidence of lung cancer among individuals of non-white/non-
black race, we chose not to further categorize other racial groups. Similarly, because of the 
lower incidence of lung cancer among individuals of Hispanic ethnicity and the concern for 
small sample sizes, Hispanic ethnicity was not operationalized or evaluated in the current 
study.   
 Socioeconomic status:  Direct measurement of an individual’s socioeconomic status is not 
possible using SEER-Medicare data; information for socioeconomic variables such as median 
household income and education are not provided at the individual level.  However, SEER-
Medicare does provide aggregate data for median household income and education 
attainment at the 2000 National Census Tract and zip code-levels in the PEDSF file, and this 
information can be used to create a proxy measure for socioeconomic status.
195
 We used 
census tract-level information on the percentage of individuals aged 25 and older with less 
than a high school education to rank patients into quartiles of education attainment. In 
addition, we used census-tract information to rank patients into quartiles of median household 
income overall.       
 Provider affiliation with CCOP:  Provider affiliation with NCI’s CCOP can be obtained 
from the semi-annual publication of CCOP Progress Reports.  We linked provider CCOP 
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affiliation information to SEER-Medicare claim files (NCH and Outpatient) via the unique 
provider identification number (UPIN) or the NPI number of each provider (starting 
07/01/2007).  Patients were considered to have received treatment from a CCOP-affiliated 
provider if at least 50% of their identified chemotherapy claims were from a provider (NCH 
or Outpatient) affiliated with CCOP.  Because UPIN and NPI information is normally 
encrypted within SEER-Medicare data, special permission was granted during the data 
application process in order to obtain unencrypted UPIN and NPI numbers within the SEER-
Medicare claims files.   
 
Table 3.3 Summary of key independent variables 
  
Variable Type Source File Definition 
Age Continuous 
& 
Categorical 
PEDSF Categorized as: 66-69; 70-79; and 80+  
Race Categorical PEDSF White; Black; Other 
Table 3.3 (continued) 
Median household income 
Categorical PEDSF Aggregate census tract level measure of 
median household income 
Percent 25 and older with 
< high school education 
Categorical PEDSF Aggregate census tract level measure of 
education attainment 
Receipt of treatment from 
a CCOP-affiliated 
provider 
Dichotomous CCOP 
progress 
reports 
linked to 
Medicare 
NCH & 
Outpatient 
claims files 
Receipt of treatment from a provider 
affiliated with the National Cancer 
Institute's Clinical Community 
Oncology Program 
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3.4.3 Additional covariates 
3.4.3.1 Additional predisposing characteristics 
 Sex: Information on patient sex was provided in the PEDSF file and categorized as ‘male’ or 
‘female’. 
 Marital status:  Information on marital status at the time of diagnosis was provided in the 
PEDSF file. We categorized marital status as ‘married’ and ‘not married’ which included all 
patients who were single, separated, divorced, or widowed at the time they were diagnosed.  
 
3.4.3.2 Additional enabling characteristics 
 Medicaid coverage preceding diagnosis:  The PEDSF file provides the number of months 
of state buy-in (Medicaid) coverage in each year a patient is eligible for Medicare.  However, 
since the actual months in which state buy-in coverage occurred during the year are not 
available, it may not be possible to determine whether Medicaid coverage preceded 
diagnosis.  Therefore, we determined that a patient had Medicaid coverage preceding 
diagnosis if information from the PEDSF file indicated one or more months of state buy-in 
coverage during the calendar year prior to diagnosis (e.g., if a patient was diagnosed in any 
month of 2006, we looked in 2005 for state buy-in coverage).  A dichotomous variable 
(yes/no) was created to indicate whether or not a patient had any state buy-in coverage during 
the calendar year preceding diagnosis.     
 Population density:  The PEDSF file includes Rural/Urban Continuum Codes from the 
Economic Research Service of the Department of Agriculture that are used to distinguish 
metropolitan and nonmetropolitan counties. The Rural/Urban Continuum Codes categorize 
metropolitan counties into 3 groups based on population size (e.g., metro area w/ population 
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of 1 million or more; metro area w/ population between 250,000 and 1 million; metro area w/ 
population less than 250,000) and nonmetropolitan counties into 6 groups based on 
urbanization and adjacency to a metro area (e.g., urban w/ 20,000 or more and adjacent to 
metro area; urban population of 20,000 or more, not adjacent to metro area; urban population 
of 2,500 to 19,999, adjacent to metro area; urban population of 2,500 to 19,999, not adjacent 
to metro area; rural or urban population less than 2,500, adjacent to metro area; rural or urban 
population less than 2,500, not adjacent to metro area).To avoid small cell sizes and to 
simplify statistical comparisons we combined similar groups. We combined the 3 
metropolitan groups to form the metropolitan statistical area (MSA) category, and we 
combined the 4 urban groups and the 2 rural groups to form the urban/rural category.   
 Additional provider affiliations:  The SEER-Medicare Provider file contains information 
about the characteristics of physicians and hospitals that provide care to patients, including 
affiliation with cooperative research groups (e.g., Eastern Cooperative Oncology Group – 
ECOG), NCI cancer center designation, teaching hospital designation, and level of affiliation 
with a medical school. The Provider file can be linked directly to MEDPAR and Outpatient 
file claims using an encrypted provider identification number. We used this linkage to 
identify whether or not patients received care from providers with the aforementioned 
affiliations. We defined care at an affiliated site as at least one chemotherapy and/or 
bevacizumab claim from a provider with the designated affiliation. An indicator variable was 
created for each distinct affiliation (cooperative research group, NCI cancer center, teaching 
hospital, medical school) to denote whether a patient received treatment from an affiliated 
provider. 
 Diagnosis year:  We operationalized the year a patient was diagnosed to capture time trends 
in the use of and outcomes associated with bevacizumab. We created a categorical variable to 
indicate which of the four years (i.e., 2004, 2005, 2006, or 2007) a patient was diagnosed in. 
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Due to the likelihood of low utilization of bevacizumab prior to the calendar year in which it 
received approval for NSCLC (2006), we combined years 2004 and 2005 into one category.  
 SEER Region:  We operationalized the SEER region in which a patient was diagnosed to 
capture geographical trends in the use and outcomes of bevacizumab.  SEER registries were 
categorized by state/region as follows: East = Connecticut and New Jersey; Midwest = Iowa, 
Michigan, New Mexico, and Utah; South = Georgia, Kentucky, and Louisiana; West = 
California, Hawaii, and Washington.   
 
3.4.3.3 Need characteristics 
 Stage:  The PEDSF file provides tumor stage information (based on AJCC 6th edition tumor 
staging guidelines) which we operationalized as a potential prognostic factor.  We 
categorized patients into two distinct staging groups: Stage IIIB and Stage IV disease. In 
addition, PEDSF also provides a summary stage variable that we used as a secondary staging 
variable and categorized patients as having regional or distant stage disease.    
 Grade: The PEDSF file provides tumor grade information which we operationalized into 
three categories: Well/moderately differentiated, poor/undifferentiated, and unknown. 
 Histology:  We used the ICD-O-3 morphology codes within the PEDSF file to identify 
histology type. Histology was then categorized as adenocarcinoma, large cell, or other/not 
otherwise specified (NOS). Adenocarcinoma included the following ICD-O-3 codes: 8140-
8147, 8250-8255, 8260, 8310, 8320, 8323, 8350, 8430, 8460, 8480-8481, 8490, 8507, 8510, 
8550-8551, 8560, 8562, and 8570-8576. Large cell included the following ICD-O-3 codes: 
8012-8015. Other/NOS included the following ICD-O-3 codes: 8020-8022, 8030-8035, 8046, 
and 8050, 8200-8201, 8230-8231, 8240-8246, 8249, and 8980. Patients with histology codes 
for squamous tumors (ICD-O-3 codes 8051-8078, 8083-8084, and 8123) or other ICD-O-3 
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codes not representative of non-squamous NSCLC (ICD-O-3 codes 8000-8011, 8041-8045, 
8580, 8720, and any code >= 8800) were excluded from the study.   
 NCI Charlson comorbidity index score:  The Charlson index198 is a measure of disease 
burden commonly used in health services and outcomes research as a proxy for health status.  
The index has been adapted
199-201
 to utilize ICD-9 coded data from administrative databases 
and has since been validated as a reliable tool to predict mortality in cancer patients.
202-204
 We 
measured patient comorbidity during the 12 months prior to diagnosis using a variation
203
 of 
the Charlson index designed specifically for research of breast, prostate, colorectal, and lung 
cancers using administrative claims data; NCI provides a statistical macro
205
 for this version 
of the Charlson index that uses physician and hospital claims (from MEDPAR, NCH, and 
Outpatient files) as well as cancer site-specific weights for the following comorbidities: 
myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular 
disease, chronic obstructive pulmonary disease, dementia, paralysis, diabetes, diabetes with 
sequelae, chronic renal failure, moderate or severe liver disease, ulcers, rheumatic disease, 
and AIDS. Index scores were categorized in accordance with previous research
15
 as no 
comorbidities, one comorbidity, two comorbidities, or three or more comorbidities. In 
addition, we evaluated for the presence of specific comorbidities (e.g., thromboembolic 
disorders) that may influence whether or not patients received bevacizumab (i.e., they may 
increase the risk of treatment-related complications).          
 Hemoptysis: The presence of hemoptysis can be a contraindication to the use of 
bevacizumab, although this may depend on the severity and amount of blood being produced 
upon coughing. We evaluated MEDPAR, NCH, and Outpatient files for the presence of ICD-
9 diagnosis codes (786.3, 786.30, and 786.39) that may be indicative of hemoptysis in 
medical claims prior to and at the time of diagnosis in order to get a sense of how the 
presence of hemoptysis may be related to the use of bevacizumab. We created an indicator 
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variable to denote whether a patient was identified as having a diagnosis for hemoptysis prior 
to or at the time of diagnosis (time of diagnosis is arbitrarily chose as the first day of the 
diagnosis month since we do not know the actual date of diagnosis).    
 Brain metastases: The presence of brain metastases can indicate signs of advanced disease 
and may influence the use of bevacizumab, particularly if there is concern for intracranial 
bleeding. We evaluated MEDPAR, NCH, and Outpatient files for the presence of ICD-9 
diagnosis code (198.3) that may be indicative of brain metastases prior to and at the time of 
diagnosis to get a sense of how the presence of brain metastases may be related to the use of 
bevacizumab. We created an indicator variable to denote whether a patient was identified as 
having a diagnosis code for brain metastases present in their claims history prior to or at the 
time of diagnosis.  
 Receipt of radiation: Receipt of radiation may be an indicator of disease severity and/or 
prognosis and therefore may influence the use of bevacizumab. PEDSF contains information 
about radiation and surgery and whether those modalities are used as part of the first course 
of treatment. We evaluated the PEDSF file and created an indicator variable to denote 
whether or not patients received radiation therapy during the first course of treatment. 
 Cancer-directed surgery: Receipt of cancer-directed surgery may be an indicator of disease 
severity and/or prognosis and therefore may influence the use of bevacizumab. PEDSF 
contains information about radiation and surgery and whether those modalities are used as 
part of the first course of treatment. We evaluated the PEDSF file and created an indicator 
variable to denote whether or not patients received cancer-directed surgery during the first 
course of treatment. Due to possible sample size issues, we did not investigate into the 
distinct types of surgical procedures that may have been performed.  
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Table 3.4 Summary of additional covariates 
Variable Type Source File Categorization 
Sex Dichotomous PEDSF Male; Female 
Marital status Dichotomous PEDSF Married; Not married (single, 
separated, widowed, divorced) 
Population density Dichotomous PEDSF Metropolitan statistical area; 
Urban/rural 
State buy-in Medicare coverage 
during year preceding diagnosis 
Dichotomous PEDSF Yes; No 
Provider affiliations       
Cooperative research group Dichotomous  Provider Yes; No 
NCI designated cancer center Dichotomous  Provider Yes; No 
Teaching hospital Dichotomous  Provider Yes; No 
Medical school Dichotomous  Provider Yes; No 
Year of diagnosis Categorical PEDSF 2004-2005, 2006, 2007 
SEER region Categorical PEDSF East = CT, NJ; Midwest = IA, 
MI, NM, UT; South = GA, KY, 
LA; West = CA, HI, WA 
AJCC tumor stage Dichotomous PEDSF Stage IIIB; Stage IV 
Summary stage Dichotomous PEDSF Distant stage; Regional stage 
Grade Categorical PEDSF Well/moderately differentiated; 
Poor/undifferentiated;  
Unknown 
Tumor histology Categorical PEDSF Adenocarcinoma; Large cell; 
Other/not otherwise specified 
NCI Charlson comorbidity index Categorical MEDPAR, 
NCH, & 
Outpatient 
0; 1; 2 
Hemoptysis Dichotomous MEDPAR, 
NCH, & 
Outpatient 
Yes; No 
Brain metastases Dichotomous MEDPAR, 
NCH, & 
Outpatient 
Yes; No 
Radiation therapy Dichotomous PEDSF Yes; No 
Cancer-directed surgery Dichotomous PEDSF Yes; No 
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3.4.3.4 Other characteristics  
 Time to treatment initiation:  We measured time to treatment initiation as a potential 
prognostic indicator that could mediate the effects of treatment on survival outcomes. Using 
Medicare NCH and Outpatient file claims, we created a continuous variable, ‘time to 
treatment start’, to identify and measure the time in days between the date of diagnosis and 
the first date initial treatment was administered; the date of the first claim for either 
chemotherapy or bevacizumab administration, whichever occurred first, was used as the first 
date of initial treatment. Given that SEER only provides the month and year of diagnosis, we 
created an artificial date of diagnosis using the 1
st
 day of the diagnosis month in order to 
measure the number of days between the date of diagnosis and the date treatment was first 
administered.  
 Chemotherapy regimen: We were interested in describing the use of other chemotherapy 
agents as first-line treatment to better illustrate the overall treatment patterns of older adults 
with advanced non-squamous non-small cell lung cancer and to describe the use of 
bevacizumab in a larger context. We used Medicare NCH and Outpatient file claims to 
identify the administration of specific chemotherapy agents by HCPCS J-code. The specific 
chemotherapy agents and their respective HCPCS J-codes are listed in Table 3.5. Beginning 
with the date of the first chemotherapy claim, we captured the use of any chemotherapeutic 
agents within the first 8 days of chemotherapy to determine the specific treatment regimen 
utilized. Patients without one claim for a platinum agent and one claim for a non-platinum 
agent during the 8-day treatment identification period were excluded from the original 
analysis as were individuals with claims for more than two chemotherapeutic agents during 
this period. We created a dichotomous variable, platinum-doublet, to indicate whether a 
platinum-based doublet was administered as first-line treatment. Similarly, to analyze a more 
specific subgroup of patients, we created an additional dichotomous variable, platinum-
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taxane, to indicate whether a platinum-taxane regimen was administered as first-line 
treatment. We also created dichotomous variables (yes/no) to indicate the use of each specific 
chemotherapy agent as part of our descriptive analysis.   
 
Table 3.5 HCPCS J-codes for chemotherapeutic agents and bevacizumab 
Drug Class Therapeutic Agent HCPCS J-code 
Monoclonal antibody Bevacizumab J9035 
Platinum-coordination complex Carboplatin J9045 
  Cisplatin J9060, 9062 
  Oxaliplatin J9263 
Taxane Docetaxel J9170 
  Paclitaxel J9264, 9265 
Folic acid antagonist Pemetrexed J9305 
DNA topoisomerase inhibitor Irinotecan J9206 
  Topotecan J9350 
Alkylating agent Cyclophosphamide J9070, 9080, 9090-9097 
Pyrimidine analog Fluorouracil J9190 
  Gemcitabine J9201 
Vinca alkaloid Vinblastine J9360 
  Vincristine J9370, 9375, 9380 
  Vinorelbine J9390 
 
3.5 Study Design and Methods 
3.5.1 Aim 1 
 To describe the utilization of bevacizumab in combination with standard platinum-based 
doublet chemotherapy as first line treatment for older adults with advanced non-small cell lung cancer 
and to identify the clinical, sociodemographic, and health system factors associated with its use. The 
a priori hypotheses for this study are as follows: 
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 H1: Among older adults with a primary diagnosis of advanced non-squamous non-small cell 
lung cancer, non-white patients are significantly less likely than white patients to receive 
bevacizumab in combination with standard platinum-based doublet chemotherapy. 
 H2: Among older adults with advanced non-small cell lung cancer, patients of lower 
socioeconomic status are significantly less likely than patients of higher socioeconomic status to 
receive bevacizumab in combination with standard platinum-based doublet chemotherapy.   
 H3: Among older adults with advanced non-small cell lung cancer, patients 70 years or older 
are significantly less likely than patients 66 to 69 years of age to receive bevacizumab in combination 
with standard platinum-based doublet chemotherapy. 
 H4: Among older adults with advanced non-small cell lung cancer, patients who receive 
treatment from a provider affiliated with the National Cancer Institute (NCI) Community Clinical 
Oncology Program (CCOP) are significantly more likely to receive bevacizumab in combination with 
standard platinum-based doublet chemotherapy compared to patients who receive treatment from 
non-CCOP-affiliated providers. 
 
3.5.1.1 Study population 
 This aim investigated the utilization of bevacizumab and factors associated with its use 
among incident cases of locally advanced or metastatic (TNM stages IIIB and IV) non-small cell lung 
cancer in older adults.  Patients with a history of cancer were excluded because prior cancer diagnoses 
and/or therapies may influence the use of subsequent treatments. Similarly, patients with Medicare 
eligibility based on end-stage renal disease or disability were excluded as these patients are likely to 
be frailer and may receive different treatment or have different treatment outcomes than the general 
Medicare patient population.  In addition, in order to accurately identify patients who were eligible to 
receive bevacizumab and detect relationships between bevacizumab use and the patient and health 
system characteristics of interest, we excluded individuals who were: diagnosed prior to reaching 66 
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years of age, diagnosed at death or autopsy, deceased within 30 days of diagnosis, missing any 
information about their diagnosis or death, diagnosed with squamous cell NSCLC (contraindication 
for bevacizumab),  diagnosed with carcinoma in situ or stage I through stage IIIA, missing any 
information about their tumor stage or histology, enrolled in a Medicare Advantage Plan or had any 
period without Medicare Parts A and B during the 12 months before or any time following diagnosis. 
Furthermore, to correctly identify and describe first-line treatment received by patients within the 
cohort, individuals who received ‘other’ or unspecified chemotherapy agents or received 
chemotherapy in an inpatient setting (i.e., in a hospital) ≤ 8 days from the date of the first 
chemotherapy claim were excluded.   
 
3.5.1.2 Dependent and key independent variables 
 The dependent variable of interest in this aim was the addition of bevacizumab to platinum-
based doublet chemotherapy for the first-line treatment of older adults with locally-advanced 
or metastatic non-small cell lung cancer.  Given that a main objective of this study was to 
identify the proportion of older adults with advanced NSCLC who received bevacizumab, we 
created a simple indicator variable to indicate whether or not bevacizumab was used within 8 
days from the date of first chemotherapy treatment (yes/no). Additionally, a second indicator 
variable to indicate whether bevacizumab was added to first-line chemotherapy with 30 days 
from the date of first chemotherapy treatment was created for purposes of a sensitivity 
analysis.  Also, in an effort to more completely capture and describe how bevacizumab was 
utilized in this cohort, we also measured a few additional aspects of bevacizumab use: time to 
bevacizumab start, duration of use, and the number of administrations. 
 Key independent variables of interest in this aim included age, race, census tract-level 
information on median household income and education attainment (proxy measures of 
socioeconomic status), as well as receipt of treatment from a CCOP-affiliated provider.   
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3.5.1.3 Control variables 
 Control variables considered in this aim included gender, marital status at the time of 
diagnosis, Medicaid coverage preceding diagnosis, population density, year of diagnosis, 
SEER region, tumor stage, grade, and histology, NCI Charlson comorbidity index score, 
presence of brain metastases, presence of hemoptysis, receipt of radiation treatment, and 
receipt of cancer-directed surgery. 
 
3.5.1.4 Methods of analysis 
 In our analysis, we first described patients with respect to demographic, clinical, and health 
system characteristics both overall and stratified by first-line bevacizumab use in order to identify 
potential underlying differences between those who received bevacizumab and those who did not. 
Analyses were further stratified by the two cohorts used in the overall study: 1) the larger cohort of 
patients receiving any platinum-based doublet chemotherapy and 2) the smaller cohort of patients 
who specifically received doublet chemotherapy consisting of a platinum agent and a taxane agent. 
Frequencies with chi-square tests of significance and t-tests were used to compare differences in 
patients by bevacizumab use across important clinical and sociodemographic variables including age, 
race, census tract level measures for education and median household income, receipt of treatment 
from a CCOP-affiliated provider, tumor stage, grade, and histology, as well as NCI Charlson 
comorbidity index score. Multivariable logistic regression was then used to model the use of 
bevacizumab and estimate the relative impact of each of the key independent variables on the odds of 
bevacizumab use while controlling for the other covariates in the model.  Multicollinearity between 
covariates was assessed prior to constructing the regression models by examining variance inflation 
factors and tolerance values.
216
  The Hosmer-Lemeshow goodness of fit test
216
 was used to determine 
whether each regression model adequately fit the data. Goodness of fit statistics including the LRT 
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and the Akaike Information Criterion (AIC) were used to compare and eventually select the final 
regression models. Additionally, hierarchical logistic regression was performed based on the 
conceptualization of Andersen’s Behavioral Model of Health Services Use. Initially, a logistic 
regression model of the use of bevacizumab was fit with the predisposing characteristics included as 
covariates, regardless of their significance in bivariate analyses. Subsequent models were created in a 
hierarchical fashion by first adding in enabling characteristics as covariates followed by the inclusion 
of need characteristics to create a third model. The idea behind this analysis was to assess how 
identified associations between the use of bevacizumab and important predisposing factors such as 
age and race are modified (if at all) when additional characteristics are successively accounted for in 
the regression models.             
 
3.5.2 Aim 2 
 To determine whether the use of bevacizumab in combination with standard platinum-based 
doublet chemotherapy as first-line treatment of older adults with advanced non-small cell lung cancer 
is associated with a benefit of improved overall survival. The a priori hypotheses for this study are as 
follows: 
 H5: Among older adults with advanced non-small cell lung cancer, patients who receive 
bevacizumab in combination with standard platinum-based doublet chemotherapy as first line 
treatment do not have significantly improved overall survival compared to patients receiving standard 
platinum-based doublet chemotherapy only. 
 
3.5.2.1 Study population 
 This aim investigated the potential benefit of bevacizumab use on overall survival among 
incident cases of locally advanced or metastatic (TNM stages IIIB and IV) non-small cell lung cancer 
in older adults.  Patients with a history of cancer were excluded because prior cancer diagnoses and/or 
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therapies may influence the use of subsequent treatments. Similarly, patients with Medicare eligibility 
based on end-stage renal disease or disability were excluded as these patients are likely to be frailer 
and may receive different treatment or have different treatment outcomes than the general Medicare 
patient population.  In addition, in order to accurately identify patients who were eligible to receive 
bevacizumab and detect relationships between bevacizumab use and the patient and health system 
characteristics of interest, we excluded individuals who were: diagnosed prior to reaching 66 years of 
age, diagnosed at death or autopsy, deceased within 30 days of diagnosis, missing any information 
about their diagnosis or death, diagnosed with squamous cell NSCLC (contraindication for 
bevacizumab),  diagnosed with carcinoma in situ or stage I through stage IIIA, missing any 
information about their tumor stage or histology, enrolled in a Medicare Advantage Plan or had any 
period without Medicare Parts A and B during the 12 months before or any time following diagnosis. 
Furthermore, to correctly identify and describe first-line treatment received by patients within the 
cohort, individuals who received ‘other’ or unspecified chemotherapy agents or received 
chemotherapy in an inpatient setting (i.e., in a hospital) ≤ 8 days from the date of the first 
chemotherapy claim were excluded.   
 
3.5.2.2 Dependent and key independent variables 
 The dependent variable in this aim was the time to event (overall survival) as measured in the 
number of days between the start of treatment until the time the event occurred (death or 
censoring); analysis of time to event included both one-year survival and survival duration.  
For survival duration, patients who did not experience the event (death) were censored at the 
end of study date. A second measurement of time to event was created for use in a sensitivity 
analysis where the beginning of follow-up started on the first day following the treatment 
identification window. That is, when the first 8 days of treatment were used to identify 
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chemotherapy regimen and bevacizumab use, follow-up time started on day 9; when the first 
30 days of treatment were used in a sensitivity analysis, follow-up time started on day 31.  
 The key independent variable of interest in this aim was the use of bevacizumab within 8 
days of the start of first-line treatment with standard platinum-based doublet chemotherapy.   
 
3.5.2.3 Control variables 
 Control variables considered in this aim included clinical and sociodemographic 
characteristics that could influence overall survival and may also have been associated with 
the use of bevacizumab in the first study (confounders):  age, race, census tract-level 
information on median household income and education attainment (proxy measures of 
socioeconomic status), receipt of treatment from a CCOP-affiliated provider, sex, marital 
status at the time of diagnosis, Medicaid coverage preceding diagnosis, population density, 
NCI Charlson comorbidity index score, year of diagnosis, SEER region, and tumor stage, 
grade, and histology. 
 
3.5.2.4 Methods of analysis 
 We conducted analyses of one-year survival and survival duration using an intent-to-treat 
approach with survival attributed to the treatment regimen the patient was first initiated on following 
diagnosis.  Our primary analysis concerned the potential benefit in overall survival with the addition 
of bevacizumab to platinum-based doublet chemotherapy as first line treatment.  Therefore, our main 
comparison contrasted overall survival between patients who received bevacizumab in addition to 
platinum-based doublet chemotherapy with those patients who received platinum-based doublet 
chemotherapy only. Additionally, we also evaluated the effect of bevacizumab on overall survival 
among patients who were treated first-line with platinum-taxane regimens specifically.      
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 Logistic regression was used to estimate the odds of death at one year following the start of 
treatment, comparing patients who received bevacizumab with those patients who did not.  Bivariate 
analyses of each independent variable with one-year survival were performed followed by multiple 
logistic regressions that incorporated the covariates associated with survival.  Interaction terms 
between bevacizumab use and demographic, clinical, and site of care variables were evaluated for 
inclusion in the final regression models using the log likelihood ratio test (LRT); the intent of the 
interaction terms was to identify those covariates that modified the survival effect of bevacizumab 
treatment.   
 For survival duration, we first conducted bivariate analyses using Kaplan-Meier survival 
curves for bevacizumab as well as each of the categorical covariates of interest to provide insight into 
the shape of the survival function and determine visually whether the survival functions of 
comparator groups were approximately parallel.  Other descriptive statistics were also generated 
including the proportion of patients censored and median of time to the event (death).  In addition, we 
used long-rank tests to measure equality across the strata of each categorical variable and determine 
whether or not the variable should be considered for inclusion in the multivariable Cox proportional 
hazard models.  For continuous variables we used bivariate Cox proportional hazard regression.  
Covariates were considered for inclusion in the final multivariable models if they had a significant 
association with survival at a p-value of 0.05 or less or they were considered to be clinically relevant. 
 Cox proportional hazard (PH) models were used to estimate the independent relationship 
between bevacizumab use and overall survival duration after controlling for independent variables 
associated with survival.  The Cox PH model is a semi-parametric model that allows for the inclusion 
of multiple predictor variables and provides a partial likelihood estimation of the hazard of an event, 
such as death.  Both continuous and categorical variables can be included in the model and selection 
of a probability distribution for the outcome of interest (death) is not required.  The Cox PH model 
factors out the baseline hazard function from that of the covariates and assumes the hazard of an event 
at time (t) that is due to an exposure (X) is a function of an unknown baseline hazard, h0(t), and the 
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exposure (X).  The equation of the hazard rate is expressed as h(t) = h0(t)*exp(β1X+β0) where β 
represents the exposure effect on the hazard of death.  Under the null hypothesis, the hazard of death 
due to the exposure variable is equal to the baseline hazard, resulting in a hazard ratio (HR) equal to 
1. In the Cox PH model, it is assumed that covariates are independent of time and hazards are 
proportional across the strata of a variable (risk is multiplicative) and constant over time; stratification 
and interaction terms that include time and the variable with non-proportional hazards can be used 
when the latter assumption is violated.    
 Results from the Kaplan-Meier survival curves, log-rank tests, and bivariate Cox PH 
regression models were used to inform our multivariate Cox PH models.  We incorporated interaction 
terms between time and the independent variables of interest, such as the NCI Charlson comorbidity 
index score, to test for significance in the models and account for violations of the proportional 
hazard assumption. Tied event data (i.e., deaths occur at the same time) can pose a threat to the 
validity of Cox partial likelihood estimate, particularly when the number of tied events is large 
(coefficients are biased towards zero); to minimize the occurrence of tied events, we utilized a small 
interval (days) to measure time to event and the Efron approximation to account for ties that occurred.  
Also, although informative censoring (i.e., an existing correlation between censoring and prediction 
of survival such as loss of insurance coverage due to severe illness) was not expected in this 
Medicare-covered population, we assessed the reasons for censoring to ensure that informative 
censoring had not occurred.               
 We performed additional analyses of overall survival duration using propensity score (PS) 
methods to address potential treatment selection bias and assess the robustness of the original results.  
Observed covariates that predict treatment exposure (bevacizumab use) and are independently 
associated with the outcome (time to event) can confound or bias the effect measure that describes the 
relationship between the exposure and outcome.
217
   Propensity score methods offer a useful approach 
to control confounding and minimize bias in effect measure estimates when the exposure of interest is 
dichotomous.
218
  A propensity score is the conditional probability of exposure for an individual given 
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all measured confounders; within a group of individuals with the same propensity score, differences 
in the outcome between exposed and unexposed individuals is conditionally independent of the 
covariates.
217
  Unbiased estimates of the average treatment effect can be estimated by matching on the 
PS between two comparable groups, by including the PS as a covariate in a multivariate model of the 
outcome, by stratifying on the PS, or fitting a weighted regression model using the inverse-probability 
of exposure weights from the estimated PS.
217, 218
   
We performed two propensity score-adjusted analyses to compare the effect of bevacizumab 
treatment on survival among patients with similar risk proﬁles as assessed by measured confounders. 
First, we used multivariate logistic regression models to calculate propensity scores representing the 
probability that a patient received bevacizumab conditional on all other measured confounders in the 
model.  In our propensity score model, we included variables that were associated with bevacizumab 
use and survival (true confounders) as well as variables related to survival only; our selection of 
covariates was based on evidence
217
 that PS models that include both confounders and variables 
related to the outcome only provide more precise exposure effect estimates compared to those models 
that best predict exposure (i.e., include variables related to exposure only).  In the first propensity 
score-adjusted analysis, discrete Cox PH regression models were fit using the propensity score as a 
continuous covariate in the model. In the second propensity score-adjusted analysis, exposed patients 
(bevacizumab) were matched to patients with the same PS from the unexposed group (chemotherapy 
only) in a 1:1 ratio. Discrete Cox PH regression models were then fit among the cohort of matched 
patients; patients for whom there was no match were excluded from this analysis.    
 A subgroup analysis of survival was performed for patients diagnosed with stage IV disease 
as the extent of the utilization and survival outcomes of bevacizumab may differ in these patients as 
compared to those with stage IIIB or the overall cohort in general. In addition, two separate 
sensitivity analyses were performed based on 1) the time interval used to identify treatment with 
bevacizumab and 2) the start of the follow-up period used to identify survival duration. In the first 
sensitivity analysis, the time period allotted to identify the use of bevacizumab from the date 
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chemotherapy was initiated was expanded from 8 days to 30 days. Survival duration in this analysis 
was measured from day of treatment initiation to the date of death or censoring, whichever occurred 
earlier (same as in the original analysis). In the second sensitivity analysis, to assess for potential 
immortal time bias, follow-up was initiated the day after completion of the treatment identification 
window. In the case when the 8-day treatment window was applied to identify the use of 
bevacizumab, follow-up time began on day 9; in the case of the 30-day treatment window, follow-up 
time began on day 31.       
 
3.5.3 Aim 3 
 To determine whether the use of bevacizumab in combination with standard platinum-based 
doublet chemotherapy as first-line treatment of older adults with advanced non-small cell lung cancer 
is associated with an increase in hospitalizations for severe treatment-related adverse events.  The a 
priori hypotheses for this study are as follows: 
 H6: Among older adults with advanced non-small cell lung cancer, patients who receive 
bevacizumab in combination with standard platinum-based doublet chemotherapy as first line 
treatment have a significantly greater incidence of severe adverse events (i.e., neutropenia, 
gastrointestinal perforation, or severe hemorrhage) resulting in hospitalization compared to patients 
receiving standard platinum-based doublet chemotherapy only.  
 
3.5.3.1 Study population 
 This aim investigated the association between the use of bevacizumab and hospitalization for 
severe treatment-related adverse events among incident cases of locally advanced or metastatic (TNM 
stages IIIB and IV) non-small cell lung cancer in older adults.  Patients with a history of cancer were 
excluded because prior cancer diagnoses and/or therapies may influence the use of subsequent 
treatments. Similarly, patients with Medicare eligibility based on end-stage renal disease or disability 
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were excluded as these patients are likely to be frailer and may receive different treatment or have 
different treatment outcomes than the general Medicare patient population.  In addition, in order to 
accurately identify patients who were eligible to receive bevacizumab and detect relationships 
between bevacizumab use and the patient and health system characteristics of interest, we excluded 
individuals who were: diagnosed prior to reaching 66 years of age, diagnosed at death or autopsy, 
deceased within 30 days of diagnosis, missing any information about their diagnosis or death, 
diagnosed with squamous cell NSCLC (contraindication for bevacizumab),  diagnosed with 
carcinoma in situ or stage I through stage IIIA, missing any information about their tumor stage or 
histology, enrolled in a Medicare Advantage Plan or had any period without Medicare Parts A and B 
during the 12 months before or any time following diagnosis. Furthermore, to correctly identify and 
describe first-line treatment received by patients within the cohort, individuals who received ‘other’ 
or unspecified chemotherapy agents or received chemotherapy in an inpatient setting (i.e., in a 
hospital) ≤ 8 days from the date of the first chemotherapy claim were excluded.   
 
3.5.3.2 Dependent and key independent variables 
 The dependent variables of interest in this aim included three distinct measures. The first 
dependent variable was a dichotomous measure of the occurrence of a hospitalization for a 
severe treatment-related adverse event within the first 180 days of treatment, starting follow-
up time on the date of the first identified chemotherapy claim. Severe treatment-related 
adverse events included potentially life-threatening complications that were associated with 
bevacizumab during randomized clinical trials as indicated on the product safety label
207
 
including neutropenia, gastrointestinal perforation, and severe hemorrhage. Hospitalization 
for arterial thromboembolic events was included based on the increased risk associated with 
the use of bevacizumab found in a meta-analysis of cancer clinical trials.
206
 In addition, 
composite measure for any of the aforementioned adverse events was also created. The 
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second dependent variable of interest was a dichotomous measure of the occurrence of a 
hospitalization for a severe treatment-related adverse event within the specified first-line 
treatment window. The first-line treatment window was described previously in section 3.4.1. 
In addition to the dichotomous measure, the third dependent variable of interest was the time 
to event of hospitalization for a severe treatment-related adverse event. Follow-up time was 
defined as the time from the date of the first identified chemotherapy claim to the first claim 
date of a hospitalization for an arterial thromboembolic event, neutropenia, gastrointestinal 
perforation, or severe hemorrhage.  Patients who did not experience the specified event 
(hospitalization) were censored at the date of death or the end of the first-line treatment 
window, whichever occurred first.       
 The key independent variable of interest in this aim was the use of bevacizumab within 8 
days of the start of first-line treatment with standard platinum-based doublet chemotherapy.   
 
3.5.3.3 Control variables 
 Control variables considered in this aim included clinical and sociodemographic 
characteristics that could influence hospitalization for the specific adverse events of interest 
and may also have been associated with the use of bevacizumab in the first study 
(confounders):  age, race, census tract-level information on median household income and 
education attainment (proxy measures of socioeconomic status), receipt of treatment from a 
CCOP-affiliated provider, sex, marital status at the time of diagnosis, Medicaid coverage 
preceding diagnosis, population density, NCI Charlson comorbidity index score, year of 
diagnosis, SEER region, and tumor stage, grade, and histology. In addition we also evaluated 
for confounding among specific comorbidities (e.g., cerebrovascular disease, chronic 
obstructive pulmonary disease, history of myocardial infarction, and congestive heart failure) 
that may have increased susceptibility to hospitalization for selected adverse events. 
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3.5.3.4 Methods of analysis 
 We conducted an evaluation of the association between bevacizumab use and any 
hospitalization for specific severe treatment-related adverse events using an intent-to-treat approach.  
Any hospitalization for arterial thromboembolic events, neutropenia, gastrointestinal perforation, or 
severe hemorrhage that occurred after the start of chemotherapy was attributed to the treatment 
regimen the patient was first initiated on.  Since our primary study objective concerned the potential 
association between the addition of bevacizumab to first-line platinum-based doublet chemotherapy 
and hospitalization, our main comparison contrasted the rate of hospitalizations between patients who 
received bevacizumab in addition to platinum-based doublet chemotherapy with those patients who 
received platinum-based doublet chemotherapy only.   
 We first used descriptive statistics including counts and percentages to describe the 
cumulative incidence of hospitalizations for each of the severe adverse events within the first 180 
days of treatment according to the utilization of bevacizumab. Logistic regression was then used to 
estimate the odds of hospitalization for each adverse event, comparing patients who received 
bevacizumab with those patients who did not.  Bivariate analyses of each independent variable with 
hospitalization for each of the severe events were performed followed by multiple logistic regressions 
that incorporated those covariates that were significantly associated with hospitalization.  Interaction 
terms between bevacizumab use and demographic, clinical, and site of care variables were evaluated 
for inclusion in the final regression models using the log likelihood ratio test (LRT); the intent of the 
interaction terms was to identify those covariates that modified the effect of bevacizumab on 
hospitalization for the specified adverse event.   
For our analysis of hospitalization events during the first-line treatment window, we 
compared bivariate Kaplan-Meier survival curves to describe the incidence of any hospitalization for 
severe treatment-related adverse events by bevacizumab use.  Corresponding log-rank tests were used 
to measure equality in the incidence of hospitalizations across strata of each independent categorical 
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variable and determine whether the variable should be considered for inclusion in the final prediction 
model. Cox proportional hazards modeling was used to estimate the independent association between 
bevacizumab use and hospitalization for arterial thromboembolic events, neutropenia, gastrointestinal 
perforation, severe hemorrhage, or the composite measure after controlling for potential confounders 
and independent variables associated with hospitalization. Results from the Kaplan-Meier survival 
curves and log-rank tests were used to inform our multivariate Cox PH models. Covariates were 
considered for inclusion in multivariable Cox proportional hazard models if they were significantly 
associated with the adverse event as indicated by a log-rank p-value of 0.05 or less. Covariates 
deemed to be clinically relevant were also considered for inclusion in the multivariable models. 
Interaction terms between time and independent variables were included in the model when the 
hazard rate for hospitalizations across strata of the independent variable violated the proportional 
hazard assumption. Tied event data (i.e., hospitalizations occur at the same time) can pose a threat to 
the validity of the Cox partial likelihood estimate, particularly when the number of tied events is large 
(coefficients are biased towards zero); to minimize the occurrence of tied events, we utilized a small 
interval (days) to measure time to event and the Efron approximation to account for ties that occurred.  
Also, although informative censoring (i.e., an existing correlation between censoring and prediction 
of survival such as loss of insurance coverage due to severe illness) was not expected, we assessed the 
reasons for censoring to ensure that informative censoring had not occurred.           
 Furthermore, we also evaluated the association between bevacizumab use and hospitalization 
for severe treatment-related adverse events using propensity score (PS) methods to address potential 
treatment selection bias and assess the robustness of the original results.  In particular, we performed 
two propensity score-adjusted analyses to compare the effect of bevacizumab treatment on 
hospitalization for severe treatment-related adverse events among patients with similar risk proﬁles as 
assessed by measured confounders. First, we used multivariate logistic regression models to calculate 
propensity scores representing the probability that a patient received bevacizumab conditional on all 
other measured confounders in the model.  In our propensity score model, we included variables that 
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were associated with bevacizumab use and hospitalization (true confounders) as well as variables 
related to hospitalization only; our selection of covariates was based on evidence
217
 that PS models 
that include both confounders and variables related to the outcome only provide more precise 
exposure effect estimates compared to those models that best predict exposure (i.e., include variables 
related to exposure only).  In the first propensity score-adjusted analysis, discrete Cox PH regression 
models were fit using the propensity score as a continuous covariate in the model. In the second 
propensity score-adjusted analysis, propensity scores were used to match exposed patients 
(bevacizumab) with patients from the unexposed group (chemotherapy only) in a 1:1 ratio using a 5-
to-1 digit greedy-match algorithm. Discrete Cox PH regression models were then fit among the cohort 
of matched patients; patients for whom there was no match were excluded from this analysis.    
Two separate sensitivity analyses of the effect of bevacizumab on hospitalization for severe 
treatment-related adverse events were performed. The first sensitivity analysis assessed the effect of 
bevacizumab on hospitalization for severe adverse events among patients receiving carboplatin-
paclitaxel as first-line treatment, a commonly selected doublet chemotherapy regimen utilized in the 
clinical trial that led to FDA approval of bevacizumab for the treatment of advanced NSCLC (ECOG 
4599). The second sensitivity analysis assessed the effect of bevacizumab on hospitalization for 
severe adverse events among patients stratified by NCI Charlson comorbidity index score. 
Consideration for comorbidity was based on the assumption that patients with greater comorbidity 
may be more susceptible to hospitalization for severe treatment-related adverse events.  
 
 
 
 
 
 CHAPTER FOUR 
 RESULTS 
 
4.1 Description of Sample Population 
 
 
Figure 4.1: Flow diagram of NSCLC cohort selection 
Primary cancer of lung and 
bronchus diagnosed between 
01/01/2004 and 12/31/2007 
N = 113,898 
Diagnosis month is missing or invalid  
Diagnosed at age < 66  
Diagnosed at death or autopsy 
Originally entitled to Medicare due to end-stage 
renal disease or disability 
n = 31,195 
Qualified cases based on age, 
diagnosis month/source and 
Medicare entitlement 
n = 82,703 
Ever enrolled in HMO during study period
a
 
n = 20,974 
Non-enrollment in Medicare Parts A or B for 
any duration during study period
a
 
n = 7,428 
Medicare fee-for-service 
coverage only 
 n = 61,729 
Continuously enrolled in 
Medicare Parts A & B 
n = 54,301 
Diagnosed with 
 Stage IIIB or Stage IV 
n = 29,696 
 
a 
Study period is from 12 months prior to diagnosis month to Medicare record of death 
or end of data, which ever comes earlier. 
Diagnosis of carcinoma in situ,  
stage I-IIIA or stage unknown 
 (AJCC 6
th
 edition) 
n = 24,605 
NSCLC cohort based on age, 
diagnosis date/source, 
entitlement and continuous 
enrollment in Medicare fee-for-
service, and stage and histology  
 N = 20,109 
Histology unknown or not of a non-small cell 
lung cancer (NSCLC) type 
n = 9,587 
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 To derive a NSCLC cohort, all patients in the SEER database with a primary cancer of the 
lung and bronchus diagnosed between January 1, 2004 and December 31, 2007 were initially 
selected. Patients were included if they were diagnosed with stage IIIB or stage IV tumors and 
maintained enrollment in fee-for-service Medicare Parts A and B beginning 12 months prior to their 
month of diagnosis through their date of death or censoring, whichever came earlier. Figure 4.1 
depicts the number of patients who were  excluded because they: 1) had missing or invalid 
information about their date of diagnosis; 2) were diagnosed prior to their 66
th
 birthday or at the time 
of death or autopsy; 3) were originally entitled to Medicare based on end-stage renal disease or 
disability; 4) were ever enrolled in a Medicare Advantage plan beginning 12 months prior to their 
month of diagnosis through their date of death or censoring, whichever came earlier; 5) were 
diagnosed with carcinoma in situ, stage I through stage IIIA, or stage unknown lung cancer; or 6) 
were diagnosed with a lung cancer tumor of unknown histology or not of non-small cell histology. 
Application of these selection criteria resulted in a cohort of 20,109 older adults with stage IIIB or 
stage IV NSCLC.  
Additional inclusion and exclusion were then applied to the NSCLC population to obtain the 
final analytic cohort for this study. Patients were included  if they received chemotherapy within 120 
days from the date of diagnosis and received an initial treatment regimen consisting of one platinum 
and one non-platinum agent, each administered within the first 8 days of chemotherapy. Patients were 
excluded from the final cohort if they were diagnosed with a lung cancer tumor of squamous cell 
histology (a contraindication to the use of bevacizumab), died within 30 days from the date of 
diagnosis, or received ‘other’ unspecified chemotherapy agents or chemotherapy in an inpatient 
setting (i.e., in a hospital) within 8 days from the first date of chemotherapy. As illustrated in Figure 
4.2, application of these additional inclusion and exclusion criteria resulted in a final analytic cohort 
of 4,746 older adults with stage IIIB or stage IV NSCLC who received an initial platinum-based 
doublet chemotherapy regimen within 120 days of diagnosis; of this group, 3,401 patients specifically 
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received a doublet regimen consisting of a platinum agent (carboplatin or cisplatin) and a taxane 
agent (paclitaxel or docetaxel).  
 
 
 
Figure 4.2: Flow diagram of final analytic cohort selection  
Non-small cell lung cancer 
(NSCLC) cohort 
N = 20,109 
Squamous cell histology 
n = 4,291 
Non-squamous NSCLC 
n = 15,818 
Medicare date of death ≤ 30 days from 
diagnosis date
a
 
n = 3,777 
No Medicare claims for chemotherapy 
≤ 120 days from diagnosis date 
n = 5,878 
Alive 30 days after diagnosis  
 n = 12,041 
Received platinum-based  
doublet chemotherapy 
 ≤ 8 days from first 
chemotherapy claim date 
n = 4,746 
Received platinum/taxane 
chemotherapy ≤ 8 days from first 
chemotherapy claim date 
N = 3,401 
 
a 
Date of diagnosis considered the first day of the diagnosis month  
b
’Other’ chemotherapy included all chemotherapy agents not otherwise specified because 
of low use in NSCLC or because the agent was not identified in the Medicare claim. 
Received chemotherapy ≤ 120 
days from diagnosis date 
 n = 6,163 
Medicare claims for ‘other’ chemotherapy 
agents or inpatient chemotherapy ≤ 8 days 
from first chemotherapy claim date
b
 
n = 401 
No inpatient or ‘other’ 
chemotherapy ≤ 8 days from first 
chemotherapy claim date 
 n = 5,762 
No Medicare claims for a platinum and 
non-platinum agent, each ≤ 8 days from 
first chemotherapy claim date 
n = 1,016 
No Medicare claims for a platinum and a 
taxane agent, each ≤ 8 days from first 
chemotherapy claim date 
n = 1,345 
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 Table 4.1 describes the breakdown of predisposing, enabling, and need characteristics among 
patients included in the final analytic cohort. The average and median ages of patients in the cohort 
were 73.4 years (standard deviation = 5.0) and 73.0 years, respectively.  A majority of patients were 
diagnosed between the ages of 70 and 79 years (60.6%), male (53.0%), married (61.9%), and of white 
race (88.9%). In addition, most patients resided in the South (Georgia, Kentucky, Louisiana; 37.9%) 
and within a metropolitan area at the time of diagnosis (85.5%), but only a minority of patients 
received state buy-in Medicare coverage during the 12 months preceding their diagnosis (8.8%) and 
few received any medical or chemotherapy treatment from a CCOP-affiliated provider (36.5% and 
21.6%, respectively). Evaluation of the need characteristics shows that a majority of patients were 
diagnosed with stage IV cancer (70.9%), as well as tumors of unknown grade (59.5%), and 
adenocarcinoma histology (55.7%).  Furthermore, most patients receiving chemotherapy treatment 
with a platinum-based doublet regimen had a low level of comorbidity, as indicated by the percentage 
with an NCI Charlson Comorbidity Index of zero (59.3%) or one (33.3%). Hemoptysis and brain 
metastases were present in 4.1% and 23.6% of patients at the time of diagnosis, respectively, while 
6.4% of patients had a form of cancer-directed surgery. 
 
 
 
 
 
 
  
1
3
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Table 4.1 Predisposing, enabling, and need characteristics of the cohort (N = 4746)  
Predisposing n (%) Enabling n (%) Need n (%) 
Age at diagnosis Median household income (census tract level) Tumor stage 
   66 to 69 1260  (26.5)    Lowest quartile 976  (20.6)    IIIB 1380  (29.1) 
   70 to 79 2878  (60.6)    Second 1179  (24.8)    IV 3366  (70.9) 
   80 and older 608  (12.8)    Third 1224  (25.8) 
 
  
  
 
   Highest 1363  (28.7)    
Sex Population density Summary stage 
   Female 2232  (47.0)    Urban/rural 689  (14.5)    Regional 410    (8.6) 
   Male 2514  (53.0)    Metro 4057  (85.5)    Distant 4336  (91.4) 
Marital status 
State buy-in Medicare coverage during year preceding 
diagnosis Grade 
   Not married 1809  (38.1)    No 4330  (91.2)    Well/Moderately differentiated 543  (11.4) 
   Married 2937  (61.9)    Yes 416    (8.8)    Poor/Undifferentiated 1382  (29.1) 
           Unknown 2821  (59.4) 
Race ≥ 50% of medical claims  from CCOP provider Tumor histology 
   White 4219  (88.9)    No 2830  (59.6)    Adenocarcinoma 2642  (55.7) 
   Black 288    (6.1)    Yes 1736  (36.5)    Large cell  256    (5.4) 
   Other 239    (5.0)        Other and NOS 1848  (38.9) 
% 25 years and older in census tract 
 w/ < HS education ≥ 50% of chemotherapy claims from CCOP provider NCI Charlson Comorbidity Index 
   Lowest quartile 1339  (28.2)    No 3541  (74.6)    0 2814  (59.3) 
   Second 1241  (26.1)    Yes 1025  (21.6)    1 1580  (33.3) 
   Third 1198  (25.2)        2 235    (5.0) 
   Highest 959  (20.2)         
    Received treatment from provider affiliated with a:     
    Cooperative research group Hemoptysis 
       No 1965  (41.4)    No 4550  (95.9) 
       Yes 2445  (51.5)    Yes 196    (4.1) 
    NCI designated cancer center Brain metastases 
       No 4128  (87.0)    No 3625  (76.4) 
       Yes 282    (5.9)    Yes 1121  (23.6) 
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Table 4.1 (Continued) 
Predisposing n (%) Enabling n (%) Need n (%) 
    Teaching hospital  Radiation therapy received 
       No 1962  (41.3)    No 2366  (49.9) 
       Yes 2442  (51.5)    Yes 2314  (48.8) 
    Medical school Cancer-directed surgery 
       No 2171  (45.7)    No 4441 (93.6) 
       Yes 2239  (47.2)    Yes 305   (6.4) 
    Year of diagnosis     
       2004-2005 2378  (50.1)     
       2006 1242  (26.2)     
       2007 1126  (23.7)     
    SEER regiona     
       East 1107  (23.3)     
       Midwest 893  (18.8)     
       South 1796  (37.9)     
       West 950  (20.0)     
a
 SEER regions: East = Connecticut and New Jersey ; Midwest = Iowa, Michigan, New Mexico, and Utah; South = Georgia, Kentucky, and Louisiana; West = 
California, Hawaii, and Washington 
Abbreviations: CCOP = Community Clinical Oncology Program; NCI = National Cancer Institute; SEER = Surveillance Epidemiology and End Results. 
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4.2 Description of Chemotherapy Use 
Table 4.2 provides descriptive statistics about the platinum-based chemotherapy received by 
patients within the cohort, including the specific chemotherapy agent combinations used and their 
median duration of use. Among the platinum agents available for use, carboplatin (92.4%) was 
utilized more frequently than either cisplatin (7.5%) or oxaliplatin (0.1%) during first-line treatment. 
Paclitaxel was the chemotherapeutic agent most often used in combination with a platinum compound 
(2699/4746, 56.9%) while docetaxel (702/4746, 14.8%) and gemcitabine (947/4746, 20.0%) were 
also utilized among a considerable proportion of patients. Overall, the majority of patients received a 
platinum and taxane doublet regimen (71.7%), with most receiving a combination of carboplatin and 
paclitaxel (56.5%) specifically. 
The median duration of treatment, measured as the median number of days between the first 
claim date of chemotherapy and the last claim date of one of the two chemotherapy agents (whichever 
agent was stopped first), varied by regimen. Among the platinum and taxane regimens, chemotherapy 
combinations involving carboplatin had a median duration of 63 days and an interquartile range 
(IQR) of approximately 25 to 111 days; by comparison, cisplatin and taxane regimens had shorter 
median durations of use at 42 days (IQR, 20 to 121 days). Median duration of treatment among the 
more commonly used non-taxane regimens ranged from 32 days with cisplatin and etoposide (IQR, 
25 to 56 days) to 70 days with carboplatin and etoposide (IQR, 30 to 107 days) as well as with 
cisplatin and gemcitabine (IQR, 22 to 119 days). 
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Table 4.2 First-line platinum-based doublet chemotherapy regimens used  
      Regimen duration (days)
a
 
Chemotherapy regimen N % Median IQR (25% - 75%) 
Platinum and taxane doublet 3401 71.66 63 28 – 106 
  Carboplatin with  
       Paclitaxel 2683 56.53 63 28 – 106 
       Docetaxel 637 13.42 63 25 – 111 
  Cisplatin with 
       Paclitaxel 16 0.34 42 20 – 121 
       Docetaxel 65 1.37 42 21 –   70 
Platinum and non-taxane doublet 1345 28.34 55 23 – 105 
  Carboplatin with  
       Gemcitabine 888 18.71 62 21 – 106 
       Etoposide 129 2.72 70 30 – 107 
       Pemetrexed 30 0.63 73 26 – 105 
       Vinorelbine 18 0.38 66 28 – 105 
       Irinotecan 2 0.04 116 86 – 147 
       Cyclophosphamide 1 0.02 --
b
 -- 
  Cisplatin with 
       Etoposide 175 3.69 32 25 –   56 
       Gemcitabine 59 1.24 70 22 – 119 
       Vinorelbine 29 0.61 44 28 –   98 
       Irinotecan 7 0.15 35 1   – 156 
       Pemetrexed 2 0.04 94 63 – 126 
  Oxaliplatin with 
       5-Fluorouracil 3 0.06 28 14 –   92 
       Gemcitabine 2 0.04 10 1   –   21  
a
 Regimen duration defined as the number of days between the first and last Medicare claim dates for the 
chemotherapy regimen; when the first and last claim dates for each of the two chemotherapy agents were not 
identical, the first and last Medicare claim dates were considered the earliest of the initial and earliest of the 
final claim dates between the two chemotherapy agents, respectively.    
b
 Patient only received one administration of the combination of carboplatin and cyclophosphamide 
Abbreviations: IQR = Interquartile range 
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4.3 Aim 1: Utilization of Bevacizumab 
The intent of the Aim 1 was to describe the utilization of bevacizumab in combination with 
standard platinum-based doublet chemotherapy as first line treatment of older adults with advanced 
NSCLC and to identify the clinical, sociodemographic, and health system factors associated with its 
use. The clinical, demographic, and health system factors were categorized based on Andersen’s 
Behavioral Model of Health Services Use to assess whether predisposing, enabling, or need 
characteristics were more closely linked to the use of bevacizumab. 
The utilization of bevacizumab within 8 days of the start of platinum-based doublet 
chemotherapy is described according to specific treatment regimen in Table 4.3. Overall, 386 of the 
4,746 (8.1%) patients in the cohort received bevacizumab. Bevacizumab was utilized more often 
among patients receiving a platinum and taxane doublet (9.8%) than among patients receiving a 
platinum and non-taxane doublet treatment (3.9%). Although bevacizumab was used in combination 
with ten different chemotherapy regimens, over 95% of patients who received bevacizumab had it 
administered alongside one of three carboplatin-based treatments in particular: carboplatin and 
paclitaxel (266/386, 68.5%), carboplatin and docetaxel (66/386, 16.9%), or carboplatin and 
gemcitabine (38/386, 9.8%).  Compared to just 2.5% of patients receiving a cisplatin-based doublet 
regimen, approximately 9% of patients who received a carboplatin-based doublet also received 
bevacizumab. 
The median duration of bevacizumab use, measured as the median number of days between 
the first and last claim dates for bevacizumab, varied by chemotherapy regimen. Among patients who 
received bevacizumab in addition to a platinum and taxane doublet regimen, the median duration of 
bevacizumab treatment was 76 days (IQR, 29 to 112 days). The median duration of bevacizumab 
treatment was 64 days (IQR, 21 to 137 days) among patients who received bevacizumab in addition 
to a platinum and non-taxane doublet regimen. Among the specific regimens most commonly used 
with bevacizumab, the median duration of bevacizumab use was similar among patients who received 
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either carboplatin and paclitaxel (median, 105 days; IQR, 42 to 217 days) or carboplatin and 
docetaxel (median, 101 days; IQR, 42 to 219 days) and greater than that seen among patients who 
received carboplatin and gemcitabine (median, 64 days; IQR, 21 to 132 days).  
 
Table 4.3 Use of bevacizumab within 8 days of chemotherapy start 
        
Duration of 
bevacizumab use
a
 
Chemotherapy regimen 
Total receiving 
chemotherapy 
No. receiving 
bevacizumab % 
Median 
(days) 
IQR        
(25% - 75%) 
Platinum and taxane  3401 333 9.8 76 29 - 112 
Carboplatin with 
Paclitaxel 2683 266 9.9 105 42 – 217 
Docetaxel 637 66 10.4 101 42 – 219 
Cisplatin with 
Paclitaxel 16 0 0.0 -- -- 
Docetaxel 65 1 1.5 208 61 – 356 
            
Platinum and non-taxane 1345 53 3.9 64 21 - 137 
Carboplatin 
Gemcitabine 888 38 4.3 64 21 – 132 
Etoposide 129 1 0.8 --
b
 -- 
Pemetrexed 30 7 23.3 42 23 – 112 
Vinorelbine 18 0 0.0 -- -- 
Irinotecan 2 0 0.0 -- -- 
Cyclophosphamide 1 0 0.0 -- -- 
Cisplatin 
Etoposide 175 1 0.6 105 -- 
Gemcitabine 59 5 8.5 201 154 – 252 
Vinorelbine 29 0 0.0 -- -- 
Irinotecan 7 0 0.0 -- -- 
Pemetrexed 2 0 0.0 -- -- 
Oxaliplatin 
5-fluorouracil 3 1 33.3 14 -- 
Gemcitabine 2 0 0.0 -- -- 
a
Duration of use defined as the number of days between the first and last Medicare claim dates for bevacizumab 
b
 Patient only received one administration of bevacizumab 
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4.3.1 Bivariate analysis of the use of bevacizumab 
 The following subsections describe the potential bivariate associations between predisposing, 
enabling, and need variables of interest and the utilization of bevacizumab with platinum-based 
doublet chemotherapy. The associations between each set of characteristics and the use of 
bevacizumab among patients who received platinum-taxane doublet chemotherapy regimens in 
particular are described separately from the larger cohort analysis.    
 
4.3.1.1 Any platinum-based doublet chemotherapy 
The bivariate analysis results comparing the characteristics of patients who received 
platinum-based chemotherapy with bevacizumab to those patients who received chemotherapy only 
are presented in Table 4.4.  
 
Age, race, socioeconomic status, and provider CCOP-affiliation 
 Estimated odds ratios (OR) suggested that patients aged 70 to 79 and 80 and older had 
decreased odds of receiving bevacizumab compared to patients aged 66 to 69. Among racial groups, 
blacks had the lowest odds of receiving bevacizumab whereas patients of non-white/non-black race 
had the highest. Patients in census tracts within the lowest quartile for percentage of adults with less 
than a high school education (i.e., census tracts with higher educational attainment) or in the highest 
quartile of median household income also had the highest odds of bevacizumab use. However, age, 
race, and socioeconomic status measures were not significantly (p<0.05) associated with the use of 
bevacizumab among patients receiving any platinum-based chemotherapy regimen. Conversely, 
patients who received at least 50% of their chemotherapy from a CCOP-affiliated provider had over 
50% greater odds of receiving bevacizumab as compared to patients who did not (OR 1.51, 95% CI 
1.20-1.91). 
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Additional predisposing variables 
Married patients had a 22% higher odds of receiving bevacizumab compared to noon-married 
patients and females had a slight greater odds of receiving bevacizumab compared to males, but 
neither of these predisposing variables were significantly associated (p<0.05) with the use of 
bevacizumab among patients receiving any platinum-based chemotherapy regimen.   
 
Additional enabling variables 
Year of diagnosis was significantly associated with the use of bevacizumab. Compared to 
patients diagnosed between 2004 and 2005, patients diagnosed in 2006 (OR 7.65; 95% CI 5.37-10.89) 
or 2007 (OR 12.16, 95% CI 8.61-17.16) were considerably more likely to receive bevacizumab; 
patients diagnosed in 2007 were also more likely to receive bevacizumab compared to patients 
diagnosed in 2006 (OR 1.59, 95% CI 1.26-2.00).  However, additional enabling variables including 
population density (i.e., residence in a rural or urban residential area versus a major metropolitan 
area), state buy-in of Medicare coverage during the year preceding diagnosis, SEER region, and 
receipt of treatment from a provider affiliated with a cooperative research group, an NCI designated 
cancer center, teaching hospital, or medical school were not significantly associated with the use of 
bevacizumab among patients receiving any platinum-based doublet regimen.  
 
Need variables 
Unlike the predisposing and enabling characteristics, nearly all of the need characteristics, 
including tumor stage, summary stage, tumor histology, NCI Charlson comorbidity index score, 
hemoptysis, brain metastases, receipt of radiation therapy, and receipt of cancer-directed surgery were 
significantly associated with the use of bevacizumab among patients who received any platinum-
based doublet chemotherapy regimen. Tumor grade was the lone need characteristic not significantly 
associated with the use of bevacizumab. 
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Table 4.4 Bivariate associations with the use of bevacizumab among patients who received platinum-based doublet chemotherapy 
  Platinum-based  
doublet chemotherapy 
      
Characteristic 
With Bevacizumab                 
(n = 386) 
Without 
Bevacizumab       
(n = 4360) Unadjusted OR 95% CI p-value 
Predisposing      
Age at diagnosis 
    
0.383 
66 to 69 112 1148 ref 
  
70 to 79 231 2647 0.89 (0.71, 1.13) 
 
80 and older 43 565 0.78 (0.54, 1.12) 
 
Sex 
    
0.635 
Female 186 2046 ref 
  
Male 200 2314 0.95 (0.77, 1.17) 
 
Marital Status 
    
0.078 
Not married 131 1678 ref 
  
Married 255 2682 1.22 (0.98, 1.52) 
 
Race  
    
0.418 
White 346 3873 ref 
  
Black 18 270 0.75 (0.46, 1.22) 
 
Other 22 217 1.13 (0.72, 1.78) 
 
% 25 years and older in census tract w/ < HS education 
    
0.543 
Lowest quartile 121 1218 ref 
  
Second 97 1144 0.82 (0.60, 1.11) 
 
Third 96 1102 0.85 (0.65, 1.13) 
 
Highest 72 887 0.88 (0.66, 1.16) 
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Enabling      
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Median household income 
(census tract level)     
0.754 
Lowest quartile 82 895 ref 
  
Second 94 1087 0.93 (0.69, 1.29) 
 
Third 94 1130 0.92 (0.67, 1.25) 
 
Highest 121 1244 1.06 (0.79, 1.42) 
 
Population density 
    
0.759 
Urban/rural 54 635 ref 
  
Metro 332 3725 1.05 (0.78, 1.41) 
 
State buy-in Medicare coverage during year preceding diagnosis 
   
0.595 
No 355 3975 ref 
  
Yes 31 385 0.90 (0.62, 1.32) 
 
≥ 50% of medical claims from CCOP provider 
    
0.037 
No 213 2617 ref 
  
Yes 161 1575 1.26 (1.01, 1.56) 
 
≥ 50% of chemotherapy claims from CCOP provider 
   
<0.001 
No 263 3278 ref 
  
Yes 111 914 1.51 (1.20, 1.91) 
 
Received treatment from provider affiliated with a:      
Cooperative research group 
    
0.819 
No 161 1804 ref 
  
Yes 205 2240 1.02 (0.83, 1.27) 
 
NCI cancer center 
    
0.929 
No 343 3785 ref 
  
Yes 23 259 0.98 (0.63, 1.52) 
 
Table 4.4 (Continued) 
     
Teaching hospital  
    
0.927 
No 163 1799 ref 
  
Yes 201 2241 0.99 (0.80, 1.23) 
 
Medical school 
    
0.758 
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No 183 1988 ref 
  
Yes 183 2056 0.97 (0.78, 1.20) 
 
Year of diagnosis 
    
<0.001 
2004-2005 41 2337 ref 
  
2006 147 1095 7.65 (5.37, 10.89) 
 
2007 198 928 12.16 (8.61, 17.16) 
 
SEER region 
    
0.103 
East 71 1036 ref 
  
Midwest 73 820 1.30 (0.92, 1.82) 
 
South 161 1635 1.44 (1.07, 1.92) 
 
West 81 869 1.36 (0.98, 1.89) 
 
      
Need      
Tumor stage 
    
<0.001 
IIIB 74 1306 ref 
  
IV 312 3054 1.80 (1.39, 2.34) 
 
Summary stage 
    
<0.001 
Regional 15 395 ref 
  
Distant 371 3965 2.46 (1.45, 4.17) 
 
Grade 
    
0.187 
Well/Moderately differentiated 49 494 ref 
  
Poor/Undifferentiated 100 1282 0.79 (0.55, 1.12) 
 
Unknown 237 2584 0.92 (0.67, 1.28) 
 
Table 4.4 (Continued) 
     
Tumor histology 
    
<0.001 
Adenocarcinoma 261 2381 Ref 
  
Large cell  12 244 0.45 (0.25, 0.81) 
 
Other and NOS 113 1735 0.59 (0.47, 0.75) 
 
NCI Comorbidity Index 
    
0.014 
0 248 2566 Ref 
  
   
1
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1 116 1464 0.82 (0.65, 1.03) 
 
2 9 226 0.41 (0.21, 0.81) 
 
Hemoptysis 
    
0.038 
No 378 4172 Ref 
  
Yes 8 188 0.47 (0.23, 0.96) 
 
Brain metastases 
    
<0.001 
No 323 3302 Ref 
  
Yes 63 1058 0.61 (0.46, 0.80) 
 
Radiation therapy received 
    
<0.001 
No 263 2103 Ref 
  
Yes 113 2201 0.41 (0.33, 0.52) 
 
Cancer-directed surgery  
    
0.021 
No 369 4035 ref 
  
Yes 15 306 0.54 (0.32, 0.91) 
 
a
 SEER regions: East = Connecticut and New Jersey ; Midwest = Iowa, Michigan, New Mexico, and Utah; South = Georgia, Kentucky, and 
Louisiana; West = California, Hawaii, and Washington 
Abbreviations: OR = Odds ratio; CI = Confidence interval; NCI = National Cancer Institute; NOS = Not otherwise specified; SEER = Surveillance 
Epidemiology and End Results. 
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Patients with stage IV tumors at diagnosis were 80% more likely to receive bevacizumab in 
addition to platinum-based doublet chemotherapy as patients diagnosed with stage IIIB tumors (OR 
1.80, 95% CI 1.39-2.34). Similarly, patients with distant stage disease at diagnosis were 
approximately 2.5 times as likely to have bevacizumab added to their platinum-based doublet 
regimen as patients diagnosed with regional tumors (OR 2.46, 95% CI 1.45-4.17). Compared to 
patients with adenocarcinoma histology, patients with large cell (OR 0.45, 95% CI 0.25-0.81) or 
histology unknown or not otherwise specified (OR 0.59, 95% CI 0.47-0.75) were significantly less 
likely to receive bevacizumab. Furthermore, as the comorbidity burden of patients increased, the use 
of bevacizumab decreased; patients with an NCI Charlson comorbidity index score of 2 were less 
than half as likely to receive bevacizumab compared to patients with a score of 0 (OR 0.41, 95% CI 
0.21-0.81). Likewise, patients with hemoptysis (OR 0.47, 95% CI 0.23-0.96) or brain metastases (OR 
0.61, 95% CI 0.46-0.80) had a significantly decreased likelihood of receiving bevacizumab in contrast 
to patients without these complications at the time of diagnosis. Lastly, patients who were treated 
with radiation (OR 0.41, 95% CI 0.33-0.52) or cancer-directed surgery (OR 0.54, 95% CI 0.32-0.91) 
were about half as likely to receive bevacizumab as patients who were not. 
 
4.3.1.2 Platinum-taxane doublet chemotherapy only 
The bivariate analysis results comparing the characteristics of patients who received 
platinum-taxane doublet chemotherapy with bevacizumab to those patients who received platinum-
taxane chemotherapy only are described in Table 4.5. 
 
Age, race, socioeconomic status, and provider CCOP-affiliation 
Similar to the results among patients receiving any platinum-based doublet chemotherapy, 
estimated ORs suggested that utilization of bevacizumab among patients who received a platinum-
taxane regimen was lower among those aged 70 to 79 and 80 and older compared to patients aged 66 
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to 69. In addition, blacks had the lowest odds of receiving bevacizumab among racial groups whereas 
patients of non-white/non-black race had the highest. Patients in census tracts with higher education 
attainment (i.e., lowest quartile of education measure) or higher median household income also had 
the highest odds of bevacizumab use. However, age, race, and socioeconomic status measures were 
not significantly (p<0.05) associated with the use of bevacizumab among patients receiving platinum-
taxane chemotherapy. Still, patients who received at least half of their chemotherapy treatment from a 
CCOP-affiliated provider had 50% greater odds of receiving bevacizumab compared to patients who 
did not (OR 1.50, 95% CI 1.17-1.93). 
 
Additional predisposing variables 
Although married patients had 20% greater odds of receiving bevacizumab compared to non-
married patients (OR 1.20, 95% CI 0.95, 1.53), there were no significant associations between 
additional predisposing characteristics (sex and marital status) and the use of bevacizumab.  
 
Additional enabling variables 
In general, the results among patients receiving platinum-taxane chemotherapy were similar 
to the results seen among patients receiving any platinum-based chemotherapy regimen as year of 
diagnosis was the only additional enabling variable significantly associated with the use of 
bevacizumab. Estimates comparing the use of bevacizumab across regions of SEER registries were 
not statistically significant, but patients in both the West (California, Hawaii, and Washington 
registries) and South (Georgia, Kentucky, and Louisiana) regions were approximately 50% more 
likely to receive bevacizumab compared to patients in the East (Connecticut and New Jersey 
registries) region.     
  
1
4
4
 
Table 4.5 Bivariate associations with the use of bevacizumab among patients who received platinum-taxane doublet chemotherapy 
 
Platinum-taxane  
doublet chemotherapy 
  
 
  
  
Characteristic 
With 
Bevacizumab                 
(n = 336) 
Without 
Bevacizumab       
(n = 3068) Unadjusted OR 95% CI p-value 
Predisposing      
Age at diagnosis 
    
0.298 
66 to 69 93 793 ref 
  70 to 79 205 1864 0.94 (0.72, 1.21) 
 80 and older 35 411 0.73 (0.48, 1.09) 
 Sex 
    
0.868 
Female 158 1441 ref 
  Male 175 1627 0.98 (0.78, 1.23) 
 Marital Status 
    
0.126 
Not married 114 1182 ref 
  Married 219 1886 1.20 (0.95, 1.53) 
 Race 
    
0.316 
White 294 2746 ref 
  Black 18 184 0.91 (0.55, 1.50) 
 Other 21 138 1.42 (0.88, 2.28) 
 % 25 years and older in census  tract w/ < HS education 
   
0.128 
Lowest quartile 108 807 ref 
 
  
Second 82 809 0.76 (0.55, 1.02)   
Third 81 805 0.75 (0.55, 1.02)   
Highest 62 641 0.72 (0.53, 1.00)   
Table 4.5 (Continued) 
     
Enabling      
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Median household income 
(census tract level)     
 
  0.350 
Lowest quartile 68 669 ref     
Second 80 769 1.02 (0.73, 1.44)   
Third 80 803 0.98 (0.70, 1.38)   
Highest 105 825 1.25 (0.91, 1.73)   
Population density     
 
  0.364 
Urban/rural 46 482 ref     
Metro 287 2586 1.16 (0.84, 1.61)   
State buy-in Medicare coverage during year preceding diagnosis    
 
  0.766 
No 307 2814 ref     
Yes 26 254 0.94 (0.62, 1.43)   
≥ 50% of medical claims from CCOP provider        0.229 
No 183 1763 ref     
Yes 142 1187 1.15 (0.92, 1.45)   
≥ 50% of chemotherapy claims from CCOP provider    
 
  0.001 
No 224 2269 ref     
Yes 101 681 1.50 (1.17, 1.93)   
Received treatment from provider affiliated with a:     
 
    
Cooperative research group     
 
  0.977 
No 176 1566 ref     
Yes 143 1268 1.00 (0.79, 1.26)   
NCI cancer center     
 
  0.591 
No 303 2671 ref     
Yes 16 163 0.86 (0.51, 1.47)   
Table 4.5 (Continued) 
     
Teaching hospital  
    
0.880 
No 147 1325 ref 
  Yes 170 1505 1.02 (0.81, 1.29) 
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Medical school 
    
0.868 
No 165 1452 ref 
  Yes 154 1382 0.98 (0.78, 1.24) 
 Year of diagnosis 
    
<0.001 
2004-2005 34 1659 ref 
  2006 132 782 8.23 (5.60, 12.12) 
 2007 167 627 12.99 (8.89, 19.00) 
 SEER region 
    
0.064 
East 61 762 ref 
  Midwest 62 561 1.38 (0.95, 2.00) 
 South 141 1181 1.49 (1.09, 2.04) 
 West 69 564 1.53 (1.06, 2.19) 
       
Need      
Tumor stage 
    
<0.001 
IIIB 63 957 ref 
  IV 270 2111 1.94 (1.46, 2.58) 
 Summary stage 
    
<0.001 
Regional 12 306 ref 
  Distant 321 2762 2.96 (1.65, 5.34) 
 Grade 
    
0.228 
       Well/Moderately differentiated 38 368 ref 
  Poor/Undifferentiated 85 900 0.91 (0.61, 1.37) 
 Unknown 210 1800 1.13 (0.79, 1.62) 
       
Table 4.5 (Continued) 
     
Tumor histology     
 
  <0.001 
Adenocarcinoma 223 1707 ref     
Large cell  9 171 0.40 (0.20, 0.80)   
Other and NOS 101 1190 0.65 (0.51, 0.83)   
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NCI Comorbidity Index     
 
  0.005 
0 219 1811 ref     
1 99 1019 0.80 (0.62, 1.03)   
2 6 167 0.30 (0.13, 0.68)   
Hemoptysis     
 
  0.078 
No 325 2930 ref     
Yes 8 138 0.52 (0.25, 1.08)   
Brain metastases     
 
  0.002 
No 276 2304 ref     
Yes 57 764 0.62 (0.46, 0.84)   
Radiation therapy received     
 
  <0.001 
No 224 1379 ref     
Yes 99 1648 0.37 (0.29, 0.47)   
Cancer-directed surgery      
 
  0.012 
No 320 2837 ref     
Yes 11 214 0.46 (0.25, 0.84)   
a
 SEER regions: East = Connecticut and New Jersey ; Midwest = Iowa, Michigan, New Mexico, and Utah; South = Georgia, Kentucky, and Louisiana; West = 
California, Hawaii, and Washington 
Abbreviations: OR = Odds ratio; CI = Confidence interval; NCI = National Cancer Institute; NOS = Not otherwise specified; SEER = Surveillance 
Epidemiology and End Results. 
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Need variables  
In general, the results among patients receiving platinum-taxane chemotherapy were similar 
to the results seen among patients receiving any platinum-based chemotherapy regimen. For instance, 
tumor stage, summary stage, tumor histology, NCI Charlson comorbidity index score, brain 
metastases, receipt of radiation therapy, and receipt of cancer-directed surgery all were significantly 
associated with the use of bevacizumab among patients receiving platinum-taxane chemotherapy. In 
these results, patients diagnosed with distant stage disease were nearly 3 times as likely to receive 
bevacizumab compared to patients diagnosed with regional stage tumors (OD 2.96, 95% CI 1.65-
5.34). Patients in worse overall health with an NCI Charlson comorbidity index score of 2 were 
approximately 70% less likely to receive bevacizumab in contrast to healthier patients with an NCI 
Charlson comorbidity index score of 0 (OR 0.30, 95% CI 0.13-0.68). Tumor grade was not 
significantly associated with the use of bevacizumab (p = 0.228) and though the OR estimate 
suggested patients with hemoptysis were about 48% less likely to receive bevacizumab compared to 
patients without, the association was not statistically significant (p = 0.078). 
  
4.3.2 Multivariate analysis of the use of bevacizumab 
The following subsections describe the multivariate analysis of the associations between the 
predisposing, enabling, and need characteristics of interest and the utilization of bevacizumab among 
patients receiving platinum-based doublet chemotherapy. Multivariate analysis of the associations 
between predisposing, enabling, and need characteristics and the use of bevacizumab among patients 
specifically receiving platinum-taxane chemotherapy regimens are described separately.  
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4.3.2.1 Any platinum-based doublet chemotherapy 
The multivariate analysis of the associations between predisposing, enabling, and need 
characteristics and the use of bevacizumab among patients receiving any platinum-based doublet 
chemotherapy are presented in Table 4.6. 
 As in the bivariate analysis, age, race, and socioeconomic status measures were unrelated to 
the use of bevacizumab, but receipt of treatment from a CCOP affiliated provider remained a 
significant independent predictor of bevacizumab use. For example, patients who received ≥ 50% of 
their chemotherapy from a CCOP-affiliated provider maintained 61% greater odds of receiving 
bevacizumab than patients who did not after controlling for other predisposing, enabling, and need 
characteristics (OR 1.64, 95% CI 1.25-2.16). Additional predisposing characteristics sex and marital 
status remained unrelated to the use of bevacizumab, whereas year of diagnosis was the only 
additional enabling characteristic significantly linked to the use of bevacizumab. Of the need 
characteristics included in the multivariate logistic regression model, tumor stage, histology, NCI 
Charlson comorbidity index, brain metastases at diagnosis, receipt of radiation, and receipt of cancer-
directed surgery were all associated with the use of bevacizumab. Though patients with hemoptysis 
had approximately 50% less odds of receiving bevacizumab than patients without, this result was not 
statistically significant (OR 0.50, 95% CI 0.24-1.07). Similarly, tumor summary stage was no longer 
significantly associated with bevacizumab use after other predisposing, enabling, and need 
characteristics were controlled for in the regression model (OR 1.27, 95% CI 0.66-2.44). 
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Table 4.6 Multivariate associations of predisposing, enabling, and need characteristics on the 
odds of bevacizumab use among patients receiving platinum-based doublet chemotherapy 
Characteristic Adjusted OR 95% CI p-value 
Predisposing       
Age     0.174 
66 to 69 Ref     
70 to 79 0.86 (0.66, 1.13)   
80 and older 0.68 (0.45, 1.02)   
Sex     0.611 
Female Ref     
Male 0.94 (0.74, 1.20)   
Marital status     0.181 
Not married Ref     
Married 1.19 (0.92, 1.55)   
Race     0.507 
White Ref     
Black 0.73 (0.42, 1.26)   
Other 1.05 (0.60, 1.83)   
% 25 years and older in census tract w/ < HS education     0.770 
Lowest quartile Ref     
Second 0.88 (0.63, 1.23)   
Third 0.82 (0.55, 1.21)   
Highest 0.81 (0.49, 1.32)   
    
Enabling       
Median household income (census tract level)     0.669 
Lowest quartile Ref     
Second 0.80 (0.53, 1.20)   
Third 0.76 (0.47, 1.21)   
Highest 0.81 (0.48, 1.37)   
Population density     0.248 
Urban/Rural Ref     
Metro 1.26 (0.85, 1.85)   
State buy-in Medicare coverage during year preceding diagnosis    0.722 
No Ref     
Yes 0.92 (0.58, 1.46)   
≥ 50% of chemotherapy claims from CCOP provider     <0.001 
No Ref     
Yes 1.64 (1.25, 2.16)   
Year of diagnosis     <0.001 
2004-2005 Ref     
2006 8.29 (5.72, 12.03)   
2007 12.96 (8.99, 18.66)   
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SEER region     0.196 
East ref     
Midwest 1.22 (0.81, 1.83)   
South 1.43 (1.02, 2.16)   
West 1.37 (0.93, 2.01)   
    
Need       
Tumor stage     0.002 
IIIB ref     
IV 1.66 (1.20, 2.29)   
Summary stage     0.470 
Regional ref     
Distant 1.27 (0.66, 2.44)   
Grade     0.929 
Well/Moderately differentiated ref     
Poor/Undifferentiated 0.93 (0.61, 1.41)   
Unknown 0.98 (0.67, 1.42)   
Histology     0.001 
Adenocarcinoma ref     
Large cell 0.54 (0.28, 1.05)   
Other and NOS 0.64 (0.49, 0.83)   
NCI Charlson Comorbidity Index     0.018 
0 ref     
1 0.79 (0.61, 1.02)   
2 0.42 (0.21, 0.85)   
Hemoptysis     0.073 
No ref     
Yes 0.50 (0.24, 1.07)   
Brain metastases     0.008 
No ref     
Yes 0.65 (0.47, 0.89)   
Radiation therapy received     <0.001 
No ref     
Yes 0.41 (0.32, 0.54)   
Cancer-directed surgery     0.018 
No ref     
Yes 0.47 (0.25, 0.88)   
Abbreviations: OR = Odds ratio; CI = Confidence interval; CCOP = Clinical Community Oncology Program; 
NOS = Not otherwise specified; NCI = National Cancer Institute 
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4.3.2.2 Platinum-taxane doublet chemotherapy only 
The multivariate analysis of the associations between predisposing, enabling, and need 
characteristics and the use of bevacizumab among patients receiving platinum-taxane doublet 
chemotherapy are presented in Table 4.7. 
 Similar to the multivariate analysis of patients receiving any platinum-based doublet 
regimen, age, race, and socioeconomic status measures were not associated with the use of 
bevacizumab whereas provider CCOP-affiliation was. For instance, patients receiving ≥ 50% of 
chemotherapy from a CCOP-affiliated provider maintained 60% greater odds of receiving 
bevacizumab compared to patients who did not (OR 1.60, 95%CI 1.19-2.15). Additional predisposing 
characteristics were unrelated to the use of bevacizumab whereas patients diagnosed in 2006 or 2007 
were significantly more likely to use bevacizumab compared to patients diagnosed in either 2004 or 
2005. Patients diagnosed with stage IV tumors also had approximately 70% greater odds of 
bevacizumab use compared to patients with stage IIIB tumors after controlling for other 
characteristics. Furthermore, tumor histology, NCI Charlson comorbidity index, brain metastases, 
receipt of radiation therapy, and cancer-directed surgery were all significantly associated with the use 
of bevacizumab among patients receiving platinum-taxane chemotherapy regimens; specifically, 
patients with adenocarcinoma histology, NCI Charlson comorbidity index scores of zero, no brain 
metastases at diagnosis, no radiation treatment, and no cancer-directed surgery had greater odds of 
receiving bevacizumab.  Despite significant bivariate associations, summary stage, tumor grade, 
hemoptysis, and cancer-directed surgery were not significantly linked to the use of bevacizumab after 
controlling for other predisposing, enabling, and need characteristics. 
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Table 4.7 Multivariate associations of predisposing, enabling and need characteristics on the 
odds of bevacizumab use among patients receiving platinum-taxane doublet chemotherapy 
Characteristic Adjusted OR 95% CI p-value 
Predisposing       
Age     0.278 
66 to 69 ref     
70 to 79 0.93 (0.69, 1.25)   
80 and older 0.69 (0.44, 1.09)   
Sex     0.966 
Female ref     
Male 1.01 (0.77, 1.32)   
Marital status     0.429 
Not married ref     
Married 1.12 (0.84, 1.50)   
Race     0.549 
White ref     
Black 0.95 (0.53, 1.69)   
Other 1.39 (0.76, 2.54)   
% 25 years and older in census tract w/ < HS education     0.425 
Lowest quartile ref     
Second 0.77 (0.53, 1.13)   
Third 0.70 (0.45, 1.09)   
Highest 0.76 (0.44, 1.31)   
    
Enabling       
Median household income (census tract level)     0.823 
Lowest quartile ref     
Second 0.94 (0.59, 1.49)   
Third 0.83 (0.49, 1.42)   
Highest 0.97 (0.53, 1.75)   
Population density     0.332 
Urban/Rural ref     
Metro 1.24 (0.81, 1.89)   
State buy-in Medicare coverage during year preceding diagnosis    0.599 
No ref     
Yes 0.87 (0.51, 1.47)   
≥ 50% of chemotherapy claims from CCOP provider     0.002 
No ref     
Yes 1.60 (1.19, 2.15)   
Year of diagnosis     <0.001 
2004-2005 ref     
2006 8.97 (5.97, 13.47)   
2007 14.14 (9.44, 21.17)   
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SEER region     0.207 
East Ref     
Midwest 1.35 (0.86, 2.12)   
South 1.50 (1.02, 2.19)   
West 1.43 (0.93,2.20)   
Need       
Tumor stage     0.004 
IIIB Ref     
IV 1.70 (1.19, 2.42)   
Summary stage     0.214 
Regional Ref     
Distant 1.59 (0.76, 3.33)   
Grade     0.655 
Well/Moderately differentiated Ref     
Poor/Undifferentiated 0.96 (0.60, 1.53)   
Unknown 1.10 (0.72, 1.68)   
Histology     0.029 
Adenocarcinoma Ref     
Large cell 0.56 (0.27, 1.18)   
Other and NOS 0.71 (0.53, 0.94)   
NCI Charlson Comorbidity Index     0.005 
0 Ref     
1 0.73 (0.55, 0.97)   
2 0.31 (0.13, 0.73)   
Hemoptysis     0.0881 
No Ref     
Yes 0.51 (0.23, 1.11)   
Brain metastases     0.024 
No Ref     
Yes 0.67 (0.48, 0.95)   
Radiation therapy received     <0.001 
No Ref     
Yes 0.37 (0.28, 0.49)   
Cancer-directed surgery     0.044 
No Ref     
Yes 0.48 (0.24, 0.98)   
Abbreviations: OR = Odds ratio; CI = Confidence interval; CCOP = Clinical Community Oncology Program; 
NOS = Not otherwise specified; NCI = National Cancer Institute 
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4.3.2.3 Hierarchical multivariate regression analysis 
A hierarchical regression model was constructed as part of a sensitivity analysis to assess for 
changes in the association between predisposing, enabling, and need characteristics and the use of 
bevacizumab. The hierarchical analysis was conducted by first including only the predisposing 
variables in a logistic regression model to evaluate their associations with the use of bevacizumab. 
Subsequent regression models were then performed, first adding enabling and then need characteristic 
variables, to evaluate their associations with the use of bevacizumab, controlling for the prior 
variables in the model. No significant differences were found between the results of the hierarchical 
analysis and the results of the multivariate analysis described above.  As such, the results of the 
multivariate regression models for predisposing characteristics, and predisposing and enabling 
characteristics are described individually within tables of Appendix B. In addition, hierarchical 
analysis results among patients who specifically received a platinum-taxane doublet regimen are 
described separately for each model. 
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4.4 Aim 2: Survival Analysis 
 Aim 2 was designed to determine whether the utilization of bevacizumab in addition to 
standard platinum-based doublet chemotherapy as first-line treatment of older adults with advanced 
NSCLC is associated with a benefit of improved overall survival. Analysis of survival was performed 
through the estimation of the hazard of death among patients who received bevacizumab in 
combination with platinum-based doublet chemotherapy relative to those patients who received 
platinum-based doublet chemotherapy only. In addition, the odds of one-year survival following the 
initiation of treatment was estimated and compared between patients who received bevacizumab with 
platinum-based doublet chemotherapy and those patients who received platinum-based doublet 
chemotherapy only. Furthermore, additional analyses of overall survival duration and one-year 
survival were performed for those patients who received first-line treatment with a platinum-taxane 
doublet regimen specifically.   
      
4.4.1 Bivariate analysis of the use of bevacizumab and survival 
 Figure 4.3 describes the median survival times and unadjusted hazard ratios (HR) comparing 
the hazard of death among patients who received bevacizumab in combination with platinum-based 
doublet chemotherapy relative to those patients who received platinum-based doublet chemotherapy 
only. Survival duration was similar between those patients who received bevacizumab and those 
patients who did not. Among patients who received first-line treatment with any platinum-based 
doublet chemotherapy, those who also received bevacizumab had a median survival duration of 9.8 
months while those who did not had a median survival duration of 8.9 months (HR 1.02, 95% CI 
0.91-1.13; p-value = 0.76). Among those who were specifically treated with a platinum-taxane 
doublet (Figure 4.4), the median survival duration was 10.0 months for patients receiving 
bevacizumab and 9.0 months for patients receiving chemotherapy only (HR 1.01, 95% CI 0.89-1.13; 
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p-value = 0.89), further indicating that bevacizumab provided not additional benefit with respect to 
improving overall survival. 
 Visual evaluation of the Kaplan-Meier survival plots detected a crossing of the survival 
curves for the two treatment groups, representing a potential violation of the proportional hazards 
assumption and thus a concern for the appropriate interpretation of effect estimates from Cox 
proportional hazards models. The proportionality of the survival curves was investigated further by 
testing for the interaction between bevacizumab and the log of survival time within Cox proportional 
hazards models (statistical significance of a time-dependent covariate suggests the survival curves for 
the predictor are non-proportional). However, in each cohort (i.e., any platinum-based doublet and 
platinum-taxane doublet), the interaction term for bevacizumab and the log of survival time was not 
statistically significant in the Cox proportional hazards models, implying the proportional hazards 
assumption was not violated.   
 
Figure 4.3 Kaplan-Meier survival curves according to the use of bevacizumab among patients 
receiving any platinum-based doublet chemotherapy 
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Figure 4.4 Kaplan-Meier survival curves according to the use of bevacizumab among patients 
receiving platinum-taxane doublet chemotherapy 
 
  
Table 4.8 displays the results for one-year survival based on the use of bevacizumab. One-
year survival was determined using the time between the first date of treatment and the date of death 
reported by Medicare, with patients who were alive at least 365 days following the start of treatment 
considered one-year survivors. Among patients who received any platinum-based doublet regimen, 
42.0% of patients who received bevacizumab and 38.7% of patients who did not survived one year or 
longer. In comparing the two groups, the estimated odds of surviving one year following the start of 
treatment was greater among patients who received bevacizumab than among those patients who did 
not (OR 1.15, 95% CI 0.93-1.42), but this finding was not statistically significant. Examining patients 
who specifically received treatment with platinum-taxane doublet regimens yielded similar results. 
Patients who received platinum-taxane doublet chemotherapy with bevacizumab had approximately 
21% greater odds of surviving at least one year from the start of treatment as compared to patients 
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who received platinum-taxane chemotherapy only, but this result also was not statistically significant 
(OR 1.21, 95% 0.96-1.51). 
 
Table 4.8 One-year survival by receipt of bevacizumab 
Treatment Patients treated, n 
Patients surviving 
 ≥ 1-year, n (%) OR (95% CI) 
Any platinum-based doublet 
chemotherapy       
without bevacizumab 4360 1687 (38.7) ref 
with bevacizumab   386   162 (42.0) 1.15  (0.93, 1.42) 
Platinum-taxane doublet 
chemotherapy       
without bevacizumab 3068 1197 (39.0) ref 
with bevacizumab   333   145 (43.5) 1.21   (0.96, 1.51) 
Abbreviations: OR = Odds ratio; CI = Confidence interval 
 
4.4.2 Bivariate analysis of survival and predisposing, enabling, and need characteristics 
Bivariate associations between overall survival duration and predisposing, enabling, and need 
characteristics were evaluated to identify variables that may confound the relationship between 
survival and the use of bevacizumab. Results are shown in Table 4.9. 
 
Predisposing characteristics 
Overall, age was not a significant predictor of survival among patients treated with platinum-
based doublet chemotherapy. However, when compared to patients aged 66 to 69, patients 80 and 
older had significantly poorer survival (HR 1.12, 95% CI 1.01-1.24); patients aged 70 to 79 also had 
an increased hazard of death in comparison to patients aged 66 to 69, but this finding was not 
statistically significant (HR 1.06, 95% CI 0.99-1.14). Both race and the census tract measure for 
education were significant bivariate predictors of overall survival in this cohort of patients receiving 
platinum-based doublet chemotherapy. For example, the hazard of death was significantly lower 
among patients of ‘other’ race in comparison to white patients (HR 0.76, 95% CI 0.66-0.87) while the 
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hazard of death was significantly higher among patients residing in census tract areas with higher 
percentages of residents with less than a high school education (highest vs. lowest quartile: HR 1.18, 
95% CI 1.08-1.29). Among additional predisposing characteristics, sex was a significant predictor of 
overall survival among patients receiving platinum-based doublet chemotherapy; the hazard of death 
was significantly higher among males as compared to females (HR 1.29, 95% CI 1.21-1.37). 
Conversely, there was little difference in survival between married and non-married patients. 
 
Enabling variables 
In addition to education, the socioeconomic status measure of median household income was 
also associated with overall survival; specifically, the hazard of death was significantly lower among 
patients residing in census tract areas of higher median household income (highest vs. lowest quartile: 
HR 0.90, 95% CI 0.83-0.99). Although provider affiliation with the CCOP was positively associated 
with the utilization of bevacizumab, there was no apparent relationship between provider CCOP-
affiliation and overall survival as the hazard of death was nearly equal between patients who received 
at least 50% of chemotherapy from a CCOP-affiliated provider and patients who did not. Among 
additional enabling characteristics, the hazard of death was significantly lower in patients receiving 
treatment from a provider affiliated with a cooperative research group (HR 0.90, 95% CI 0.85-0.96). 
A statistically significant difference in the hazard of death was also found for SEER region based on 
the result of significantly greater survival in patients from the West region compared to patients from 
the Midwest region (HR 0.87, 95% CI 0.79-0.96; not shown in table). 
 
Need variables 
Several need characteristics were also significantly associated with overall survival, including 
tumor stage, tumor grade, tumor histology, NCI Charlson comorbidity index score, the presence of 
brain metastases, receipt of radiation treatment, and receipt of any cancer-directed surgery. In regards 
to tumor characteristics, overall survival was significantly poorer among patients diagnosed with 
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stage IV disease compared to patients diagnosed with stage IIIB (HR 1.50, 95% CI 1.40-1.60), 
patients with poor/undifferentiated (HR 1.48, 95% CI 1.33-1.65) or unknown (HR 1.41, 95% CI 1.31-
1.56) tumor grade compared to patients with well/moderately differentiated tumors, patients with 
large cell (HR 1.17, 95% CI 1.03-1.34) or other/not otherwise specified (HR 1.12, 95% CI 1.05-1.19) 
histology compared to patients with adenocarcinoma. Patients with an NCI Charlson comorbidity 
index of 1 or 2 each had significantly higher hazards of death compared to patients with an index of 0 
and the hazard of death was significantly greater among patients with brain metastases compared to 
those without (HR 1.17, 95% CI 1.09-1.25). Lastly, patients who received radiation treatment had 
significantly poorer survival compared to those who did not (HR 1.09, 95% CI 1.03-1.16), whereas 
patients who received cancer-directed surgery had significantly better survival in comparison to 
patients who did not have any surgery (HR 0.50, 95% CI 0.44-0.57). 
Bivariate associations between overall survival duration and predisposing, enabling, and need 
characteristics were also evaluated among patients who specifically received platinum-taxane doublet 
chemotherapy. Results of this analysis were nearly identical to those previously described (Appendix 
C: Table C-1). 
 
Table 4.9 Bivariate associations between overall survival and predisposing, enabling, and need 
characteristics among patients receiving platinum-based doublet chemotherapy 
    Median survival time     
Characteristic 
No. of 
patients Months (95% CI) 
Log-rank 
 p-value HR (95% CI) 
Predisposing         
Age at diagnosis     0.065   
66 to 69 1260   9.4  (8.8, 10.0)    ref 
70 to 79 2878 8.9  (8.4, 9.4)   1.06  (0.99, 1.14) 
80 and older 608 8.7  (7.8, 9.5)   1.12  (1.01, 1.24) 
Sex     < 0.001   
Female 2232 10.3  (9.8, 10.8)     ref 
Male 2514 8.0  (7.5, 8.4)   1.29  (1.21, 1.37) 
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Marital Status     0.340   
Not married 1809 8.8  (8.1, 9.3)     ref 
Married 2937 9.1  (8.7, 9.6)   0.97  (0.91, 1.03 
Race     < 0.001   
White 4219 8.8  (8.5, 9.2)     ref 
Black 288   9.4  (7.9, 10.5)   0.97  (0.86, 1.10) 
Other 239   14.0  (10.1, 15.9)   0.76  (0.66, 0.87) 
% 25 years and older in census tract 
 w/ < HS education  0.001   
Lowest quartile 1339   9.5  (8.7, 10.2)     ref 
Second 1241 9.1  (8.5, 9.8)   1.08  (0.99, 1.17) 
Third 1198 8.8  (7.8, 9.5)   1.12  (1.03, 1.22) 
Highest 959 8.7  (7.8, 9.4)   1.18  (1.08, 1.29) 
          
Enabling         
Median household income 
(census tract level)  0.003   
Lowest quartile 977 9.2  (8.5, 9.9)     ref 
Second 1181 8.5  (7.8, 9.1)   1.05  (0.96, 1.15) 
Third 1224 8.7  (8.0, 9.4)   1.00  (0.91, 1.09) 
Highest 1365   9.7  (9.0, 10.4)   0.90  (0.83, 0.99) 
Population density     0.178   
Urban/rural 689   9.2  (8.4, 10.0)     ref 
Metro 4057 9.0  (8.6, 9.4)   0.94  (0.87, 1.03) 
State buy-in Medicare coverage during 
year preceding diagnosis    0.622   
No 4330 9.0  (8.7, 9.4)    ref 
Yes 416 8.8  (7.5, 9.9)   0.97  (0.88, 1.08) 
≥ 50% of chemotherapy claims from 
CCOP provider    0.405   
No 3541 8.8  (8.4, 9.2)    ref 
Yes 1025 9.3  (8.7, 9.9)   0.97  (0.90, 1.04) 
Received treatment from provider 
affiliated with a cooperative research 
group   0.001   
No 1965 8.3  (7.7, 8.8)    ref  
Yes 2445 9.4  (8.8, 9.9)   0.90  (0.85, 0.96) 
Year of diagnosis     0.216   
2004-2005 2378 8.6  (8.2, 9.1)     ref 
2006 1242   9.5  (8.8, 10.2)   0.94  (0.87, 1.01) 
2007 1126   9.3  (8.7, 10.0)   0.98  (0.90, 1.05) 
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SEER region     0.046   
East 1107 9.4  (8.5, 9.9)     ref 
Midwest 893 8.2  (7.3, 9.0)   1.09  (0.99, 1.20) 
South 1896 8.8  (8.3, 9.4)   1.02  (0.94, 1.10) 
West 950   9.7  (9.0, 10.5)   0.95  (0.87, 1.04) 
     
Need         
Tumor stage     < 0.001   
IIIB 1380   12.6  (11.8, 13.6)     ref 
IV 3366 7.7  (7.4, 8.2)   1.50  (1.40, 1.60) 
Summary stage     < 0.001   
Regional 410   15.4  (13.2, 17.8)     ref 
Distant 4335 8.6  (8.2, 8.9)   1.64  (1.47, 1.83) 
Grade     < 0.001   
Well/Moderate  543   12.3  (10.8, 14.3)     ref 
Poor/Undifferentiated 1382 8.1  (7.5, 8.7)   1.48  (1.33, 1.65) 
Unknown 2821 9.0  (8.5, 9.4)   1.41  (1.28, 1.56) 
Tumor histology     < 0.001   
Adenocarcinoma 2642   9.6  (9.1, 10.0)     ref 
Large cell  256 7.7  (6.1, 9.5)   1.17  (1.03, 1.34) 
Other and NOS 1848 8.3  (7.9, 8.8)   1.12  (1.05, 1.19) 
NCI Charlson Comorbidity Index   < 0.001   
0 2814 9.5  (8.9, 9.9)     ref 
1 1580 8.7  (8.2, 9.3)   1.11  (1.04, 1.18) 
2 235 6.9  (5.6, 8.5)   1.43  (1.25, 1.64) 
Hemoptysis     0.634   
No 4550 9.0  (8.6, 9.4)     ref 
Yes 196   9.1  (7.7, 10.1)   0.96  (0.83, 1.12) 
Brain metastases     < 0.001   
No 3625 9.1  (8.6, 9.4)     ref 
Yes 1121 8.9  (8.3, 9.5)   1.17  (1.09, 1.25) 
Radiation therapy received    0.004   
No 2366   9.7  (9.2, 10.2)     ref 
Yes 2314 8.4  (8.0, 8.8)   1.09  (1.03, 1.16) 
Cancer-directed surgery     < 0.001   
No 4404 8.7  (8.3, 9.0)     ref 
Yes 321   18.7  (14.7, 22.9)   0.50  (0.44, 0.57) 
Abbreviations: CI = Confidence interval; HR = Hazard ratio; CCOP = Clinical Community Oncology Program; 
SEER = Surveillance, Epidemiology, and End Results; NOS = Not otherwise specified; NCI = National Cancer 
Institute. 
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 4.4.3 Multivariate analysis of bevacizumab and survival 
 Multivariate Cox proportional hazards models were used to evaluate the effect of 
bevacizumab on overall survival while adjusting for potential confounders. Several different hazards 
models were constructed, selecting clinical, sociodemographic, and health care system variables 
based on Andersen’s Behavioral Model of Health Services Use and/or their significant bivariate 
associations with survival. Results from the multivariate Cox proportional hazards models evaluating 
the effect of bevacizumab on overall survival among patients who received any platinum-based 
doublet chemotherapy as well as among those who specifically received platinum-taxane doublet 
chemotherapy are presented in Table 4.10. 
 
Table 4.10 Effect of adding bevacizumab to platinum-based doublet chemotherapy on hazard 
ratios for overall survival  
  Any platinum doublet Platinum-taxane doublet 
  Sample, n   Sample, n   
  Bevacizumab   Bevacizumab   
Models    Yes   No HR (95% CI)    Yes   No HR (95% CI) 
Unadjusted 386  4360 1.02  (0.91, 1.13) 333  3068 1.01  (0.89, 1.13) 
Multivariate-adjusted          
Predisposing
a
 386  4351 1.04  (0.93, 1.16) 333  3062 1.04  (0.92, 1.16) 
Enabling
b
 366  4040 1.04  (0.93, 1.17) 319  2832 1.03  (0.90, 1.17) 
Need
c
 364  4200 0.96  (0.85, 1.07) 313  2956 0.95  (0.84, 1.08) 
Predisposing & enabling 366  4031 1.07  (0.95, 1.20) 319  2826 1.06  (0.93, 1.20) 
Predisposing, enabling, & 
need 346  3890 1.00  (0.89, 1.13) 300  2729 0.99  (0.87, 1.13) 
Identified confounders
d,e
 346  3890 0.96  (0.86, 1.08) 300  2736 0.95  (0.84, 1.08) 
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Propensity score-adjusted
f,g
       
Covariate adjustment 333  3890 1.03  (0.91, 1.16) 300  2736 1.00  (0.87, 1.14) 
Matching
h
 346    346 0.94  (0.78, 1.16) 300    300 0.99  (0.83, 1.20) 
a 
The model was adjusted for age, sex, marital status, race, and census tract level of education 
b
 The model was adjusted for census tract level of median household income, population density, state buy-in 
Medicare coverage during year preceding diagnosis, ≥ 50% of chemotherapy from provider affiliated with the 
Community Clinical Oncology Program, treatment from a provider affiliated with a cooperative research group, 
year of diagnosis, and SEER region 
c
 The model was adjusted for stage at diagnosis, tumor grade, histology, NCI Charslon comorbidity index, 
hemoptysis, brain metastases, radiation, and cancer-directed surgery 
d 
The model for patients receiving any platinum-based doublet was adjusted for sex, race, census tract level of 
education, census tract level of median household income, treatment from a provider affiliated with a 
cooperative research group, SEER region, stage at diagnosis, tumor grade, histology, NCI Charslon comorbidity 
index, brain metastases, radiation, and cancer-directed surgery 
e 
The model for patients receiving platinum-taxane doublet chemotherapy was adjusted for sex, race, treatment 
from a provider affiliated with a cooperative research group,  stage at diagnosis, tumor grade, histology, NCI 
Charslon comorbidity index, brain metastases, radiation, and cancer-directed surgery 
f 
The propensity of receiving bevacizumab was estimated among patients who received any platinum-based 
doublet using a multivariable logistic regression model that included sex, race, census tract level of education, 
census tract level of median household income, treatment from a provider affiliated with a cooperative research 
group, SEER region,  stage at diagnosis, tumor grade, histology, NCI Charslon comorbidity index, brain 
metastases, radiation, and cancer-directed surgery 
g 
The propensity of receiving bevacizumab was estimated among patients who received a platinum-taxane 
doublet using a multivariable logistic regression model that included sex, race, treatment from a provider 
affiliated with a cooperative research group, SEER region,  stage at diagnosis, tumor grade, histology, NCI 
Charslon comorbidity index, brain metastases, radiation, and cancer-directed surgery 
h 
Using a greedy match algorithm, patients receiving platinum-based chemotherapy only were matched on 
estimated propensity scores to patients receiving  platinum-based chemotherapy with bevacizumab 
Abbreviations: HR = Hazard ratio; CI = Confidence interval; SEER = Surveillance, Epidemiology, and End 
Results; NCI = National Cancer Institute. 
 
4.4.3.1 Multivariate adjustment: predisposing, enabling, and need characteristics 
 Overall, bevacizumab did not have any significant effect on survival in the Cox proportional 
hazards models that adjusted for clinical, sociodemographic, and health care system variables 
categorized based on Andersen’s Behavioral Model of Health Services Use. However, the estimated 
hazard ratio (HR) fell on either side of the null value, depending on which covariates were included in 
the regression model. For example, when predisposing characteristics, enabling characteristics, or 
both were controlled for, the estimated hazard ratios were 1.04, 1.04, and 1.07, respectively. 
Conversely, when need characteristics were controlled for in addition to predisposing and enabling 
characteristics, the estimated HR was approximately 1.00 (95% CI 0.89-1.13) and when need 
 166 
characteristics alone were controlled for, the estimated HR  was 0.96 (95% CI 0.85-1.07). Results 
from the Cox hazards models that adjusted for clinical, sociodemographic, and health care system 
variables categorized based on Andersen’s Behavioral Model of Health Services Use among patients 
who specifically received platinum-taxane doublet chemotherapy were similar to those seen among 
patients who received any platinum-based doublet chemotherapy. In addition, full results from 
multivariable Cox proportional hazards models estimating the effects of bevacizumab and each of the 
predisposing, enabling, and need characteristics on overall survival are included in Appendix D 
(Table D-1); briefly, need characteristics including AJCC stage, tumor grade, and comorbidity score 
at the time of diagnosis remained significant independent predictors of overall survival, irrespective 
of treatment received. 
 
4.4.3.2 Multivariate adjustment: variables with bivariate associations with overall survival 
 Additional multivariable Cox proportional hazards models were constructed in which 
covariates were selected based on significant bivariate associations with overall survival. Among 
patients who received any platinum-based doublet chemotherapy, the Cox hazards model included 
sex, race, census tract level of education, census tract level of median household income, treatment 
from a provider affiliated with a cooperative research group, SEER region, AJCC stage at diagnosis, 
tumor grade, histology, NCI Charlson comorbidity index, brain metastases, radiation, and cancer-
directed surgery. The Cox hazards model among patients who specifically received platinum-taxane 
doublet chemotherapy was similar, but did not include SEER region or the census tract level variables 
as these were not significantly associated with overall survival in this subgroup of patients. Results 
from these multivariable Cox hazards models again show that bevacizumab did not have a significant 
effect on overall survival, even after adjusting for identified confounders. The hazard ratios and 
confidence intervals, both among patients who received any platinum-based doublet (HR 0.96, 95% 
CI 0.86-1.08) and among those who received a platinum-taxane doublet (HR 0.95, 95% CI 0.84-
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1.08), are nearly identical to those seen in the multivariable-adjusted models that contained only need 
characteristics, which is likely due to the similarities in the covariates included in each of the models. 
      
4.4.3.3 Propensity score adjustment 
In addition to the multivariable-adjusted survival analyses, Cox proportional hazards models 
were also constructed using estimated propensity scores. Initially, propensity score analysis was 
performed to balance measured confounders between patients who received chemotherapy with 
bevacizumab and patients who received platinum-based chemotherapy only. Of note, identified 
confounders differed between patients receiving any platinum-based doublet chemotherapy and 
patients receiving platinum-taxane chemotherapy specifically, therefore, distinct propensity scores 
were calculated for each cohort of patients.   
Multivariate logistic regression models were first used to calculate propensity scores 
representing the probability that a patient received bevacizumab conditional on all other measured 
confounders in the model.  In each propensity score model, variables that were associated with 
bevacizumab use and overall survival (true confounders) as well as variables related to overall 
survival only were included. For the cohort of patients receiving any platinum-based doublet 
chemotherapy, the propensity score  model included sex, race, census tract level of education, census 
tract level of median household income, treatment from a provider affiliated with a cooperative 
research group, SEER region,  AJCC stage at diagnosis, tumor grade, histology, NCI Charslon 
comorbidity index, brain metastases, radiation, and cancer-directed surgery as confounders. The 
model used to derive propensity  scores in the cohort of patients receiving platinum-taxane 
chemotherapy included sex, race, treatment from a provider affiliated with a cooperative research 
group, SEER region,  AJCC stage at diagnosis, tumor grade, histology, NCI Charslon comorbidity 
index, brain metastases, radiation, and cancer-directed surgery.  
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Following propensity score estimation, the propensity scores were applied to Cox 
proportional hazards models to perform two distinct propensity score-adjusted analyses. In the first 
propensity score-adjusted analysis, discrete Cox PH regression models were fit using the propensity 
score as a continuous covariate in the regression model. In the second propensity score-adjusted 
analysis, propensity score estimates were used to first match exposed patients (receiving 
bevacizumab) to patients from the unexposed group (receiving chemotherapy only) in a 1:1 ratio 
using a 5-to-1 digit greedy-match algorithm. The algorithm allows for the capture of the best possible 
matches (those pairs matched to the fifth digit of the PS) while also maximizing the number of 
possible matches by including pairs matched to the fourth, third, second, and first digits of the PS 
(adequacy of the matches decrease with the number of digits matched on); non-matched individuals 
are excluded from the derived cohort of matched patients. Application of the 1:1 greedy-match 
algorithm resulted in 346 matched pairs among patients receiving any platinum-based doublet 
chemotherapy and 300 matched pairs among patients receiving platinum-taxane doublet 
chemotherapy specifically.  
After deriving the matched cohort, Chi-square tests were used to assess for even balance of 
measured covariates across the groups of matched patients; uneven balance of the covariates across 
groups may signal a poor propensity score model and/or the need to include unbalanced covariates as 
independent variables in subsequent regression models evaluating treatment effects. In this study, 
Chi-square test results showed that, with the exception of age, marital status at diagnosis, hemoptysis, 
and year of diagnosis among patients receiving any platinum-based doublet chemotherapy and year of 
diagnosis only among patients receiving platinum-taxane chemotherapy, measured covariates were 
evenly distributed between patients who received chemotherapy with bevacizumab and propensity 
score-matched patients who received chemotherapy only (Appendix E: Table E-1); age, marital 
status, hemoptysis, and year of diagnosis were thus included as additional covariates in the propensity 
score models assessing the effect of bevacizumab on survival among patients receiving any platinum-
based doublet chemotherapy and year of diagnosis was included in the models among patients 
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receiving platinum-taxane regimens in particular. Following the evaluation of covariate balance 
across matched treatment groups, discrete Cox PH regression models were then fit to estimate the 
effect of bevacizumab on overall survival among the cohort of matched patients; patients who were 
not matched were excluded from this analysis.    
Overall, bevacizumab did not have a significant effect on survival in any of the propensity 
score-adjusted models. Among patients who received any platinum-based doublet and among patients 
who received platinum-taxane regimens in particular, the estimated hazards ratios and confidence 
intervals for the use of bevacizumab were similar to the unadjusted estimates and were slightly higher 
than those seen in the multivariable models that adjusted for covariates with significant bivariate 
associations with overall survival. In the samples of patients matched on estimated propensity scores, 
the estimated hazards ratio for the effect of bevacizumab on survival were lower than unadjusted 
estimates among patients who received any platinum-based doublet (HR 0.94, 95% CI 0.78-1.12) and 
among patients who received platinum-taxane regimens (HR 0.99, 95% CI 0.83-1.20) in particular, 
but neither result was statistically significant.      
 
4.4.3.4 Subgroup analyses 
Subgroup analysis of the effect of bevacizumab on overall survival was performed for 
patients diagnosed with stage IV disease. In addition to an unadjusted model, a multivariable Cox 
proportional hazards model was constructed for the subgroup and included covariates with significant 
bivariate associations with overall survival. The results from the subgroup analysis of patients 
diagnosed with stage IV NSCLC are shown in Table 4.11.   The unadjusted hazards ratios for 
bevacizumab among patients with stage IV disease were lower than the unadjusted hazards ratios that 
were estimated among all patients who received any platinum-based doublet chemotherapy or 
received platinum-taxane chemotherapy specifically. Adjusting for confounders in multivariable Cox 
proportional hazards models lowered the resulting estimated hazards ratios among patients who 
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receive any platinum-based doublet chemotherapy (HR 0.92, 95% CI 0.80-1.03) and among patients 
who received platinum-taxane chemotherapy in particular (HR 0.92, 95% CI 0.80-1.06). Although the 
estimated hazards ratios slightly favored the use of bevacizumab, the estimated effect of bevacizumab 
on overall survival was not statistically significant among patients diagnosed with stage IV disease. 
 
Table 4.11 Effect of adding bevacizumab to platinum-based doublet chemotherapy on hazard 
ratios for overall survival among patients diagnosed with stage IV disease 
  Any platinum doublet Platinum-taxane doublet 
  Sample, n   Sample, n   
  Bevacizumab   Bevacizumab   
Models Yes No HR (95% CI) Yes No HR (95% CI) 
Unadjusted 312  3054 0.91  (0.80, 1.03) 270  2111 0.90  (0.79, 1.03) 
Multivariate-adjusted
a,b
 282  2723 0.92  (0.81, 1.05) 247  1885 0.92  (0.80, 1.06) 
a 
The model for patients receiving any platinum-based doublet was adjusted for sex, race, census tract level of 
education, census tract level of median household income, treatment from a provider affiliated with a 
cooperative research group, SEER region, tumor grade, histology, NCI Charslon comorbidity index, brain 
metastases, radiation, and cancer-directed surgery 
b 
The model for patients receiving platinum-taxane doublet chemotherapy was adjusted for sex, race census tract 
level of median household income, treatment from a provider affiliated with a cooperative research group,   
tumor grade, histology, NCI Charslon comorbidity index, radiation, and cancer-directed surgery 
Abbreviations: HR = Hazard ratio; CI = Confidence interval; SEER = Surveillance, Epidemiology, and End 
Results; NCI + National Cancer Institute. 
 
4.4.3.5 Sensitivity analyses  
Finally, two separate sensitivity analyses were conducted. The first sensitivity analysis 
assessed for changes in the effect estimate of bevacizumab on overall survival when the interval for 
identifying the concurrent use of bevacizumab with platinum-based doublet chemotherapy was 
expanded from 8 to 30 days. In this analysis, patients who had a Medicare claim for bevacizumab 
within 30 days of chemotherapy initiation were considered to have received bevacizumab in addition 
to platinum-based doublet chemotherapy and all other patients were considered to have received 
platinum-based doublet chemotherapy only. The second sensitivity analysis assessed for the potential 
impact of immortal time bias on the effect estimate of bevacizumab on overall survival. In this 
analysis survival time was measured as the number of days starting from the first day after the end of 
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the treatment identification interval (Day 9 for the 8 day interval and Day 31 for the 30 days interval) 
to the time of death or censoring, whichever occurred first.  
 
Expansion of treatment identification interval from 8 days to 30 days 
 Table 4.12 displays results of the sensitivity analysis exploring the impact of increasing the 
interval for identifying the concurrent use of bevacizumab with platinum-based doublet chemotherapy 
from 8 days to 30 days. In each of the Cox proportional hazards models, extension of the interval to 
identify the utilization of bevacizumab from 8 days to 30 days resulted in a decrease in the estimated 
hazards ratio. For example, among patients who received platinum-taxane doublet chemotherapy, the 
unadjusted hazards ratio for the effect of bevacizumab on overall survival was 1.01 (95% CI 0.89-
1.13) using the 8-day interval compared to 0.97 (95% CI 0.86-1.08) using the 30-day interval. 
However, consistent with results from the primary analyses, bevacizumab was not significantly 
associated with overall survival in any of the Cox proportional hazards models even after extending 
the interval to identify the use of bevacizumab from 8 days to 30 days.   
 
Table 4.12 Impact of increasing the interval for identifying the concurrent use of bevacizumab 
with platinum-based doublet chemotherapy (from 8 days to 30 days) on the estimated effect of 
bevacizumab on survival 
  Any platinum doublet
a 
Platinum-taxane doublet
b 
  Sample, n   Sample, n   
  Bevacizumab Bevacizumab 
Models Yes   No HR (95% CI) Yes   No HR (95% CI) 
8-day interval         
Unadjusted model 386    4360 1.02  (0.91, 1.13) 333    3068 1.01  (0.89, 1.13) 
Multivariate-adjusted model 346    3890 0.96 (0.86, 1.08) 300    2736 0.95  (0.84, 1.08) 
30-day interval         
Unadjusted model 456    4290 0.97  (0.88, 1.07) 389    3012 0.97  (0.86, 1.08) 
Multivariate-adjusted model 409    3827 0.93  (0.83, 1.04) 351    2685 0.92  (0.81, 1.03) 
a
 Multivariate models adjusted for sex, race, census tract levels of education and median household income, 
treatment from a provider affiliated with a cooperative research group, SEER region, stage at diagnosis, tumor 
grade, histology, NCI Charslon comorbidity index, brain metastases, radiation, and cancer-directed surgery 
b
 Multivariate models adjusted for sex, race, treatment from a provider affiliated with a cooperative research 
group,  stage at diagnosis, tumor grade, histology, NCI Charslon comorbidity index, brain metastases, radiation, 
and cancer-directed surgery 
Abbreviations: HR = Hazard ratio; CI = Confidence interval; Surveillance, Epidemiology, and End Results; 
NCI = National Cancer Institute. 
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Measurement of survival starting after the end of the treatment identification interval 
 Results of the sensitivity analysis investigating the influence of immortal time bias on the 
effect estimates for bevacizumab on overall survival are presented in Table 4.13. Measuring survival 
starting on Day 9 (the first day following the 8-day interval used to identify concurrent use of 
bevacizumab with platinum-based doublet chemotherapy) had little influence on the estimated 
hazards ratio. Both the unadjusted and adjusted hazards models among patients who received any 
platinum-based doublet or platinum-taxane doublet chemotherapy yielded effect estimates that were 
nearly identical to those seen in the same models when survival was measured starting the first date of 
treatment. For example, among patients who received platinum-taxane chemotherapy, the 
multivariable-adjusted model measuring survival on Day 9 and the corresponding model measuring 
survival on Day 1 both produced an estimated hazard ratio of 0.95 (95% CI: Day 1, 0.84-1.08; Day 9, 
0.83-1.07) . Measuring survival starting on Day 31 (the first day following the alternative 30-day 
interval to identify concurrent use of bevacizumab) also had little influence on the estimated hazards 
ratio. Similar to the results just described, effect estimates in both the unadjusted and multivariable-
adjusted hazards models were comparable to those seen in the same models when survival was 
measured starting the first date of treatment. To illustrate, using an interval of 30 days to identify the 
use of bevacizumab among patients who received platinum-taxane chemotherapy, the multivariable-
adjusted model measuring survival on Day 31 produced an estimated hazard ratio of 0.90 (95% CI 
0.79-1.01) and the corresponding model measuring survival on Day 1 yielded an estimated hazard 
ratio of 0.92 (95% CI 0.81-1.03).      
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Table 4.13 Estimated effect of bevacizumab on survival when the measure of survival is 
initiated at the end of the interval used to identify bevacizumab treatment   
  Any platinum doublet
a 
Platinum-taxane doublet
b 
  Sample, n   Sample, n   
  Bevacizumab Bevacizumab 
Models Yes   No HR (95% CI) Yes   No HR (95% CI) 
8-day interval         
Unadjusted model 383    4353 1.01  (0.90, 1.12) 330    3064 1.00  (0.89, 1.12) 
Multivariate-adjusted model 343    3886 0.96  (0.85, 1.07) 297    2733 0.95  (0.83, 1.07) 
30-day interval         
Unadjusted model 440    4177 0.96  (0.87, 1.06) 374    2937 0.95  (0.85, 1.06) 
Multivariate-adjusted model 394    3729 0.92  (0.82, 1.03) 337    2618 0.90  (0.79, 1.01) 
a
 Multivariate models adjusted for sex, race, census tract level of education, census tract level of median 
household income, treatment from a provider affiliated with a cooperative research group, SEER region, AJCC 
stage at diagnosis, tumor grade, histology, NCI Charslon comorbidity index, brain metastases, radiation, and 
cancer-directed surgery 
b
 Multivariate models adjusted for sex, race, cooperative research group,  AJCC stage at diagnosis, tumor grade, 
histology, NCI Charslon comorbidity index, brain metastases, radiation, and cancer-directed surgery 
Abbreviations: HR = Hazard ratio; CI = Confidence interval; Surveillance, Epidemiology, and End Results; 
NCI = National Cancer Institute. 
 
4.4.4 Summary of survival analysis 
 No significant survival benefit was found with the concurrent use of bevacizumab and 
platinum-based doublet chemotherapy compared to platinum-based doublet chemotherapy alone. 
Controlling for confounding variables through the use of multivariable-adjusted and propensity score-
adjusted models resulted in lower estimated hazard ratios (favoring the use of bevacizumab) 
compared to unadjusted models, but the findings were not statistically significant. A subgroup 
analysis evaluating treatment effects among patients with stage IV disease, and sensitivity analyses 
evaluating the influence of varying the treatment identification interval and starting points for 
measurement of survival also yielded lower, yet insignificant, estimated hazard ratios. Thus, the 
finding that concurrent use of bevacizumab with platinum-based doublet chemotherapy did not 
significantly improve overall survival compared to use of platinum-based doublet chemotherapy 
alone was robust across several analytical models.     
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4.5 Aim 3: Hospitalizations for Serious Adverse Events 
Aim 3 was designed to determine whether the concurrent use of bevacizumab with standard 
platinum-based doublet chemotherapy is associated with an increase in hospitalization for severe 
treatment-related adverse events in comparison to platinum-based doublet chemotherapy alone. 
Hospitalization for each severe adverse event was defined as the presence of an inpatient (MEDPAR) 
claim with at least one of the corresponding ICD-9 or CPT codes listed in Appendix A during the 
specified evaluation period. 
Two distinct time windows were used to perform separate evaluations of hospitalizations: 1) 
a 6-month window starting from the first day of treatment; and 2) the duration between the first day 
and last day of the initial treatment regimen plus 30 days or the day a second-line treatment was 
initiated, whichever occurred first. Analysis of hospitalizations for severe adverse events over the 6-
month window was performed through estimation of the odds of hospitalization for an adverse event 
among patients who received bevacizumab concurrent with platinum-based doublet chemotherapy 
relative to those patients who received platinum-based doublet chemotherapy only. Since the duration 
of first-line treatment varied across patients, analysis of hospitalizations for severe adverse events 
using the treatment duration window was performed through the estimation of the hazard of 
hospitalization for an adverse event among patients who received bevacizumab concurrent with 
platinum-based doublet chemotherapy relative to those patients who received platinum-based doublet 
chemotherapy only. 
Separate analyses were done to evaluate the hazard of hospitalization for each of the severe 
adverse events of interest, including arterial thromboembolic events, gastrointestinal perforation, 
neutropenia, and severe hemorrhage as well as a composite measure of hospitalization for any of the 
aforementioned severe adverse events.  Furthermore, additional analyses of hospitalization for severe 
treatment-related adverse events were performed for those patients who received first-line treatment 
with a platinum-taxane doublet regimen in particular. Finally, a sensitivity analysis was also 
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performed to assess the association between the use of bevacizumab and the hazard of hospitalization 
for severe treatment-related adverse events among patients who specifically received first-line 
treatment with carboplatin-paclitaxel chemotherapy.   
 
4.5.1 Hospitalization within 180 days from the start of treatment   
4.5.1.1 Bivariate analysis of bevacizumab and hospitalization for severe adverse events 
 The cumulative incidence of hospitalization for severe adverse events within 180 days from 
the start of treatment is shown in Table 4.14 for patients who received any platinum doublet and in 
Table 4.15 for patients who received a platinum-taxane regimen. The incidence of hospitalization for 
severe adverse events was similar between the larger cohort of patients who received any platinum-
based doublet chemotherapy and the cohort of patients who received platinum-taxane regimens 
specifically. Among patients treated with any platinum-based doublet chemotherapy, those who 
received bevacizumab had lower incidence of arterial thromboembolic events (1.8% vs. 2.8%) but 
higher incidence of gastrointestinal perforation (2.3% vs. 1.1%) and neutropenia (10.1% vs. 8.6%) 
compared to patients who did not receive bevacizumab. However, the receipt of bevacizumab was 
only significantly associated with increased odds of hospitalization for gastrointestinal perforation 
(any platinum-based doublet: OR 2.24, 95% CI 1.09-4.61; platinum-taxane doublet: OR 2.20, 95% CI 
1.01-4.78). The incidence of hospitalization for any adverse event was also higher among patients 
who received bevacizumab compared to those patients who did not (17.1% vs. 13.8%), but the 
increased odds was only statistically significant among patients who received a platinum-taxane 
doublet regimen specifically (OR 1.37, 95% CI 1.01-1.85). 
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Table 4.14 Cumulative incidence (%) and odds ratios of hospitalization for severe adverse 
events within 180 days of the start of first-line treatment with any platinum-doublet 
 
  Any platinum doublet   
  Bevacizumab   
Adverse event 
No  
(n = 4360) 
Yes 
(n = 386) OR (95% CI) 
Arterial thromboembolic events 122 (2.8)         7 (1.8) 0.64 (0.30, 1.38) 
        
Gastrointestinal perforation   46 (1.1)         9 (2.3) 2.24 (1.09, 4.61) 
        
Neutropenia 377 (8.6)       39 (10.1) 1.19 (0.84, 1.68) 
        
Severe hemorrhage 196 (4.5)       17 (4.4) 0.98 (0.59, 1.62) 
        
Any adverse event   603 (13.8)       66 (17.1) 1.29 (0.97, 1.70) 
  
 
Table 4.15 Cumulative incidence (%) and odds ratios of hospitalization for severe adverse 
events within 180 days of the start of first-line treatment with a platinum-taxane doublet 
 
  Platinum-taxane doublet   
  Bevacizumab   
Adverse event 
No  
(n = 3068) 
Yes  
(n = 333) OR (95% CI) 
Arterial thromboembolic events          80 (2.6)         6 (1.8) 0.69 (0.30, 1.58) 
        
Gastrointestinal perforation          34 (1.1)         8 (2.4) 2.20 (1.01, 4.79) 
        
Neutropenia        268 (8.7)       35 (10.5) 1.23 (0.85, 1.78) 
        
Severe hemorrhage        127 (4.1)       14 (4.2) 1.02 (0.58, 1.79) 
        
Any adverse event        417 (13.6)       59 (17.7) 1.37 (1.01, 1.85) 
 
Bivariate associations between predisposing, enabling, and need characteristics with 
hospitalization for severe adverse events within 180 days from the start of treatment were assessed to 
inform multivariable regression models. The bivariate analysis results among patients who received 
any platinum-based doublet chemotherapy are presented in Table 4.16. Tumor histology (Chi-square 
p-value = 0.003) and brain metastases (p = 0.004) were significantly associated with hospitalization 
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for arterial thromboembolic events. The presence of brain metastases (p = 0.033) was also 
significantly associated with hospitalization for gastrointestinal perforation, as was the absence of 
radiation therapy (p = 0.049), NCI Charlson Comorbidity score (p = 0.037) and year of diagnosis (p = 
0.017). Hospitalization for neutropenia was associated with the receipt of radiation treatment (p = 
0.007) and residence in a non-metropolitan area at the time of diagnosis (p =0.006) whereas female 
sex (p = 0.032), race (p = 0.029), education (p = 0.039), SEER region (p = 0.26), greater comorbidity 
(p < 0.001), and presence of hemoptysis (p = 0.045) were associated with hospitalization for severe 
hemorrhage. Female sex (p = 0.032), SEER region (p = 0.013), and greater comorbidity (p < 0.001) 
were all associated with hospitalization for any severe adverse event.    
Among patients who received platinum-taxane doublet chemotherapy specifically (Table 
4.17), tumor histology (p = 0.005) and greater comorbidity (p = 0.027) were significantly associated 
with hospitalization for arterial thromboembolic events. Greater comorbidity (p = 0.008) was also 
associated with hospitalization for gastrointestinal perforation as was year of diagnosis (p = 0.015). 
No predisposing, enabling, or need characteristics were statistically significantly associated with 
hospitalization for neutropenia whereas female sex (p = 0.021) and greater comorbidity (p < 0.001) 
were both associated with hospitalization for severe hemorrhage and hospitalization for any severe 
adverse event (female sex, p = 0.018; greater comorbidity, p < 0.001).     
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Table 4.16 Bivariate associations between hospitalization for severe adverse events within 180 days of the start of treatment and  
predisposing, enabling, and need characteristics among patients receiving platinum-based doublet chemotherapy 
 
     ATE GI Perforation    Neutropenia 
Severe 
Hemorrhage Any Adverse Event 
Characteristic n (%) P n (%) P n (%) P n (%) P n (%) P 
Predisposing                   
Age at diagnosis 0.916   0.324   0.684   0.103   0.458 
66 to 69 31 (2.5)   18 (1.4)   111 (8.8)   44 (3.5)   168 (13.3)   
70 to 79 84 (2.9)   31 (1.1)   256 (8.9)   140 (4.9)   414 (14.4)   
80 and older 14 (2.3)   6 (1.0)   49 (8.1)   29 (4.8)   87 (14.3)   
Sex   0.082   0.971   0.432   0.032   0.032 
Female 78 (3.1)   29 (1.2)   228 (9.1)   128 (5.1)   380 (15.1)   
Male 51 (2.3)   26 (1.2)   188 (8.4)   85 (3.8)   289 (12.9)   
Marital Status   0.559   0.572   0.566   0.138   1.000 
Not married 46 (2.5)   23 (1.3)   164 (9.1)   71 (3.9)   255 (14.1)   
Married 83 (2.8)   32 (1.1)   252 (8.6)   142 (4.8)   414 (14.1)   
Race   0.226   0.973   0.275   0.029   0.262 
White 120 (2.8)   49 (1.2)   362 (8.6)   186 (4.4)   593 (14.1)   
Black 4 (1.4)   3 (1.0)   33 (11.5)   21 (7.3)   48 (16.7)   
Other 5 (2.1)   3 (1.3)   21 (8.8)   6 (2.5)   28 (11.7)   
% 25 years and older in census 
 tract w/ < HS education  0.896   0.911   0.657   0.039   0.466 
Lowest quartile 35 (2.6)   15 (1.1)   108 (8.1)   51 (3.8)   173 (12.9)   
Second 33 (2.7)   16 (1.3)   117 (9.4)   51 (4.1)   179 (14.4)   
Third 36 (3.0)   12 (1.0)   108 (9.0)   51 (4.3)   172 (14.4)   
Highest 24 (2.5)   12 (1.3)   83 (8.7)   60 (6.3)   145 (15.1)   
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Table 4.16 (Continued) 
          
Enabling                     
Median household income 
(census tract level)    0.856   0.678   0.614   0.503   0.553 
Lowest quartile 24 (2.5)   8 (0.8)   93 (9.5)   42 (4.3)   139 (14.2)   
Second 34 (2.9)   15 (1.3)   106 (9.0)   62 (5.3)   180 (15.3)   
Third 31 (2.5)   14 (1.1)   108 (8.8)   49 (4.0)   168 (13.7)   
Highest 40 (2.9)   18 (1.3)   109 (8.0)   60 (4.4)   182 (13.4)   
Population density 0.658   0.222   0.006   0.854   0.050 
Urban/rural 17 (2.5)   5 (0.7)   80 (11.6)   30 (4.4)   114 (16.5)   
Metro 112 (2.8)   50 (1.2)   336 (8.3)   183 (4.5)   555 (13.7)   
State buy-in Medicare coverage during year 
preceding diagnosis  0.092   0.160   0.782   0.420   0.101 
No 112 (2.6)   47 (1.1)   378 (8.7)   191 (4.4)   599 (13.8)   
Yes 17 (4.1)   8 (1.9)   38 (9.1)   22 (5.3)   70 (16.8)   
≥ 50% of chemotherapy claims from CCOP-
affiliated provider  0.191   0.521   0.499   0.663   0.278 
No 102 (2.9)   43 (1.2)   314 (8.9)   160 (4.5)   510 (14.4)   
Yes 22 (2.1)   10 (1.0)   84 (8.2)   44 (4.3)   134 (13.1)   
Received treatment from provider affiliated with 
a cooperative research group 0.340   0.962   0.345   0.935   0.129 
No 60 (3.1)   23 (1.2)   184 (9.4)   112 (5.7)   301 (15.3)   
Yes 63 (2.6)   29 (1.2)   209 (8.5)   89 (3.6)   335 (13.7)   
Year of diagnosis 0.313   0.017   0.637   0.312   0.144 
2004-2005 59 (2.5)   32 (1.3)   200 (8.4)   105 (4.4)   321 (13.5)   
2006 32 (2.6)   6 (0.5)   116 (9.3)   49 (3.9)   169 (13.6)   
2007 38 (3.4)   17 (1.5)   100 (8.9)   59 (5.2)   179 (15.9)   
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Table 4.16 (continued) 
          
SEER region   0.287   0.257   0.068   0.026   0.013 
East 38 (3.4)   16 (1.4)   90 (8.1)   63 (5.7)   162 (14.6)   
Midwest 24 (2.7)   7 (0.8)   98 (11.0)   47 (5.3)   154 (17.2)   
South 40 (2.2)   17 (0.9)   155 (8.6)   72 (4.0)   229 (12.8)   
West 27 (2.8)   15 (1.6)   73 (7.7)   31 (3.3)   124 (13.1)   
           
Need                     
Tumor stage   0.272   0.122   0.649   0.355   0.892 
IIIB 32 (2.3)   11 (0.8)   125 (9.1)   56 (4.1)   196 (14.2)   
IV 97 (2.9)   44 (1.3)   291 (8.6)   157 (4.7)   473 (14.1)   
Summary stage 0.963   0.137   0.721   0.254   0.676 
Regional 11 (2.7)   2 (0.5)   34 (8.3)   14 (3.4)   55 (13.4)   
Distant 118 (2.7)   53 (1.2)   382 (8.8)   199 (4.6)   614 (14.2)   
Grade   0.805   0.300   0.284   0.669   0.814 
Well/Moderately differentiated 12 (2.2)   7 (1.3)   41 (7.6)   21 (3.9)   69 (12.7)   
Poor/Undifferentiated 45 (3.3)   20 (1.4)   120 (8.7)   73 (5.3)   206 (14.9)   
Unknown 72 (2.6)   28 (1.0)   255 (9.0)   119 (4.2)   394 (14.0)   
Tumor histology 0.003   0.687   0.589   0.872   0.991 
Adenocarcinoma 65 (2.5)   29 (1.1)   238 (9.0)   121 (4.6)   374 (14.2)   
Large cell  1 (0.4)   2 (0.8)   25 (9.8)   10 (3.9)   36 (14.1)   
Other and NOS 63 (3.4)   24 (1.3)   153 (8.3)   82 (4.4)   259 (14.0)   
NCI Charlson Comorbidity Index 0.064   0.037   0.082   <0.001   <0.001 
0 66 (2.3)   25 (0.9)   234 (8.3)   91 (3.2)   351 (12.5)   
1 50 (3.2)   28 (1.8)   142 (9.0)   98 (6.2)   255 (16.1)   
2 11 (4.7)   2 (0.9)   30 (12.8)   22 (9.4)   51 (21.7)   
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Table 4.16 (Continued) 
          
Hemoptysis   0.882   0.850   0.644   0.045   0.623 
No 124 (2.7)   53 (1.2)   397 (8.7)   198 (4.4)   639 (14.0)   
Yes 5 (2.6)   2 (1.0)   19 (9.7)   15 (7.7)   30 (15.3)   
Brain metastases 0.004   0.033   0.879   0.375   0.558 
No 84 (2.3)   35 (1.0)   319 (8.8)   168 (4.6)   505 (13.9)   
Yes 45 (4.0)   20 (1.8)   97 (8.7)   45 (4.0)   164 (14.6)   
Radiation therapy received 0.504   0.049   0.007   0.741   0.063 
No 60 (2.5)   35 (1.5)   181 (7.7)   108 (4.6)   312 (13.2)   
Yes 66 (2.9)   20 (0.9)   229 (9.9)   101 (4.4)   349 (15.1)   
Cancer-directed surgery 0.915   0.358   0.230   0.215   0.270 
No 121 (2.7)   53 (1.2)   41 (0.9)   395 (8.9)   203 (4.6)   
Yes 8 (2.6)   2 (0.7)   1 (0.3)   21 (6.9)   10 (3.3)   
Abbreviations: ATE = Arterial thromboembolic event; GI = Gastrointestinal; CCOP = Clinical Community Oncology Program; SEER = Surveillance, 
Epidemiology, and End Results; NOS = Not otherwise specified; NCI = National Cancer Institute. 
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Table 4.17 Bivariate associations between hospitalization for severe adverse events within 180 days of the start of treatment and 
predisposing, enabling, and need characteristics among patients receiving platinum-taxane doublet chemotherapy 
 
     ATE GI Perforation    Neutropenia 
Severe 
Hemorrhage Any Adverse Event 
Characteristic n (%) P n (%) P n (%) P n (%) P n (%) P 
Predisposing                   
Age at diagnosis 0.841   0.515   0.316   0.115   0.209 
66 to 69 20 (2.3)   12 (1.4)   72 (8.1)   26 (2.9)   113 (12.8)   
70 to 79 56 (2.7)   26 (1.3)   188 (9.1)   96 (4.6)   296 (14.3)   
80 and older 10 (2.2)   4 (0.9)   43 (9.6)   19 (4.3)   67 (15.0)   
Sex   0.063   0.937   0.253   0.021   0.018 
Female 54 (3.0)   22 (1.2)   170 (9.4)   88 (4.9)   276 (15.3)   
Male 32 (2.0)   20 (1.3)   133 (8.3)   53 (3.3)   200 (12.5)   
Marital Status 0.393   0.999   0.292   0.507   0.639 
Not married 29 (2.2)   16 (1.2)   124 (9.6)   50 (3.9)   186 (14.4)   
Married 57 (2.7)   26 (1.2)   179 (8.5)   91 (4.3)   290 (13.8)   
Race   0.280   0.541   0.647   0.288   0.722 
White 81 (2.7)   39 (1.3)   266 (8.8)   122 (4.0)   423 (13.9)   
Black 3 (1.5)   1 (0.5)   21 (10.4)   13 (6.4)   32 (15.8)   
Other 2 (1.3)   2 (1.3)   16 (10.1)   6 (3.8)   21 (13.2)   
% 25 years and older in census 
 tract w/ < HS education  0.924   0.456   0.737   0.068   0.553 
Lowest quartile 24 (2.6)   11 (1.2)   75 (8.2)   30 (3.3)   118 (12.9)   
Second 20 (2.2)   14 (1.6)   79 (8.9)   32 (3.6)   122 (13.7)   
Third 24 (2.7)   7 (0.8)   86 (9.7)   38 (4.3)   129 (14.6)   
Highest 17 (2.4)   10 (1.4)   63 (9.0)   41 (5.8)   107 (15.2)   
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Table 4.17 (continued) 
Enabling 
Median household income 
(census tract level)    0.932   0.574   0.516   0.778   0.542 
Lowest quartile 17 (2.3)   7 (0.9)   69 (9.4)   29 (3.9)   103 (14.0)   
Second 23 (2.7)   14 (1.6)   78 (9.2)   40 (4.7)   129 (15.2)   
Third 21 (2.4)   9 (1.0)   84 (9.5)   37 (4.2)   125 (14.2)   
Highest 25 (2.7)   12 (1.3)   72 (7.7)   35 (3.8)   119 (12.8)   
Population density 0.467   0.500   0.053   0.979   0.136 
Urban/rural 11 (2.1)   5 (0.9)   59 (11.2)   22 (4.2)   85 (16.1)   
Metro 75 (2.6)   37 (1.3)   244 (8.5)   119 (4.1)   391 (13.6)   
State buy-in Medicare coverage during year 
preceding diagnosis  0.975   0.411   0.667   0.111   0.305 
No 79 (2.5)   37 (1.2)   280 (9.0)   124 (4.0)   431 (13.8)   
Yes 7 (2.5)   5 (1.8)   23 (8.2)   17 (6.1)   45 (16.1)   
≥ 50% of chemotherapy claims from CCOP-
affiliated provider  0.589   0.325   0.663   0.327   0.450 
No 18 (2.3)   7 (0.9)   66 (8.4)   28 (3.6)   103 (13.2)   
Yes 66 (2.6)   33 (1.3)   223 (8.9)   109 (4.4)   355 (14.2)   
Received treatment from provider affiliated with 
a cooperative research group 0.678   0.859   0.489   0.942   0.211 
No 39 (2.8)   18 (1.3)   134 (9.5)   60 (4.3)   215 (15.2)   
Yes 44 (2.5)   21 (1.2)   153 (8.8)   75 (4.3)   238 (13.7)   
Year of diagnosis 0.759   0.015   0.754   0.291   0.589 
2004-2005 41 (2.4)   24 (1.4)   147 (8.7)   75 (4.4)   231 (13.6)   
2006 22 (2.4)   4 (0.4)   87 (9.5)   30 (3.3)   125 (13.7)   
2007 23 (2.9)   14 (1.8)   69 (8.7)   36 (4.5)   120 (15.1)   
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Table 4.17 (Continued) 
          
SEER region 0.896   0.640   0.191   0.241   0.056 
East 22 (2.7)   12 (1.5)   69 (8.4)   38 (4.6)   112 (13.6)   
Midwest 17 (2.7)   7 (1.1)   66 (10.6)   33 (5.3)   109 (17.5)   
South 30 (2.3)   13 (1.0)   122 (9.2)   49 (3.7)   173 (13.1)   
West 17 (2.7)   10 (1.6)   46 (7.3)   21 (3.3)   82 (13.0)   
           
Need                     
Tumor stage 0.055   0.104   0.190   0.164   0.086 
IIIB 18 (1.8)   8 (0.8)   81 (7.9)   35 (3.4)   127 (12.5)   
IV 68 (2.9)   34 (1.4)   222 (9.3)   106 (4.5)   349 (14.7)   
Summary stage 0.724   0.067   0.115   0.329   0.192 
Regional 9 (2.8)   1 (0.3)   21 (6.6)   10 (3.1)   37 (11.6)   
Distant 77 (2.5)   41 (1.3)   282 (9.1)   131 (4.2)   439 (14.2)   
Grade   0.481   0.858   0.430   0.854   0.804 
Well/Moderately differentiated 9 (2.2)   5 (1.2)   35 (8.6)   12 (3.0)   52 (12.8)   
Poor/Undifferentiated 32 (3.2)   13 (1.3)   81 (8.2)   52 (5.3)   144 (14.6)   
Unknown 45 (2.2)   24 (1.2)   187 (9.3)   77 (3.8)   280 (13.9)   
Tumor histology 0.005   0.564   0.531   0.686   0.948 
Adenocarcinoma 47 (2.4)   23 (1.2)   180 (9.3)   75 (3.9)   269 (13.9)   
Large cell  0 (0.0)   1 (0.6)   17 (9.4)   8 (4.4)   24 (13.3)   
Other and NOS 39 (3.0)   18 (1.4)   106 (8.2)   58 (4.5)   183 (14.2)   
NCI Charlson Comorbidity Index 0.027   0.008   0.141   <0.001   <0.001 
0 40 (1.4)   20 (0.7)   174 (6.2)   61 (2.2)   250 (8.9)   
1 36 (2.3)   22 (1.4)   98 (6.2)   66 (4.2)   183 (11.6)   
2 8 (3.4)   0 (0.0)   23 (9.8)   14 (6.0)   34 (14.5)   
Hemoptysis 0.320   0.503   0.542   0.057   0.391 
No 84 (2.6)   41 (1.3)   292 (9.0)   130 (4.0)   459 (14.1)   
Yes 2 (1.4)   1 (0.7)   11 (7.5)   11 (7.5)   17 (11.6)   
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Table 4.17 (Continued) 
          
Brain metastases 0.074   0.091   0.689   0.994   0.558 
No 58 (2.2)   27 (1.0)   227 (8.8)   107 (4.1)   356 (13.8)   
Yes 28 (3.4)   15 (1.8)   76 (9.3)   34 (4.1)   120 (14.6)   
Radiation therapy received 0.202   0.031   0.140   0.723   0.136 
No 49 (2.8)   15 (0.9)   167 (9.6)   74 (4.2)   259 (14.8)   
Yes 34 (2.1)   27 (1.7)   130 (8.1)   64 (4.0)   209 (13.0)   
Cancer-directed surgery 0.843   0.230   0.288   0.276   0.054 
No 81 (2.5)   41 (1.3)   288 (9.0)   135 (4.2)   455 (14.3)   
Yes 5 (2.3)   1 (0.5)   15 (7.0)   6 (2.8)   21 (9.8)   
Abbreviations: ATE = Arterial thromboembolic event; GI = Gastrointestinal; CCOP = Clinical Community Oncology Program; SEER = Surveillance, 
Epidemiology, and End Results; NOS = Not otherwise specified; NCI = National Cancer Institute. 
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4.5.1.2 Multivariate analysis of bevacizumab and hospitalization for severe adverse events  
Multivariable logistic regression models were created to assess the relationship between the 
use of bevacizumab and hospitalization for each severe adverse event within 180 days of treatment 
start by selecting clinical, sociodemographic, and health system characteristics with statistically 
significant bivariate associations with the specified adverse event; separate regression models were 
created for each of the two cohorts (any platinum-based doublet chemotherapy and platinum-taxane 
doublet chemotherapy), based on the significant bivariate associations between hospitalization for the 
specified adverse event and the independent variables identified within each cohort. Several 
multivariable logistic regression models were also created by selecting clinical, sociodemographic, 
and health system characteristics based on Andersen’s Behavioral Model of Health Services Use, 
including a model of: 1) all predisposing characteristics only; 2) all enabling characteristics only; 3) 
all need characteristics only; 4) both predisposing and enabling characteristics; and 5) all 
predisposing, enabling, and need characteristics. However, the results from these regression models 
do not provide much additional insight into the association between the use of bevacizumab and 
hospitalization for severe treatment-related adverse events beyond the information obtained from 
regression models created using only confounding variables (identified through bivariate associations 
with bevacizumab use and severe adverse events). Therefore the results of the predisposing, enabling, 
and need logistic regression models were only included as a table in the appendices (Appendix F:  
Table F-1) and will not be described further in this section. 
Results from both the multivariable adjusted logistic regression models (that included only 
identified confounding variables) and the propensity score-adjusted regression models that evaluated 
the effect of bevacizumab on hospitalization for severe adverse events among patients who received 
platinum-based doublet chemotherapy are described in Table 4.18. After adjusting for confounders in 
a multivariable logistic regression model, patients who received bevacizumab in addition to any 
platinum-based doublet chemotherapy maintained lower odds of hospitalization for arterial 
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thromboembolic events compared to patients who received chemotherapy only (OR 0.71, 95% CI 
0.33-1.53), though the result was not statistically significant. Conversely, multivariable-adjusted 
estimates of the odds of hospitalization for gastrointestinal perforation (OR 2.61, 95% CI 1.18-5.80) 
and any severe adverse event (OR 1.32, 95% CI 1.00-1.75) were significantly higher among patients 
who received bevacizumab compared to patients who received chemotherapy only. Patients receiving 
bevacizumab also had higher odds of hospitalization for neutropenia (OR 1.25, 95% CI 0.87-1.80) 
and severe hemorrhage (OR 1.06, 95% CI 0.64-1.77) compared to patients receiving chemotherapy 
only, but neither of these results was statistically significant. Results of multivariable-adjusted models 
estimated among patients who specifically received platinum-taxane chemotherapy were similar to 
those seen in the larger cohort.  
In addition to the multivariable-adjusted survival analyses, Cox proportional hazards models 
were also constructed using estimated propensity scores. Initially, propensity score analysis was 
performed to balance measured confounders between patients who received chemotherapy with 
bevacizumab and patients who received platinum-based chemotherapy only. Multivariate logistic 
regression models were first used to calculate propensity scores representing the probability that a 
patient received bevacizumab conditional on all other measured confounders in the model. In each 
propensity score model, variables that were associated with bevacizumab use and hospitalization for 
the specified adverse event (true confounders) as well as variables related to hospitalization only were 
included. Distinct propensity scores were calculated for each adverse event based on the confounders 
identified in the larger cohort of patients receiving any platinum-based doublet chemotherapy. 
Following propensity score estimation, the propensity scores were applied to logistic 
regressions models to perform two distinct propensity score-adjusted analyses. In the first propensity 
score-adjusted analysis, discrete logistic regression models were fit using the propensity score as a 
continuous covariate in the regression model. In the second propensity score-adjusted analysis, 
propensity score estimates were used to first match exposed patients (receiving bevacizumab) to 
patients from the unexposed group (receiving chemotherapy only) in a 1:1 ratio using a 5-to-1 digit 
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greedy-match algorithm. The algorithm allows for the capture of the best possible matches (those 
pairs matched to the fifth digit of the PS) while also maximizing the number of possible matches by 
including pairs matched to the fourth, third, second, and first digits of the PS (adequacy of the 
matches decrease with the number of digits matched on); non-matched individuals are excluded from 
the derived cohort of matched patients. Application of the 1:1 greedy-match algorithm resulted in a 
maximum of 386 matched pairs among patients receiving any platinum-based doublet chemotherapy 
and 333 matched pairs among patients receiving platinum-taxane doublet chemotherapy specifically; 
fewer patients were matched for gastrointestinal perforation because of missing information for 
certain covariates that were used to estimate the propensity scores.  
Propensity score-adjusted analyses that included the predicted probability of receiving 
bevacizumab as a linear covariate in each of the logistic regression models estimated similar odds 
ratios to those observed in the multivariate adjusted models; this is likely due to the similarity 
between the covariates included in the multivariable-adjusted models and the covariates included in 
the logistic regression models to estimate the propensity scores for bevacizumab use. Likewise, 
estimates from propensity score-matched analyses were also similar to estimates from the 
multivariable-adjusted models although the confidence intervals around the estimates were noticeably 
larger given the smaller sample sizes in matched analyses. For example, among propensity score-
matched patients who received any platinum-based chemotherapy, patients receiving bevacizumab 
had lower odds of hospitalization for arterial thromboembolic events (OR 0.53, 95% CI 0.21-1.34), 
but higher odds of hospitalization for neutropenia (OR 1.36, 95% CI 0.81-2.27), severe hemorrhage 
(OR 1.00, 95% CI 0.50-1.99), and any adverse event (OR 1.33, 95% CI 0.89-1.97) compared to 
patients who received chemotherapy only; however, no results among propensity score-matched 
patients were statistically significant. Estimates of the hospitalization for gastrointestinal perforation 
among patients receiving any platinum-based doublet chemotherapy could not be performed for the 
propensity-score matched patients due to the occurrence of all hospitalizations within the cohort of 
patients who received bevacizumab; no hospitalizations for gastrointestinal perforation occurred 
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among patients who received chemotherapy only. Among propensity score-matched patients 
receiving platinum-taxane chemotherapy, the estimated odds of hospitalization for gastrointestinal 
perforation with the use of bevacizumab was nearly three times the odds for chemotherapy only (OR 
2.71, 95% CI 0.71, 10.30); still, given the small number of events in each group (8 with bevacizumab; 
3 with chemotherapy only), the observed difference was not statistically significant. Additional 
results among patients receiving platinum-taxane chemotherapy in particular were comparable to 
those observed among patients receiving any platinum-based doublet chemotherapy.  
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Table 4.18 Odds ratios of  hospitalization for severe adverse events among patients receiving bevacizumab in addition to platinum-based 
doublet chemotherapy compared to patients who received platinum-based doublet chemotherapy only 
 
 
  
 
Any platinum doublet 
 
Platinum-taxane doublet 
Adverse event  OR (95% CI)  OR (95% CI) 
Arterial thromboembolic events Sample sizes, n   Sample sizes, n   
Unadjusted 386    4360 0.64 (0.30, 1.38) 333    3068 0.69 (0.30, 1.58) 
Multivariable adjusted models:  
 
 
   Brain metastases, CHF, CVD,  
  histology,  and MI 
 
386    4360 0.71 (0.33, 1.53) 
 
 
 Histology, CHF, CVD, and MI  
 
333    3068 0.72 (0.31, 1.68) 
Propensity score-adjusted models
a
  
 
 
   Covariate adjustment 386    4360 0.71 (0.33, 1.53) 333    3068 0.72 (0.31, 1.66) 
  Matching 386      386 0.53 (0.21, 1.34) 333      333 0.54 (0.20, 1.47) 
Gastrointestinal perforation  
 
 
 Unadjusted 386    4360 2.24 (1.09, 4.61) 333    3068 2.20 (1.01, 4.79) 
Multivariable adjusted models:  
 
 
 Brain metastases, PVD, receipt of 
radiation, and year of diagnosis 
 
376    4304 2.61 (1.18, 5.80) 
 
 
 PVD, receipt of radiation, and year of 
diagnosis  
 
323    3027 2.41 (1.00, 5.80) 
Propensity score-adjusted models
b
  
 
 
    Covariate adjustment 376    4304 2.67 (1.22, 5.84) 323    3027 2.67 (1.13, 6.30) 
   Matching
c 
376      376 N/A 323      323   2.71 (0.71, 10.30) 
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Table 4.18 (Continued)  
 
 
 
Neutropenia       
Unadjusted 386    4360 1.19 (0.84, 1.68) 333    3068 1.23 (0.85, 1.78) 
Multivariable adjusted models:  
 
 
 CHF, PVD, population density, and   
receipt of radiation 
 
386    4360 1.25 (0.87, 1.80) 
 
 
    CHF, and PVD  
 
333    3068 1.25 (0.86, 1.82) 
Propensity score-adjusted models
d
  
 
 
    Covariate adjustment 386    4360 1.25 (0.87, 1.79) 333    3068 1.25 (0.86, 1.82) 
   Matching 386      386 1.36 (0.81, 2.27) 333     333 1.23 (0.73, 2.07) 
Severe hemorrhage       
Unadjusted 386    4360 0.98 (0.59, 1.63) 333    3068 1.02 (0.58, 1.79) 
Multivariable adjusted models:  
 
 
 COPD, DM, hemoptysis, MI, race, 
region, history of severe hemorrhage, 
and sex 
 
386    4360 1.06 (0.64, 1.77) 
 
 
 COPD, DM, MI, history of severe 
hemorrhage, and sex  
 
333    3068 1.06 (0.60, 1.87) 
Propensity score-adjusted models
e
  
 
 
    Covariate adjustment 386    4360 1.06 (0.64, 1.77) 333    3068 1.06 (0.60, 1.87) 
   Matching 386      386 1.00 (0.50, 1.99) 333      333 1.00 (0.47, 2.13) 
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Table 4.18 (Continued) 
    
Any severe adverse event       
Unadjusted 386    4360 1.29 (0.97, 1.70) 333    3068 1.37 (1.02, 1.85) 
Multivariable adjusted models:  
 
 
 CHF, COPD, CVD, MI, PVD, region 
and sex 
 
386    4360 1.32 (1.00, 1.75) 
 
 
 CHF, COPD, CVD, MI, PVD, and sex  
 
333    3068 1.42 (1.05, 1.91) 
Propensity score-adjusted models
f
  
 
 
    Covariate adjustment 386    4360 1.33 (1.00, 1.76) 333    3068 1.42 (1.05, 1.92) 
   Matching 386      386 1.33 (0.89, 1.97) 333      333 1.38 (0.90, 2.10) 
a The propensity of receiving bevacizumab was estimated using a multiple logistic regression model that included brain metastases, CHF, CVD, histology, and 
MI 
b The propensity of receiving bevacizumab was estimated using a multiple logistic regression model that included brain metastases, PVD, receipt of radiation, 
and year of diagnosis 
c Estimates for the propensity score-matched analysis are not available in the larger platinum-based cohort; all hospitalizations for GI perforation occurred 
among patients who received bevacizumab 
d The propensity of receiving bevacizumab was estimated using a multiple logistic regression model that included CHF, PVD, population density, and receipt of 
radiation 
e The propensity of receiving bevacizumab was estimated using a multiple logistic regression model that included COPD, DM, hemoptysis, MI, race, SEER 
region, history of severe hemorrhage, sex 
f The propensity of receiving bevacizumab was estimated using a multiple logistic regression model that included  CHF, COPD, CVD, MI, PVD, SEER region, 
and sex  
 
Abbreviations: OR = Odds ratio; CI = Confidence interval; CHF = Congestive heart failure; CVD = Cerebrovascular disease; MI = Myocardial infarction; PVD = 
Peripheral vascular disease; N/A = Not available; COPD = Chronic obstructive pulmonary disease; DM = Diabetes mellitus 
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4.5.2 Hospitalization within first-line treatment duration window 
4.5.2.1 Bivariate analysis of bevacizumab and hospitalization for severe adverse events 
 The cumulative incidence of hospitalization for severe adverse events during the first-line 
treatment duration window is shown in Table 4.19. The incidence of hospitalization for severe 
adverse events was similar between the larger cohort of patients who received any platinum-based 
doublet chemotherapy and the cohort of patients who received platinum-taxane regimens specifically. 
Among patients treated with any platinum-based doublet chemotherapy, those who received 
bevacizumab had higher incidence of arterial thromboembolic event (1.8% vs. 1.5%), gastrointestinal 
perforation (1.8% vs. 0.8%), neutropenia (7.8% vs. 6.9%), and severe hemorrhage (3.9% vs. 2.9%) 
compared to patients who did not receive bevacizumab. However, the differences in the incidence of 
hospitalization for these events were not statistically significant. Still, the incidence of hospitalization 
for any adverse event was more than 4% higher among patients who received bevacizumab compared 
to those patients who did not (14.0% vs. 9.8%), a finding that was statistically significant among 
patients who received any platinum-based doublet chemotherapy (log-rank p-value = 0.003) and 
among patients who received platinum-taxane chemotherapy specifically (log-rank p-value = 0.002).   
 
Table 4.19 Cumulative incidence (%) of hospitalization for severe adverse events during the 
first-line treatment window 
  Any platinum doublet   Platinum-taxane doublet   
  Bevacizumab   Bevacizumab   
Adverse event 
No                        
(n = 4360) 
Yes                                
(n = 386) 
log-rank       
p-value 
No                        
(n = 3068) 
Yes                       
(n = 333) 
log-rank           
p-value 
ATE      64 (1.5)      7 (1.8) 0.534       37 (1.2)       6 (1.8) 0.362 
GI perforation      34 (0.8)      7 (1.8) 0.107       27 (0.9)       6 (1.8) 0.221 
Neutropenia    300 (6.9)    30 (7.8) 0.179     218 (7.1)     28 (8.4) 0.109 
Severe hemorrhage    127 (2.9)    15 (3.9) 0.142       78 (2.5)     14 (4.2) 0.056 
Any adverse event    429 (9.8)    54 (14.0) 0.003     304 (9.9)     50 (15.0) 0.002 
Abbreviations: ATE = Arterial thromboembolic event; GI = Gastrointestinal. 
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 Bivariate associations between predisposing, enabling, and need characteristics with the 
hazard hospitalization for severe adverse events during first-line treatment duration were assessed to 
inform multivariable regression models. Among patients who received any platinum-based doublet 
chemotherapy ( Table 4.20), distant stage disease and receipt of chemotherapy from a provider not 
affiliated with a cooperative research group were significantly associated with the hazard of 
hospitalization for arterial thromboembolic events (log-rank p-value = 0.017) and gastrointestinal 
perforation (p-value = 0.007), respectively. Residence in a non-metropolitan area (p = 0.007) and year 
of diagnosis (p = 0.049) were significantly associated with the hazard of hospitalization for 
neutropenia, and year of diagnosis (p = 0.022) and stage IV disease (p = 0.023) were significantly 
associated with the hazard of hospitalization for severe hemorrhage. Distant stage disease (p = 0.002), 
year of diagnosis (p = 0.014), stage IV disease (p = 0.008), receipt of radiation treatment (p = 0.039), 
and non-receipt of cancer-directed surgery (p = 0.012) were all significantly associated with 
hospitalization for any severe adverse event.  
Among patients who received platinum-taxane doublet chemotherapy specifically (Table 
4.21), no characteristics were significantly associated with the hazard of hospitalization for arterial 
thromboembolic events. Receipt of chemotherapy treatment from a provider not affiliated with a 
cooperative research group (log-rank p-value = 0.001) was significantly associated with the hazard of 
hospitalization for gastrointestinal perforation whereas residence in a non-metropolitan area (p = 
0.022), stage IV disease (p = 0.037), and distant stage disease (p = 0.041) were significantly 
associated with the hazard of hospitalization for neutropenia. Hemoptysis (p = 0.015) was 
significantly associated with the hazard of hospitalization for severe hemorrhage while year of 
diagnosis (p = 0.019), receipt of treatment from a provider not affiliated with CCOP (0.022), stage IV 
disease (p = 0.003), distant stage disease (p = 0.006), and no cancer-directed surgery (p = 0.034) were 
significantly associated with the hazard of hospitalization for any severe adverse events.      
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Table 4.20 Bivariate associations between the hazard rate of hospitalization for severe adverse events during first-line treatment and  
predisposing, enabling, and need characteristics among patients receiving platinum-based doublet chemotherapy. 
 
     ATE GI Perforation    Neutropenia 
Severe 
Hemorrhage Any Adverse Event 
Characteristic n (%) P n (%) P n (%) P n (%) P n (%) P 
Predisposing                   
Age at diagnosis 0.149   0.327   0.219   0.199   0.389 
66 to 69 18 (1.4)   13 (1.0)   84 (6.7)   29 (2.3)   116 (9.2)   
70 to 79 48 (1.7)   23 (0.8)   203 (7.1)   92 (3.2)   301 (10.5)   
80 and older 5 (0.8)   5 (0.8)   43 (7.1)   21 (3.5)   66 (10.9)   
Sex   0.808   0.597   0.488   0.232   0.419 
Female 31 (1.4)   18 (0.8)   152 (6.8)   56 (2.5)   211 (9.5)   
Male 40 (1.6)   23 (0.9)   178 (7.1)   86 (3.4)   272 (10.8)   
Marital Status 0.671   0.087   0.582   0.516   0.856 
Not married 25 (1.4)   18 (1.0)   124 (6.9)   47 (2.6)   178 (9.8)   
Married 46 (1.6)   23 (0.8)   206 (7.0)   95 (3.2)   305 (10.4)   
Race   0.443   0.592   0.891   0.115   0.158 
White 64 (37.0)   37 (0.9)   287 (6.8)   130 (3.1)   435 (10.3)   
Black 4 (1.4)   1 (0.3)   28 (9.7)   10 (3.5)   31 (10.8)   
Other 3 (1.3)   3 (1.3)   15 (6.3)   2 (0.8)   17 (7.1)   
% 25 years and older in census 
 tract w/ < HS education  0.940   0.847   0.517   0.747   0.945 
Lowest quartile 20 (1.5)   12 (0.9)   76 (5.7)   36 (2.7)   123 (9.2)   
Second 16 (1.3)   9 (0.7)   95 (7.7)   31 (2.5)   126 (10.2)   
Third 20 (1.7)   11 (0.9)   91 (7.6)   35 (2.9)   129 (10.8)   
Highest 15 (1.6)   9 (0.9)   68 (7.1)   40 (4.2)   105 (10.9)   
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Table 4.20 (Continued) 
          
Enabling                     
Median household income 
(census tract level)    0.991   0.384   0.312   0.324   0.971 
Lowest quartile 16 (1.6)   6 (0.6)   77 (7.9)   28 (2.9)   102 (10.5)   
Second 18 (1.5)   11 (0.9)   81 (6.9)   45 (3.8)   129 (10.9)   
Third 18 (1.5)   12 (1.0)   87 (7.1)   28 (2.3)   123 (10.0)   
Highest 19 (1.4)   12 (0.9)   85 (6.2)   41 (3.0)   129 (9.5)   
Population density 0.591   0.677   0.007   0.946   0.106 
Urban/rural 9 (1.3)   3 (0.4)   70 (10.2)   22 (3.2)   89 (12.9)   
Metro 62 (1.5)   38 (0.9)   260 (6.4)   120 (3.0)   394 (9.7)   
State buy-in Medicare coverage during 
year preceding diagnosis  0.863   0.895   0.447   0.348   0.067 
No 63 (1.5)   35 (0.8)   300 (6.9)   130 (3.0)   440 (10.2)   
Yes 8 (1.9)   6 (1.4)   30 (7.2)   12 (2.9)   43 (10.3)   
≥ 50% of chemotherapy claims from 
CCOP-affiliated provider  0.396   0.113   0.108   0.329   0.092 
No 56 (1.6)   28 (0.8)   246 (6.9)   109 (3.1)   366 (10.3)   
Yes 12 (1.2)   10 (1.0)   66 (6.4)   27 (2.6)   95 (9.3)   
Received treatment from provider 
affiliated with a cooperative research 
group 0.534   0.007   0.876   0.579   0.151 
No 30 (1.5)   21 (1.1)   145 (7.4)   62 (3.2)   218 (11.1)   
Yes 38 (1.6)   16 (0.7)   163 (6.7)   73 (3.0)   238 (9.7)   
Year of diagnosis 0.595   0.341   0.049   0.022   0.014 
2004-2005 34 (1.4)   21 (0.9)   147 (6.2)   55 (2.3)   215 (9.0)   
2006 16 (1.3)   4 (0.3)   104 (8.4)   42 (3.4)   135 (10.9)   
2007 21 (1.9)   16 (1.4)   79 (7.0)   45 (4.0)   133 (11.8)   
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Table 4.20 (Continued) 
SEER region 0.256   0.515   0.397   0.604   0.050 
East 19 (1.7)   11 (1.0)   70 (6.3)   37 (3.3)   111 (10.0)   
Midwest 17 (1.9)   6 (0.7)   81 (9.1)   34 (3.8)   118 (13.2)   
South 22 (1.2)   14 (0.8)   126 (7.0)   50 (2.8)   173 (9.6)   
West 13 (1.4)   10 (1.1)   53 (5.6)   21 (2.2)   81 (8.5)   
           
Need                     
Tumor stage 0.051   0.219   0.056   0.023   0.008 
IIIB 17 (1.2)   9 (0.7)   101 (7.3)   38 (2.8)   140 (10.1)   
IV 54 (1.6)   32 (1.0)   229 (6.8)   104 (3.1)   343 (10.2)   
Summary stage 0.017   0.488   0.028   0.174   0.002 
Regional 4 (1.0)   2 (0.5)   27 (6.6)   12 (2.9)   37 (9.0)   
Distant 67 (1.5)   39 (0.9)   303 (7.0)   130 (3.0)   446 (10.3)   
Grade   0.177   0.810   0.641   0.736   0.217 
Well/Moderately 
differentiated 6 (1.1)   5 (0.9)   33 (6.1)   13 (2.4)   47 (8.7)   
Poor/Undifferentiated 21 (1.5)   13 (0.9)   96 (6.9)   44 (3.2)   144 (10.4)   
Unknown 44 (1.6)   23 (0.8)   201 (7.1)   85 (3.0)   292 (10.4)   
Tumor histology 0.490   0.158   0.589   0.076   0.468 
Adenocarcinoma 34 (1.3)   20 (0.8)   189 (7.2)   74 (2.8)   264 (10.0)   
Large cell  2 (0.8)   1 (0.4)   22 (8.6)   7 (2.7)   28 (10.9)   
Other and NOS 35 (1.9)   20 (1.1)   119 (6.4)   61 (3.3)   191 (10.3)   
NCI Charlson Comorbidity Index 0.270   0.099   0.133   0.186   0.478 
0 38 (1.4)   20 (0.7)   178 (6.3)   61 (2.2)   249 (8.8)   
1 24 (1.5)   21 (1.3)   118 (7.5)   64 (4.1)   186 (11.8)   
2 8 (3.4)   0 (0.0)   25 (10.6)   16 (6.8)   38 (16.2)   
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Table 4.20 (Continued) 
          
Hemoptysis 0.266   0.847   0.678   0.195   0.899 
No 66 (1.5)   38 (0.8)   313 (6.9)   133 (2.9)   462 (10.2)   
Yes 5 (2.6)   3 (1.5)   17 (8.7)   9 (4.6)   21 (10.7)   
Brain metastases 0.410   0.139   0.628   0.156   0.253 
No 50 (1.4)   27 (0.7)   249 (6.9)   114 (3.1)   369 (10.2)   
Yes 21 (1.9)   14 (1.2)   81 (7.2)   28 (2.5)   114 (10.2)   
Radiation therapy received 0.722   0.112   0.544   0.384   0.039 
No 36 (1.5)   25 (1.1)   143 (6.0)   69 (2.9)   226 (9.6)   
Yes 34 (1.5)   16 (0.7)   183 (7.9)   70 (3.0)   253 (10.9)   
Cancer-directed surgery 0.177   0.045   0.140   0.156   0.012 
No 67 (1.5)   40 (0.9)   312 (7.0)   136 (3.1)   460 (10.4)   
Yes 4 (1.3)   1 (0.3)   18 (5.9)   6 (2.0)   23 (7.5)   
Abbreviations: ATE = Arterial thromboembolic event; GI = Gastrointestinal; CCOP = Clinical Community Oncology Program; SEER = Surveillance, 
Epidemiology, and End Results; NOS = Not otherwise specified; NCI = National Cancer Institute. 
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Table 4.21 Bivariate associations between the hazard of hospitalization for severe adverse events during first-line treatment and 
predisposing, enabling, and need characteristics among patients receiving platinum-taxane doublet chemotherapy 
 
     ATE GI Perforation    Neutropenia 
Severe 
Hemorrhage Any Adverse Event 
Characteristic n (%) P n (%) P n (%) P n (%) P n (%) P 
Predisposing                   
Age at diagnosis 0.283   0.600   0.074   0.248   0.051 
66 to 69 11 (1.2)   9 (1.0)   54 (6.1)   17 (1.9)   78 (8.8)   
70 to 79 29 (1.4)   20 (1.0)   154 (7.4)   62 (3.0)   223 (10.8)   
80 and older 3 (0.7)   4 (0.9)   38 (8.5)   13 (2.9)   53 (11.9)   
Sex   0.989   0.553   0.889   0.154   0.480 
Female 19 (1.2)   14 (0.9)   110 (6.9)   33 (2.1)   152 (9.5)   
Male 24 (1.3)   19 (1.1)   136 (7.5)   59 (3.3)   202 (11.2)   
Marital Status 0.273   0.182   0.442   0.710   0.240 
Not married 17 (1.3)   12 (0.9)   96 (7.4)   32 (2.5)   135 (10.4)   
Married 26 (1.2)   21 (1.0)   150 (7.1)   60 (2.9)   219 (10.4)   
Race   0.290   0.920   0.970   0.371   0.262 
White 39 (30.0)   30 (1.0)   215 (7.1)   84 (2.8)   318 (10.5)   
Black 3 (1.5)   1 (0.5)   19 (9.4)   6 (3.0)   23 (11.4)   
Other 1 (0.6)   2 (1.3)   12 (7.5)   2 (1.3)   13 (8.2)   
% 25 years and older in census 
 tract w/ < HS education  0.685   0.390   0.746   0.952   0.899 
Lowest quartile 12 (1.3)   10 (1.1)   54 (5.9)   20 (2.2)   84 (9.2)   
Second 7 (0.8)   9 (1.0)   68 (7.6)   20 (2.2)   91 (10.2)   
Third 15 (1.7)   6 (0.7)   72 (8.1)   28 (3.2)   101 (11.4)   
Highest 9 (1.3)   8 (1.1)   52 (7.4)   24 (3.4)   78 (11.1)   
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Enabling                     
Median household income 
(census tract level)    0.521   0.856   0.574   0.689   0.757 
Lowest quartile 11 (1.5)   5 (0.7)   58 (7.9)   18 (2.4)   77 (10.4)   
Second 11 (1.3)   11 (1.3)   62 (7.3)   30 (3.5)   98 (11.5)   
Third 13 (1.5)   8 (0.9)   70 (7.9)   21 (2.4)   96 (10.9)   
Highest 8 (0.9)   9 (1.0)   56 (6.0)   23 (2.5)   83 (8.9)   
Population density 0.321   0.556   0.022   0.607   0.175 
Urban/rural 4 (0.8)   3 (0.6)   53 (10.0)   16 (3.0)   67 (12.7)   
Metro 39 (1.4)   30 (1.0)   193 (6.7)   76 (2.6)   287 (10.0)   
State buy-in Medicare 
coverage during year 
preceding diagnosis   0.321   0.364   0.079   0.618   0.097 
No 41 (1.3)   29 (0.9)   227 (7.3)   84 (2.7)   325 (10.4)   
Yes 2 (0.7)   4 (1.4)   19 (6.8)   8 (2.9)   29 (10.4)   
≥ 50% of chemotherapy claims from 
CCOP-affiliated provider  0.506   0.756   0.055   0.112   0.022 
No 32 (1.3)   23 (0.9)   179 (7.2)   73 (2.9)   263 (10.5)   
Yes 9 (1.2)   7 (0.9)   53 (6.8)   16 (2.0)   73 (9.3)   
Received treatment from provider 
affiliated with a cooperative research 
group 0.184   0.001   0.813   0.563   0.142 
No 15 (1.1)   16 (1.1)   110 (7.8)   42 (3.0)   161 (11.4)   
Yes 26 (1.5)   13 (0.7)   120 (6.9)   47 (2.7)   172 (9.9)   
Year of diagnosis 0.719   0.060   0.071   0.121   0.019 
2004-2005 23 (1.4)   15 (0.9)   111 (6.6)   38 (2.2)   159 (9.4)   
2006 9 (1.0)   3 (0.3)   79 (8.6)   27 (3.0)   102 (11.2)   
2007 11 (1.4)   15 (1.9)   56 (7.1)   27 (3.4)   93 (11.7)   
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SEER region 0.475   0.519   0.489   0.733   0.261 
East 8 (1.0)   7 (0.9)   53 (6.4)   20 (2.4)   75 (9.1)   
Midwest 12 (1.9)   6 (1.0)   59 (9.5)   25 (4.0)   88 (14.1)   
South 16 (1.2)   12 (0.9)   99 (7.5)   32 (2.4)   133 (10.1)   
West 7 (1.1)   8 (1.3)   35 (5.5)   15 (2.4)   58 (9.2)   
           
Need                     
Tumor stage 0.059   0.474   0.037   0.053   0.003 
IIIB 8 (0.8)   8 (0.8)   67 (6.6)   24 (2.4)   93 (9.1)   
IV 35 (1.5)   25 (1.0)   179 (7.5)   68 (2.9)   261 (11.0)   
Summary stage 0.137   0.807   0.041   0.382   0.006 
Regional 3 (0.9)   2 (0.6)   18 (5.7)   8 (2.5)   26 (8.2)   
Distant 40 (1.3)   31 (1.0)   228 (7.4)   84 (2.7)   328 (10.6)   
Grade   0.471   0.575   0.865   0.910   0.541 
Well/Moderately 
differentiated 5 (1.2)   5 (1.2)   31 (7.6)   9 (2.2)   42 (10.3)   
Poor/Undifferentiated 13 (1.3)   9 (0.9)   64 (6.5)   29 (2.9)   101 (10.3)   
Unknown 25 (1.2)   19 (0.9)   151 (7.5)   54 (2.7)   211 (10.5)   
Tumor histology 0.887   0.191   0.387   0.052   0.953 
Adenocarcinoma 24 (1.2)   18 (0.9)   147 (7.6)   47 (2.4)   201 (10.4)   
Large cell  1 (0.6)   1 (0.6)   15 (8.3)   5 (2.8)   18 (10.0)   
Other and NOS 18 (1.4)   14 (1.1)   84 (6.5)   40 (3.1)   135 (10.5)   
NCI Charlson Comorbidity Index 0.473   0.201   0.491   0.639   0.741 
0 24 (1.2)   16 (0.8)   136 (6.7)   42 (2.1)   186 (9.2)   
1 13 (1.2)   17 (1.5)   82 (7.3)   39 (3.5)   132 (11.8)   
2 5 (2.9)   0 (0.0)   20 (11.6)   11 (6.4)   28 (16.2)   
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Hemoptysis 0.791   0.759   0.712   0.015   0.702 
No 41 (1.3)   31 (1.0)   235 (7.2)   84 (2.6)   340 (10.4)   
Yes 2 (1.4)   2 (1.4)   
111 
(76.0)   8 (5.5)   14 (9.6)   
Brain metastases 0.143   0.244   0.840   0.221   0.173 
No 32 (1.2)   22 (0.9)   182 (7.1)   73 (2.8)   269 (10.4)   
Yes 11 (1.3)   11 (1.3)   64 (7.8)   19 (2.3)   85 (10.4)   
Radiation therapy received 0.961   0.165   0.890   0.175   0.210 
No 20 (1.2)   20 (1.2)   104 (6.5)   40 (2.5)   159 (9.9)   
Yes 22 (1.3)   13 (0.7)   138 (7.9)   50 (2.9)   191 (10.9)   
Cancer-directed surgery 0.284   0.053   0.236   0.544   0.034 
No 40 (1.3)   32 (1.0)   234 (7.3)   89 (2.8)   339 (10.6)   
Yes 3 (1.4)   1 (0.5)   12 (5.6)   3 (1.4)   15 (7.0)   
Abbreviations: ATE = Arterial thromboembolic event; GI = Gastrointestinal; CCOP = Clinical Community Oncology Program; SEER = Surveillance, 
Epidemiology, and End Results; NOS = Not otherwise specified; NCI = National Cancer Institute. 
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4.5.2.2 Multivariate analysis of bevacizumab and hospitalization for severe adverse events  
Multivariable proportional hazards models were created to assess the relationship between the 
use of bevacizumab and hospitalization for each severe adverse event during the duration of first-line 
treatment by selecting clinical, sociodemographic, and health system characteristics with statistically 
significant bivariate associations with the specified adverse event. In addition, for each adverse event, 
separate proportional hazards models were created for the two cohorts (any platinum-based doublet 
chemotherapy and platinum-taxane doublet chemotherapy), based on the significant bivariate 
associations between hospitalization for the specified adverse event and the independent variables 
identified within each cohort. Several multivariable proportional hazards models were also created by 
selecting clinical, sociodemographic, and health system characteristics based on Andersen’s 
Behavioral Model of Health Services Use, including a model of: 1) all predisposing characteristics 
only; 2) all enabling characteristics only; 3) all need characteristics only; 4) both predisposing and 
enabling characteristics; and 5) all predisposing, enabling, and need characteristics. However, results 
from these hazards models do not provide much additional insight into the association between the 
use of bevacizumab and hospitalization for severe adverse events beyond that obtained from hazards 
models only confounding variables (identified through bivariate associations with bevacizumab use 
and severe adverse events). Therefore the results of the predisposing, enabling, and need logistic 
regression models were only included as a table in the appendices (Appendix F; Table F-2) and will 
not be described further in this section. 
Results from multivariable adjusted proportional hazards models (that included only 
identified confounding variables) and the propensity score-adjusted hazards models that evaluated the 
effect of bevacizumab on hospitalization for severe adverse events during the duration of first-line 
treatment among patients who received platinum-based doublet chemotherapy are described in Table 
4.22. After adjusting for confounders in multivariable logistic regression models, patients who 
received bevacizumab in addition to any platinum-based doublet chemotherapy maintained higher 
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estimated hazard rates of hospitalization for all adverse events compared to patients who received 
chemotherapy only: arterial thromboembolic events (HR 1.13, 95% CI 0.47-2.31); gastrointestinal 
perforation (HR 1.67, 95% CI 0.63, 3.74); neutropenia (HR 1.17, 95% CI 0.77, 1.72); severe 
hemorrhage (HR 1.20, 95% CI 0.66, 2.04); and any adverse event (HR 1.31, 95% CI 0.94, 1.79). 
However, none of the results were statistically significant. Overall, results from multivariable-
adjusted models among patients who specifically received platinum-taxane chemotherapy were 
similar to those seen in the larger cohort; point estimates of the hazard ratio were slightly higher in 
the platinum-taxane cohort for each of the adverse events, further suggesting that patients who 
received bevacizumab had higher rates of hospitalization than patients who received chemotherapy 
only, but these results were not statistically significant.  
In addition to the multivariable-adjusted analyses, Cox proportional hazards models were also 
constructed using estimated propensity scores. Initially, propensity score analysis was performed to 
balance measured confounders between patients who received chemotherapy with bevacizumab and 
patients who received platinum-based chemotherapy only. Multivariate logistic regression models 
were first used to calculate propensity scores representing the probability that a patient received 
bevacizumab conditional on all other measured confounders in the model. In each propensity score 
model, variables that were associated with bevacizumab use and hospitalization for the specified 
adverse event (true confounders) as well as variables related to hospitalization only were included. 
Distinct propensity scores were calculated for each adverse event based on the confounders identified 
in the larger cohort of patients receiving any platinum-based doublet chemotherapy. 
Following propensity score estimation, the propensity scores were applied to Cox 
proportional hazards models to perform two distinct propensity score-adjusted analyses. In the first 
propensity score-adjusted analysis, discrete Cox models were fit using the propensity score as a 
continuous covariate in the model. In the second propensity score-adjusted analysis, propensity score 
estimates were used to first match exposed patients (receiving bevacizumab) to patients from the 
unexposed group (receiving chemotherapy only) in a 1:1 ratio using a 5-to-1 digit greedy-match 
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algorithm. The algorithm allows for the capture of the best possible matches (those pairs matched to 
the fifth digit of the PS) while also maximizing the number of possible matches by including pairs 
matched to the fourth, third, second, and first digits of the PS (adequacy of the matches decrease with 
the number of digits matched on); non-matched individuals are excluded from the derived cohort of 
matched patients. Application of the 1:1 greedy-match algorithm resulted in a maximum of 386 
matched pairs among patients receiving any platinum-based doublet chemotherapy and 333 matched 
pairs among patients receiving platinum-taxane doublet chemotherapy specifically; fewer patients 
were matched in the estimates of hospitalization for gastrointestinal perforation and any severe 
adverse event because of missing information for certain covariates used to estimate the propensity 
scores within these analyses.  
Propensity score-adjusted analyses that included the predicted probability of receiving 
bevacizumab as a linear covariate in each of the Cox proportional hazards models estimated similar 
hazards ratios to those observed in the multivariate-adjusted models; this is likely due to the similarity 
between the covariates included in the multivariable-adjusted models and the covariates included in 
the logistic regression models to estimate the propensity scores for bevacizumab use. Estimates from 
propensity score-matched analyses differed somewhat from multivariable-adjusted results although 
no findings were statistically significant and the confidence intervals around the estimates from 
propensity score-matched analyses were noticeably larger given the smaller sample sizes. For 
example, among propensity score-matched patients who received any platinum-based chemotherapy, 
patients receiving bevacizumab retained higher hazards of hospitalization for arterial thromboembolic 
events (HR 1.03, 95% CI 0.35-3.02), gastrointestinal perforation (HR 1.86, 95% CI 0.43, 12.69), 
neutropenia (HR 1.27, 95% CI 0.76-2.13), severe hemorrhage (HR 1.00, 95% CI 0.49-2.07), and any 
adverse event (HR 1.30, 95% CI 0.84-2.03) compared to patients who received chemotherapy only. 
Among propensity score-matched patients receiving platinum-taxane chemotherapy, the estimated 
hazards of hospitalization for severe adverse events were generally similar to those seen in the larger 
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cohort although the hazard ratio estimates and width of the 95% confidence intervals of 
hospitalization for arterial thromboembolic events (HR 2.35, 95% CI 0.61,11.21) and gastrointestinal 
perforation (HR1.06 , 95% CI 0.26, 5.20) were noticeably different; still, no findings within the 
platinum-taxane cohort were statistically significant.  
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Table 4.22 Hazards ratios of hospitalization for severe adverse events among patients receiving bevacizumab in addition to platinum-
based doublet chemotherapy compared to patients who received platinum-based doublet chemotherapy only 
   Any platinum doublet    Platinum-taxane doublet 
Adverse event Sample sizes, n HR (95% CI)  Sample sizes, n   HR (95% CI) 
Arterial thromboembolic events     
 
  
Unadjusted 386     4360 1.28 (0.53, 2.61)  333     3068 1.49 (0.57, 3.29) 
Multivariable adjusted models  
 
 
  Summary stage 386     4360 1.13 (0.47, 2.31)  333     3068 1.35 (0.51, 3.00) 
Propensity score-adjusted models
a
  
 
 
  Covariate adjustment 386     4360 1.13 (0.47, 2.31)  333     3068 1.35 (0.51, 3.00) 
Matching 386       386 1.03 (0.35, 3.02)  333       333   2.35 (0.61, 11.21) 
Gastrointestinal perforation  
 
 
  Unadjusted 386     4360 1.93 (0.79, 4.10)  333     3068 1.73 (0.64, 3.92) 
Multivariable adjusted models  
 
 
  Cooperative research group-affiliated 
provider 366     4044 1.67 (0.63, 3.74)  319     2834 1.81 (0.61, 4.45) 
Propensity score-adjusted models
b
  
 
 
  Covariate adjustment 366     4044 1.67 (0.63, 3.74)  319     2834 1.81 (0.61, 4.45) 
Matching 366       366   1.86 (0.43, 12.69)  319       319 1.06 (0.26, 5.20) 
Neutropenia  
 
 
  Unadjusted 386     4360 1.30 (0.83, 1.85)  333    3068 1.38 (0.91, 2.01) 
Multivariable adjusted models  
 
 
  Population density, year of diagnosis, 
AJCC stage 386     4360 1.17 (0.77, 1.72)  333     3068 1.23 (0.79, 1.85) 
Propensity score-adjusted models
c
  
 
 
  Covariate adjustment 386     4360 1.15 (0.76, 1.68)  333     3068 1.21 (0.78, 1.81) 
Matching 386       386 1.27 (0.76, 2.13)  333       333 1.19 (0.68, 2.10) 
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Severe hemorrhage  
 
 
  Unadjusted 386     4360 1.49 (0.84, 2.46)  333     3068 1.73 (0.94, 2.96) 
Multivariable adjusted models  
 
 
  Year of diagnosis, AJCC stage, 
histology, hemoptysis at diagnosis 386     4360 1.20 (0.66, 2.04)  333     3068 1.48 (0.76, 2.70) 
Propensity score-adjusted models
d
  
 
 
  Covariate adjustment 386     4360 1.15 (0.63, 1.96)  333     3068 1.41 (0.73, 2.59) 
Matching 386       386 1.00 (0.49, 2.07)  333       333 1.20 (0.52, 3.02) 
Any severe adverse event  
 
 
  Unadjusted 386     4360 1.53 (1.14, 2.01)  333     3068 1.62 (1.19, 2.16) 
Multivariable adjusted models  
 
 
  CCOP-affiliated provider, year of 
diagnosis, AJCC stage, receipt of 
radiation treatment, cancer-directed 
surgery  364     4128 1.31 (0.94, 1.79)  315     2901 1.38 (0.97, 1.94) 
Propensity score-adjusted models
e
  
 
 
  Covariate adjustment 364     4128 1.31 (0.93, 1.79)  315     2901 1.37 (0.96, 1.93) 
Matching 364       364 1.30 (0.84, 2.03)  315       315 1.21 (0.77, 1.91) 
a The propensity of receiving bevacizumab was estimated using a multiple logistic regression model that included summary stage at diagnosis 
b The propensity of receiving bevacizumab was estimated using a multiple logistic regression model that included cooperative research group-affiliated provider 
c The propensity of receiving bevacizumab was estimated using a multiple logistic regression model that included population density, year of diagnosis, and 
AJCC stage at diagnosis 
d The propensity of receiving bevacizumab was estimated using a multiple logistic regression model that included year of diagnosis, AJCC stage, histology, and 
hemoptysis at diagnosis 
e The propensity of receiving bevacizumab was estimated using a multiple logistic regression model that included  CCOP-affiliated provider, year of diagnosis, 
AJCC stage, receipt of radiation treatment, and cancer-directed surgery  
Abbreviations: HR = Hazard ratio; CI = Confidence interval; AJCC = American Joint Committee on Cancer; CCOP = Community Clinical Oncology Program. 
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4.5.3 Summary of analysis of severe treatment-related adverse events 
In multivariable-adjusted analyses, patients receiving bevacizumab had significantly higher 
odds of hospitalization for gastrointestinal perforation or any severe treatment-related adverse event 
within 180 days from the start of treatment compared to patients who received chemotherapy alone. 
However, when patients were matched on their estimated propensity to receive bevacizumab, the 
increased odds of hospitalization for either gastrointestinal perforation or any severe adverse event 
among patients receiving bevacizumab was no longer significant. In addition, unadjusted estimates of 
the hazard of hospitalization for severe treatment-related adverse events during first-line treatment 
suggested a significant increase in the hazard of hospitalization for any severe adverse event among 
patients who received bevacizumab in comparison to those who did not. However, after controlling 
for confounding variables through the use of multivariable-adjusted and propensity score-adjusted 
models, the increased hazard was no longer statistically significant. An important limitation to note in 
this analysis is the small number of events identified; a small baseline risk of hospitalization for each 
of the specified adverse events and the small overall sample size likely hindered the ability of this 
study to identify a significant difference in hospitalizations between patients receiving bevacizumab 
and patients receiving chemotherapy alone, particularly if the true effect estimate is not considerably 
large. Thus, although the general findings in this analysis suggest no significant difference in 
hospitalization for severe adverse events between patients who received bevacizumab and those who 
did not, the results should be interpreted with an understanding of this limitation.    
 
  
CHAPTER FIVE  
DISCUSSION 
 
5.1 Utilization of Bevacizumab 
 The objective of this study was to describe the utilization of bevacizumab in combination 
with standard platinum-based doublet chemotherapy as first line treatment of older adults with 
advanced NSCLC and to identify the clinical, sociodemographic, and health system factors associated 
with its use. Key independent variables of interest included patient age, race, socioeconomic status (as 
measured through census tract level data on education level and median household income), and 
receipt of chemotherapy treatment from a provider affiliated with the National Cancer Institute’s 
Community Clinical Oncology Program (CCOP). The analysis started with assessment of the 
utilization of bevacizumab across a cohort of older patients who received any platinum-based doublet 
regimen as their initial chemotherapy treatment. A subgroup analysis was also performed to evaluate 
the use of bevacizumab among older patients who were specifically initiated on a platinum-taxane 
doublet regimen. 
Overall, bevacizumab was not utilized to a large extent among the cohort of Medicare 
patients with advanced NSCLC treated first line with platinum-based doublet chemotherapy. Less 
than 10% of the entire cohort received bevacizumab within 8 days from the start of chemotherapy 
treatment and only 812/4746 (17.1%) of patients received bevacizumab at any point following their 
NSCLC diagnosis. Similar results were found in the subgroup analysis of patients specifically 
receiving platinum-taxane regimens with less than 10% receiving bevacizumab within 8 days of 
treatment start and less than 20% ever receiving bevacizumab. However, it is important to note that 
the proportion of patients who received bevacizumab significantly increased with increasing year of 
diagnosis. Less than 2% of patients diagnosed in 2004 or 2005 received bevacizumab within 8 days of 
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chemotherapy start compared to approximately 12% of patients diagnosed in 2006 and 18% of 
patients diagnosed in 2007.  
A primary reason for the low utilization of bevacizumab overall as well as the trend of 
increased use observed over time is likely to be the fact that bevacizumab was not approved by the 
FDA for the treatment of NSCLC until October 2006. Thus, it may be unreasonable to expect 
frequent use of bevacizumab as a component of initial treatment among patients in the study cohort, 
particularly given that approximately half of the patients were diagnosed in 2004-2005. Still, the 
utilization of bevacizumab in this cohort following FDA approval was low (< 25% of patients), 
suggesting that many oncologists may have been hesitant to adopt the practice of adding bevacizumab 
to platinum-based doublet chemotherapy in older adults with advanced NSCLC, perhaps because of 
uncertainty with regard to its safety and/or effectiveness in these patients. Given that approval of 
bevacizumab for the treatment of advanced NSCLC was largely based on results of the ECOG 4599 
trial,
56
 a study in which over half of patients were under the age of 65, little clinical evidence was 
available to most oncologists regarding the use of bevacizumab among older patients until a sub-
group analysis of ECOG 4599 patients 70 years and older was presented at the American Society of 
Clinical Oncology Annual Meeting in mid-2007.
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Despite the finding of low overall utilization among Medicare patients with advanced 
NSCLC, chronological age did not appear to be a significant determinant of bevacizumab use. 
Approximately 9% of patients aged 66-69 and 8% of patients aged 70 and older treated with any 
platinum-based doublet chemotherapy also received bevacizumab during initial treatment. This 
finding was contrary to the hypothesis that older patients (i.e., those aged 70 and older) would be less 
likely than younger patients to receive bevacizumab in addition to first-line chemotherapy. Although 
a possible explanation for this finding might be that patients 70 years and older were as healthy or 
healthier in general as compared to younger patients and therefore potentially equally fit as candidates 
for the receipt of bevacizumab, patients aged 70 and older were significantly more likely to have an 
NCI Charlson comorbidity score greater than 0 as compared to patients 66-69 years of age (41.1% vs. 
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35.7%). In addition, among the 9 patients with an NCI Charlson comorbidity score of 2 who received 
bevacizumab, all of them were 70 years of age or older. Thus, a more reasonable explanation for the 
lack of difference in utilization of bevacizumab across age groups may be that oncologists had an 
expectation for a greater level of comorbidity in older adults and were willing to make treatment 
decisions primarily based on whether or not they felt patients would benefit from the addition of 
bevacizumab, regardless of age. Still, without additional information such as patient preferences or 
the determinants of physician treatment decisions, the reason the use of bevacizumab did not vary 
significantly across age groups in this study can only be speculated. 
The utilization of bevacizumab also did not differ significantly across racial groups, a finding 
contrary to the hypothesis that non-white patients would be significantly less likely than white 
patients to receive bevacizumab in addition to platinum-based doublet chemotherapy.  However, 
similar to the results from an earlier study
7
 of older patients with advanced NSCLC using SEER-
Medicare data, blacks were significantly less likely than whites to receive chemotherapy treatment 
and significantly less likely to receive platinum-based doublet chemotherapy in particular. As a 
consequence, only a small number of black patients met inclusion criteria for the study, resulting in a 
lack of sufficient statistical power to identify a significant difference in the use of bevacizumab 
between blacks and whites. For example, given the sample sizes of whites and blacks and the use of 
bevacizumab among 6.25% of black patients in the study, more than 11% of white patients needed to 
have received bevacizumab in order to have a statistically significant difference between blacks and 
whites with power = 0.8 and alpha = 0.05. On the contrary, only 8.2% of whites received 
bevacizumab in addition to platinum-based doublet chemotherapy. Therefore, given the limited 
sample of black patients who received platinum-based doublet chemotherapy, a conclusive evaluation 
of the use of bevacizumab between blacks and whites could not be made in this study.  
To increase sample size and attempt to address the issue of statistical power, blacks could be 
combined with other non-white patients into one group in order to make a more general comparison 
of the utilization of bevacizumab between whites and non-whites. However, among patients who 
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received platinum-based doublet chemotherapy, a greater proportion of non-white patients (9.2%) 
received bevacizumab than either whites or blacks. As a result, when blacks and other non-whites are 
combined into one group, the difference in the utilization of bevacizumab between whites and non-
whites is smaller than the difference in utilization between whites and blacks. Thus, since the 
combination of blacks and other non-whites creates a more heterogeneous group of patients than 
either group alone, comparing the use of bevacizumab between white and non-white patients in this 
study is not a useful assessment. 
Similar to age and race, socioeconomic status variables (i.e., % in census tract aged 25 years 
and older with less than a high school education and census tract level median household income) 
were not significantly associated with the use of bevacizumab among patients receiving platinum-
based doublet chemotherapy. However, the receipt of any chemotherapy as well as the receipt of 
platinum-based doublet chemotherapy in particular, differed substantially across quartiles for both 
education and median household income measures. Patients from census tracts with a lower 
percentage of individuals with less than a high school education were significantly more likely to 
receive chemotherapy or platinum-based doublet chemotherapy than patients from census tracts with 
a higher number of less educated individuals. Likewise, the use of chemotherapy and platinum-based 
doublet chemotherapy in particular, significantly increased as the census tract level of median 
household income increased. These differences remained significant even after controlling for 
important clinical factors such as stage and comorbidity level. Therefore, it appears that treatment 
differences across socioeconomic status measures exist, but are more likely to involve the decision of 
whether or not to treat patients with chemotherapy to begin with; once the decision has been made to 
treat patients with platinum-based doublet chemotherapy, socioeconomic status measures have little 
influence in the decision of whether or not to add bevacizumab to the first-line chemotherapy 
regimen.    
The most relevant finding from this study was that patients who received 50% or more of their 
chemotherapy from a provider affiliated with NCI’s CCOP were significantly more likely to receive 
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bevacizumab in addition to platinum-based doublet chemotherapy than patients who received less 
than half of their chemotherapy from a CCOP-affiliated provider. This result is not all that surprising 
since the goals of the CCOP include real-world implementation of cancer treatment clinical trials, and 
the rapid diffusion of novel evidence-based treatments into practice.
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 Considering that bevacizumab  
received FDA approval for the treatment of advanced NSCLC around the midpoint when patients 
were diagnosed in this study, it seems reasonable that providers participating in the CCOP, 
particularly those who accrue and enroll patients in NCI treatment trials, may have earlier and greater 
exposure to the dissemination of bevacizumab trial results than non-affiliated providers, and therefore 
would have a greater likelihood of adopting the use of bevacizumab for the treatment of their older 
patients with advanced non-small cell lung cancer. The finding that receipt of chemotherapy 
treatment from CCOP-affiliated providers was associated with an increased use of bevacizumab 
provides empirical evidence to support the CCOP’s success in promoting the diffusion of novel, 
evidence-based treatments into community practice thus providing access to state-of-the-art cancer 
care among cancer patients in the community setting.  
Nevertheless, one cannot delineate from this study whether the greater uptake of 
bevacizumab among CCOP-affiliated providers is a direct result of the infrastructure provided by the 
CCOP or the individual characteristics of participating providers. Although the CCOP has established 
a foundation to enable providers to have quicker and greater access to trial results and novel 
treatments, providers who participate in the CCOP may be more motivated to seek out current clinical 
information, engage in innovative practice methods, and/or utilize state-of-the-art therapies than non-
participants. Oncologists, irrespective of CCOP affiliation, are likely to gain new clinical knowledge 
about novel therapies and treatment practices through the provision of clinical guidelines and 
dissemination of trial results by large professional organizations. For instance, interim results of the 
ECOG 4599 trial were presented in June 2005 at the ASCO Annual Meeting,
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 following which the 
National Comprehensive Cancer Network (NCCN) updated its NCCN Clinical Practice Guidelines in 
Oncology™ for non-small cell lung cancer in October 2005209 to include the use of bevacizumab plus 
 215 
chemotherapy as first-line treatment for advanced NSCLC. Thus, knowledge of the effectiveness of 
bevacizumab was widely disseminated to a broad population of providers well before FDA approval 
of bevacizumab for NSCLC, suggesting that the early distribution of trial results was not restricted to 
CCOP-affiliated providers and that the greater use of bevacizumab among patients treated by CCOP-
affiliated providers was more likely influenced by the individual characteristics of providers (e.g., 
greater motivation to engage in innovative treatment practices compared to non-CCOP-affiliated 
providers) as opposed to the CCOP infrastructure. That is to say, regardless of their participation in 
the provider-based research network, CCOP-affiliated providers would have been more likely than 
non-CCOP-affiliated providers to use bevacizumab among their patients.  
It is important to point out, however, that the current study did not assess whether receipt of 
treatment from a CCOP-affiliated provider was associated with greater use of bevacizumab among 
patients diagnosed before FDA approval, specifically (i.e., patients diagnosed prior to October 2006). 
The benefit of doing such an analysis would provide some idea about whether the broad 
dissemination of clinical trial information and practice guidelines influenced the early use of 
bevacizumab prior to its FDA approval for use in NSCLC. Greater use among patients treated by 
CCOP-affiliated providers would support the idea that CCOP-affiliated providers are quicker to adapt 
to changes in clinical guidelines, more willing to adopt novel treatments based solely on early trial 
results, and are more motivated to engage in state-of-the-art practices (i.e., differences in the early 
adoption of bevacizumab may be explained by differences in personal characteristics between CCOP-
affiliated and non-CCOP-affiliated providers); similar uptake between CCOP-affiliated and non-
CCOP-affiliated providers would support the idea that practice guidelines and the dissemination of 
clinical trial results by professional organizations are as influential in the early adoption of 
bevacizumab as participation in provider-based research networks. However, restricting the analysis 
of bevacizumab use to patients diagnosed prior to FDA approval does not provide a complete picture 
about the association between provider CCOP affiliation and the uptake of bevacizumab. FDA 
approval of treatments is likely to be an important influence in the utilization of new therapies; less 
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than 2% of patients diagnosed prior to 2006 received bevacizumab compared to nearly 12% of 
patients diagnosed in 2006. With the small number of patients receiving bevacizumab prior to FDA 
approval overall, it is unlikely that utilization differed significantly based on provider affiliation with 
the CCOP. Conversely, the greater use of bevacizumab observed among patients treated by a CCOP-
affiliated provider following FDA approval of bevacizumab for the treatment of advanced NSCLC 
suggests that even when the dissemination of clinical evidence and practice guidelines is widespread, 
providers participating in the CCOP are more eager to adopt novel treatments and state-of-the-art 
practices than non-participating providers.            
Apart from year of diagnosis and receipt of chemotherapy treatment from a CCOP-affiliated 
provider, the utilization of bevacizumab among patients included in this study appeared to be largely 
influenced by several need or clinical-based characteristics including tumor histology, stage at 
diagnosis, receipt of radiation treatment, receipt of cancer-directed surgery, the presence of brain 
metastases, and comorbidity burden. Patients with adenocarcinoma were significantly more likely 
than patients with tumors of different histology to receive bevacizumab, even after controlling for 
demographic, clinical, and health care system characteristics in the regression models. A possible 
explanation for the greater use of bevacizumab among patients with adenocarcinoma histology is that 
nearly 90% of patients in the ECOG 4599 trial that led to FDA approval of bevacizumab for NSCLC 
had tumors of adenocarcinoma histology.
188
 Thus, oncologists may have felt more comfortable in 
adding bevacizumab to chemotherapy among older patients with tumor characteristics for which 
clinical evidence of safety and efficacy had been established.  
Standard treatment options for patients with stage IIIB NSCLC include sequential or 
concurrent chemotherapy and radiation treatment or chemotherapy followed by cancer-directed 
surgery. Indeed in this study, patients with stage IIIB disease were more likely to receive radiation 
treatment and more likely to receive cancer-directed surgery than patients with stage IV disease. In 
addition, stage IIIB patients were significantly less likely to receive bevacizumab in addition to 
platinum-based doublet chemotherapy as compared to stage IV patients, a finding that may explain (at 
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least in part) why patients who received radiation treatment and/or cancer-directed surgery were less 
likely to receive bevacizumab than patients who did not receive either of these therapies. 
Furthermore, because bevacizumab inhibits angiogenesis, a process involved in wound healing, there 
is the potential for bevacizumab to contribute to complications in patients undergoing surgery.
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Given the relatively long half-life of bevacizumab (~20 days), it is commonly recommended that 
surgery be delayed at least 28 days following the cessation of bevacizumab; similarly, it is not 
recommended to initiate bevacizumab until at least 28 days following surgery and after complete 
healing of the surgical wound.
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 Thus, in the current study, bevacizumab may have been avoided in 
select patients for whom cancer-directed surgery was a potential treatment option because of the 
necessary delay between the use of bevacizumab and the performance of surgical procedures.  
Moreover, the association between bevacizumab and risk of severe hemorrhage as well as the 
exclusion of patients with brain metastases from the ECOG 4599 trial may explain why patients with 
brain metastases in the current study were significantly less likely to receive bevacizumab compared 
to patients without brain metastases. With little or no knowledge about the safety and efficacy of 
bevacizumab in patients with brain metastases at the time, oncologists may have chosen to be more 
vigilant in the addition of bevacizumab to platinum-based doublet chemotherapy among these 
patients until more clinical evidence was available. Similarly, nearly all (~97%) patients with NCI 
Charlson comorbidity index of 2 had a history of cardiovascular conditions including cerebrovascular 
disease, congestive heart failure, peripheral vascular disease, and/or myocardial infarction. Further, 
the ECOG 4599 trial only included patients with a performance status of 0 or 1. Although 
performance status and the NCI Charlson comorbidity index are not equivalent measures, patients 
with a comorbidity index of 2 may have been representative of patients with poorer performance 
status (i.e., > 1). Combined with a concern for severe hemorrhage or other cardiovascular-related 
complications among a patient population already plagued with cardiovascular conditions, uncertainty 
regarding the safety and efficacy of bevacizumab among patients with greater comorbidity and/or 
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poorer performance status may have cautioned oncologists against the use of bevacizumab among 
these patients. 
When all predisposing, enabling, and need characteristics available within the SEER-
Medicare database were considered, need characteristics clearly had the largest influence on the 
utilization of bevacizumab among older patients with advanced NSCLC. In fact, aside from the year 
of diagnosis and receipt of treatment from a CCOP-affiliated provider, predisposing and enabling 
characteristics were not associated with the use of bevacizumab. A potential reason for this finding is 
that patients included in the study were already engaged in a “health service” at the time the decision 
of whether or not to utilize bevacizumab was made; to be included in the study, patients had to 
receive platinum-based doublet chemotherapy within four months of diagnosis. Personal determinants 
of health service use (i.e., predisposing and enabling characteristics such as age, race, and 
socioeconomic status) may have influenced whether or not patients sought or received chemotherapy 
to begin with. However, if this is the case, one would expect the subgroup of patients receiving 
platinum-based doublet chemotherapy to be rather homogenous with regard to predisposing and 
enabling characteristics compared to the larger overall population with advanced NSCLC. Thus, once 
engaged in the treatment process, only need/clinical characteristics of the patient (e.g., stage of 
disease and comorbidity burden) and health care system characteristics (e.g., provider affiliation with 
the CCOP) are left to differ and potentially influence the use of bevacizumab. Furthermore, given that 
need characteristics are more likely to influence treatment outcomes than predisposing or enabling 
characteristics, it is not surprising that these clinical measures had the greatest influence on 
bevacizumab utilization in this study.    
 
5.2 Effect of Bevacizumab on Survival 
 The primary objective of this study was to determine whether the utilization of bevacizumab 
in combination with standard platinum-based doublet chemotherapy as first line treatment of older 
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adults with advanced NSCLC significantly improved overall survival. In addition, a sub-group 
analysis was performed to evaluate whether the addition of bevacizumab significantly improved 
survival among older patients treated first-line with platinum-taxane regimens. Multivariable logistic 
regression and Cox proportional hazard models were created to assess whether demographic, 
socioeconomic, or health system characteristics of interest modified any identified effect of 
bevacizumab on one-year survival or overall survival duration, respectively. 
Results from the multivariable models that controlled for observable patient demographic, 
clinical, and health system characteristics indicated that the addition of bevacizumab to platinum-
based doublet chemotherapy did not provide a significant survival advantage over chemotherapy 
alone. Finding no survival benefit with the use of bevacizumab is consistent with results observed in a 
subgroup analysis
5
 of patients 70 years and older in the ECOG 4599 trial as well as an earlier study
7
 
of SEER-Medicare data specifically evaluating the effectiveness of adding bevacizumab to 
carboplatin-paclitaxel. However, differences in overall survival duration between patients in the 
current study and participants from the subgroup analysis of ECOG 4599 were observed. Median 
survival duration was shorter among patients in the current study as compared to older clinical 
participants of the ECOG 4599 trial. In this study, patients receiving bevacizumab in addition to 
platinum-taxane chemotherapy had a median survival of 10.0 months whereas patients receiving 
platinum-taxane chemotherapy alone had a median survival of 9.0 months, yielding a survival benefit 
with bevacizumab of approximately 1 month. In comparison, among older ECOG 4599 trial 
participants, those receiving bevacizumab in combination with carboplatin-paclitaxel actually had a 
median survival of 11.3 months vs. 12.1 months for participants receiving carboplatin-paclitaxel 
alone. Without knowledge from additional analysis, a potential hypothesis for the shorter median 
survival duration comparing patients in the current study with older participants from the ECOG 4599 
trial may be the differences in age distribution across the two studies. Although median age in the 
current study was 73 years vs. 74 years in the ECOG subgroup analysis, nearly 13% of patients in the 
current study were 80 years of age or older compared to less than 2% of older participants in ECOG 
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4599. However, in the current study, the median survival duration of patients aged less than 80 years 
was no better than the median survival duration of the full cohort. Therefore, distinctions in overall 
survival duration observed between the current study and the subgroup analysis of elderly participants 
in ECOG 4599 may be more plausibly explained by differences in comorbidity, performance status, 
or other influential clinical characteristics not measured or identifiable in SEER-Medicare data.        
Subgroup and sensitivity analyses of the effect of bevacizumab on overall survival among 
patients receiving platinum-based doublet chemotherapy did not lead to results different from those in 
the original analysis. In the subgroup analysis of patients with stage IV disease, those who received 
bevacizumab had a more favorable hazard of death compared to patients who received chemotherapy 
alone, but this finding was not statistically significant. The finding that the hazard ratio estimate in 
stage IV patients was slightly lower than the hazard ratio observed in the overall cohort is not 
surprising. Given that patients with stage IV disease were significantly more likely to receive 
bevacizumab than patients with stage IIIB disease, if patients with stage IIIB have noticeably longer 
survival duration than stage IV patients, removing stage IIIB patients from the analysis essentially 
decreases the average overall survival duration among patients receiving platinum-based doublet 
chemotherapy only while likely having a smaller, if any, effect on the average survival among 
patients receiving bevacizumab in addition to chemotherapy.   
As briefly stated beforehand, age was not significantly associated with survival in the overall 
cohort. In addition, although older patients (i.e., > 70 years of age) had significantly poorer survival 
compared to younger patients (i.e., 66-69 years of age) among those receiving platinum-based doublet 
chemotherapy alone, there was no significant difference in survival across age groups among patients 
receiving bevacizumab in addition to chemotherapy. An initial assumption for the lack of difference 
in survival across age groups among patients receiving bevacizumab may be that older patients were 
similar to younger patients with respect to other measured clinical characteristics that were associated 
with survival, such as stage at diagnosis and comorbidity level. However, further investigation 
showed that patients 70 and older receiving bevacizumab were significantly more likely to have an 
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NCI Charlson comorbidity index greater than 0 and were more likely to have cerebrovascular disease, 
congestive heart failure, or peripheral vascular disease compared to patients aged 66 to 69 receiving 
bevacizumab. If greater comorbidity adversely offsets the potential survival benefit of bevacizumab, 
then a greater difference in survival across age groups among patients receiving bevacizumab would 
have been expected, with older patients deriving a significantly smaller survival advantage from the 
use of bevacizumab compared to younger patients. Without knowledge about other clinical factors 
such as performance status or disease severity, it is difficult to ascertain whether the lack of difference 
in survival benefit with bevacizumab across age groups is due to unobserved, underlying distinctions 
between patient groups, differences in secondary treatment, or that the addition of bevacizumab to 
platinum-based doublet chemotherapy is equally effective (or ineffective) in improving overall 
survival in older patients with advanced NSCLC, regardless of age.           
   Race was associated with overall survival in bivariate analyses, but no survival advantage 
of was observed with the use of bevacizumab among any of the individual categories for race. Still, 
some survival differences across racial categories were observed within treatment subgroups. For 
example, whites had significantly poorer survival compared to non-whites among patients treated 
with chemotherapy alone, although no survival difference was observed between whites and non-
whites among patients receiving bevacizumab. It is important to note that because so few blacks and 
patients of ‘other’ race groups (i.e. patients not categorized as white or black) met study inclusion 
criteria and/or received treatment with bevacizumab, this study was not powered to compare the 
potential survival benefit of bevacizumab between whites and either blacks or other non-white 
patients.; the distribution of race in this study was similar to that seen in ECOG 4599 where more 
than 90% of trial participants were categorized as being of white race. Nevertheless, an exploratory 
analysis comparing the effect of bevacizumab on survival between whites and patients of other non-
white race groups, found that patients of other race groups had noticeably longer survival compared 
to whites. However, there is an absence of clinical information or additional studies in the literature to 
help explain or support this finding. Given the potential survival advantage with bevacizumab among 
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patients of other non-white race groups in this study as well as the lack of clinical trial evidence to 
support or oppose the use of bevacizumab among non-white patients, there is a clear need for future 
analyses to evaluate the effect of bevacizumab on overall survival in cohorts with relatively larger 
proportions of minority patient groups.  
Similar to race, socioeconomic status variables, including census tract measures of education 
level and median household income, were significantly associated with overall survival in bivariate 
analyses, but no survival advantage was observed with the use of bevacizumab among any of the 
individual quartiles for either education level or median household income. For example, in the 
bivariate analyses, patients from census tracts categorized in quartiles with the lowest percentage of 
residents with less than a high school education or the highest median household income had 
significantly greater survival than patients from census tracts categorized in any other quartile, 
suggesting that higher education and higher income (i.e. proxies for socioeconomic status) are 
correlated with improved survival. However, when treatment with bevacizumab was accounted for in 
the proportional hazards models, neither education level nor median household income remained 
significantly associated with overall survival. This finding implies that when patients with advanced 
NSCLC receive similar treatment, survival outcomes are not directly influenced by indicators of 
patient socioeconomic status.  
  Whether or not patients received the majority of their chemotherapy treatment from a CCOP-
affiliated provider had little relevance on overall survival and did not mediate any association 
between bevacizumab and survival either. For example, among patients who received treatment from 
a CCOP-affiliated provider, there was no significant difference in overall survival when comparing 
patients who received bevacizumab with patient who received platinum-based doublet chemotherapy 
alone. In addition, among patients who received bevacizumab, those patients who were  treated by a 
CCOP-affiliated provider did not fare any better with respect to overall survival  than patients who 
were not treated by a CCOP-affiliated provider. Thus, although patients treated by CCOP-affiliated 
 223 
providers were more likely to receive bevacizumab in addition to platinum-based doublet 
chemotherapy, they did not appear to derive any significant survival advantage because of it. 
A notable finding in this study was that overall survival significantly differed between men 
and women, regardless of treatment received. For instance, among patients receiving platinum-based 
doublet chemotherapy alone, women had significantly longer survival than men. Similarly, women 
also had considerably longer survival than men among patients receiving bevacizumab in addition to 
platinum-based doublet chemotherapy. However, when the effect of bevacizumab on survival was 
assessed within each sex, neither women nor men exhibited a significant difference. A likely 
explanation for the overall difference in survival between sexes is that men were significantly more 
likely to have greater comorbidity than women; approximately 42% of men had an NCI Charlson 
comorbidity index > 0 compared to about 36% of women with more than 6% of men having an index 
of 2 vs. less than 4% of women.   
In addition to tumor stage, several other clinical characteristics including tumor histology, 
receipt of radiation treatment, receipt of cancer-directed surgery, the presence of brain metastases, 
and comorbidity burden were significantly associated with overall survival in bivariate analyses, 
though they did not influence the effect of bevacizumab on survival. For instance, patients with 
adenocarcinoma generally had longer overall survival than patients with tumors of different histology.  
However, among patients receiving bevacizumab, overall survival duration did not differ significantly 
across tumor histology categories, even when histology was categorized dichotomously as 
adenocarcinoma and non-adenocarcinoma. Similarly, among patients with adenocarcinoma tumors, 
receipt of bevacizumab was not significantly associated with improved survival. This latter finding is 
in contrast to a subgroup analysis of ECOG 4599 that evaluated the effect of bevacizumab by tumor 
histology.
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 Among trial participants with adenocarcinoma in the subgroup analysis, the combination 
of bevacizumab with carboplatin-paclitaxel chemotherapy was associated with a significant increase 
in overall survival compared to carboplatin-paclitaxel alone. Interestingly, among patients with 
adenocarcinoma in the current study, those who received bevacizumab were significantly more likely 
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to have an NCI Charlson index of zero compared to patients receiving chemotherapy alone, yet no 
survival advantage with bevacizumab was observed.  
 
5.3 Effect of Bevacizumab on Hospitalization for Severe Adverse Events 
The primary objective of this study was to determine whether the utilization of bevacizumab 
in combination with standard platinum-based doublet chemotherapy as first line treatment of older 
adults with advanced NSCLC was associated with a significant increase in hospitalizations for severe 
treatment-related adverse events including, arterial thromboembolic events, gastrointestinal 
perforation, neutropenia, and severe hemorrhage. In addition, sub-group analyses were performed to 
evaluate whether the addition of bevacizumab to platinum-based doublet chemotherapy significantly 
increased the risk of hospitalization for severe adverse events among patients stratified by NCI 
Charlson comorbidity index or among patients specifically treated first-line with carboplatin-
paclitaxel chemotherapy. Multivariable logistic regression models were created to assess whether 
demographic, socioeconomic, or health system characteristics of interest modified any identified 
effect of bevacizumab on the odds of hospitalization for severe adverse events during the first 180 
days of treatment. Likewise, multivariable Cox proportional hazard models were performed to 
evaluate whether the same characteristics influenced any identified association between bevacizumab 
and the hazard of hospitalization within the identified first-line treatment window. 
Over the first 180 days of treatment, patients receiving bevacizumab in combination with 
platinum-based doublet chemotherapy had significantly greater cumulative incidence of 
hospitalization for gastrointestinal perforation and hospitalization for any severe adverse event 
compared to patients receiving platinum-based doublet chemotherapy alone. By comparison, when 
evaluation of hospitalization for severe adverse events was restricted to the duration of the first-line 
treatment window, only the cumulative incidence of hospitalization for any severe adverse events was 
significantly higher among patients receiving bevacizumab compared to patients receiving 
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chemotherapy alone. Lastly, the overall cumulative incidence of hospitalization for severe adverse 
events with the use of bevacizumab did not vary significantly across key independent variables of 
interest including age, race, and the census tract level measures of education and median household 
income.         
  In general, although direct comparisons cannot be made because of differences in the way 
adverse events were measured and identified between studies, the incidence rates of hospitalization 
for severe adverse events in this study were not unlike the rates of adverse events reported in clinical 
trials and other observational studies. For example, in both the current study and the subgroup 
analysis of older participants in ECOG 4599,
5
 irrespective of treatment, 3% to 4% of patients 
experienced significant hemorrhage. Similarly, though gastrointestinal perforation has not been 
evaluated in clinical trials for bevacizumab in NSCLC, the cumulative incidence of 1% to 2% among 
patients in the current study is consistent with findings from clinical
211,212
 and observational
213,214
 
studies of gastrointestinal perforation with the use of bevacizumab in metastatic colorectal cancer. 
However, the cumulative incidence rates of arterial thromboembolic events and neutropenia identified 
in this study were lower than the rates reported in the subgroup analysis of ECOG 4599. Given that 
these incidence rates were lower among both treatment groups (i.e., patients receiving or not 
receiving bevacizumab), it seems plausible that the distinctions between studies are due to differences 
in the way these adverse events were identified and measured.  
Overall, results from multivariable logistic regression models evaluating the effect of 
bevacizumab on the odds of hospitalization for severe adverse events during the first 180 days of 
chemotherapy treatment were similar to unadjusted results. Among patients receiving any platinum-
based doublet chemotherapy, those patients who also received bevacizumab were at significantly 
increased risk for hospitalization for gastrointestinal perforation after controlling for additional 
characteristics (peripheral vascular disease and brain metastases). However, the increased risk of 
hospitalization for gastrointestinal perforation with the use of bevacizumab was not statistically 
significant among patients receiving platinum-taxane chemotherapy in particular. Among patients 
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receiving platinum-taxane chemotherapy, only the risk of hospitalization for any severe adverse event 
was significantly increased with the use of bevacizumab. Still, it is important to note that some of the 
hospitalizations detected during the first 180 days of treatment occurred well after the cessation of 
first-line treatment. In addition, there is the possibility that some of the hospitalizations identified 
were not related to chemotherapy or bevacizumab treatment. Thus, it is not possible to establish 
causality between treatment and hospitalization in this analysis and therefore the findings of increased 
odds of hospitalization for gastrointestinal perforation or any severe adverse event with the use of 
bevacizumab should be interpreted cautiously.  
Restricting the evaluation of hospitalization for severe adverse events to the duration of first-
line treatment may provide a better picture of the potential relationship between bevacizumab and the 
risk of the specified adverse events than observation over the first 6 months of treatment. Although 
results between the analyses were generally similar, in multivariable Cox proportional hazard models 
evaluating the effect of bevacizumab on the hazard of hospitalization for severe adverse events during 
the first-line treatment window, utilization of bevacizumab was not significantly associated with 
hospitalization for any of the severe adverse events. However, the hazard ratio estimates in the 
multivariable-adjusted models did suggest that the hazard of hospitalization for each of the adverse 
events is elevated with the use of bevacizumab in comparison to chemotherapy alone. Again, this is 
consistent with results from the ECOG 4599 trial
56
 which found a significant increase in the incidence 
of neutropenia and bleeding events among trial participants receiving bevacizumab-carboplatin-
paclitaxel; severe bleeding, but not neutropenia, was significantly elevated among participants 
receiving bevacizumab-carboplatin-paclitaxel in the subgroup analysis of older patients in ECOG 
4599.
5
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5.4 Implications of Study 
 Results from the current study have potentially important implications with respect to the 
treatment of older patients with advanced non-small cell lung cancer. In general, the utilization of 
bevacizumab in addition to standard platinum-based doublet chemotherapy was relatively low. The 
low use of bevacizumab can be explained in part due to the time at which many patients in the cohort 
were diagnosed and treated relative to the time when bevacizumab was approved by the FDA for use 
in combination with chemotherapy in the treatment of advanced NSCLC. Utilization of bevacizumab 
increased following the dissemination of initial clinical trial results and revision of NCCN guidelines 
to recommend bevacizumab plus chemotherapy as first-line treatment of advanced NSCLC in mid-to-
late 2005 followed by FDA approval of bevacizumab in October 2006. Still, less than 25% of patients 
receiving platinum-based doublet chemotherapy in the calendar year following the FDA’s approval 
also received bevacizumab at the start of treatment. This suggests that many oncologists are prudent 
in their use of newer anti-cancer therapies, particularly treatments without published evidence of their 
efficacy in specific populations such as older adults. 
In relation to the uptake of bevacizumab, a key finding in this study was the greater 
utilization of bevacizumab among patients who received a majority of their chemotherapy from a 
provider affiliated with the National Cancer Institute’s Community Clinical Oncology Program. The 
CCOP provides a research network among community oncologists where newly developed cancer 
interventions can be evaluated through clinical trials populated by patients recruited through 
participating physicians. In addition, CCOP allows for rapid dissemination of new findings and quick 
diffusion of new evidence-based therapies throughout the research network. Ideally, community 
oncologists engaged in CCOP stay well-informed about and have convenient access to evidence-
based information on novel cancer interventions. In turn, CCOP-affiliated oncologists, through 
clinical trial recruitment and implementation of these novel interventions, provide rapid adoption of 
innovative changes to cancer prevention and treatment in the community setting. Considering the 
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wide dissemination of clinical trial results purporting the effectiveness of bevacizumab by both 
ASCO and the NCCN and the initiation of treatment in nearly half of the patients included in this 
study prior to FDA approval for advanced NSCLC, current study results provide clear evidence of a 
more rapid adoption of bevacizumab among CCOP-affiliated providers and successful promotion of 
access to state-of-the-art cancer care in the community setting among Medicare patients with 
advanced NSCLC.  
Future studies should delineate the specific determinants of the greater uptake of 
bevacizumab by CCOP-affiliated providers to determine whether the adoption of this novel treatment 
by CCOP participants was influenced by the individual characteristics of providers, the underlying 
infrastructure of the CCOP, or a combination of the two. This knowledge will inform policymakers 
about how to further improve the diffusion and uptake of innovative treatments in the community 
setting by establishing whether provider characteristics (e.g., the motivation to engage in innovative 
treatment practices) and or organizational/practice-site characteristics (e.g., system-level access to 
new clinical information and/or novel therapies) differ between CCOP and non-CCOP participants. In 
turn, this will allow policymakers to determine whether efforts to improve the dissemination of 
information and adoption of novel treatments should be focused on promoting greater community 
provider participation in the CCOP, establishing additional opportunities for community providers to 
stay informed and gain access to new therapies (particularly for those unable to participate in the 
CCOP), and/or encouraging community providers who may otherwise be less motivated to seek out 
current clinical trial results, engage in novel practice methods, or adopt state-of-the-art treatments.   
In addition to the greater use of bevacizumab among patients treated by CCOP-affiliated 
providers, another important finding in this study was the lack of age, race, and socioeconomic 
disparities in the use of bevacizumab among patients receiving platinum-based doublet 
chemotherapy. An earlier evaluation
15
 of patients with advanced NSCLC in the SEER-Medicare 
database found significantly decreased use of any chemotherapy among older patients, patients of 
black race (as compared to whites), and patients of lower socioeconomic status (as measured by 
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census tract level of median household income). Older patients and black patients were also 
significantly less likely to receive platinum-based doublet regimens as compared to younger patients 
and white patients, respectively. The current study found similar differences as older patients, patients 
of black race, and patients of lower socioeconomic status were significantly less likely to receive any 
chemotherapy and black patients and patients of lower socioeconomic status were less likely to 
receive platinum-based doublet regimens. Thus, important disparities continue to exist in regards to 
the decision to initiate chemotherapy. However, the results of the current study suggest that once 
oncologists and their patients have committed to pursuing chemotherapeutic treatment with platinum-
based doublet chemotherapy, the decision to add bevacizumab to the treatment regimen is not 
influenced by patient age, race, or proxy measures of socioeconomic status.  
Despite positive findings with regards to its utilization, the absence of a clear survival 
advantage with bevacizumab when added to standard platinum-based doublet chemotherapy among 
this cohort of Medicare beneficiaries raises concern about its future utility in the treatment of older 
patients with advanced NSCLC. Previous subgroup analysis of older participants in ECOG 4599 and 
an earlier observational cohort study of SEER-Medicare both reported no significant improvement in 
overall survival with the addition of bevacizumab to carboplatin-paclitaxel chemotherapy. The results 
of the current study further extrapolate this finding among a cohort of Medicare beneficiaries treated 
first-line with a broader range of platinum-based doublet chemotherapy regimens. Furthermore, when 
the cost of adding bevacizumab to standard platinum-based doublet chemotherapy is considered, the 
relative absence of a survival advantage among older patients with advanced NSCLC brings 
additional doubt as to the cost-effectiveness of this novel therapy.
215
  
Still, as some patients receiving bevacizumab in the current study survived 2 or more years 
beyond the start of treatment, it is possible that there are older adults who have derived significant 
benefit from the receipt of bevacizumab. However, determining whether specific individuals survived 
longer specifically because of the receipt of bevacizumab during first-line treatment is not possible 
without additional information. This unknown gap in information can create a conundrum for 
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companies or agencies that administer health insurance plans such as the Centers for Medicare and 
Medicaid Services (CMS) as they make policy decisions with respect to the coverage of novel 
treatments. In the case of bevacizumab, use of this new agent adds significant cost to treatment which 
the health plan assists in paying for, and there is a lack of evidence to support its effectiveness in 
improving survival among a population sample of older adults with advanced NSCLC. However, as 
just mentioned, it is possible that some individuals benefit significantly from the use of bevacizumab. 
Thus, in the absence of additional information, health plans may be forced to decide whether to 
continue coverage at the risk of incurring significant additional treatment costs with the possibility 
that patients do not actually derive any benefit, or to discontinue coverage in part or in whole at the 
risk of denying some patients access to a treatment that they would otherwise benefit from. 
Interestingly, this is a dilemma that the CMS faced recently with regards to bevacizumab; despite a 
decision in 2011 by the FDA to revoke the breast cancer indication of bevacizumab because of safety 
and effectiveness concerns, the CMS chose to maintain coverage of bevacizumab in the treatment of 
patients with metastatic breast cancer. Therefore, given that bevacizumab has maintained its 
indication for the first-line treatment of advanced non-squamous non-small cell lung cancer with 
platinum-based chemotherapy, evidence from clinical trials showing that bevacizumab improves 
overall survival, progression-free survival, and treatment response rates in the larger population of 
patients with advanced NSCLC, and the precedent set forth by CMS in its coverage of bevacizumab 
in the treatment of metastatic breast cancer, health insurance plans should retain coverage of 
bevacizumab in the treatment of advanced NSCLC regardless of patient age. In addition, to 
discourage overutilization of bevacizumab and unnecessary increases in overall treatment costs, 
health plans should consider implementing additional policies that restrict coverage of bevacizumab 
to patients who demonstrate a potential to derive benefit from its use (e.g., patients receiving 
platinum-based doublet chemotherapy, patients with low comorbidity burden, etc.).             
Policymakers responsible for developing treatment guidelines and practicing oncologists also 
face similar dilemmas regarding the utility of bevacizumab. Policymakers must utilize available 
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evidence from clinical trials and observational studies that assess the availability, 
efficacy/effectiveness, and safety of treatment alternatives when making therapeutic 
recommendations for populations of affected patients. Oncologists face the challenge of making 
individual treatment decisions (such as whether or not to add bevacizumab to first-line chemotherapy) 
based on whether or not they think their patient will benefit at the point of care. Overall results of 
clinical trials clearly show improvements in survival and treatment response with the addition of 
bevacizumab to platinum-based chemotherapy in the treatment of advanced NSCLC. However, 
results from the current study as well as those from the previous literature including subgroup 
analyses of older clinical trial participants consistently indicate that bevacizumab does not provide a 
survival benefit to older patients. Without additional knowledge beyond what has been described in 
this study and the previous literature, differentiating subpopulations of patients or individuals who are 
most likely to benefit from the receipt of bevacizumab may be extremely challenging. However, the 
recent development of a prognostic model
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 based on information from ECOG 4599 may prove 
useful to oncologists as a clinical decision tool and to researchers as an instrument to further evaluate 
and understand the effectiveness of bevacizumab in advanced NSCLC. Still, until there is additional 
empirical evidence to support the use of bevacizumab among patients based on specific clinical 
characteristics, guidelines should restrict the recommendation of bevacizumab as a first-line treatment 
option to those patients with characteristics representative of those observed in clinical trials, e.g., 
patients who are younger, have a good performance status (0 or 1), adenocarcinoma histology, and 
are treated with platinum-based doublet chemotherapy. Similarly, the use of bevacizumab should not 
be recommended by guidelines as a standard component of care in the treatment of older adults with 
advanced NSCLC based on evidence indicating older patients derive no survival benefit from its use. 
Nevertheless, individual oncologists should not restrict the use of bevacizumab based on patient age 
alone; although the broad use of bevacizumab among older adults is not recommended, oncologists 
should use bevacizumab sensibly based on clinical characteristics and preferences of the individual 
patient and knowledge of outcomes observed among similar patients.    
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Finally, although estimates were not statistically significant, the hazard of hospitalization for 
severe treatment-related adverse events including arterial thromboembolic events, gastrointestinal 
perforation, neutropenia, and severe hemorrhage appears to be elevated with the use of bevacizumab. 
Furthermore, the hazards of hospitalization for neutropenia and any severe adverse event were 
significantly increased with the use of bevacizumab among patients with greater comorbidity; 
additional caution is warranted when making treatment decisions regarding the use of bevacizumab in 
patients who may be at greater risk of complications at baseline. Combined with added cost of 
treatment and uncertainty about its effectiveness in improving survival beyond that of standard 
platinum-based doublet chemotherapy, the potential of increased risk for severe treatment-related 
adverse events necessitates prudent use of bevacizumab among older patients with advanced NSCLC.   
 
5.5 Limitations and Ideas for Further Study 
 Results of this study must be interpreted with several limitations in mind that are 
characteristic of observational studies, particularly those that utilize data collected from 
administrative health care claims. First, inclusion and exclusion criteria restricted the study cohort to 
Medicare fee-for-service beneficiaries with a primary cancer diagnosis of advanced NSCLC on or 
after the age of 66 who were living in a SEER region at the time of diagnosis. Therefore, the cohort 
derived for this study may not be representative of all older patients with advanced NSCLC in the 
United States,
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 although the study cohort is probably more representative than the sample of older 
participants from ECOG 4599.  Nevertheless, results from the study may not be generalizable to 
Medicare patients enrolled in an HMO, diagnosed with another form of cancer previous or 
simultaneous to their diagnosis of NSCLC, diagnosed before the age of 66, or living outside of a 
SEER region at the time of diagnosis. Careful consideration of these limitations to the generalizability 
of the study findings is necessary before attempting to extrapolate the results to a broader population 
of patients with advanced NSCLC. Future research should consider evaluating the utilization and 
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effectiveness of bevacizumab among Medicare beneficiaries enrolled in an HMO as well as those 
diagnosed outside of the SEER regions to gain a fuller understanding of its use and utility in a broader 
population of older adults with advanced NSCLC. 
 A second limitation of this study involves the absence of clinical details and patient behaviors 
within the SEER-Medicare database, such as performance status, genetic and molecular markers, 
disease severity, baseline lung function, treatment dose, tumor response, patient smoking status, and 
patient preferences for treatment. These variables may be highly associated with the selection of 
treatment, overall survival, the incidence of severe treatment-related adverse events, or a combination 
thereof. Inability to identify and account for these potential associations may lead to residual bias in 
the effect estimates for bevacizumab. However, it is probable that patients in worse overall health 
(i.e., poor performance status and/or poor baseline lung function) would have been selected for 
treatment without bevacizumab and therefore, under the assumption these patients have shorter 
survival duration, we would expect the difference in survival to be larger (perhaps significantly) 
between those patients receiving bevacizumab and those not. Similarly, if patients in poorer overall 
health are more susceptible to severe treatment-related adverse events and are selected into treatment 
without bevacizumab, we would expect the difference in hospitalization for adverse events between 
those receiving bevacizumab and those not to be relatively smaller. The fact that large differences in 
survival or hospitalization for specific treatment-related adverse events were not observed provides 
confidence that the effect estimates for bevacizumab in the current study were not overly biased from 
the lack of information on important clinical characteristics. In addition, results from propensity 
score-adjusted models and sensitivity analyses confirmed the robustness of the study findings. 
Nonetheless, the potential for selection bias due to unmeasured confounders should not be discounted 
when interpreting the results of the current study.  
A possible solution to account for residual bias in observational studies is instrumental 
variable analysis, a methodology widely used in econometrics that can account for both observed and 
unobserved measures. The key to instrumental variable analysis is the identification of at least one 
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variable that is associated with treatment selection but is exogenous to the measured outcome other 
than through its association with the treatment. Essentially, the goal of instrumental variable analysis 
is to mimic the randomization process used in clinical trials; patients receive different treatments in 
accordance with varying values of the instrument, but treatment groups are similar across other 
observed and unobserved characteristics of patients. This study attempted instrumental variable 
analysis using two potential instruments including receipt of treatment from a CCOP-affiliated 
provider and a lagged measure of Health Service Area
217
 use of bevacizumab. However, neither 
variable successfully met the criteria for a good instrument. For example, despite having a significant 
association with bevacizumab and no direct link to overall survival, receipt of treatment from a 
CCOP-affiliated provider was significantly related to other observed patient characteristics, including 
those associated with treatment outcomes; thus, it is plausible that unobserved characteristics would 
not have been well balanced across treatment groups using receipt of treatment from a CCOP-
affiliated provider as an instrument. Furthermore, although measurement of Health Service Area 
(HSA) utilization of bevacizumab among patients diagnosed in 2004-2006 was an independent 
predictor of bevacizumab use among patients diagnosed in 2007 (i.e., higher HSA utilization of 
bevacizumab in 2004-2006 was significantly associated with greater use of bevacizumab among 
patients diagnosed in 2007), it was also predictive of patient mortality (i.e., low HSA utilization of 
bevacizumab in 2004-2006 was significantly associated with poorer survival among patients 
diagnosed in 2007).  Given the potential for residual bias from unobserved characteristics that could 
not be accounted for in the current study, future research should identify and validate the prognostic 
value of additional clinical and patient behavior measures with respect to the utilization, safety, and 
effectiveness of bevacizumab. In addition, given the similar survival times between patients receiving 
and patients not receiving bevacizumab, additional outcome measures such as the quality of life over 
the survival period may be valuable in further evaluating the effectiveness of bevacizumab and 
identifying its utility in the treatment of older adults with advanced NSCLC. 
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 A third limitation to consider is the possibility of  measurement error with the 
operationalization of several variables including census tract measures of education attainment and 
median household income, race, and comorbidity status. The absence of patient level socioeconomic 
data in SEER necessitated the application of aggregate, census tract level information for each 
individual although it is possible that such information is not representative of an individual’s true 
education level or household income. Likewise, comorbidity was measured using a validated 
algorithm and health care claims data. Although this method has been used extensively in the 
literature, there are limitations in using administrative claims data to assess comorbidity including the 
lack of capture of diagnoses and services outside of the health plan. However, it is unlikely that any 
potential measurement errors were unevenly distributed across treatment groups. Moving forward, 
future research may consider alternative data sources with richer and more valid information on 
patient level socioeconomic measures, race and ethnicity, and specific comorbid diseases along with 
the levels of disease severity.  
 The fourth limitation of this study that warrants discussion is the restriction of cases to 
patients diagnosed through 2007. As has been previously mentioned, bevacizumab did not receive 
FDA approval for the treatment of advanced NSCLC until late 2006. Therefore, without a significant 
uptake of bevacizumab in the treatment of Medicare fee-for-service beneficiaries diagnosed within 
SEER regions, the cohort of patients receiving bevacizumab in this study was destined to be relatively 
small. It is possible that studies with more recently diagnosed patients and/or larger samples of older 
adults may come up with results different from the current analysis. Future evaluation of 
bevacizumab within a larger cohort of patients, particularly one that includes a larger sample of non-
white patients as well as more recently diagnosed cases, would be informative in developing a greater 
understanding of the safety and effectiveness of bevacizumab in older adults with advanced NSCLC. 
Finally, a fifth limitation to consider when interpreting the results of this study is that 
subsequent treatment may have influenced survival. For example, some patients not receiving 
bevacizumab first-line may have received it during subsequent treatment and this may have prolonged 
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their survival beyond that of patients never receiving bevacizumab at all. Patients who received 
bevacizumab subsequent to first-line therapy were categorized in the platinum-based chemotherapy 
only group and therefore, if they derived longer survival from the use of secondary treatment with 
bevacizumab, this may narrow the measured effect of bevacizumab on survival between patients 
receiving and not receiving bevacizumab during initial treatment, particularly if all other patients in 
the analysis derived no additional benefit from other secondary treatments. A potential solution to this 
situation is to control for the subsequent use of bevacizumab or exclude patients receiving subsequent 
bevacizumab treatment from the analysis. However, this would take away from the intent-to-treat 
approach of the current analysis and further limit the generalizability of the results. In addition, such 
an analysis may not be practical to oncologists as it is unlikely they would attempt to predict which 
patients are candidates for secondary treatment with bevacizumab (or any other agent) at the time 
initial treatment decisions are being made. However, future studies may want to evaluate the effects 
of subsequent treatment on survival outcomes following initial treatment with bevacizumab, when 
and where subsequent treatment can be clearly delineated and measured.   
 
5.6 Conclusions 
 The objectives of this study were to determine the utilization, effectiveness, and safety of 
adding bevacizumab to standard platinum-based doublet chemotherapy in the treatment of Medicare 
fee-for-service beneficiaries with advanced NSCLC. This study showed that the utilization of 
bevacizumab among older patients was largely driven by clinical characteristics including stage, 
histology, and comorbidity level. In addition, greater utilization of bevacizumab among older patients 
receiving chemotherapy treatment through CCOP-affiliated physicians provides evidence of the rapid 
diffusion and uptake of novel therapies by oncologists engaged in community-based clinical research 
networks. However, this study also confirmed previous findings that the addition of bevacizumab to 
standard platinum-based doublet chemotherapy does not provide a discernible survival advantage 
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over chemotherapy alone in the treatment of advanced NSCLC in Medicare beneficiaries. With no 
clear survival benefit detected among older adults in clinical trials or observational study analyses, 
and the potential for increased harm with the use of bevacizumab supports the argument that 
bevacizumab is not suitable as a standard therapy in the first-line treatment of older patients with 
advanced NSCLC. Without additional evidence to support its safety and effectiveness in the Medicare 
population, oncologists should reserve the use of bevacizumab to patients in whom they believe there 
will be clear benefit.     
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APPENDIX A 
 ADMINISTRATIVE DIAGNOSTIC AND PROCEURAL CODES FOR ADVERSE EVENTS 
Table A-1. Administrative diagnostic and procedural codes used to identify hospitalization for specific adverse events of interest 
Adverse event Definition Specific administrative codes for relevant conditions 
ATE Presence of an inpatient administrative claim with 
at least one ICD-9-CM diagnosis code suggesting 
the presence of a severe arterial thromboembolic 
event requiring hospitalization 
 
ICD-9-CM Diagnosis: 410.xx 413.xx 415.1 415.11 430 431 432 432.0 
432.1 432.9 433.01 433.11 433.21 433.31 433.81 433.91 434 434.0 
434.01 434.1 434.11 434.9 434.91 435 435.8 435.9 V12.54  
GI perforation Presence of an inpatient administrative claim with 
at least one ICD-9-CM diagnosis code OR one 
ICD-9-CM operative procedure code OR one CPT 
code indicating a diagnosis or surgical procedure 
suggesting the presence of gastrointestinal 
perforation  
ICD-9-CM Diagnosis: 531.1 531.10 531.11 531.2 531.20 531.21 532.1 
532.2 533.1 533.2 534.1 534.2 569.83 863.1 863.3 863.5 863.9 
ICD-9-CM Diagnostic Procedure: 88.01 88.02  
ICD-9-CM Operative Procedure: 17.31 45.61 45.62 45.71 45.72 
45.74 45.9 46.1 46.10 46.11 46.13 46.2 46.7 46.79 47.0 47.01 47.09  
CPT: 43361 44120 44121 44125 44126 44127 44128 44130 44140 
44144 44145 44202 44203 44204 44205 44227 44602 44603 44604 
44605 44620 44625 44626 74150 74160 74170 74176 74177 74178   
Neutropenia Presence of an inpatient administrative claim with 
at least one ICD-9-CM diagnosis code suggesting 
the presence of severe neutropenia requiring 
hospitalization 
ICD-9-CM Diagnosis: 288.xx (includes any code beginning with 288) 
Severe 
hemorrhage 
Presence of an inpatient administrative claim with 
at least one ICD-9-CM diagnosis code suggesting 
the presence of a severe bleeding event requiring 
hospitalization 
ICD-9-CM Diagnosis: 430 431 432 432.0 432.1 432.9 459.0 530.82 
531.0 531.2 531.4 531.6 532.0 532.2 532.4 532.6 533.0 533.2 533.4 
533.6 534.0 534.2 534.4 534.6 535.01 535.11 535.21 535.41 535.51 
535.61 535.71 537.83 562.02 562.03 562.12 562.13 569.3 569.85 578 
578.0 578.9 623.8 626.8 784.7 784.8 786.3 786.30 786.39 
Abbreviations: ICD-9-CM = International Classification of Diseases, 9
th
 revision, Clinical Modification; CPT = Common Procedural Terminology; ATE = 
Arterial thromboembolic events; GI = Gastrointestinal.
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APPENDIX B  
HIERARCHICAL ANALYSIS OF THE USE OF BEVACIZUMAB 
 
Table B-1. Multivariate associations of predisposing characteristics on the odds of 
bevacizumab use among patients receiving platinum-based doublet chemotherapy 
  
Characteristic Adjusted OR 95% CI p-value   
Predisposing         
Age     0.411   
66 to 69 ref       
70 to 79 0.88 (0.70, 1.11)     
80 and older 0.80 (0.56, 1.15)     
Sex     0.466   
Female ref       
Male 0.92 (0.74, 1.14)     
Marital status     0.140   
Not married ref       
Married 1.19 (0.94, 1.49)     
Race     0.518   
White ref       
Black 0.78 (0.47, 1.29)     
Other 1.13 (0.72, 1.78)     
% 25 years and older in census tract w/ < HS education     0.568   
Lowest quartile ref       
Second 0.85 (0.63, 1.10)     
Third 0.83 (0.66, 1.15)     
Highest 0.87 (0.63, 1.16)     
Abbreviations: OR = Odds ratio; CI = Confidence interval; HS = High school. 
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Table B-2. Multivariate associations of predisposing and enabling characteristics on the odds of 
bevacizumab use among patients receiving platinum-based doublet chemotherapy 
Characteristic Adjusted OR 95% CI p-value 
Predisposing       
Age     0.244 
66 to 69 ref     
70 to 79 0.86 (0.67, 1.10)   
80 and older 0.73 (0.50, 1.08)   
Sex     0.283 
Female ref     
Male 0.88 (0.70, 1.11)   
Marital status     0.115 
Not married ref     
Married 1.22 (0.95, 1.56)   
Race     0.381 
White ref     
Black 0.71 (0.42, 1.21)   
Other 1.13 (0.67, 1.91)   
% 25 years and older in census tract w/ < HS education     0.655 
Lowest quartile ref     
Second 0.89 (0.64, 1.22)   
Third 0.82 (0.56, 1.19)   
Highest 0.75 (0.47, 1.20)   
Enabling       
Median household income (census tract level)     0.655 
Lowest quartile ref     
Second 0.83 (0.57, 1.20)   
Third 0.77 (0.49, 1.22)   
Highest 0.85 (0.52, 1.40)   
Population density     0.290 
Urban/Rural ref     
Metro 1.21 (0.85, 1.74)   
State buy-in Medicare coverage during year preceding 
diagnosis     0.837 
No ref     
Yes 0.96 (0.62, 1.48)   
≥ 50% of chemotherapy claims from CCOP  provider     <0.001 
No ref     
Yes 1.62 (1.25, 2.10)   
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Table B-2 (Continued) 
   
Year of diagnosis     <0.001 
2004-2005 ref     
2006 7.77 (5.43, 11.12)   
2007 12.55 (8.83, 17.83)   
SEER region     0.209 
East ref     
Midwest 1.62 (0.78, 1.69)   
South 1.40 (1.01, 1.93)   
West 1.25 (0.87, 1.81)   
Abbreviations: OR = Odds ratio; CI = Confidence interval; HS = High school; CCOP = Clinical Community 
Oncology Program. 
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Table B-3. Multivariate associations of predisposing characteristics on the odds of 
bevacizumab use among patients receiving platinum-taxane doublet chemotherapy 
  
Characteristic Adjusted OR 95% CI p-value   
Predisposing         
Age     0.310   
66 to 69 ref       
70 to 79 0.92 (0.71, 1.19)     
80 and older 1.05 (0.49, 1.09)     
Sex     0.736   
Female ref       
Male 1.25 (0.76, 1.21)     
Marital status     0.221   
Not married ref       
Married 1.51 (0.91, 1.50)     
Race     0.305   
White ref       
Black 1.27 (0.58, 1.63)     
Other 1.80 (0.90, 2.34)     
% 25 years and older in census tract w/ < HS education     0.131   
Lowest quartile ref       
Second 1.34 (0.55, 1.01)     
Third 1.20 (0.55, 1.01)     
Highest 1.20 (0.53, 1.04)     
Abbreviations: OR = Odds ratio; CI = Confidence interval; HS = High school. 
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Table B-4. Multivariate associations of predisposing and enabling characteristics on the odds of 
bevacizumab use among patients receiving platinum-taxane doublet chemotherapy 
Characteristic OR 95% CI p-value 
Predisposing       
Age     0.304 
66 to 69 ref     
70 to 79 0.89 (0.68, 1.18)   
80 and older 0.72 (0.47, 1.10)   
Sex     0.487 
Female ref     
Male 0.92 (0.71, 1.18)   
Marital status     0.189 
Not married ref     
Married 1.20 (0.92, 1.57)   
Race     0.312 
White ref     
Black 0.92 (0.53, 1.60)   
Other 1.53 (0.87, 2.69)   
% 25 years and older in census tract w/ < HS education     0.483 
Lowest quartile ref     
Second 0.81 (0.57, 1.15)   
Third 0.74 (0.49, 1.12)   
Highest 0.71 (0.42, 1.19)   
Enabling       
Median household income (census tract level)     0.773 
Lowest quartile ref     
Second 0.96 (0.63, 1.47)   
Third 0.87 (0.53, 1.43)   
Highest 1.04 (0.60, 1.81)   
Population density     0.337 
Urban/Rural ref     
Metro 1.21 (0.82, 1.80)   
State buy-in Medicare coverage during year preceding 
diagnosis     0.750 
No ref     
Yes 0.92 (0.57, 1.51)   
≥ 50% of chemotherapy claims from CCOP provider     0.002 
No ref     
Yes 1.57 (1.19, 2.08)   
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Table B-4 (continued) 
   
Year of diagnosis     <0.001 
2004-2005 ref     
2006 8.34 (5.65, 12.31)   
2007 13.16 (8.96, 19.32)   
SEER region     0.147 
East ref     
Midwest 1.29 (0.84, 1.98)   
South 1.52 (1.06, 2.16)   
West 1.34 (0.89, 2.01)   
Abbreviations: OR = Odds ratio; CI = Confidence interval; HS = High school; CCOP = Clinical Community 
Oncology Program. 
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APPENDIX C 
 BIVARIATE ASSOCIATIONS WITH OVERALL SURVIVAL AMONG PATIENTS RECEIVING 
PLATINUM-TAXANE CHEMOTHERAPY 
 
Table C-1. Bivariate associations between overall survival and  predisposing, enabling, and 
need characteristics among patients receiving platinum-taxane doublet chemotherapy 
    
Median survival 
time     
Characteristic 
No. of 
patients Months (95% CI) P HR (95% CI) 
Predisposing         
Age at diagnosis     0.083   
66 to 69 886   9.7  (8.87, 10.37)   ref 
70 to 79 2069   8.9  (8.33, 9.50)   1.07  (0.99, 1.16) 
80 and older 446   8.8  (7.73, 9.80)   1.14  (1.01, 1.28) 
Sex     < 0.001   
Female 1599   10.3  (9.77, 10.90)    ref 
Male 1802   8.1    (7.60, 8.67)   1.29  (1.20, 1.38) 
Marital Status     0.284   
Not married 1296   8.7  (8.03, 9.37)    ref 
Married 2105   9.4  (8.77, 9.87)   0.96  (0.89, 1.03) 
Race/Ethnicity      0.002   
White 3040   8.9    (8.50, 9.37)    ref 
Black 202   9.6    (8.07, 11.00)   0.96  (0.83, 1.12) 
Other 159   14.4  (10.47, 16.37)   0.74  (0.62, 0.87) 
% 25 years and older in census 
tract w/ < HS education     0.092   
Lowest quartile 915   9.5  (8.53, 10.23)    ref 
Second 891   8.9  (8.33, 9.70)   1.04  (0.95, 1.15) 
Third 886   9.4  (8.37, 10.20)   1.04  (0.95, 1.15) 
Highest 703   8.7  (7.70, 9.43)   1.14  (1.03, 1.26) 
          
Enabling         
Median household income 
(census tract level)     0.080   
Lowest quartile 737   9.4  (8.57, 10.07)    ref 
Second 849   8.6  (7.70, 9.33)   1.04  (0.94, 1.16) 
Third 883   8.8  (8.00, 9.73)   1.01  (0.91, 1.12) 
Highest 930   9.8  (8.73, 10.53)   0.92  (0.83, 1.02) 
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Table C-1 (Continued) 
    
Population density     0.571   
Urban/rural 528   9.2  (8.37, 10.07)    ref 
Metro 2873   9.1  (8.60, 9.53)   0.97  (0.88, 1.07) 
State buy-in Medicare coverage during year 
preceding diagnosis    0.637   
No 3121   9.1  (8.70, 9.57)    ref 
Yes 280   8.7  (7.47, 10.73)   0.97  (0.85, 1.10) 
≥ 50% of chemotherapy claims from 
CCOP-affiliated provider    0.455   
No 2493   8.9  (8.43, 9.43)    ref 
Yes 782   9.5  (8.67, 10.07)   0.97  (0.89, 1.05) 
Received treatment from provider affiliated 
with a cooperative research group    0.002   
No 1411   8.3  (7.70, 8.77)    ref 
Yes 1742   9.7  (9.10, 10.07)   0.89  (0.83, 0.96) 
Year of diagnosis     0.413   
2004-2005 1693   8.7  (8.20, 9.33)    ref 
2006 914   9.5  (8.50, 10.33)   0.95  (0.87, 1.03) 
2007 794   9.5  (8.73, 10.47)   0.97  (0.89, 1.06) 
SEER region     0.286   
East 823   9.5  (8.57, 10.27)    ref 
Midwest 623   8.4  (7.40, 9.43)   1.09  (0.98, 1.22) 
South 1322   8.9  (8.37, 9.67)   1.02  (0.94, 1.12) 
West 633   9.5  (8.53, 10.33)   0.98  (0.88, 1.09) 
          
Need         
Tumor stage     < 0.001   
IIIB 1020   12.8  (11.87, 14.03)    ref 
IV 2381   7.8    (7.40, 8.30)   1.50  (1.39, 1.62) 
Summary stage     < 0.001   
Regional 318   16.0  (14.23, 19.00)    ref 
Distant 3083   8.7    (8.23, 9.10)   1.65  (1.46, 1.86) 
Grade     < 0.001   
Well/Moderately 
differentiated 406   12.1  (10.57, 14.10)    ref 
Poor/Undifferentiated 985   8.3    (7.60, 9.00)   1.44  (1.28, 1.63) 
Unknown 2010   8.9    (8.43, 9.50)   1.40  (1.25, 1.56) 
Tumor histology     0.003   
Adenocarcinoma 1930   9.7  (9.13, 10.17)    ref 
Large cell  180   8.5  (6.97, 10.67)   1.12  (0.97, 1.31) 
Other and NOS 1291   8.3  (7.73, 8.87)   1.14  (1.06, 1.22) 
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Table C-1 (Continued) 
    
NCI Charlson Comorbidity Index   < 0.001   
0 2029   9.4  (8.77, 9.90)    ref 
1 1117   9.1  (8.47, 9.77)   1.10  (1.03, 1.19) 
2 173   6.8  (5.03, 8.57)   1.46  (1.26, 1.69) 
Hemoptysis     0.980   
No 3255   9.1  (8.67, 9.57)    ref 
Yes 146   9.1  (7.63, 10.07)   0.99  (0.84, 1.17) 
Brain metastases     < 0.001   
No 2580   9.1  (8.60, 9.67)    ref 
Yes 821   9.1  (8.13, 9.77)   1.14  (1.06, 1.23) 
Radiation therapy received     0.019   
No 1603   9.9  (9.37, 10.57)    ref 
Yes 1747   8.5  (7.93, 8.93)   1.08  (1.01, 1.15) 
Cancer-directed surgery     < 0.001   
No 3157   8.7    (8.27, 9.10)    ref 
Yes 225   19.2  (14.50, 23.57)   0.46  (0.39, 0.54) 
Abbreviations: CI = Confidence interval; HR = Hazard ratio; CCOP = Clinical Community Oncology 
Program; SEER = Surveillance, Epidemiology, and End Results; NOS = Not otherwise specified; NCI = 
National Cancer Institute. 
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APPENDIX D 
 MULTIVARIABLE-ADJUSTED ASSOCIATIONS WITH OVERALL SURVIVAL 
Table D-1. Multivariable-adjusted model evaluating the effects of the use of bevacizumab and 
all predisposing, enabling, and need characteristics on overall survival among patients receiving 
platinum-based doublet chemotherapy. 
 
  
Any platinum-based doublet  
(n = 4746) 
Platinum-taxane doublet 
 (n = 3401) 
Characteristic HR (95% CI) HR (95% CI) 
Bevacizumab     
No Ref ref 
Yes 1.00  (0.88, 1.13) 0.99  (0.86, 1.13) 
   
Predisposing 
  Age at diagnosis 
  66 to 69 ref ref 
70 to 79 1.07  (0.99, 1.14) 1.07  (0.99, 1.16) 
80 and older 1.13  (1.03, 1.24) 1.15  (1.03, 1.28) 
Sex 
  Female ref ref 
Male 1.31  (1.24, 1.38) 1.30  (1.22, 1.38) 
Marital Status 
  Not married ref ref 
Married 0.90  (0.83, 0.97) 0.89  (0.81, 0.98) 
Race 
  White ref ref 
Black 0.92  (0.78, 1.06) 0.91  (0.75, 1.08) 
Other 0.76  (0.60, 0.92) 0.72  (0.52, 0.91) 
% 25 years and older in census 
 tract w/ < HS education  
  Lowest quartile ref ref 
Second 1.06  (0.97, 1.15) 1.02  (0.90, 1.13) 
Third 1.10  (0.99, 1.21) 0.99  (0.86, 1.12) 
Highest 1.16  (1.03, 1.30) 1.08  (0.92, 1.24) 
  
  Enabling 
  Median household income 
(census tract level) 
  Lowest quartile ref ref 
Second 1.08  (0.98, 1.19) 1.08  (0.95, 1.21) 
Third 1.06  (0.94, 1.18) 1.05  (0.90, 1.20) 
Highest 1.04  (0.90, 1.18) 1.00  (0.83, 1.17) 
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Table D-1 (Continued) 
  
Population density 
  Urban/rural ref ref 
Metro 1.01  (0.91, 1.11) 1.03  (0.91, 1.15) 
State buy-in Medicare coverage 
during year preceding diagnosis 
  No ref ref 
Yes 0.92  (0.80, 1.05) 0.93  (0.78, 1.08) 
≥ 50% of chemotherapy claims 
from CCOP provider 
  No ref ref 
Yes 0.97  (0.89, 1.05) 0.99  (0.90, 1.09) 
Received treatment from 
provider affiliated with a 
cooperative group affiliation 
  No ref ref 
Yes 0.91  (0.84, 0.98) 0.89  (0.81, 0.97) 
Year of diagnosis 
  2004-2005 ref ref 
2006 0.92  (0.84, 1.00) 0.93  (0.84, 1.02) 
2007 0.94  (0.86, 1.03) 0.94  (0.83, 1.04) 
SEER region 
  East ref ref 
Midwest 1.05  (0.95, 1.15) 1.04  (0.92, 1.17) 
South 1.10  (0.99, 1.20) 1.08  (0.95, 1.20) 
West 1.04  (0.95, 1.13) 1.04  (0.94, 1.15) 
  
  Need 
  Tumor stage 
  IIIB ref ref 
IV 1.49  (1.42, 1.56) 1.52  (1.43, 1.60) 
Grade 
  Well/Moderately 
differentiated ref ref 
Poor/Undifferentiated 1.32  (1.21, 1.44) 1.28  (1.14, 1.42) 
Unknown 1.16  (1.05, 1.27) 1.17  (1.04, 1.30) 
Tumor histology 
  Adenocarcinoma ref ref 
Large cell  1.02  (0.87, 1.16) 1.02  (0.85, 1.19) 
Other and NOS 0.99  (0.92, 1.06) 1.02  (0.94, 1.10) 
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Table D-1 (Continued) 
  
NCI Charlson Comorbidity Index 
 0 ref ref 
1 1.04  (0.98, 1.11) 0.99  (0.91, 1.08) 
2 1.37  (1.22, 1.51) 1.43  (1.26, 1.60) 
Hemoptysis 
  No ref ref 
Yes 1.05  (0.89, 1.21) 1.10  (0.92, 1.28) 
Brain metastases 
  No ref ref 
Yes 1.09  (1.01, 1.17) 1.08  (0.99, 1.17) 
Radiation therapy received 
  No ref ref 
Yes 1.06  (0.99, 1.13) 1.06  (0.99, 1.14) 
Cancer-directed surgery 
  No ref ref 
Yes 0.49  (0.32, 0.65) 0.48  (0.28, 0.68) 
Abbreviations: CI = Confidence interval; HR = Hazard ratio; CCOP = Clinical Community Oncology Program; 
SEER = Surveillance, Epidemiology, and End Results; NOS = Not otherwise specified; NCI = National Cancer 
Institute. 
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APPENDIX E 
CHARCTERISTICS OF PATIENTS MATCHED ON ESTIMATED PROPENSITY SCORES FOR RECEIPT OF BEVACIZUMAB  
(FOR OVERALL SURVIVAL ANALYSIS)  
Table E-1. Baseline characteristics among patients matched on estimated propensity score for receipt of bevacizumab, n (%)  
  
Platinum-based doublet 
chemotherapy   
Platinum-taxane doublet 
chemotherapy   
  Bevacizumab   Bevacizumab   
Characteristic 
Yes                      
(n = 346) 
No                        
(n = 346) P 
Yes                      
(n = 300) 
No                        
(n = 300) P 
Predisposing             
Age at diagnosis     0.030     0.425 
66 to 69   98 (28.3)   76 (22.0)     80 (26.7)   88 (29.3)   
70 to 79 211 (61.0) 213 (61.6)   189 (63.0) 174 (58.0)   
80 and older   37 (10.7)   57 (16.5)     31 (10.3)   38 (12.7)   
Sex     0.704     0.935 
Female 168 (48.6) 163 (47.1)   157 (52.3) 158 (52.7)   
Male 178 (51.4) 183 (52.9)   143 (47.7) 142 (47.3)   
Marital Status     0.020     0.238 
Not married 121 (35.0) 151 (43.6)   105 (35.0) 119 (39.7)   
Married 225 (65.0) 195 (56.4)   195 (65.0) 181 (60.3)   
Race     0.456     0.806 
White 308 (89.0) 314 (90.8)   263 (87.7) 268 (89.3)   
Black 18 (5.2) 19 (5.5)   18 (6.0) 15 (5.0)   
Other 20 (5.8) 13 (3.8)   19 (6.3) 17 (5.7)   
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Table E-1 (Continued) 
      
% 25 years and older in census tract 
w/ < HS education     0.239     0.298 
Lowest quartile 114 (32.9) 132 (38.2)   103 (34.3) 83 (27.7)   
Second   87 (25.1)   91 (26.3)     74 (24.7) 80 (26.7)   
Third   82 (23.7)   62 (17.9)     69 (23.0) 83 (27.7)   
Highest   63 (18.2)   61 (17.6)     54 (18.0) 53 (17.7)   
       
Enabling           
Median household income 
(census tract level)   0.216     0.882 
Lowest quartile   71 (20.5)   56 (16.2)   59 (19.7) 62 (20.7)   
Second   82 (23.7)   84 (24.3)   71 (23.7) 63 (21.0)   
Third   84 (24.3)   89 (25.7)   73 (24.3) 77 (25.7)   
Highest 109 (31.5) 117 (33.8)   97 (32.3) 98 (32.7)   
Population density     0.654     0.198 
Urban/rural   44 (12.7)   48 (13.9)     37 (12.3)   48 (16.0)   
Metro 302 (87.3) 298 (86.1)   263 (87.7) 252 (84.0)   
State buy-in Medicare coverage during year 
preceding diagnosis     0.309     0.322 
No 317 (91.6) 324 (93.6)   276 (92.0) 269 (89.7)   
Yes 29 (8.4) 22 (6.4)   24 (8.0)   31 (10.3)   
≥ 50% of chemotherapy claims from CCOP-
affiliated provider     0.174     0.057 
No 242 (69.9) 258 (74.6)   205 (68.3) 226 (75.3)   
Yes 104 (30.1)   88 (25.4)     95 (31.7)   74 (24.7)   
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Table E-1 (Continued) 
      
Received treatment from provider affiliated with a:            
Cooperative research group   0.316     0.805 
No 151 (43.6) 138 (39.9)   133 (44.3) 130 (43.3)   
Yes 195 (56.4) 208 (60.1)   167 (55.7) 170 (56.7)   
Teaching hospital      0.885     0.679 
No 155 (44.8) 154 (44.5)   139 (46.3) 145 (48.3)   
Yes 189 (54.6) 192 (55.5)   159 (53.0) 155 (51.7)   
Year of diagnosis     <0.001     <0.001 
2004-2005   37 (10.7) 195 (56.4)     31 (10.3) 158 (52.7)   
2006 135 (39.0) 197 (56.9)   121 (40.3)   75 (25.0)   
2007 174 (50.3)   54 (15.6)   148 (49.3)   67 (22.3)   
SEER region     0.952     0.280 
East   62 (17.9)   64 (18.5)     54 (18.0)   71 (23.7)   
Midwest   72 (20.8)   73 (21.1)     62 (20.7)   50 (16.7)   
South   69 (19.9)   63 (18.2)     59 (19.7)   61 (20.3)   
West 143 (41.3) 146 (42.2)   125 (41.7) 118 (39.3)   
       
Need              
Tumor stage     0.099     0.914 
IIIB   64 (18.5)   48 (13.9)     53 (17.7)   52 (17.3)   
IV 282 (81.5) 298 (86.1)   237 (79.0) 248 (82.7)   
Summary stage     0.506     0.505 
Regional 12 (3.5)   9 (2.6)     9 (3.0) 12 (4.0)   
Distant 334 (96.5) 337 (97.4)   291 (97.0) 288 (96.0)   
Grade     0.267     0.833 
Well/Moderately differentiated   44 (12.7) 31 (9.0)     36 (12.0)   33 (11.0)   
Poor/Undifferentiated   90 (26.0)   90 (26.0)     76 (25.3)   72 (24.0)   
Unknown 212 (61.3) 225 (65.0)   188 (62.7) 195 (65.0)   
  
2
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Table E-1 (Continued) 
      
Tumor histology     0.270     0.971 
Adenocarcinoma 231 (66.8) 212 (61.3)   198 (66.0) 198 (66.0)   
Large cell  11 (3.2) 10 (2.9)     9 (3.0) 10 (3.3)   
Other and NOS 104 (30.1) 124 (35.8)     93 (31.0)   92 (30.7)   
NCI Charlson Comorbidity Index   0.919     0.863 
0 231 (66.8) 226 (65.3)   205 (68.3) 211 (70.3)   
1 106 (30.6) 111 (32.1)     89 (29.7)   83 (27.7)   
2   9 (2.6)   9 (2.6)     6 (2.0)   6 (2.0)   
Hemoptysis     0.009     0.794 
No 338 (97.7) 324 (93.6)   292 (97.3) 293 (97.7)   
Yes   8 (2.3) 22 (6.4)     8 (2.7)   7 (2.3)   
Brain metastases     0.916     0.824 
No 293 (84.7) 292 (84.4)   251 (83.7) 253 (84.3)   
Yes   53 (15.3)   54 (15.6)     49 (16.3)   47 (15.7)   
Radiation therapy received   0.803     0.659 
No 244 (70.5) 241 (69.7)   209 (69.7) 204 (68.0)   
Yes 102 (29.5) 105 (30.3)     91 (30.3)   96 (32.0)   
Cancer-directed surgery      0.994     0.190 
No 333 (96.2) 332 (96.0)   291 (97.0) 284 (94.7)   
Yes 12 (3.5) 12 (3.5)     8 (2.7) 14 (4.7)   
Abbreviations: CCOP = Clinical Community Oncology Program; SEER = Surveillance, Epidemiology, and End Results; NOS = Not otherwise specified; NCI = 
National Cancer Institute. 
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APPENDIX F 
ADDITIONAL ANALYSES OF THE ASSOCIATION BETWEEN BEVACIZUMAB AND 
HOSPITALIZATION FOR SEVERE TREATMENT-RELATED ADVERSE EVENTS 
Table F-1.Multivariable-adjusted models evaluating the effect of bevacizumab on the odds of  
hospitalization for severe adverse events within 180 days of treatment start while controlling for 
predisposing, enabling, and need characteristics 
 
  Any platinum doublet   
Platinum-taxane 
doublet 
Adverse event OR (95% CI)   OR (95% CI) 
Arterial thromboembolic events       
Multivariable adjusted models       
Predisposing 0.65 (0.30, 1.40)   0.69 (0.30, 1.61) 
Enabling 0.61 (0.28, 1.34)   0.65 (0.27, 1.53) 
Need 0.74 (0.34, 1.62)   0.81 (0.35, 1.91) 
Predisposing, enabling, and need 0.73 (0.33, 1.64)   0.82 (0.34, 2.01) 
Gastrointestinal perforation       
Multivariable adjusted models       
Predisposing 2.24 (1.09, 4.62)   2.19 (1.00, 4.80) 
Enabling 2.71 (1.18, 6.19)   2.71 (1.08, 6.76) 
Need 2.29 (1.09, 4.81)   2.13 (0.95, 4.76) 
Predisposing, enabling, and need 2.83 (1.20, 6.71)   2.64 (1.01, 6.85) 
Neutropenia       
Multivariable adjusted models       
Predisposing 1.20 (0.85, 1.70)   1.25 (0.59, 1.81) 
Enabling 1.12 (0.77, 1.64)   1.22 (0.82, 1.83) 
Need 1.20 (0.83, 1.74)   1.19 (0.79, 1.77) 
Predisposing, enabling, and need 1.13 (0.76, 1.69)   1.17 (0.76, 1.81) 
Severe hemorrhage       
Multivariable adjusted models       
Predisposing 1.00 (0.60, 1.67)   1.04 (0.59, 1.84) 
Enabling 0.95 (0.55, 1.64)   1.16 (0.64, 2.11) 
Need 1.01 (0.59, 1.72)   1.07 (0.59, 1.95) 
Predisposing, enabling, and need 1.00 (0.56, 1.78)   1.24 (0.65, 2.36) 
Any severe adverse event       
Multivariable adjusted models       
Predisposing 1.30 (0.99, 1.72)   1.40 (1.03, 1.89) 
Enabling 1.22 (0.91, 1.65)   1.36 (0.98, 1.87) 
Need 1.32 (0.99, 1.78)   1.38 (1.01, 1.90) 
Predisposing, enabling, and need 1.27 (0.93, 1.75)   1.38 (0.98, 1.96) 
Abbreviations: HR = Hazard ratio; CI = Confidence interval. 
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Table F-2. Multivariable-adjusted models evaluating the effect of bevacizumab on the hazard of  
hospitalization for severe adverse events during the first-line treatment window while 
controlling for predisposing, enabling, and need characteristics 
 
  Any platinum doublet   
Platinum-taxane 
doublet 
Adverse event HR (95% CI)   HR (95% CI) 
Arterial thromboembolic events       
Multivariable adjusted models       
Predisposing 1.24 (0.51, 2.61)   1.58 (0.58, 3.68) 
Enabling 1.12 (0.42, 2.65)   1.87 (0.58, 5.61) 
Need 1.08 (0.44, 2.29)   1.36 (0.50, 3.16) 
Predisposing, enabling, and need 0.96 (0.33, 2.45)   2.71 (0.72, 9.95) 
Gastrointestinal perforation       
Multivariable adjusted models       
Predisposing 2.76 (1.04, 6.41)   2.13 (0.71, 5.55) 
Enabling 2.36 (0.78, 6.50)   1.61 (0.46, 5.02) 
Need 2.14 (0.84, 4.85)   1.86 (0.65, 4.65) 
Predisposing, enabling, and need   4.57 (1.18, 17.05)   0.64 (0.05, 5.37) 
Neutropenia       
Multivariable adjusted models       
Predisposing 1.35 (0.91, 1.95)   1.48 (0.96, 2.18) 
Enabling 1.26 (0.81, 1.89)   1.32 (0.83, 2.04) 
Need 1.10 (0.71, 1.64)   1.11 (0.70, 1.68) 
Predisposing, enabling, and need 1.12 (0.68, 1.75)   1.12 (0.66, 1.81) 
Severe hemorrhage       
Multivariable adjusted models       
Predisposing 1.48 (0.83, 2.45)   1.77 (0.95, 3.05) 
Enabling 1.18 (0.63, 2.05)   1.64 (0.84, 3.03) 
Need 1.44 (0.79, 2.45)   1.63 (0.85, 2.89) 
Predisposing, enabling, and need 1.13 (0.58, 2.08)   1.85 (0.88, 3.73) 
Any severe adverse event       
Multivariable adjusted models       
Predisposing 1.56 (1.16, 2.05)   1.71 (1.25, 2.29) 
Enabling 1.35 (0.97, 1.83)   1.51 (1.07, 2.10) 
Need 1.39 (1.01, 1.86)   1.39 (1.00, 1.90) 
Predisposing, enabling, and need 1.26 (0.89, 1.76)   1.37 (0.93, 1.96) 
Abbreviations: HR = Hazard ratio; CI = Confidence interval 
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